

## Non-alcoholic fatty liver disease

Assessment and management of non-alcoholic fatty liver disease (NAFLD) in adults, children and young people

*NICE guideline*

*Methods, evidence and recommendations*

*December 2015*

*Draft for consultation*

*Commissioned by the National Institute for  
Health and Care Excellence*



**Disclaimer**

Healthcare professionals are expected to take NICE clinical guidelines fully into account when exercising their clinical judgement. However, the guidance does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of each patient, in consultation with the patient and, where appropriate, their guardian or carer.

**Copyright**

National Clinical Guideline Centre, 2015

**Funding**

National Institute for Health and Care Excellence

# Contents

Guideline Development Group members .....	11
NCGC technical team members .....	11
Co-optees .....	11
<b>Acknowledgements .....</b>	<b>13</b>
<b>1 Guideline summary.....</b>	<b>14</b>
1.1 Algorithm .....	14
1.2 Full list of recommendations .....	15
1.3 Key research recommendations .....	18
<b>2 Introduction .....</b>	<b>19</b>
<b>3 Development of the guideline .....</b>	<b>21</b>
3.1 What is a NICE clinical guideline? .....	21
3.2 Remit .....	21
3.3 Who developed this guideline? .....	22
3.3.1 What this guideline covers.....	22
3.3.2 What this guideline does not cover .....	22
3.3.3 Relationships between the guideline and other NICE guidance .....	22
<b>4 Methods.....</b>	<b>24</b>
4.1 Developing the review questions and outcomes.....	24
4.2 Searching for evidence.....	28
4.2.1 Clinical literature search.....	28
4.2.2 Health economic literature search.....	28
4.3 Identifying and analysing evidence of effectiveness .....	29
4.3.1 Inclusion and exclusion criteria .....	30
4.3.2 Type of studies .....	30
4.3.3 Methods of combining evidence.....	30
4.3.4 Appraising the quality of evidence by outcomes .....	35
4.3.5 Assessing clinical importance .....	42
4.3.6 Clinical evidence statements.....	42
4.4 Identifying and analysing evidence of cost-effectiveness .....	43

4.4.1	Literature review .....	43
4.4.2	Undertaking new health economic analysis .....	45
4.4.3	Cost-effectiveness criteria.....	45
4.4.4	In the absence of economic evidence.....	46
4.5	Developing recommendations.....	46
4.5.1	Research recommendations .....	47
4.5.2	Validation process.....	47
4.5.3	Updating the guideline.....	47
4.5.4	Disclaimer.....	47
4.5.5	Funding.....	48
<b>5</b>	<b>Risk factors for NAFLD.....</b>	<b>49</b>
5.1	Introduction .....	49
5.2	Review question: Which risk factors for NAFLD or severe NAFLD (NASH, fibrosis) aid in the identification of people who should be investigated further?.....	49
5.3	Clinical evidence.....	50
5.3.1	Risk factors for NAFLD.....	52
5.3.2	Risk factors for NASH .....	58
5.3.3	Risk factors for fibrosis.....	58
5.4	Economic evidence .....	59
5.4.1	Published evidence .....	59
5.4.2	New cost-effectiveness analysis.....	59
5.5	Evidence statements.....	59
5.5.1	Clinical .....	59
5.5.2	Economic.....	60
5.6	Recommendations and link to evidence.....	61
<b>6</b>	<b>Diagnosis of NAFLD .....</b>	<b>63</b>
6.1	Introduction .....	63
6.2	Review question: What is (are) the appropriate investigation(s) for diagnosing NAFLD in adults, young people and children?.....	63
6.3	Clinical evidence.....	64
6.4	Economic evidence .....	74
6.4.1	Published evidence .....	74

6.4.2	Unit costs.....	74
6.4.3	New cost-effectiveness analysis.....	74
6.5	Evidence statements.....	75
6.5.1	Clinical .....	75
6.5.2	Economic.....	77
6.6	Recommendations and link to evidence.....	78
<b>7</b>	<b>Diagnosing the severity of NAFLD.....</b>	<b>84</b>
7.1	Introduction .....	84
7.2	Review question: Which assessment tool is most accurate in identifying the severity or stage of NAFLD?.....	84
7.3	Clinical evidence.....	85
7.4	Economic evidence .....	107
7.4.1	Published literature.....	107
7.4.2	Unit costs.....	109
7.4.3	New cost-effectiveness analysis.....	109
7.5	Evidence statements.....	112
7.5.1	Clinical .....	112
7.5.2	Economic.....	115
7.6	Recommendations and link to evidence.....	116
<b>8</b>	<b>Monitoring NAFLD progression .....</b>	<b>121</b>
8.1	Introduction .....	121
8.2	Review question: How often should we monitor adults, young people and children with NAFLD or NASH (with or without fibrosis) to determine the risk of disease progression?.....	121
8.3	Clinical evidence.....	121
8.3.1	Fibrosis progression rate.....	125
8.3.2	Risk factors for change in NAFLD histology.....	125
8.4	Economic evidence .....	129
8.4.1	Published literature.....	129
8.4.2	Unit costs.....	129
8.4.3	New cost-effectiveness analysis.....	129
8.5	Evidence statements.....	129

8.5.1	Clinical .....	129
8.5.2	Economic .....	129
8.6	Recommendations and link to evidence.....	130
<b>9</b>	<b>Extra-hepatic conditions .....</b>	<b>133</b>
9.1	Introduction .....	133
9.2	Review question: Should a diagnosis of NAFLD in adults, young people and children prompt assessment for additional extra-hepatic conditions and, if so, which? .....	133
9.3	Clinical evidence.....	134
9.4	Economic evidence .....	149
9.4.1	Published literature.....	149
9.4.2	Unit costs.....	149
9.5	Evidence statements.....	149
9.5.1	Clinical .....	149
9.5.2	Economic.....	150
9.6	Recommendations and link to evidence.....	150
<b>10</b>	<b>Weight reduction interventions.....</b>	<b>154</b>
10.1	Introduction .....	154
10.2	Review question: What is the clinical and cost-effectiveness of dietary interventions for weight reduction for adults, young people and children with NAFLD compared with standard care? .....	154
10.3	Clinical evidence.....	155
10.4	Economic evidence .....	155
10.5	Evidence statements.....	155
10.5.1	Clinical .....	155
10.5.2	Economic.....	155
10.6	Recommendations and link to evidence.....	155
<b>11</b>	<b>Dietary modification and supplements .....</b>	<b>157</b>
11.1	Introduction .....	157
11.2	Review question: What is the clinical and cost-effectiveness of dietary modifications or supplements for adults, young people and children with NAFLD compared with standard care? .....	157
11.3	Clinical evidence.....	158
11.4	Economic evidence .....	168

11.4.1	Published literature.....	168
11.4.2	Unit costs.....	168
11.5	Evidence statements.....	168
11.5.1	Clinical .....	168
11.5.2	Economic.....	169
11.6	Recommendations and link to evidence.....	169
<b>12</b>	<b>Exercise interventions.....</b>	<b>173</b>
12.1	Introduction .....	173
12.2	Review question: What is the clinical and cost-effectiveness of exercise programmes for adults, young people and children with NAFLD compared with standard care?.....	173
12.3	Clinical evidence.....	174
12.4	Economic evidence .....	178
12.5	Evidence statements.....	178
12.5.1	Clinical .....	178
12.5.2	Economic.....	178
12.6	Recommendations and link to evidence.....	178
<b>13</b>	<b>Lifestyle modification.....</b>	<b>180</b>
13.1	Introduction .....	180
13.2	Review question: What is the clinical and cost-effectiveness of lifestyle modification programmes for diet and exercise interventions for adults, young people and children with NAFLD compared with diet alone, exercise alone or standard care?.....	180
13.3	Clinical evidence.....	181
13.4	Economic evidence .....	195
13.4.1	Published literature.....	195
13.4.2	Review of economic evidence from NICE public health guidance .....	195
13.5	Evidence statements.....	205
13.5.1	Clinical .....	205
13.5.2	Economic.....	206
13.6	Recommendations and link to evidence.....	206
<b>14</b>	<b>Alcohol advice .....</b>	<b>210</b>
14.1	Introduction .....	210
14.2	Review question: Should people with NAFLD restrict their consumption of alcohol to below national recommended levels?.....	210



14.3	Clinical evidence.....	211
14.4	Economic evidence .....	214
14.5	Evidence statements.....	214
14.5.1	Clinical .....	214
14.5.2	Economic.....	214
14.6	Recommendations and link to evidence.....	214
<b>15</b>	<b>Fructose advice.....</b>	<b>216</b>
15.1	Introduction .....	216
15.2	Review question: Should people with NAFLD restrict their consumption of fructose or sugar?.....	216
15.3	Clinical evidence.....	217
15.4	Economic evidence .....	217
15.5	Evidence statements.....	217
15.5.1	Clinical .....	217
15.5.2	Economic.....	217
15.6	Recommendations and link to evidence.....	217
<b>16</b>	<b>Caffeine advice .....</b>	<b>218</b>
16.1	Introduction .....	218
16.2	Review question: Should people with NAFLD modify their consumption of caffeine from coffee?.....	218
16.3	Clinical evidence.....	218
16.4	Economic evidence .....	223
16.5	Evidence statements.....	223
16.5.1	Clinical .....	223
16.5.2	Economic.....	223
16.6	Recommendations and link to evidence.....	223
<b>17</b>	<b>Pharmacological interventions .....</b>	<b>225</b>
17.1	Introduction .....	225
17.2	Review question: What is the clinical and cost-effectiveness of pharmacological interventions for adults, young people and children with NAFLD?.....	225
17.3	Clinical evidence.....	226
17.4	Economic evidence .....	281

17.4.1	Published literature.....	281
17.4.2	Unit costs.....	283
17.5	Evidence statements.....	283
17.5.1	Clinical .....	283
17.5.2	Economic.....	288
17.6	Recommendations and link to evidence.....	288
<b>18</b>	<b>Acronyms and abbreviations.....</b>	<b>295</b>
<b>19</b>	<b>Glossary .....</b>	<b>297</b>
19.1	Guideline-specific terms .....	297
19.2	General terms .....	299
<b>20</b>	<b>Reference list.....</b>	<b>309</b>

## 1 Guideline Development Group members

Name	Role
Christopher Byrne	Professor of Endocrinology and Metabolism, University of Southampton
Chris Day (Chair)	Professor of Liver Medicine and Honorary Consultant Hepatologist, Newcastle University
David Fitzmaurice	Professor of Primary Care, University of Birmingham
Irene McGill	Patient/carer member
Kevin Moore	Professor of Hepatology, University College London (until June 2015 due to health reasons)
Benjamin Mullish	Specialist Trainee/Academic Clinical Fellow in Hepatology and Gastroenterology, Imperial College London
Philip Newsome	Professor of Experimental Hepatology and Honorary Consultant Hepatologist, Birmingham University
Tanja Pardela	Paediatric Liver Modern Matron, King's College Hospital
Rachel Pryke	General Practitioner Partner, Winyates Health Centre, Redditch
Jane Putsey	Patient/carer member
Indra van Mourik	Consultant Paediatric Hepatologist, Birmingham Children's Hospital NHS Foundation Trust
Bronwen Williams	Gastroenterology and Hepatology Research Nurse, Hull Royal Infirmary

## 2 NCGC technical team members

Name	Role
Joanna Ashe	Senior Information Scientist
Kate Ashmore	Document Editor/Process Assistant (from April 2015)
Serena Carville	Associate Director and Guideline Lead
Angela Cooper	Senior Research Fellow (until December 2014)
Lefteris Floros	Health Economist
Jessica Glen	Senior Research Fellow (from December 2014)
Martin Harker	Senior Health Economist
Qudsia Malik	Senior Research Fellow
Amelia Unsworth	Senior Project Manager (until October 2015)
Claire Wallnutt	Information Scientist (from January 2015)
Natalie Wood	Project Manager (from October 2015)
Giulia Zuodar	Document Editor/Process Assistant (until April 2015)

## 3 Co-optees

Name	Role
Ashley Guthrie	Consultant Radiologist, Leeds Teaching Hospitals NHS Trust
Jill Johnson	Specialist Dietitian, Queen Elizabeth Hospital Birmingham NHS Foundation Trust
Roy Sherwood	Professor of Clinical Biochemistry, King's College London
Dina Tiniakos	Clinical Senior Lecturer & Honorary Consultant Histopathologist, Newcastle University

NAFLD

Acknowledgements

<b>Name</b>	<b>Role</b>
Michael Trenell	Professor of Movement & Metabolism & NIHR Senior Research Fellow, Newcastle University

1

# 1 Acknowledgements


2 The development of this guideline was greatly assisted by the following people:

- 3 • Hannah Carré, Project Administrator, NCGC
- 4 • Jill Cobb, Information Scientist, NCGC
- 5 • Emily Davies, Senior Research Fellow, NCGC
- 6 • Margherita Fanos, Research Fellow, NCGC
- 7 • Jessica Flynn, Office Manager, NCGC
- 8 • Lina Gulhane, Joint Head of Information Science & Knowledge Manager, NCGC
- 9 • Grace Marsden, Senior Health Economist, NCGC
- 10 • Grace Massey, Document Delivery, NCGC
- 11 • Paul Miller, Senior Information Scientist, NCGC
- 12 • Jill Parnham, Operations Director, NCGC
- 13 • Jacoby Patterson, Systematic Reviewer
- 14 • Elizabeth Pearton, Information Scientist, NCGC
- 15 • Ben Pordes, Project Manager, NCGC
- 16 • Emma Pottinger, Research Fellow, NCGC
- 17 • Gill Ritchie, Associate Director, NCGC
- 18 • Julie Robinson, Document Delivery, NCGC
- 19 • Carlos Sharpin, Joint Head of Information Science/Research Fellow, NCGC
- 20 • Josh South, Administrator, NCGC
- 21 • Heather Stegenga, Research Fellow, NCGC
- 22 • Thomas Strong, Document Delivery, NCGC
- 23 • David Wonderling, Head of Health Economics, NCGC
- 24 • Ruth Wong, Information Scientist, NCGC
- 25

# 1 Guideline summary

## 2 1.1 Algorithm

**Algorithm: Assessment and monitoring of NAFLD in adults, children and young people**



## 1 1.2 Full list of recommendations

### 2 Assessment

#### 3 *When to suspect NAFLD*

- 4 1. Suspect non-alcoholic fatty liver disease (NAFLD) in people who have:
  - 5 • type 2 diabetes or
  - 6 • metabolic syndrome.

#### 7 *Diagnosing NAFLD*

- 8 2. Take an alcohol history to rule out alcohol-related liver disease. See also  
9 NICE's [cirrhosis guideline](#)<sup>a</sup>.
- 10 3. Do not use routine liver blood tests to rule out NAFLD.

#### 11 *Diagnosing NAFLD in adults*

- 12 4. Consider testing adults for NAFLD if they:
  - 13 • have type 2 diabetes or metabolic syndrome and
  - 14 • alcohol-related liver disease has been ruled out.
- 15 5. Use the fatty liver index (FLI) test if testing adults for NAFLD.
- 16 6. Diagnose adults with NAFLD if:
  - 17 • they have an FLI score of 60 or above and
  - 18 • other suspected causes of fatty liver have been ruled out.
- 19 7. Consider retesting adults for NAFLD using FLI every 5 years if they have:
  - 20 • an FLI score of less than 60 and
  - 21 • type 2 diabetes or metabolic syndrome.

#### 22 *Diagnosing NAFLD in children and young people*

- 23 8. Test children and young people for NAFLD using ultrasound if they:
  - 24 • have type 2 diabetes or metabolic syndrome and
  - 25 • do not misuse alcohol.
- 26 9. Diagnose children and young people with NAFLD if:
  - 27 • they have fatty liver on ultrasound and
  - 28 • other suspected causes of fatty liver have been ruled out.
- 29 10. Retest children and young people for NAFLD using ultrasound every 3 years if  
30 they have:
  - 31 • a normal ultrasound and
  - 32 • type 2 diabetes or metabolic syndrome.

33

34

**1 Diagnosing advanced liver fibrosis**

- 2 11. Use the enhanced liver fibrosis (ELF) test to test people for advanced liver  
3 fibrosis if NAFLD has been diagnosed (either by targeted case-finding as in  
4 recommendations 4 and 8 or by incidental findings).
- 5 12. Diagnose people with advanced liver fibrosis and refer them to a relevant  
6 specialist in hepatology, if they have:
- 7 • an ELF score of 10.51 or above and
  - 8 • NAFLD.

**9 Monitoring****10 Advanced liver fibrosis**

- 11 13. Retest adults with NAFLD and an ELF score of less than 10.51 for advanced  
12 liver fibrosis using ELF every 3 years.
- 13 14. Retest children and young people with NAFLD and an ELF score of less than  
14 10.51 for advanced liver fibrosis using ELF every 2 years.
- 15 15. Monitor adults and young people over 16 with NAFLD and advanced liver  
16 fibrosis for cirrhosis in line with NICE's [cirrhosis guideline](#)<sup>b</sup>.

**17 Extra-hepatic conditions**

- 18 16. Be aware that NAFLD is a risk factor for type 2 diabetes, hypertension and  
19 chronic kidney disease.
- 20 17. Be aware that in people with type 2 diabetes, NAFLD is a risk factor for atrial  
21 fibrillation, myocardial infarction, ischemic stroke and cardiovascular death.

**22 Managing NAFLD****23 Lifestyle modifications****24 Weight reduction**

- 25 18. Manage overweight and obesity in people with NAFLD in line with the  
26 recommendations on physical activity and diet in NICE's [obesity guideline](#).

**27 Exercise**

- 28 19. Explain to people with NAFLD that there is some evidence that exercise  
29 reduces liver fat content.

**30 Combined interventions**

- 31 20. Consider the lifestyle interventions in NICE's obesity guideline for people  
32 with NAFLD regardless of their BMI.

**33 Supplements**

- 34 21. Explain to adults with NAFLD that there is some evidence that the following  
35 probiotics could be effective for reducing liver fat content and liver fibrosis:
- 36 • *Bifidobacterium bifidum*
  - 37 • *Bifidobacterium breve*



- 1 • *Bifidobacterium infantis*
- 2 • *Bifidobacterium longum*
- 3 • *Lactobacillus acidophilus*
- 4 • *Lactobacillus casei*
- 5 • *Lactobacillus delbrueckii bulgaricus*
- 6 • *Lactobacillus paracasei*
- 7 • *Lactobacillus plantarum*
- 8 • *Lactobacillus rhamnosus*
- 9 • *Streptococcus thermophilus*.
- 10 22. Explain to children and young people with NAFLD, and their parents or
- 11 carers, that there is no evidence that probiotics reduce liver fat content and
- 12 liver fibrosis.
- 13 23. Do not offer omega-3 fatty acids to adults with NAFLD because there is not
- 14 enough evidence to recommend their use.
- 15 24. Explain to children and young people with NAFLD, and their parents or
- 16 carers, that there is some evidence that the omega-3 fatty acid
- 17 docosahexaenoic acid reduces liver fat content and alanine aminotransferase
- 18 levels but the clinical significance of these changes is uncertain.
- 19 **Alcohol advice**
- 20 25. Explain to people with NAFLD who drink alcohol of the importance of staying
- 21 within the national recommended limits for alcohol consumption.
- 22 **Fructose advice**
- 23 No clinical recommendations.
- 24 **Caffeine advice**
- 25 No clinical recommendations.
- 26 **Pharmacological treatment**
- 27 26. In secondary care settings only, consider pioglitazone<sup>c</sup> or vitamin E<sup>d</sup> for adults
- 28 with advanced liver fibrosis, whether they have diabetes or not.
- 29 27. Before prescribing pioglitazone or vitamin E, take into account any
- 30 comorbidities that the person has and the risk of adverse events associated
- 31 with these conditions.
- 32 28. In secondary or tertiary care settings only, consider vitamin E for children and
- 33 young people with advanced liver fibrosis, whether they have diabetes or
- 34 not.
- 35 29. Offer the ELF test to people with advanced liver fibrosis 2 years after they
- 36 start new pharmacological therapy to assess if treatment is effective.
- 37 30. If an adult's ELF test score has risen, stop either vitamin E or pioglitazone and
- 38 consider switching to the other pharmacological therapy.

- 1                    31.    If a child or young person's ELF test score has risen, stop vitamin E.
- 2                    32.    Be aware that people with NAFLD who are taking statins should keep taking
- 3                           statins.
- 4                    33.    Only consider stopping statins if liver blood tests double within 3 months of
- 5                           starting statins, including in people with abnormal baseline liver blood tests.

6

### 7 **1.3 Key research recommendations**

- 8                    • Which non-invasive tests most accurately identify non-alcoholic steatohepatitis (NASH) in people
- 9                           with non-alcoholic fatty liver disease (NAFLD)?
- 10                   • Which non-invasive tests most accurately diagnose NAFLD and advanced liver fibrosis in children
- 11                          and young people?
- 12                   • What is the clinical and cost effectiveness of using probiotics or prebiotics to treat NAFLD in
- 13                          adults, young people and children?
- 14                   • Should people with NAFLD restrict their consumption of alcohol to below national limits?
- 15                   • What is the clinical and cost effectiveness of pharmacological therapy in children and young
- 16                          people with advanced liver fibrosis?

## 2 Introduction

### 2 Background

Primary non-alcoholic fatty liver disease (NAFLD) is an excess of fat in the liver (steatosis) that is not a result of excessive alcohol consumption or other secondary causes. These secondary causes include for example, side effects of certain medications, hepatitis C virus infection and particular endocrine conditions. NAFLD ranges from hepatic steatosis, through to inflammatory non-alcoholic steatohepatitis (NASH), to fibrosis or cirrhosis. A proportion of these people will die from liver failure or hepatocellular cancer (HCC) or need a liver transplant.

The prevalence of NAFLD in the general population is estimated at 20–30%. Around 2–3% of the population have NASH. NAFLD is more common in people who have central obesity (excessive abdominal fat), insulin resistance or type 2 diabetes, hypertension and dyslipidaemia. This group of chronic conditions is indicative of increased cardiovascular risk and together comprise ‘metabolic syndrome’.

The prevalence of NAFLD is increasing, placing a greater burden on healthcare resources. The rate of progression of NAFLD is variable; being overweight and having diabetes are associated with an increased risk of progressive disease. The average age of people with NASH is 40–50 years and for NASH-cirrhosis 50–60 years. However the emerging epidemic of childhood obesity means that increasing numbers of younger people have NAFLD, with some prevalence studies showing that up to 38% of obese children have evidence of NAFLD. With NAFLD progressing through its spectrum even in childhood, the age that people develop significant liver disease is likely to fall and early diagnosis and management are therefore important issues at all ages. There is currently no licensed treatment for NAFLD.

### 23 Current practice

NAFLD is usually first suspected in primary care incidentally either by abnormal liver blood tests or an abnormal liver ultrasound appearance picked up as part of an investigation for an unrelated condition. The care pathway in primary care for someone with suspected NAFLD is unclear, and practice regarding further investigation and referral varies widely. NAFLD is increasingly being identified through case-finding in hospital outpatient departments for people with associated conditions such as diabetes, obesity or hypertension. However, this practice is not universal and there is no guidance about which people should be investigated for NAFLD or how this should be done. Once people with NAFLD have been referred to secondary care, their condition may be investigated further to determine whether or not they have progressive disease. However, as there is currently no guidance about who or how to investigate these people, investigation tends to be ad hoc. As there is currently no licensed treatment for NAFLD, most people are discharged back to their GP. Some people are given advice on lifestyle, which is usually focused on achieving weight loss, but, again, in the absence of clear guidance, this is highly variable.

### 37 Need for and scope of the guideline

Guidance is needed for use in both primary and secondary care settings.

This guideline covers identifying, diagnosing and assessing disease severity of adults, children and young people with NAFLD. It also covers both pharmacological and non-pharmacological treatments, disease monitoring and the risk of extra-hepatic conditions associated with NAFLD.

1 The guideline does not cover the investigation of people with incidentally found abnormal liver blood  
2 tests, of which NAFLD is but 1 of the common causes, and does not cover the complications of NAFLD  
3 cirrhosis.

4 Although hepatocellular carcinoma (HCC) has been reported in people with NAFLD without cirrhosis,  
5 it's likely very low incidence was not felt to merit consideration of the cost-effectiveness of  
6 surveillance for this complication. NICE has produced guidance on the components of good patient  
7 experience in adult NHS services. All healthcare professionals should follow the recommendations in  
8 patient experience in adult NHS services.

9 Although there are many causes for steatosis, and therefore a potentially wide differential diagnosis  
10 in practice, the principal differential is between primary, metabolic syndrome-related NAFLD and  
11 alcohol-related liver disease. Discriminating between these is reliant upon a detailed history and  
12 seeking corroboration from family members where available to ensure that any history of occult  
13 excessive alcohol consumption is excluded. An arbitrary threshold for ethanol consumption of  
14 <20g/day for women and <30g/day for men is adopted to sustain a diagnosis of NAFLD. For people  
15 with abnormal liver blood tests and either suspected or confirmed fatty liver, alternative causes must  
16 be excluded with a detailed drug history and laboratory tests for chronic viral hepatitis (HBVsAg and  
17 HCV serology), autoimmune liver disease (ANA, AMA, SMA, LKM1 antibodies, immunoglobulins) and  
18 other treatable metabolic diseases (haemochromatosis, Wilson's disease, coeliac disease, alpha-1  
19 antitrypsin deficiency). Importantly, 80% of people with NAFLD have normal standard liver blood  
20 tests.

# 1 3 Development of the guideline

## 2 3.1 What is a NICE clinical guideline?

3 NICE clinical guidelines are recommendations for the care of individuals in specific clinical conditions  
4 or circumstances within the NHS – from prevention and self-care through primary and secondary  
5 care to more specialised services. We base our clinical guidelines on the best available research  
6 evidence, with the aim of improving the quality of healthcare. We use predetermined and systematic  
7 methods to identify and evaluate the evidence relating to specific review questions.

8 NICE clinical guidelines can:

- 9 • provide recommendations for the treatment and care of people by health professionals
- 10 • be used to develop standards to assess the clinical practice of individual health professionals
- 11 • be used in the education and training of health professionals
- 12 • help patients to make informed decisions
- 13 • improve communication between patient and health professional.

14 While guidelines assist the practice of healthcare professionals, they do not replace their knowledge  
15 and skills.

16 We produce our guidelines using the following steps:

- 17 • Guideline topic is referred to NICE from the Department of Health.
- 18 • Stakeholders register an interest in the guideline and are consulted throughout the development  
19 process.
- 20 • The scope is prepared by the National Clinical Guideline Centre (NCGC).
- 21 • The NCGC establishes a Guideline Development Group.
- 22 • A draft guideline is produced after the group assesses the available evidence and makes  
23 recommendations.
- 24 • There is a consultation on the draft guideline.
- 25 • The final guideline is produced.

26 The NCGC and NICE produce a number of versions of this guideline:

- 27 • the 'full guideline' contains all the recommendations, plus details of the methods used and the  
28 underpinning evidence
- 29 • the 'NICE guideline' lists the recommendations
- 30 • 'information for the public' is written using suitable language for people without specialist  
31 medical knowledge
- 32 • NICE Pathways brings together all connected NICE guidance.

33 This version is the full version. The other versions can be downloaded from NICE at [www.nice.org.uk](http://www.nice.org.uk).

## 34 3.2 Remit

35 NICE received the remit for this guideline from the Department of Health. NICE commissioned the  
36 NCGC to produce the guideline.

37 The remit for this guideline is:

38 The management of liver disease (non-alcoholic).

### 1 **3.3 Who developed this guideline?**

2 A multidisciplinary Guideline Development Group (GDG) comprising health professionals and  
3 researchers as well as lay members developed this guideline (see the list of Guideline Development  
4 Group members and the acknowledgements).

5 The National Institute for Health and Care Excellence (NICE) funds the National Clinical Guideline  
6 Centre (NCGC) and thus supported the development of this guideline. The GDG was convened by the  
7 NCGC and chaired by Professor Chris Day in accordance with guidance from NICE.

8 The group met every 5 to 6 weeks during the development of the guideline. At the start of the  
9 guideline development process all GDG members declared interests including consultancies, fee-paid  
10 work, shareholdings, fellowships and support from the healthcare industry. At all subsequent GDG  
11 meetings, members declared arising conflicts of interest.

12 Members were either required to withdraw completely or for part of the discussion if their declared  
13 interest made it appropriate. The details of declared interests and the actions taken are shown in  
14 Appendix B.

15 Staff from the NCGC provided methodological support and guidance for the development process.  
16 The team working on the guideline included a project manager, systematic reviewers (research  
17 fellows), health economists and information scientists. They undertook systematic searches of the  
18 literature, appraised the evidence, conducted meta-analysis and cost-effectiveness analysis where  
19 appropriate and drafted the guideline in collaboration with the GDG.

#### 20 **3.3.1 What this guideline covers**

21 This guideline covers the assessment and management of non-alcoholic fatty liver disease (NAFLD) in  
22 adults, children and young people. For further details please refer to the scope in Appendix A and the  
23 review questions in Section 4.1.

#### 24 **3.3.2 What this guideline does not cover**

25 This guideline does not cover people with secondary causes of fatty liver (for example, chronic  
26 hepatitis C infection, total parenteral nutrition treatment and drug-induced fatty liver), management  
27 of end-stage liver disease, hepatocellular carcinoma or liver transplant associated with NAFLD, and  
28 the assessment and management of cirrhosis.

#### 29 **3.3.3 Relationships between the guideline and other NICE guidance**

##### 30 **Related NICE diagnostics guidance:**

- 31 • SonoVue (sulphur hexafluoride microbubbles) – contrast agent for contrast-enhanced ultrasound  
32 imaging of the liver. NICE diagnostics guidance 5 (2012).

##### 33 **Related NICE medical technology guidance:**

- 34 • Virtual Touch Quantification to diagnose and monitor liver fibrosis in chronic viral hepatitis B and  
35 C. NICE medical technology guidance MTG27 (2015).

##### 36 **Related NICE clinical guidelines:**

- 37 • Diabetes (type 1 and type 2) in children and young people: diagnosis and management. NICE  
38 guideline 18 (2015).  
39 • Suspected cancer: recognition and referral. NICE guideline 12 (2015).

Development of the guideline

- 1 • Obesity: identification, assessment and management of overweight and obesity in children, young  
2 people and adults. NICE clinical guideline 189 (2014).
- 3 • Chronic kidney disease: early identification and management of chronic kidney disease in adults in  
4 primary and secondary care. NICE clinical guideline 182 (2014).
- 5 • Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the  
6 primary and secondary prevention of cardiovascular disease. NICE clinical guideline 181 (2014).
- 7 • Atrial fibrillation: the management of atrial fibrillation. NICE clinical guideline 180 (2014).
- 8 • Hypertension: clinical management of primary hypertension in adults. NICE clinical guideline 127  
9 (2011).
- 10 • Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol  
11 dependence. NICE clinical guideline 115 (2011).
- 12 • Alcohol-use disorders: diagnosis and clinical management of alcohol-related physical  
13 complications. NICE clinical guideline 100 (2010).

**14 Related NICE public health guidance:**

- 15 • Physical activity: brief advice for adults in primary care. NICE public health guidance 44 (2013).
- 16 • Hepatitis B and C: ways to promote and offer testing to people at increased risk of infection. NICE  
17 public health guidance 43 (2012).
- 18 • Walking and cycling: local measures to promote walking and cycling as forms of travel or  
19 recreation. NICE public health guidance 41 (2012).
- 20 • Alcohol-use disorders: preventing harmful drinking. NICE public health guidance 24 (2010).
- 21 • Promoting physical activity for children and young people. NICE public health guidance 17 (2009).

**22 Related NICE guidance currently in development:**


- 23 • Type 2 diabetes (update). NICE guideline. Publication expected December 2015.
- 24 • Cirrhosis: assessment and management of cirrhosis. NICE guideline. Publication expected June  
25 2016.
- 26 • Hepatitis C: diagnosis and management of hepatitis C. NICE guideline. Publication expected May  
27 2018.

## 4 Methods

This chapter sets out in detail the methods used to review the evidence and to develop the recommendations that are presented in subsequent chapters of this guideline. This guidance was developed in accordance with the methods outlined in the NICE guidelines manual, 2012 versions.<sup>122,125</sup>

Sections 4.1 to 4.3 describe the process used to identify and review clinical evidence (summarised in Figure 1), Sections 4.2 and 4.4 describe the process used to identify and review the health economic evidence, and Section 4.5 describes the process used to develop recommendations.

**Figure 1: Step-by-step process of review of evidence in the guideline**



### 4.1 Developing the review questions and outcomes

Review questions were developed using a PICO framework (patient, intervention, comparison and outcome) for intervention reviews; using a framework of population, index tests, reference standard and target condition for reviews of diagnostic test accuracy; and using population, presence or absence of factors under investigation (for example prognostic factors) and outcomes for prognostic reviews.



1 This use of a framework guided the literature searching process, critical appraisal and synthesis of  
 2 evidence, and facilitated the development of recommendations by the GDG. The review questions  
 3 were drafted by the NCGC technical team and refined and validated by the GDG. The questions were  
 4 based on the key clinical areas identified in the scope (Appendix A).

5 A total of 13 review questions were identified.

6 Full literature searches, critical appraisals and evidence reviews were completed for all the specified  
 7 review questions.

8 **Table 1: Review questions**

Chapter	Review question	Outcomes
5	Which risk factors for NAFLD or severe NAFLD (NASH, fibrosis) aid in the identification of people who should be investigated further?	<ul style="list-style-type: none"> <li>• Diagnosis of NAFLD</li> <li>• Diagnosis of NASH or fibrosis</li> </ul>
6	What is (are) the appropriate investigation(s) for diagnosing NAFLD in adults, young people and children?	Diagnostic accuracy outcomes for detecting steatosis: Sensitivity, specificity and AUC
7	Which assessment tool is most accurate in identifying the severity or stage of NAFLD?	Diagnostic accuracy outcomes for detecting NASH or fibrosis: Sensitivity, specificity and AUC
8	How often should we monitor adults, young people and children with NAFLD or NASH (with or without fibrosis) to determine the risk of disease progression?	Rate of: <ul style="list-style-type: none"> <li>• Progression from NAFLD to NASH</li> <li>• Progression from NASH to NASH with fibrosis</li> <li>• Progression from NASH with fibrosis to cirrhosis</li> </ul>
9	Should a diagnosis of NAFLD in adults, young people and children prompt assessment for additional extra-hepatic conditions and, if so, which?	Critical: <ul style="list-style-type: none"> <li>• Cardiovascular disease (MI, stroke, TIA, angina, PAD, hypertension)</li> <li>• Type 2 diabetes</li> <li>• Colorectal cancer</li> <li>• Dyslipidaemia (hypertriglyceridemia).</li> </ul> Important: <ul style="list-style-type: none"> <li>• Polycystic ovarian syndrome (PCOS) for adults and young people</li> <li>• Chronic kidney disease (CKD)</li> <li>• Obstructive sleep apnoea syndrome</li> <li>• Vitamin D levels</li> <li>• Obesity</li> <li>• Insulin resistance.</li> </ul>
10	What is the clinical and cost-effectiveness of dietary interventions for weight reduction for adults, young people and children with NAFLD compared with standard care?	Critical: <ul style="list-style-type: none"> <li>• Progression of NAFLD as assessed by:               <ul style="list-style-type: none"> <li>○ Liver biopsy</li> <li>○ MRI/MRS</li> <li>○ Ultrasound (absence of steatosis only)</li> <li>○ The Enhanced Liver Fibrosis (ELF) score</li> <li>○ Transient elastography</li> <li>○ NAFLD fibrosis score</li> </ul> </li> <li>• Quality of life</li> </ul>

Chapter	Review question	Outcomes
		<ul style="list-style-type: none"> <li>• Serious adverse events</li> </ul> <p>Important:</p> <ul style="list-style-type: none"> <li>• Weight loss</li> <li>• Liver function tests</li> <li>• Adverse events</li> </ul>
11	What is the clinical and cost-effectiveness of dietary modifications or supplements for adults, young people and children with NAFLD compared with standard care?	<p>Critical:</p> <ul style="list-style-type: none"> <li>• Progression of NAFLD as assessed by: <ul style="list-style-type: none"> <li>○ Liver biopsy</li> <li>○ MRI/MRS</li> <li>○ Ultrasound (absence of steatosis only)</li> <li>○ The Enhanced Liver Fibrosis (ELF) score</li> <li>○ Transient elastography</li> <li>○ NAFLD fibrosis score</li> </ul> </li> <li>• Quality of life</li> <li>• Serious adverse events</li> </ul> <p>Important:</p> <ul style="list-style-type: none"> <li>• Weight loss</li> <li>• Liver function tests</li> <li>• Adverse events</li> </ul>
12	What is the clinical and cost-effectiveness of exercise programmes for adults, young people and children with NAFLD compared with standard care?	<p>Critical:</p> <ul style="list-style-type: none"> <li>• Progression of NAFLD as assessed by: <ul style="list-style-type: none"> <li>○ Liver biopsy</li> <li>○ MRI/MRS</li> <li>○ Ultrasound (absence of steatosis only)</li> <li>○ The Enhanced Liver Fibrosis (ELF) score</li> <li>○ Transient elastography</li> <li>○ NAFLD fibrosis score</li> </ul> </li> <li>• Quality of life</li> <li>• Serious adverse events</li> </ul> <p>Important:</p> <ul style="list-style-type: none"> <li>• Weight loss</li> <li>• Liver function tests</li> <li>• Adverse events</li> </ul>
13	What is the clinical and cost-effectiveness of lifestyle modification programmes for diet and exercise interventions for adults, young people and children with NAFLD compared with diet alone, exercise alone or standard care?	<p>Critical:</p> <ul style="list-style-type: none"> <li>• Progression of NAFLD as assessed by: <ul style="list-style-type: none"> <li>○ Liver biopsy</li> <li>○ MRI/MRS</li> <li>○ Ultrasound (absence of steatosis only)</li> <li>○ The Enhanced Liver Fibrosis (ELF) score</li> <li>○ Transient elastography</li> <li>○ NAFLD fibrosis score</li> </ul> </li> <li>• Quality of life</li> <li>• Serious adverse events</li> </ul> <p>Important:</p>

NAFLD

Methods

Chapter	Review question	Outcomes
		<ul style="list-style-type: none"> <li>• Weight loss</li> <li>• Liver function tests</li> <li>• Adverse events</li> </ul>
14	Should people with NAFLD restrict their consumption of alcohol to below national recommended levels?	<ul style="list-style-type: none"> <li>• Progression of NAFLD as assessed by:               <ul style="list-style-type: none"> <li>○ Liver biopsy</li> <li>○ MRI or MRS</li> <li>○ Ultrasound (absence of steatosis only)</li> <li>○ The Enhanced Liver Fibrosis (ELF) score</li> <li>○ Transient elastography</li> <li>○ NAFLD fibrosis score</li> </ul> </li> </ul>
15	Should people with NAFLD restrict their consumption of fructose or sugar?	<p>Critical:</p> <ul style="list-style-type: none"> <li>• Progression of NAFLD as assessed by:               <ul style="list-style-type: none"> <li>○ Liver biopsy</li> <li>○ MRI/MRS</li> <li>○ Ultrasound (absence of steatosis only)</li> <li>○ The Enhanced Liver Fibrosis (ELF) score</li> <li>○ Transient elastography</li> <li>○ NAFLD fibrosis score</li> </ul> </li> </ul> <p>Important:</p> <ul style="list-style-type: none"> <li>• Liver function tests</li> <li>• Adverse events</li> </ul>
16	Should people with NAFLD modify their consumption of caffeine from coffee?	<p>Critical:</p> <ul style="list-style-type: none"> <li>• Progression of NAFLD as assessed by:               <ul style="list-style-type: none"> <li>○ Liver biopsy</li> <li>○ MRI/MRS</li> <li>○ Ultrasound (absence of steatosis only)</li> <li>○ The Enhanced Liver Fibrosis (ELF) score</li> <li>○ Transient elastography</li> <li>○ NAFLD fibrosis score</li> </ul> </li> <li>• Quality of life</li> <li>• Serious adverse events</li> </ul> <p>Important:</p> <ul style="list-style-type: none"> <li>• Liver function tests</li> <li>• Weight</li> </ul>
17	What is the clinical and cost-effectiveness of pharmacological interventions for adults, young people and children with NAFLD?	<p>Critical:</p> <ul style="list-style-type: none"> <li>• Progression of NAFLD as assessed by:               <ul style="list-style-type: none"> <li>○ Liver biopsy</li> <li>○ MRI or MRS</li> <li>○ Ultrasound (absence of steatosis only)</li> <li>○ The Enhanced Liver Fibrosis (ELF) score</li> <li>○ Transient elastography</li> <li>○ NAFLD fibrosis score</li> </ul> </li> <li>• Quality of life</li> <li>• Mortality</li> <li>• Serious adverse events</li> </ul>

Chapter	Review question	Outcomes
		Important: <ul style="list-style-type: none"> <li>• Liver function tests</li> <li>• Adverse events</li> </ul>

## 1 4.2 Searching for evidence

### 2 4.2.1 Clinical literature search

3 Systematic literature searches were undertaken to identify all published clinical evidence relevant to  
 4 the review questions. Searches were undertaken according to the parameters stipulated within the  
 5 NICE guidelines manual.<sup>125</sup> Databases were searched using relevant medical subject headings, free-  
 6 text terms and study-type filters where appropriate. Where possible, searches were restricted to  
 7 articles published in English. Studies published in languages other than English were not reviewed. All  
 8 searches were conducted in Medline, Embase, and The Cochrane Library. Additional subject specific  
 9 databases were used for some questions: AMED, and Cinahl for the exercise, lifestyle and diet  
 10 reviews, as well as PsycINFO for the lifestyle review. All searches were updated on 27 August 2015.  
 11 No papers published after this date were considered.

12 Search strategies were quality assured by cross-checking reference lists of highly relevant papers,  
 13 analysing search strategies in other systematic reviews, and asking GDG members to highlight any  
 14 additional studies. Searches were quality assured by a second information scientist before being run.  
 15 The questions, the study types applied, the databases searched and the years covered can be found  
 16 in Appendix G.

17 The titles and abstracts of records retrieved by the searches were sifted for relevance, with  
 18 potentially significant publications obtained in full text. These were assessed against the inclusion  
 19 criteria.

20 During the scoping stage, a search was conducted for guidelines and reports on the websites listed  
 21 below from organisations relevant to the topic.

- 22 • Guidelines International Network database ([www.g-i-n.net](http://www.g-i-n.net))
- 23 • National Guideline Clearing House ([www.guideline.gov](http://www.guideline.gov))
- 24 • National Institute for Health and Care Excellence (NICE) ([www.nice.org.uk](http://www.nice.org.uk))
- 25 • National Institutes of Health Consensus Development Program ([consensus.nih.gov](http://consensus.nih.gov))
- 26 • NHS Evidence Search ([www.evidence.nhs.uk](http://www.evidence.nhs.uk)).

27 All references sent by stakeholders were considered. Searching for unpublished literature was not  
 28 undertaken. The NCGC and NICE do not have access to drug manufacturers' unpublished clinical trial  
 29 results, so the clinical evidence considered by the GDG for pharmaceutical interventions may be  
 30 different from that considered by the MHRA and European Medicines Agency for the purposes of  
 31 licensing and safety regulation.

### 32 4.2.2 Health economic literature search

33 Systematic literature searches were also undertaken to identify health economic evidence within  
 34 published literature relevant to the review questions. The evidence was identified by conducting a  
 35 broad search relating to non-alcoholic fatty liver disease in the NHS Economic Evaluation Database  
 36 (NHS EED), the Health Technology Assessment database (HTA) and the Health Economic Evaluations  
 37 Database (HEED) with no date restrictions (NHS EED ceased to be updated after March 2015; HEED  
 38 was used for searches up to 13 June 2014 but subsequently ceased to be available). Additionally, the  
 39 search was run on Medline and Embase using a health economic filter, from 1 January 2013, to

1 ensure recent publications that had not yet been indexed by the economic databases were  
2 identified. This was supplemented by an additional searches that looked for economic papers  
3 specifically relating to the modelling of liver disease in NHS EED, HTA and HEED with no date  
4 restrictions (NHS EED ceased to be updated after March 2015; HEED was used for searches up to 13  
5 June 2014, but subsequently ceased to be available) and additionally in Medline and Embase using a  
6 health economic filter, from 1 January 2013, to ensure no modelling studies were missed. Where  
7 possible, searches were restricted to articles published in English. Studies published in languages  
8 other than English were not reviewed.

9 The health economic search strategies are included in Appendix G. All searches were updated on  
10 27 August 2015. No papers published after this date were considered.

### 11 **4.3 Identifying and analysing evidence of effectiveness**

12 Research fellows conducted the tasks listed below, which are described in further detail in the rest of  
13 this section:

- 14 • Identified potentially relevant studies for each review question from the relevant search results  
15 by reviewing titles and abstracts. Full papers were then obtained.
- 16 • Reviewed full papers against pre-specified inclusion and exclusion criteria to identify studies that  
17 addressed the review question in the appropriate population, and reported on outcomes of  
18 interest (review protocols are included in Appendix C).
- 19 • Critically appraised relevant studies using the appropriate study design checklist as specified in  
20 the NICE guidelines manual.<sup>122,125</sup> Prognostic studies were critically appraised using NCGC  
21 checklists.
- 22 • Extracted key information about interventional study methods and results using 'Evidbase', NCGC's  
23 purpose-built software. Evidbase produces summary evidence tables, including critical appraisal  
24 ratings. Key information about non-interventional study methods and results was manually  
25 extracted onto standard evidence tables and critically appraised separately (evidence tables are  
26 included in Appendix H).
- 27 • Generated summaries of the evidence by outcome. Outcome data were combined, analysed and  
28 reported according to study design:
  - 29 o Randomised data were meta-analysed where appropriate and reported in GRADE profile  
30 tables.
  - 31 o Observational data were presented as a range of values in GRADE profile tables or meta-  
32 analysed if appropriate.
  - 33 o Prognostic data were meta-analysed where appropriate and reported in GRADE profile tables.
  - 34 o Diagnostic data studies were meta-analysed where appropriate or presented as a range of  
35 values in adapted GRADE profile tables
- 36 • A sample of a minimum of 10% of the abstract lists of the first sifts by new reviewers and those  
37 for complex review questions (for example, prognostic reviews) were double-sifted by a senior  
38 research fellow and any discrepancies were rectified. All of the evidence reviews were quality  
39 assured by a senior research fellow. This included checking:
  - 40 o papers were included or excluded appropriately
  - 41 o a sample of the data extractions
  - 42 o correct methods were used to synthesise data
  - 43 o a sample of the risk of bias assessments.

### 1 4.3.1 Inclusion and exclusion criteria

2 The inclusion and exclusion of studies was based on the criteria defined in the review protocols,  
3 which can be found in Appendix C. Excluded studies by review question (with the reasons for their  
4 exclusion) are listed in Appendix M. The GDG was consulted about any uncertainty regarding  
5 inclusion or exclusion.

6 The key population inclusion criterion was:

- 7 • Adults, children and young people with suspected or confirmed primary NAFLD.
- 8 • No subgroups of people have been identified as needing specific consideration.

9 The key population exclusion criterion was:

- 10 • People with secondary causes of fatty liver (for example, chronic hepatitis C infection, total  
11 parenteral nutrition treatment and drug-induced fatty liver).

12 Literature reviews, conference abstracts, posters, letters, editorials, comment articles, unpublished  
13 studies and studies not in English were excluded.

### 14 4.3.2 Type of studies

15 Randomised trials, non-randomised trials, and observational studies (including diagnostic or  
16 prognostic studies) were included in the evidence reviews as appropriate.

17 For most intervention reviews in this guideline, parallel randomised controlled trials (RCTs) were  
18 included because they are considered the most robust type of study design that could produce an  
19 unbiased estimate of the intervention effects. If non-randomised studies were appropriate for  
20 inclusion, for example, non-drug trials with no randomised evidence, the GDG identified a priori in  
21 the protocol the variables which must either be equivalent at baseline or that the analysis had to  
22 adjust for any baseline differences. If the study did not fulfil either criterion it was excluded. Please  
23 refer to Appendix C for full details on the study design of studies selected for each review question.

24 For diagnostic review questions, diagnostic RCTs, cross-sectional studies and retrospective studies  
25 were included. For prognostic review questions, prospective and retrospective cohort studies were  
26 included. Case-control studies were not included.

27 Qualitative research was not considered in this guideline as no review questions exploring outcomes  
28 that would require investigation of qualitative research were prioritised in the scope.

### 29 4.3.3 Methods of combining evidence

#### 30 4.3.3.1 Data synthesis for intervention reviews

31 Where possible, meta-analyses were conducted using Cochrane Review Manager (RevMan5)<sup>1</sup>  
32 software to combine the data given in all studies for each of the outcomes of interest for the review  
33 question.

34 Most analyses were stratified for age (under 18 years and 18 years or over), which meant that  
35 different studies with predominant age-groups in different age strata were not combined and  
36 analysed together. For some questions population was not stratified by age (diagnosis, assessment,  
37 extra-hepatic conditions, caffeine and the omega-3 section of the diet modification reviews) as the  
38 GDG felt that studies could be considered together in these instances and there was no clinical  
39 rationale for stratification.

1 The primary outcome for most of the reviews was progression of NAFLD. This could be as measured  
2 by a range of different techniques. For example:

- 3 • liver biopsy
- 4 • MRI or MRS
- 5 • ultrasound (presence or absence of steatosis only)
- 6 • the enhanced liver fibrosis (ELF) score
- 7 • transient elastography
- 8 • NAFLD fibrosis score.

9 The GDG felt that for liver biopsy progression measured using only the NAFLD activity score (NAS) by  
10 Brunt/Kleiner/NASH-CRN was acceptable and that progression of liver fat as measured by other  
11 methods such as ISHAK score would be excluded. It was acknowledged that papers could report  
12 progression of NAFLD by the means listed above as either dichotomous (for example, an  
13 improvement of 2 or more on the NAS) or continuous (mean and SD of NAFLD fibrosis score). With  
14 respect to ultrasound, the experience of the GDG was that whilst ultrasound is a useful tool for  
15 identifying whether there is steatosis of the liver or not, it is not an appropriate technique for  
16 quantifying the degree of fat within the liver because of wide inter-observer variability. Furthermore,  
17 the degree of hepatic steatosis cannot be interpreted as a marker of severity of NAFLD. As such, the  
18 GDG considered that measurement of the degree of steatosis on ultrasound should not be  
19 considered as a relevant outcome, and that the use of ultrasound should only be reported if it was  
20 used to indicate presence or absence of steatosis.

#### 43.3.1.1 *Analysis of different types of data*

##### 22 **Dichotomous outcomes**

23 Fixed-effects (Mantel-Haenszel) techniques (using an inverse variance method for pooling) were used  
24 to calculate risk ratios (relative risk) for the binary outcomes, which included:

- 25 • progression of NAFLD (author thresholds of improvement/no improvement) as assessed by:
  - 26 o liver biopsy
  - 27 o MRI or MRS
  - 28 o ultrasound (presence or absence of steatosis only)
  - 29 o the enhanced liver fibrosis (ELF) score
  - 30 o transient elastography
  - 31 o NAFLD fibrosis score
- 32 • serious adverse events
- 33 • weight loss
- 34 • liver blood tests (for example ALT levels, ALT/AST ratio)
- 35 • adverse events.

36 The absolute risk difference was also calculated using GRADEpro<sup>57</sup> software, using the median event  
37 rate in the control arm of the pooled results.

38 For binary variables where there were zero events in either arm or a less than 1% event rate, Peto  
39 odds ratios, rather than risk ratios were calculated. Peto odds ratios are more appropriate for data  
40 with a low number of events.

41 Where there was sufficient information provided, hazard ratios were calculated in preference for  
42 outcomes such as mortality where the time to the event occurring was important for decision-  
43 making.

## 1 **Continuous outcomes**

2 The continuous outcomes were analysed using an inverse variance method for pooling weighted  
3 mean differences. These outcomes included:

- 4 • progression of NAFLD as assessed by:
  - 5 o liver biopsy
  - 6 o MRI or MRS
  - 7 o the enhanced liver fibrosis (ELF) score
  - 8 o transient elastography
  - 9 o NAFLD fibrosis score
- 10 • health-related quality of life (HRQoL)
- 11 • weight loss
- 12 • liver blood tests (for example ALT levels, ALT/AST ratio).

13 Where the studies within a single meta-analysis had different scales of measurement, standardised  
14 mean differences were used (providing all studies reported either change from baseline or final  
15 values rather than a mixture of both), where each different measure in each study was 'normalised'  
16 to the standard deviation value pooled between the intervention and comparator groups in that  
17 same study.

18 The means and standard deviations of continuous outcomes are required for meta-analysis.  
19 However, in cases where standard deviations were not reported, the standard error was calculated if  
20 the p values or 95% confidence intervals (95% CI) were reported, and meta-analysis was undertaken  
21 with the mean and standard error using the generic inverse variance method in Cochrane Review  
22 Manager (RevMan5)<sup>1</sup> software. Where p values were reported as 'less than', a conservative approach  
23 was undertaken. For example, if a p value was reported as 'p ≤0.001', the calculations for standard  
24 deviations were based on a p value of 0.001. If these statistical measures were not available then the  
25 methods described in Section 16.1.3 of the Cochrane Handbook (version 5.1.0, updated March 2011)  
26 were applied.

### **13.3.1.2 Generic inverse variance**

28 If a study reported only the summary statistic and 95% CI the generic-inverse variance method was  
29 used to enter data into RevMan5.<sup>1</sup> If the control event rate was reported this was used to generate  
30 the absolute risk difference in GRADEpro.<sup>57</sup> If multivariate analysis was used to derive the summary  
31 statistic but no adjusted control event rate was reported no absolute risk difference was calculated.

### **13.3.1.3 Heterogeneity**

33 Statistical heterogeneity was assessed for each meta-analysis estimate by considering the chi-  
34 squared test for significance at p<0.1 or an I-squared (I<sup>2</sup>) inconsistency statistic (with an I-squared  
35 value of more than 50% indicating significant heterogeneity) as well as the distribution of effects.  
36 Where significant heterogeneity was present, predefined subgrouping of studies was carried out as  
37 per the review question protocols.

38 If the subgroup analysis resolved heterogeneity within all of the derived subgroups, then each of the  
39 derived subgroups were adopted as separate outcomes (providing at least 1 study remained in each  
40 subgroup. Assessments of potential differences in effect between subgroups were based on the chi-  
41 squared tests for heterogeneity statistics between subgroups. Any subgroup differences were  
42 interpreted with caution as separating the groups breaks the study randomisation and as such is  
43 subject to uncontrolled confounding.



1 If predefined strategies of subgrouping were unable to explain statistical heterogeneity within each  
2 derived subgroup, then a random effects (DerSimonian and Laird) model was employed to the entire  
3 group of studies in the meta-analysis. A random-effects model assumes a distribution of populations,  
4 rather than a single population. This leads to a widening of the confidence interval around the overall  
5 estimate, thus providing a more realistic interpretation of the true distribution of effects across more  
6 than 1 population. If, however, the GDG considered the heterogeneity was so large that meta-  
7 analysis was inappropriate, then the results were described narratively.

#### **8.3.3.2 Data synthesis for prognostic factor reviews**

9 Odds ratios (ORs), risk ratios (RRs), or hazard ratios (HRs), with their 95% CIs, for the effect of the  
10 pre-specified prognostic factors were extracted from the studies. Studies were only included if the  
11 confounders pre-specified by the GDG were either matched at baseline or were adjusted for in  
12 multivariate analysis.

13 Studies of lower risk of bias were preferred, taking into account the analysis and the study design. In  
14 particular, prospective cohort studies were preferred if they reported multivariable analyses that  
15 adjusted for key confounders identified by the GDG at the protocol stage for that outcome.

16 If more than 1 study covered the same combination of population, risk factor and outcome, and  
17 adjusted for the same key confounders, then meta-analysis was used to pool results. Meta-analysis  
18 was carried out using the generic inverse variance function on RevMan5<sup>1</sup> using fixed effects.  
19 Heterogeneity was assessed using the same criteria as for intervention studies, with an  $I^2$  of 50–74%  
20 representing serious inconsistency and an  $I^2$  of 75% or more representing very serious inconsistency.  
21 If serious or very serious heterogeneity existed, then subgrouping strategies were based on pre-  
22 specified subgrouping criteria as for interventional reviews. If subgrouping failed to explain  
23 heterogeneity, then the random-effects model was used. If subgrouping successfully explained  
24 heterogeneity then each of the subgroups was presented as a separate outcome (for example,  
25 mortality in people under 30 years and mortality in people 30 years and over) and a fixed-effects  
26 model was used.

27 Where evidence was not meta-analysed, because studies differed in population, outcome or risk  
28 factors, then no alternative pooling strategies were carried out, on the basis that such pooling would  
29 have little meaning. Results from single studies were presented.

#### **8.3.3.3 Data synthesis for prognostic monitoring review**

31 The monitoring review question (Chapter 8) was undertaken using a stepwise approach in agreement  
32 with the GDG. The information extracted from the papers included the number of patients with  
33 NAFLD, NAFL and NASH at initial biopsy, the average time between biopsies, and the numbers who  
34 had progressed, regressed or remained stable in fibrosis staging on the Brunt/CRN criteria. For  
35 papers with mixed NAFLD populations, the data are presented as a total and also separately for those  
36 with initial NASH and NAFL where possible. If the fibrosis progression rate was reported this was also  
37 included in the modified clinical evidence summary table (a calculation based on the difference  
38 between fibrosis stage at baseline and follow-up using the Brunt/CRN criteria, divided by the time in  
39 years between the 2 measurements). The GDG recognised that the fibrosis progression rate was  
40 useful in comparing the included studies as they each had very different average times between the  
41 biopsies. This additional information was available within 1 identified meta-analysis<sup>179</sup> as the authors  
42 had contacted the authors of primary studies for further information and had calculated fibrosis  
43 progression scores specifically for people within the studies who started with no fibrosis at baseline.  
44 After discussion with the GDG these summary statistics were included in the evidence table. The  
45 mean fibrosis progression rate for the studies where it was possible to extract was calculated for

1 NAFLD, NAFL and NASH populations and meta-analysed using the generic inverse variance method  
2 described in section 4.3.3.1.2.

3 The GDG was also interested in which population required more intensive monitoring. Clinical  
4 evidence was extracted from studies that listed multivariate analysis on factors associated with  
5 fibrosis progression. Following discussion it was felt most useful to present these grouped into  
6 factors from initial biopsy and at follow-up. These were presented in modified GRADE tables with  
7 quality assessments and forest plots. The GDG felt that the forest plots axis should be labelled so that  
8 the point estimate reflected those with the identified risk factor, rather than favouring those  
9 without, in order to ease understanding.

#### 10.3.3.4 Data synthesis for diagnostic test accuracy reviews

11 For diagnostic test accuracy studies, a positive result on the index test was found if the patient had  
12 values of the measured quantity above or below a threshold value, and different thresholds could be  
13 used. Few of the diagnostic tests listed in the review protocols had widely acknowledged or  
14 commonly pre-specified thresholds, therefore results for all thresholds used were reported and the  
15 GDG agreed groups of threshold ranges to aid with presentation of results. Diagnostic test accuracy  
16 measures used in the analysis were: area under the receiver operating characteristics (ROC) curve  
17 (AUC), and, for different thresholds (if appropriate), sensitivity and specificity. The threshold of a  
18 diagnostic test is defined as the value at which the test can best differentiate between those with  
19 and without the target condition. In practice this varies amongst studies. If a test has a high  
20 sensitivity then very few people with the condition will be missed (few false negatives). For example,  
21 a test with a sensitivity of 97% will only miss 3% of people with the condition. Conversely, if a test has  
22 a high specificity then few people without the condition would be incorrectly diagnosed (few false  
23 positives). For example, a test with a specificity of 97% will only incorrectly diagnose 3% of people  
24 who do not have the condition as positive. For this guideline, sensitivity was considered more  
25 important than specificity. A high sensitivity (true positives) of a test can pick up the majority of the  
26 correct cases with NAFLD, NASH or fibrosis who may benefit from treatment (non-pharmacological  
27 or pharmacological) and on-going monitoring; conversely, a high specificity (true negatives) can  
28 correctly exclude people without NAFLD, NASH or fibrosis who would not require management or  
29 monitoring. Coupled forest plots of sensitivity and specificity with their 95% CIs across studies (at  
30 various thresholds) were produced for each test, using RevMan5.<sup>1</sup> In order to do this, 2x2 tables (the  
31 number of true positives, false positives, true negatives and false negatives) were directly taken from  
32 the study if given, or else were derived from raw data or calculated from the set of test accuracy  
33 statistics.

34 Diagnostic meta-analysis was conducted where appropriate, that is, when 3 or more studies were  
35 available per threshold. Test accuracy for the studies was pooled using the bivariate method for the  
36 direct estimation of summary sensitivity and specificity using a random-effects approach in WinBUGS  
37 software.<sup>2</sup> See Appendix L for further details. The advantage of this approach is that it produces  
38 summary estimates of sensitivity and specificity that account for the correlation between the 2  
39 statistics. Other advantages of this method have been described elsewhere.<sup>158,202,203</sup> The bivariate  
40 method uses logistic regression on the true positives, true negatives, false positives and false  
41 negatives reported in the studies. Overall sensitivity and specificity and confidence regions were  
42 plotted (using methods outlined by Novielli 2010<sup>133</sup>). Pooled sensitivity and specificity and their 95%  
43 CIs were reported in the clinical evidence summary tables. For scores with fewer than 3 studies,  
44 individual studies' sensitivity and the paired specificity were reported where possible. If an even  
45 number of studies were reported the results of the study with the lower sensitivity value of the 2  
46 middle studies was reported.

47 Heterogeneity or inconsistency amongst studies was visually inspected in the coupled forest plots  
48 and pooled diagnostic meta-analysis plots.

- 1 Area under the ROC curve (AUC) data for each study were also plotted on a graph, for each  
 2 diagnostic test. The AUC describes the overall diagnostic accuracy across the full range of thresholds.  
 3 The following criteria were used for evaluating AUCs:
- 4 •  $\leq 0.50$ : worse than chance
  - 5 • 0.50–0.60: very poor
  - 6 • 0.61–0.70: poor
  - 7 • 0.71–0.80: moderate
  - 8 • 0.81–0.92: good
  - 9 • 0.91–1.00: excellent or perfect test.
- 10 Heterogeneity or inconsistency amongst studies was visually inspected.

#### 11 4.3.4 Appraising the quality of evidence by outcomes

##### 12 4.3.4.1 Interventional studies

13 The evidence for outcomes from the included RCTs and, where appropriate, observational studies  
 14 were evaluated and presented using an adaptation of the ‘Grading of Recommendations Assessment,  
 15 Development and Evaluation (GRADE) toolbox’ developed by the international GRADE working group  
 16 (<http://www.gradeworkinggroup.org/>). The software (GRADEpro<sup>57</sup>) developed by the GRADE working  
 17 group was used to assess the quality of each outcome, taking into account individual study quality  
 18 and the meta-analysis results.

19 Each outcome was first examined for each of the quality elements listed and defined in Table 2.

20 **Table 2: Description of quality elements in GRADE for intervention studies**

Quality element	Description
Risk of bias	Limitations in the study design and implementation may bias the estimates of the treatment effect. Major limitations in studies decrease the confidence in the estimate of the effect. Examples of such limitations are selection bias (often due to poor allocation concealment), performance and detection bias (often due to a lack of blinding of the patient, healthcare professional or assessor) and attrition bias (due to missing data causing systematic bias in the analysis).
Indirectness	Indirectness refers to differences in study population, intervention, comparator and outcomes between the available evidence and the review question.
Inconsistency	Inconsistency refers to an unexplained heterogeneity of effect estimates between studies in the same meta-analysis.
Imprecision	Results are imprecise when studies include relatively few patients and few events (or highly variable measures) and thus have wide confidence intervals around the estimate of the effect relative to clinically important thresholds. 95% confidence intervals denote the possible range of locations of the true population effect at a 95% probability, and so wide confidence intervals may denote a result that is consistent with conflicting interpretations (for example a result may be consistent with both clinical benefit AND clinical harm) and thus be imprecise.
Publication bias	Publication bias is a systematic underestimate or overestimate of the underlying beneficial or harmful effect due to the selective publication of studies. A closely related phenomenon is where some papers fail to report an outcome that is inconclusive, thus leading to an overestimate of the effectiveness of that outcome.
Other issues	Sometimes randomisation may not adequately lead to group equivalence of confounders, and if so this may lead to bias, which should be taken into account. Potential conflicts of interest, often caused by excessive pharmaceutical company

Quality element	Description
	involvement in the publication of a study, should also be noted.

1 Details of how the 4 main quality elements (risk of bias, indirectness, inconsistency and imprecision)  
 2 were appraised for each outcome are given below. Publication or other bias was only taken into  
 3 consideration in the quality assessment if it was apparent.

#### 4B.4.1.1 Risk of bias

5 The main domains of bias for RCTs are listed in Table 3. Each outcome had its risk of bias assessed  
 6 within each study first. For each study, if there were no risks of bias in any domain, the risk of bias  
 7 was given a rating of 0. If there was risk of bias in just 1 domain, the risk of bias was given a ‘serious’  
 8 rating of –1, but if there was risk of bias in 2 or more domains the risk of bias was given a ‘very  
 9 serious’ rating of –2. A weighted average score was then calculated across all studies contributing to  
 10 the outcome, by taking into account the weighting of studies according to study precision. For  
 11 example if the most precise studies tended to each have a score of –1 for that outcome, the overall  
 12 score for that outcome would tend towards –1.

13 **Table 3: Principle domains of bias in randomised controlled trials**

Limitation	Explanation
Selection bias (sequence generation and allocation concealment)	If those enrolling patients are aware of the group to which the next enrolled patient will be allocated, either because of a non-random sequence that is predictable, or because a truly random sequence was not concealed from the researcher, this may translate into systematic selection bias. This may occur if the researcher chooses not to recruit a participant into that specific group because of: <ul style="list-style-type: none"> <li>• knowledge of that participant’s likely prognostic characteristics, and</li> <li>• a desire for one group to do better than the other.</li> </ul>
Performance and detection bias (lack of blinding of patients and healthcare professionals)	Patients, caregivers, those adjudicating or recording outcomes, and data analysts should not be aware of the arm to which patients are allocated. Knowledge of the group can influence: <ul style="list-style-type: none"> <li>• the experience of the placebo effect</li> <li>• performance in outcome measures</li> <li>• the level of care and attention received, and</li> <li>• the methods of measurement or analysis</li> </ul> all of which can contribute to systematic bias.
Attrition bias	Attrition bias results from an unaccounted for loss of data beyond a certain level (a differential of 10% between groups). Loss of data can occur when participants are compulsorily withdrawn from a group by the researchers (for example, when a per-protocol approach is used) or when participants do not attend assessment sessions. If the missing data are likely to be different from the data of those remaining in the groups, and there is a differential rate of such missing data from groups, systematic attrition bias may result.
Selective outcome reporting	Reporting of some outcomes and not others on the basis of the results can also lead to bias, as this may distort the overall impression of efficacy.
Other limitations	For example: <ul style="list-style-type: none"> <li>• Stopping early for benefit observed in randomised trials, in particular in the absence of adequate stopping rules.</li> <li>• Use of unvalidated patient-reported outcome measures.</li> <li>• Lack of washout periods to avoid carry-over effects in crossover trials.</li> <li>• Recruitment bias in cluster-randomised trials.</li> </ul>

**4.1.1.2 Indirectness**

2 Indirectness refers to the extent to which the populations, interventions, comparisons and outcome  
3 measures are dissimilar to those defined in the inclusion criteria for the reviews. Indirectness is  
4 important when these differences are expected to contribute to a difference in effect size, or may  
5 affect the balance of harms and benefits considered for an intervention. As for the risk of bias, each  
6 outcome had its indirectness assessed within each study first. For each study, if there were no  
7 sources of indirectness, indirectness was given a rating of 0. If there was indirectness in just 1 source  
8 (for example in terms of population), indirectness was given a 'serious' rating of -1, but if there was  
9 indirectness in 2 or more sources (for example, in terms of population and treatment) the  
10 indirectness was given a 'very serious' rating of -2. A weighted average score was then calculated  
11 across all studies contributing to the outcome by taking into account study precision. For example, if  
12 the most precise studies tended to have an indirectness score of -1 each for that outcome, the  
13 overall score for that outcome would tend towards -1.

**4.1.1.3 Inconsistency**

15 Inconsistency refers to an unexplained heterogeneity of results for an outcome across different  
16 studies. When estimates of the treatment effect across studies differ widely, this suggests true  
17 differences in the underlying treatment effect, which may be due to differences in populations,  
18 settings or doses. When heterogeneity existed within an outcome (chi-squared  $p < 0.1$ , or  $I^2 > 50\%$ ), but  
19 no plausible explanation could be found, the quality of evidence for that outcome was downgraded.  
20 Inconsistency for that outcome was given a 'serious' score of -1 if the  $I^2$  was 50–74%, and a 'very  
21 serious' score of -2 if the  $I^2$  was 75% or more.

22 If inconsistency could be explained based on pre-specified subgroup analysis (that is, each subgroup  
23 had an  $I^2 < 50\%$ ), the GDG took this into account and considered whether to make separate  
24 recommendations on new outcomes based on the subgroups defined by the assumed explanatory  
25 factors. In such a situation the quality of evidence was not downgraded for those emergent  
26 outcomes.

27 Since the inconsistency score was based on the meta-analysis results, the score represented the  
28 whole outcome and so weighted averaging across studies was not necessary.

**4.1.1.4 Imprecision**

30 The criteria applied for imprecision were based on the 95% CIs for the pooled estimate of effect, and  
31 the minimal important differences (MID) for the outcome. The MIDs are the threshold for  
32 appreciable benefits and harms, separated by a zone either side of the line of no effect where there  
33 is assumed to be no clinically important effect. If either end of the 95% CI of the overall estimate of  
34 effect crossed 1 of the MID lines, imprecision was regarded as serious and a 'serious' score of -1 was  
35 given. This was because the overall result, as represented by the span of the confidence interval, was  
36 consistent with 2 interpretations as defined by the MID (for example, both no clinically important  
37 effect and clinical benefit were possible interpretations). If both MID lines were crossed by either or  
38 both ends of the 95% CI then imprecision was regarded as very serious and a 'very serious' score of  
39 -2 was given. This was because the overall result was consistent with all 3 interpretations defined by  
40 the MID (no clinically important effect, clinical benefit and clinical harm). This is illustrated in Figure  
41 2. As for inconsistency, since the imprecision score was based on the meta-analysis results, the score  
42 represented the whole outcome and so weighted averaging across studies was not necessary.

43 The position of the MID lines is ideally determined by values reported in the literature. 'Anchor-  
44 based' methods aim to establish clinically meaningful changes in a continuous outcome variable by  
45 relating or 'anchoring' them to patient-centred measures of clinical effectiveness that could be  
46 regarded as gold standards with a high level of face validity. For example, a MID for an outcome

Methods

1 could be defined by the minimum amount of change in that outcome necessary to make patients feel  
2 their quality of life had 'significantly improved'. MIDs in the literature may also be based on expert  
3 clinician or consensus opinion concerning the minimum amount of change in a variable deemed to  
4 affect quality of life or health. For binary variables, any MIDs reported in the literature will inevitably  
5 be based on expert consensus, as such MIDs relate to all-or-nothing population effects rather than  
6 measurable effects on an individual, and so are not amenable to patient-centred 'anchor' methods.


7 In the absence of values identified in the literature, the alternative approach to deciding on MID  
8 levels is the 'default' method, as follows:

- 9 • For categorical outcomes the MIDs were taken to be RRs of 0.75 and 1.25. For 'positive' outcomes  
10 such as 'patient satisfaction', the RR of 0.75 is taken as the line denoting the boundary between  
11 no clinically important effect and a clinically significant harm, whilst the RR of 1.25 is taken as the  
12 line denoting the boundary between no clinically important effect and a clinically significant  
13 benefit. For 'negative' outcomes such as 'bleeding', the opposite occurs, so the RR of 0.75 is taken  
14 as the line denoting the boundary between no clinically important effect and a clinically  
15 significant benefit, whilst the RR of 1.25 is taken as the line denoting the boundary between no  
16 clinically important effect and a clinically significant harm.
- 17 • For continuous outcome variables the MID was taken as half the median baseline standard  
18 deviation of that variable, across all studies in the meta-analysis. Hence the MID denoting the  
19 minimum clinically significant benefit was positive for a 'positive' outcome (for example, a quality  
20 of life measure where a higher score denotes better health), and negative for a 'negative'  
21 outcome (for example, a visual analogue scale [VAS] pain score). Clinically significant harms will be  
22 the converse of these. If baseline values are unavailable, then half the median comparator group  
23 standard deviation of that variable will be taken as the MID.
- 24 • If standardised mean differences have been used, then the MID will be set at the absolute value  
25 of +0.5. This follows because standardised mean differences are mean differences normalised to  
26 the pooled standard deviation of the 2 groups, and are thus effectively expressed in units of  
27 'numbers of standard deviations'. The 0.5 MID value in this context therefore indicates half a  
28 standard deviation, the same definition of MID as used for non-standardised mean differences.

29 The default MID value was subject to amendment after discussion with the GDG. If the GDG decided  
30 that the MID level should be altered, after consideration of absolute as well as relative effects, this  
31 was allowed, provided that any such decision was not influenced by any bias towards making  
32 stronger or weaker recommendations for specific outcomes.

33 For this guideline, no appropriate MIDs for continuous or dichotomous outcomes were found in the  
34 literature, and so the default method was adopted for imprecision and the clinical importance of  
35 each effect size was discussed with the GDG.

**Figure 2:** Illustration of precise and imprecise outcomes based on the 95% CI of dichotomous outcomes in a forest plot (Note that all 3 results would be pooled estimates, and would not, in practice, be placed on the same forest plot)



#### 4.3.4.1.5 Overall grading of the quality of clinical evidence

2 Once an outcome had been appraised for the main quality elements, as above, an overall quality  
 3 grade was calculated for that outcome. The scores (0, -1 or -2) from each of the main quality  
 4 elements were summed to give a score that could be anything from 0 (the best possible) to -8 (the  
 5 worst possible). However scores were capped at -3. This final score was then applied to the starting  
 6 grade that had originally been applied to the outcome by default, based on study design. All RCTs  
 7 started as High and the overall quality became Moderate, Low or Very Low if the overall score was  
 8 -1, -2 or -3 points respectively. The significance of these overall ratings is explained in Table 4. The  
 9 reasons for downgrading in each case were specified in the footnotes of the GRADE tables.

10 Observational interventional studies started at Low, and so a score of -1 would be enough to take  
 11 the grade to the lowest level of Very Low. Observational studies could, however, be upgraded if  
 12 there were all of: a large magnitude of effect, a dose-response gradient, and if all plausible  
 13 confounding would reduce the demonstrated effect.

14 **Table 4: Overall quality of outcome evidence in GRADE**

Level	Description
High	Further research is very unlikely to change our confidence in the estimate of effect
Moderate	Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate
Low	Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate
Very low	Any estimate of effect is very uncertain

**14.3.4.2 Prognostic reviews**

2 The quality of evidence for prognostic studies was evaluated according to the criteria given in Table  
 3 5. If data were meta-analysed, the quality for pooled studies was presented. If the data were not  
 4 pooled, then a quality rating was presented for each study.

5 **Table 5: Description of quality elements for prospective studies**

Quality element	Description of cases where the quality measure would be downgraded
Study design	Case-control studies rather than prospective cohort studies
Patient recruitment	If potential for selection bias
Validity of risk factor measure(s)	If non-validated and no reasonable face validity
Validity of outcome measure	If non-validated and no reasonable face validity
Blinding	If assessors of outcome not blinded to risk factor measurement (or vice versa)
Adequate duration of follow-up (or retrospective duration)	If follow-up (or retrospective) period inadequate to allow events to occur, or retrospective period so short that causality is in doubt because the outcome may have preceded the risk factor
Confounder consideration	If there is a lack of consideration of all reasonable confounders in a multivariable analysis
Attrition	If attrition is too high and there is no attempt to adjust for this
Directness	If the population, risk factors or outcome differ from that in the review question

**43.4.2.1 Inconsistency**

7 Inconsistency was assessed as for intervention studies.

**43.4.2.2 Imprecision**

9 In meta-analysed outcomes, or for non-pooled outcomes, the position of the 95% CIs in relation to  
 10 the null line determined the existence of imprecision. If the 95% CI did not cross the null line then no  
 11 serious imprecision was recorded. If the 95% CI crossed the null line then serious imprecision was  
 12 recorded.

**43.4.2.3 Overall grading**

14 Quality rating started at high for prospective studies, and each major limitation brought the rating  
 15 down by 1 increment to a minimum grade of Very Low, as explained for interventional reviews. For  
 16 prognostic reviews prospective cohort studies with a multivariate analysis are regarded as the gold  
 17 standard because RCTs are usually inappropriate for these types of review for ethical or pragmatic  
 18 reasons. Furthermore, if the study is looking at more than 1 risk factor of interest then randomisation  
 19 would be inappropriate as it can only be applied to 1 of the risk factors.

**20.3.4.3 Diagnostic reviews**

21 Risk of bias and indirectness of evidence for diagnostic data were evaluated by study using the  
 22 Quality Assessment of Diagnostic Accuracy Studies version 2 (QUADAS-2) checklists (see Appendix H  
 23 in the NICE guidelines manual 2014<sup>122</sup>). Risk of bias and applicability in primary diagnostic accuracy  
 24 studies in QUADAS-2 consists of 4 domains (see Figure 3):

- 25 • patient selection
- 26 • index test
- 27 • reference standard



- 1 • flow and timing.

2 **Figure 3: Summary of QUADAS-2 with list of signalling, risk of bias and applicability questions.**

Domain	Patient selection	Index test	Reference standard	Flow and timing
Description	Describe methods of patient selection. Describe included patients (prior testing, presentation, intended use of index test and setting)	Describe the index test and how it was conducted and interpreted	Describe the reference standard and how it was conducted and interpreted	Describe any patients who did not receive the index test(s) and/or reference standard or who were excluded from the 2x2 table (refer to flow diagram). Describe the time interval and any interventions between index test(s) and reference standard
Signalling questions (yes/no/unclear)	Was a consecutive or random sample of patients enrolled?	Were the index test results interpreted without knowledge of the results of the reference standard?	Is the reference standard likely to correctly classify the target condition?	Was there an appropriate interval between index test(s) and reference standard?
	Was a case-control design avoided?	If a threshold was used, was it pre-specified?	Were the reference standard results interpreted without knowledge of the results of the index test?	Did all patients receive a reference standard?
	Did the study avoid inappropriate exclusions?			Did all patients receive the same reference standard?
				Were all patients included in the analysis?
Risk of bias; (high/low/unclear)	Could the selection of patients have introduced bias?	Could the conduct or interpretation of the index test have introduced bias?	Could the reference standard, its conduct or its interpretation have introduced bias?	Could the patient flow have introduced bias?
Concerns regarding applicability (high/low/unclear)	Are there concerns that the included patients do not match the review question?	Are there concerns that the index test, its conduct, or interpretation differ from the review question?	Are there concerns that the target condition as defined by the reference standard does not match the review question?	

3

**4B.4.3.1 Inconsistency**

5 Inconsistency refers to an unexplained heterogeneity of results for an outcome across different  
6 studies. Inconsistency was assessed by inspection of the sensitivity value (based on the primary  
7 measure) using the point estimates and 95% CIs of the individual studies on the forest plots.  
8 Particular attention was placed on values above or below 50% (diagnosis based on chance alone) and  
9 the threshold set by the GDG (the threshold above which would be acceptable to recommend a test)  
10 of 90%. The evidence was downgraded by 1 increment if the individual studies varied across 2 areas  
11 (50–90% and 90–100%) and by 2 increments if the individual studies varied across 3 areas (0–50%,  
12 50–90% and 90–100%).

#### 4.3.3.2 Imprecision

2 The judgement of precision was based on visual inspection of the confidence region around the  
3 summary sensitivity and specificity point from the diagnostic meta-analysis, if a diagnostic meta-  
4 analysis was conducted. Where a diagnostic meta-analysis was not conducted imprecision was  
5 assessed according to the range of point estimates or, if only 1 study contributed to the evidence,  
6 the confidence interval around the single study. As a rule of thumb (after discussion with the GDG) a  
7 variation of 0–20% was considered precise, 20–40% serious imprecisions, and >40% very serious  
8 imprecision. Imprecision was assessed on the primary outcome measure for decision-making  
9 (sensitivity).

#### 4.3.3 Overall grading

11 Quality rating started at High for prospective and retrospective cross sectional studies, and each  
12 major limitation (risk of bias, indirectness, inconsistency and imprecision) brought the rating down by  
13 1 increment to a minimum grade of Very Low, as explained for interventional studies.

#### 4.3.5 Assessing clinical importance

15 The GDG assessed the evidence by outcome in order to determine if there was, or potentially was, a  
16 clinically important benefit, a clinically important harm or no clinically important difference between  
17 interventions. To facilitate this, binary outcomes were converted into absolute risk differences  
18 (ARDs) using GRADEpro<sup>57</sup> software: the median control group risk across studies was used to  
19 calculate the ARD and its 95% CI from the pooled risk ratio.

20 The assessment of clinical benefit, harm, or no benefit or harm was based on the point estimate of  
21 absolute effect for intervention studies, which was standardised across the reviews. The GDG  
22 considered for most of the outcomes in the intervention reviews that if at least 100 more  
23 participants per 1000 (10%) achieved the outcome of interest in the intervention group compared to  
24 the comparison group for a positive outcome then this intervention would be considered beneficial.  
25 The same point estimate but in the opposite direction applied for a negative outcome. For the critical  
26 outcome of mortality any reduction represented a clinical benefit. For adverse events 50 events or  
27 more per 1000 represented clinical harm. For continuous outcomes if the mean difference was  
28 greater than the minimally important difference (MID) then this represented a clinical benefit or harm.  
29 For outcomes such as mortality any reduction or increase was considered to be clinically important.

30 This assessment was carried out by the GDG for each critical outcome, and an evidence summary  
31 table was produced to compile the GDG's assessments of clinical importance per outcome, alongside  
32 the evidence quality and the uncertainty in the effect estimate (imprecision).

#### 4.3.6 Clinical evidence statements

34 Clinical evidence statements are summary statements that are included in each review chapter, and  
35 which summarise the key features of the clinical effectiveness evidence presented. The wording of  
36 the evidence statements reflects the certainty or uncertainty in the estimate of effect. The evidence  
37 statements are presented by outcome and encompass the following key features of the evidence:

- 38 • The number of studies and the number of participants for a particular outcome.
- 39 • An indication of the direction of clinical importance (if 1 treatment is beneficial or harmful  
40 compared to the other, or whether there is no difference between the 2 tested treatments).
- 41 • A description of the overall quality of the evidence (GRADE overall quality).

## 1 4.4 Identifying and analysing evidence of cost-effectiveness

2 The GDG is required to make decisions based on the best available evidence of both clinical  
3 effectiveness and cost-effectiveness. Guideline recommendations should be based on the expected  
4 costs of the different options in relation to their expected health benefits (that is, their ‘cost-  
5 effectiveness’) rather than the total implementation cost.<sup>122</sup> Thus, if the evidence suggests that a  
6 strategy provides significant health benefits at an acceptable cost per patient treated, it should be  
7 recommended even if it would be expensive to implement across the whole population.

8 Health economic evidence was sought relating to the key clinical issues being addressed in the  
9 guideline. Health economists:

- 10 • Undertook a systematic review of the published economic literature.
- 11 • Undertook new cost-effectiveness analysis in priority areas.

### 12 4.4.1 Literature review

13 The health economists:

- 14 • Identified potentially relevant studies for each review question from the health economic search  
15 results by reviewing titles and abstracts. Full papers were then obtained.
- 16 • Reviewed full papers against pre-specified inclusion and exclusion criteria to identify relevant  
17 studies (see below for details).
- 18 • Critically appraised relevant studies using economic evaluations checklists as specified in the NICE  
19 guidelines manual.<sup>122,125</sup>
- 20 • Extracted key information about the studies’ methods and results into economic evidence tables  
21 (included in Appendix I).
- 22 • Generated summaries of the evidence in NICE economic evidence profile tables (included in the  
23 relevant chapter for each review question) – see below for details.

#### 24 4.4.1.1 Inclusion and exclusion criteria

25 Full economic evaluations (studies comparing costs and health consequences of alternative courses  
26 of action: cost-utility, cost-effectiveness, cost-benefit and cost-consequences analyses) and  
27 comparative costing studies that addressed the review question in the relevant population were  
28 considered potentially includable as economic evidence.

29 Studies that only reported cost per hospital (not per patient), or only reported average cost-  
30 effectiveness without disaggregated costs and effects were excluded. Literature reviews, abstracts,  
31 posters, letters, editorials, comment articles, unpublished studies and studies not in English were  
32 excluded. Studies published before 1999 and studies from non-OECD countries or the USA were also  
33 excluded, on the basis that the applicability of such studies to the present UK NHS context is likely to  
34 be too low for them to be helpful for decision-making.

35 Remaining health economic studies were prioritised for inclusion based on their relative applicability  
36 to the development of this guideline and the study limitations. For example, if a high quality, directly  
37 applicable UK analysis was available, then other less relevant studies may not have been included.  
38 However, in this guideline, no economic studies were excluded on the basis that more applicable  
39 evidence was available.

40 For more details about the assessment of applicability and methodological quality see Table 6 below  
41 and the economic evaluation checklist (Appendix G of the 2012 NICE guidelines manual<sup>125</sup>) and the  
42 health economics review protocol in Appendix D.

1 When no relevant health economic studies were found from the economic literature review, relevant  
 2 UK NHS unit costs related to the compared interventions were presented to the GDG to inform the  
 3 possible economic implications of the recommendations.

#### 4.4.1.2 NICE economic evidence profiles

5 NICE economic evidence profile tables were used to summarise cost and cost-effectiveness estimates  
 6 for the included health economic studies in each review chapter. The economic evidence profile  
 7 shows an assessment of applicability and methodological quality for each economic study, with  
 8 footnotes indicating the reasons for the assessment. These assessments were made by the health  
 9 economist using the economic evaluation checklist from the NICE guidelines manual.<sup>125</sup> It also shows  
 10 the incremental costs, incremental effects (for example, quality-adjusted life years [QALYs]) and  
 11 incremental cost-effectiveness ratio (ICER) for the base case analysis in the study, as well as  
 12 information about the assessment of uncertainty in the analysis. See Table 6 for more details.

13 When a non-UK study was included in the profile, the results were converted into pounds sterling  
 14 using the appropriate purchasing power parity.<sup>134</sup>

15 **Table 6: Content of NICE economic evidence profile**

Item	Description
Study	Surname of first author, date of study publication and country perspective with a reference to full information on the study.
Applicability	An assessment of applicability of the study to this guideline, the current NHS situation and NICE decision-making. <sup>(a)</sup> <ul style="list-style-type: none"> <li>• Directly applicable – the study meets all applicability criteria, or fails to meet 1 or more applicability criteria but this is unlikely to change the conclusions about cost-effectiveness.</li> <li>• Partially applicable – the study fails to meet 1 or more applicability criteria, and this could change the conclusions about cost-effectiveness.</li> <li>• Not applicable – the study fails to meet 1 or more of the applicability criteria, and this is likely to change the conclusions about cost-effectiveness. Such studies would usually be excluded from the review.</li> </ul>
Limitations	An assessment of methodological quality of the study: <sup>(a)</sup> <ul style="list-style-type: none"> <li>• Minor limitations – the study meets all quality criteria, or fails to meet 1 or more quality criteria, but this is unlikely to change the conclusions about cost-effectiveness.</li> <li>• Potentially serious limitations – the study fails to meet 1 or more quality criteria, and this could change the conclusions about cost-effectiveness.</li> <li>• Very serious limitations – the study fails to meet 1 or more quality criteria, and this is highly likely to change the conclusions about cost-effectiveness. Such studies would usually be excluded from the review.</li> </ul>
Other comments	Information about the design of the study and particular issues that should be considered when interpreting it.
Incremental cost	The mean cost associated with one strategy minus the mean cost of a comparator strategy.
Incremental effects	The mean QALYs (or other selected measure of health outcome) associated with one strategy minus the mean QALYs of a comparator strategy.
Cost-effectiveness	Incremental cost-effectiveness ratio (ICER): the incremental cost divided by the incremental effects (usually in £ per QALY gained).
Uncertainty	A summary of the extent of uncertainty about the ICER reflecting the results of deterministic or probabilistic sensitivity analyses, or stochastic analyses of trial data, as appropriate.

1 (a) *Applicability and limitations were assessed using the economic evaluation checklist in Appendix G of the 2012 NICE*  
2 *guidelines manual*<sup>125</sup>

### 3 4.4.2 Undertaking new health economic analysis

4 As well as reviewing the published health economic literature for each review question, as described  
5 above, new health economic analysis was undertaken by the health economist in selected areas.  
6 Priority areas for new analysis were agreed by the GDG after formation of the review questions and  
7 consideration of the existing health economic evidence.

8 The GDG identified the highest priority areas for original health economic modelling as:

- 9 • risk factors for NAFLD or severe NAFLD
- 10 • the appropriate investigations for diagnosing NAFLD
- 11 • the appropriate investigations for identifying the stage of NAFLD
- 12 • how often people with NAFLD or NASH should be monitored.

13 This was due to the number of people affected by these questions and the current uncertainty as to  
14 what the most cost-effective solutions would be, due to the lack of published economic models  
15 encompassing the whole pathway of liver disease from early NAFLD to end-stage liver disease. New  
16 work was therefore conducted, which entailed the development of the NCGC Liver Disease Pathway  
17 Model to address all of the questions prioritised for this guideline (as well as to address additional  
18 questions raised in the Cirrhosis NICE guideline).

19 The following general principles were adhered to in developing the cost-effectiveness analysis:

- 20 • Methods were consistent with the NICE reference case for interventions with health outcomes in  
21 NHS settings.<sup>122,126</sup>
- 22 • The GDG was involved in the design of the model, selection of inputs and interpretation of the  
23 results.
- 24 • Model inputs were based on the systematic review of the clinical literature supplemented with  
25 other published data sources where possible.
- 26 • When published data were not available GDG expert opinion was used to populate the model.
- 27 • Model inputs and assumptions were reported fully and transparently.
- 28 • The results were subject to sensitivity analysis and limitations were discussed.
- 29 • The model was peer-reviewed by another health economist at the NCGC.

30 Full methods for the cost-effectiveness analysis are described in Appendix N.

### 31 4.4.3 Cost-effectiveness criteria

32 NICE's report 'Social value judgements: principles for the development of NICE guidance' sets out the  
33 principles that GDGs should consider when judging whether an intervention offers good value for  
34 money.<sup>124</sup> In general, an intervention was considered to be cost-effective (given that the estimate  
35 was considered plausible) if either of the following criteria applied:

- 36 • the intervention dominated other relevant strategies (that is, it was both less costly in terms of  
37 resource use and more clinically effective compared with all the other relevant alternative  
38 strategies), or
- 39 • the intervention cost less than £20,000 per QALY gained compared with the next best strategy.

40 If the GDG recommended an intervention that was estimated to cost more than £20,000 per QALY  
41 gained, or did not recommend 1 that was estimated to cost less than £20,000 per QALY gained, the  
42 reasons for this decision are discussed explicitly in the 'Recommendations and link to evidence'

1 section of the relevant chapter, with reference to issues regarding the plausibility of the estimate or  
 2 to the factors set out in ‘Social value judgements: principles for the development of NICE  
 3 guidance’.<sup>124</sup>

4 When QALYs or life years gained are not used in the analysis, results are difficult to interpret unless 1  
 5 strategy dominates the others with respect to every relevant health outcome and cost.

#### 6 **4.4.4 In the absence of economic evidence**

7 When no relevant published health economic studies were found, and a new analysis was not  
 8 prioritised, the GDG made a qualitative judgement about cost-effectiveness by considering expected  
 9 differences in resource use between options and relevant UK NHS unit costs, alongside the results of  
 10 the review of clinical effectiveness evidence.

11 The UK NHS costs reported in the guideline are those that were presented to the GDG and were  
 12 correct at the time recommendations were drafted. They may have changed subsequently before the  
 13 time of publication. However, we have no reason to believe they have changed substantially.

## 14 **4.5 Developing recommendations**

15 Over the course of the guideline development process, the GDG was presented with:

- 16 • Evidence tables of the clinical and economic evidence reviewed from the literature. All evidence  
 17 tables are in Appendices H and I.
- 18 • Summaries of clinical and economic evidence and quality (as presented in Chapters 0–17).
- 19 • Forest plots and diagnostic meta-analysis plots (Appendix K).
- 20 • A description of the methods and results of the cost-effectiveness analysis undertaken for the  
 21 guideline (Appendix N).

22 Recommendations were drafted on the basis of the GDG’s interpretation of the available evidence,  
 23 taking into account the balance of benefits, harms and costs between different courses of action.  
 24 This was either done formally in an economic model, or informally. Firstly, the net clinical benefit  
 25 over harm (clinical effectiveness) was considered, focusing on the critical outcomes. When this was  
 26 done informally, the GDG took into account the clinical benefits and harms when 1 intervention was  
 27 compared with another. The assessment of net clinical benefit was moderated by the importance  
 28 placed on the outcomes (the GDG’s values and preferences), and the confidence the GDG had in the  
 29 evidence (evidence quality). Secondly, the GDG assessed whether the net clinical benefit justified any  
 30 differences in costs between the alternative interventions.

31 When clinical and economic evidence was of poor quality, conflicting or absent, the GDG drafted  
 32 recommendations based on its expert opinion. The considerations for making consensus-based  
 33 recommendations include the balance between potential harms and benefits, the economic costs  
 34 compared to the economic benefits, current practices, recommendations made in other relevant  
 35 guidelines, patient preferences and equality issues. The consensus recommendations were agreed  
 36 through discussions in the GDG. The GDG also considered whether the uncertainty was sufficient to  
 37 justify delaying making a recommendation to await further research, taking into account the  
 38 potential harm of failing to make a clear recommendation (see Section 4.5.1 below).

39 The GDG considered the appropriate ‘strength’ of each recommendation. This takes into account the  
 40 quality of the evidence but is conceptually different. Some recommendations are ‘strong’ in that the  
 41 GDG believes that the vast majority of healthcare and other professionals and patients would choose  
 42 a particular intervention if they considered the evidence in the same way that the GDG has. This is  
 43 generally the case if the benefits clearly outweigh the harms for most people and the intervention is  
 44 likely to be cost-effective. However, there is often a closer balance between benefits and harms, and

1 some patients would not choose an intervention whereas others would. This may happen, for  
2 example, if some patients are particularly averse to some side effect and others are not. In these  
3 circumstances the recommendation is generally weaker, although it may be possible to make  
4 stronger recommendations about specific groups of patients.

5 The GDG focused on the following factors in agreeing the wording of the recommendations:

- 6 • The actions health professionals need to take.
- 7 • The information readers need to know.
- 8 • The strength of the recommendation (for example the word 'offer' was used for strong  
9 recommendations and 'consider' for weak recommendations).
- 10 • The involvement of patients (and their carers if needed) in decisions on treatment and care.
- 11 • Consistency with NICE's standard advice on recommendations about drugs, waiting times and  
12 ineffective interventions (see Section 9.2 in the 2014 NICE guidelines manual<sup>122</sup>).

13 The main considerations specific to each recommendation are outlined in the 'Recommendations  
14 and link to evidence' sections within each chapter.

#### 15 **4.5.1 Research recommendations**

16 When areas were identified for which good evidence was lacking, the GDG considered making  
17 recommendations for future research. Decisions about inclusion were based on factors such as:

- 18 • the importance to patients or the population
- 19 • national priorities
- 20 • potential impact on the NHS and future NICE guidance
- 21 • ethical and technical feasibility.

#### 22 **4.5.2 Validation process**

23 This guidance is subject to a 6-week public consultation and feedback as part of the quality assurance  
24 and peer review of the document. All comments received from registered stakeholders are  
25 responded to in turn and posted on the NICE website.

#### 26 **4.5.3 Updating the guideline**

27 Following publication, and in accordance with the NICE guidelines manual, NICE will undertake a  
28 review of whether the evidence base has progressed significantly to alter the guideline  
29 recommendations and warrant an update.

#### 30 **4.5.4 Disclaimer**

31 Healthcare providers need to use clinical judgement, knowledge and expertise when deciding  
32 whether it is appropriate to apply guidelines. The recommendations cited here are a guide and may  
33 not be appropriate for use in all situations. The decision to adopt any of the recommendations cited  
34 here must be made by practitioners in light of individual patient circumstances, the wishes of the  
35 patient, clinical expertise and resources.

36 The National Clinical Guideline Centre disclaims any responsibility for damages arising out of the use  
37 or non-use of this guideline and the literature used in support of this guideline.

**1 4.5.5 Funding**

- 2 The National Clinical Guideline Centre was commissioned by the National Institute for Health and
- 3 Care Excellence to undertake the work on this guideline.



# 5 Risk factors for NAFLD

## 5.1 Introduction

Non-alcoholic fatty liver disease (NAFLD) – ranging from simple fatty liver, through non-alcoholic steatohepatitis (NASH) and fibrosis to NASH-cirrhosis – is highly prevalent, being present in more than 20% of the general population in Europe and North America and higher in the Middle East and South Asia. In most studies, the prevalence is higher in individuals with features of metabolic syndrome including obesity, diabetes, hypertension and an increased waist circumference. Furthermore, several studies have suggested that the presence of these factors also increases the likelihood that people have more advanced forms of NAFLD (fibrosis and NASH). In light of these reports, this review investigates which risk factors (or combination of risk factors) are good indicators of NAFLD and NASH or fibrosis.

## 5.2 Review question: Which risk factors for NAFLD or severe NAFLD (NASH, fibrosis) aid in the identification of people who should be investigated further?

For full details see review protocol in Appendix C.

**Table 7: Characteristics of review question**

<b>Population</b>	<ul style="list-style-type: none"> <li>• Adults (18 years and over)</li> <li>• Young people (11 years or older and younger than 18 years) and children (younger than 11 years)</li> </ul>
<b>Prognostic variables under consideration</b>	<ul style="list-style-type: none"> <li>• Waist circumference</li> <li>• BMI</li> <li>• Raised triglycerides</li> <li>• Low HDL-cholesterol</li> <li>• Type 2 diabetes (HOMA-IR, HbA1c)</li> <li>• Hypertension (Blood pressure; systolic or diastolic)</li> <li>• Age</li> <li>• Combinations of the above</li> </ul>
<b>Confounding factors</b>	<ul style="list-style-type: none"> <li>• Waist circumference</li> <li>• BMI</li> <li>• Raised triglycerides</li> <li>• Low HDL-cholesterol</li> <li>• Type 2 diabetes (HOMA-IR, HbA1c)</li> <li>• Hypertension (Blood pressure; systolic or diastolic)</li> <li>• Age</li> <li>• Vitamin D levels</li> </ul>
<b>Outcomes</b>	<ul style="list-style-type: none"> <li>• Diagnosis of NAFLD</li> <li>• Diagnosis of NASH or fibrosis</li> </ul>
<b>Study design</b>	Prospective and retrospective cohorts with multivariate analysis that adjust for $\geq 3$ of the above confounders in their model.

### 1 5.3 Clinical evidence

2 Six studies were included in the review altogether, all of which were based on an adult  
3 population.<sup>63,85,97,183,188,220</sup> Evidence from these are summarised in the clinical GRADE evidence profile  
4 below. See also the study selection flow chart in Appendix E, forest plots in Appendix K, study  
5 evidence tables in Appendix H and exclusion list in Appendix M.

6 All 6 of the adult studies were cohort studies with a multivariate analysis model which adjusted for 3  
7 or more confounders outlined in the protocol, investigating the association of the prognostic  
8 variables and NAFLD. There were no cohort studies identified investigating the association of the  
9 prognostic variables with NASH or fibrosis in adults. There were also no cohort studies identified  
10 investigating the association between the prognostic factors and NAFLD, NASH or fibrosis in young  
11 people and children.

12 **Table 8: Summary of studies included in the review**

Study	Population	Analysis	Prognostic variable(s)	Confounders (list)	Limitations
Hamabe 2011 <sup>63</sup> (retrospective cohort study in adults)	Single cohort recruited, Japan, n=2029	Logistic regression analysis	Age, hypertension and metabolic syndrome (continuous)	Age, obesity, hypertension, dyslipidaemia, dysglycaemia, gender, cigarette smoking, light alcohol intake.	High risk of bias. Multivariate analysis not adjusted for ≥3 key confounders.
Kim 2014 <sup>85</sup> (prospective cohort study in adults)	Single cohort recruited, Korea, n=2307	Logistic regression analysis	BMI, blood pressure, triglycerides (unclear if dichotomous or continuous)	For the MV analysis - all variables considered in the study: age, BMI, MS, weight difference, gender. For the model – all variables considered in the study: age, baseline BMI, weight difference, blood pressure, HDL, triglycerides, fasting blood sugar, gender	High risk of bias, blinding not reported.
Lee 2010 <sup>97</sup> (prospective cohort study in adults)	Single cohort recruited, Korea, n=1705	Cox proportional hazards regression analysis	BMI ≥25 kg/m <sup>2</sup> , blood pressure ≥130/85 mmHg, triglycerides ≥150mg/dl, HDL-c <40 (men) and <50 (women) mg/dl, metabolic syndrome (3-5 components at baseline)	Confounders for dichotomous outcomes: BMI, blood pressure, triglycerides, HDL-c, fasting glucose	Low risk of bias

## NAFLD

### Risk factors for NAFLD

Study	Population	Analysis	Prognostic variable(s)	Confounders (list)	Limitations
				Metabolic syndrome: sex and age confounders adjusted	
Speliotes 2010 <sup>183</sup> [FRAMINGHAM HEART STUDY] (prospective cohort study in adults)	Single cohort recruited, USA, n=3529	Multivariate regression analysis	Diabetes, HOMA-IR, HDL, hypertension, triglycerides and metabolic syndrome (dichotomous variables)	Age, BMI, waist circumference, gender, alcoholic drinks/week, menopausal status, HRT, smoking, VAT (visceral adipose tissue)	High risk of bias as no blinding mentioned.
Sung 2012 <sup>188</sup> (prospective cohort study in adults)	Single cohort recruited, Korea, n=3577	Logistic regression analysis	Age, triglycerides, HDL-c, waist circumference and diastolic BP	Age, triglycerides, HDL-c, waist circumference, diastolic BP, gender, glucose, insulin, hsCRP, ALT, platelets and smoking	High risk of bias as there was no mention of blinding.
Xu 2013 <sup>220</sup> (prospective cohort study in adults)	Single cohort recruited, China, n=6905	Cox proportional hazards regression analysis	Age, BMI, waist circumference, blood pressure, triglycerides and HDL-c (dichotomous-no details)	Age, gender, BMI, waist circumference, systolic and diastolic blood pressure, gamma-glutamyl-transferase, triglycerides, total cholesterol, FPG, serum uric acid, direct and indirect bilirubin, haemoglobin, platelet count and HDL-c	Low risk of bias.

### 5.3.1 Risk factors for NAFLD

**Table 9: Waist circumference as a risk factor for NAFLD (adults)**

Quality assessment							Adjusted effects	Quality
Number of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Pooled effect with 95% CIs [if meta-analysed] or effect and 95% CI in single study	
<b>Waist circumference (continuous) for predicting NAFLD</b>								
1	Prospective cohort	low	no serious inconsistency	no serious indirectness	none	none	adjusted OR: 1.08 (1.06, 1.10)	HIGH
<b>Waist circumference (dichotomous-unclear) for predicting NAFLD</b>								
1	Prospective cohort	low	no serious inconsistency	no serious indirectness	none	none	adjusted HR: 1.08 (1.06, 1.10)	HIGH

**Table 10: Hypertension as a risk factor for NAFLD (adults)**

Quality assessment							Adjusted effects	Quality
Number of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Pooled effect with 95% CIs [if meta-analysed] or effect and 95% CI in single study	
<b>Hypertension (continuous) for predicting NAFLD</b>								
1	Retrospective cohort	low	no serious inconsistency	no serious indirectness	serious <sup>a</sup>	none	adjusted OR: 0.90 (0.64, 1.27)	MODERATE
<b>Blood pressure (≥130/85 mmHg versus &lt;130/85 mmHg) for predicting NAFLD</b>								

Quality assessment							Adjusted effects	Quality
Number of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Pooled effect with 95% CIs [if meta-analysed] or effect and 95% CI in single study	
1	Prospective cohort (pooled populations; obese and not obese)	serious <sup>b</sup>	no serious inconsistency	no serious indirectness	serious <sup>a</sup>	none	adjusted OR: 1.18 (0.93, 1.48)	LOW
<b>Blood pressure (<math>\geq 130/85</math> mmHg) for predicting NAFLD</b>								
1	Prospective cohort	low	no serious inconsistency	no serious indirectness	serious <sup>a</sup>	none	adjusted HR: 0.99 (0.72, 1.36)	MODERATE
<b>Hypertension (dichotomous) for predicting NAFLD</b>								
1	Prospective cohort	serious <sup>c</sup>	no serious inconsistency	no serious indirectness	none	none	adjusted OR: 1.52 (1.17, 1.97)	MODERATE
<b>Diastolic BP (continuous) for predicting NAFLD</b>								
1	Prospective cohort	serious <sup>d</sup>	no serious inconsistency	no serious indirectness	serious <sup>a</sup>	none	adjusted OR: 1.00 (0.99, 1.02)	LOW
<b>Diastolic BP (dichotomous- unclear) for predicting NAFLD</b>								
1	Prospective cohort	low	no serious inconsistency	no serious indirectness	serious <sup>a</sup>	none	adjusted HR: 1.01 (1.0, 1.02)	MODERATE
<b>Systolic BP (dichotomous- unclear) predicting NAFLD</b>								
1	Prospective cohort	low	no serious inconsistency	no serious indirectness	serious <sup>a</sup>	none	adjusted HR: 1.0 (0.99, 1.01)	MODERATE

1  
2  
3  
4

(a) 95% CI around the mean crosses the null line

(b) Multivariable logistic regression analysis adjusted for triglycerides, not adjusted for  $\geq 3$  key covariate, no mention of blinding.

(c) Multivariable logistic regression analysis adjusted for age, BMI, waist circumference, triglycerides, HDL-c and systolic BP, no blinding.

(d) Multivariable logistic regression analysis adjusted for age, waist circumference, triglycerides and HDL-c, no blinding.

**Table 11: Triglycerides as a risk factor for NAFLD (adults)**

Quality assessment							Adjusted effects	Quality
Number of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Pooled effect with 95% CIs [if meta-analysed] or effect and 95% CI in single study	
<b>Triglycerides (≥150 versus &gt;150 mg/dl ) for predicting NAFLD</b>								
1	Prospective cohort	low	no serious inconsistency	no serious indirectness	none	none	adjusted HR: 2.10 (1.52, 2.90)	HIGH
<b>Triglycerides (continuous) for predicting NAFLD</b>								
1	Prospective cohort	serious <sup>a</sup>	no serious inconsistency	no serious indirectness	none	none	adjusted OR: 1.38 (1.18, 1.61)	MODERATE
<b>Triglycerides (unclear if dichotomous or continuous) for predicting NAFLD</b>								
1	Prospective cohort	serious <sup>b</sup>	no serious inconsistency	no serious indirectness	none	none	adjusted OR: 1.25 (1.19, 1.31)	MODERATE
<b>Triglycerides (dichotomous-unclear) for predicting NAFLD</b>								
1	Prospective cohort	low	no serious inconsistency	no serious indirectness	none	none	adjusted HR: 1.21 (1.07, 1.37)	HIGH
<b>Triglycerides (unclear if dichotomous or continuous) for predicting NAFLD</b>								
1	Prospective cohort	serious <sup>c</sup>	no serious inconsistency	no serious indirectness	none	none	adjusted OR: 1.41 (1.11, 1.80)	MODERATE

(a) Multivariable logistic regression analysis adjusted for age, WC, diastolic BP and HDL-c, no blinding.

(b) Multivariable logistic regression analysis adjusted for HOMA-IR and hypertension, no blinding.

(c) Multivariable logistic regression analysis adjusted for blood pressure, not adjusted for ≥3 covariates, no blinding.

**Table 12: LOW HDL-cholesterol as a risk factor for NAFLD (adults)**

Quality assessment							Adjusted effects	Quality
Number of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Pooled effect with 95% CIs [if meta-analysed] or effect and 95% CI in single study	
<b>HDL-c (Males &lt;40, Females &lt;50 md/dl) for predicting NAFLD</b>								
1	Prospective cohort	low	no serious inconsistency	no serious indirectness	serious <sup>a</sup>	none	adjusted HR: 1.23 (0.91, 1.66)	MODERATE
<b>HDL-c (continuous) for predicting NAFLD</b>								
1	Prospective cohort	serious <sup>b</sup>	no serious inconsistency	no serious indirectness	serious <sup>a</sup>	none	adjusted OR: 0.82 (0.55, 1.24)	LOW
<b>HDL-c (dichotomous-unclear) for predicting NAFLD</b>								
1	Prospective cohort	low	no serious inconsistency	no serious indirectness	none	none	adjusted HR: 0.57 (0.34, 0.96)	HIGH

(a) 95% CI around crosses the null line.

(b) Multivariable logistic regression analysis adjusted for age, triglycerides, waist circumference, diastolic BP, no blinding.

**Table 13: Type 2 diabetes as a risk factor for NAFLD (adults)**

Quality assessment							Adjusted effects	Quality
Number of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Pooled effect with 95% CIs [if meta-analysed] or effect and 95% CI in single study	
<b>Diabetes (dichotomous) for predicting NAFLD</b>								
1	Prospective cohort	serious <sup>a</sup>	no serious inconsistency	no serious indirectness	none	none	adjusted OR: 1.64 (1.11, 2.42)	MODERATE

(a) Multivariable logistic regression analysis adjusted for triglycerides and hypertension and metabolic syndrome, no mention of blinding.

(b) 95% CI around the mean crosses 1 default MID.

**Table 14: Age as a risk factor for NAFLD (adults)**

Quality assessment							Adjusted effects	Quality
Number of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Pooled effect with 95% CIs [if meta-analysed] or effect and 95% CI in single study	
<b>Age (continuous) for predicting NAFLD</b>								
1	Retrospective cohort	serious <sup>a</sup>	no serious inconsistency	no serious indirectness	none	none	adjusted OR: 0.95 (0.94, 0.97)	MODERATE
<b>Age (continuous) for predicting NAFLD</b>								
1	Prospective cohort	low	no serious inconsistency	no serious indirectness	none	none	adjusted OR: 0.99 (0.98, 1.00)	HIGH
<b>Age (dichotomous- unclear) for predicting NAFLD</b>								
1	Prospective cohort	low	no serious inconsistency	no serious indirectness	none	none	adjusted HR: 0.98 (0.97, 0.99)	HIGH
<b>Age (continuous) for predicting NAFLD</b>								
1	Prospective cohort (pooled populations; obese and not obese)	serious <sup>b</sup>	no serious inconsistency	no serious indirectness	none	none	OR (95% CI) 1.03 (1.02-1.04)	MODERATE

(a) Multivariable logistic regression analysis adjusted for hypertension, not adjusted for  $\geq 3$  key covariates.

(b) Multivariable logistic regression analysis adjusted for BMI, not adjusted for  $\geq 3$  key covariate.



**Table 15: BMI as a risk factor for NAFLD (adults)**

Quality assessment							Adjusted effects	Quality
Number of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Pooled effect with 95% CIs [if meta-analysed] or effect and 95% CI in single study	
<b>BMI (<math>\geq 25</math> kg/m<sup>2</sup> versus <math>&lt; 25</math> kg/m<sup>2</sup>) for predicting NAFLD</b>								
1	Prospective cohort	low	no serious inconsistency	no serious indirectness	none	none	adjusted HR: 2.46 (1.88, 3.22)	HIGH
<b>BMI (unclear if dichotomous or continuous) for predicting NAFLD</b>								
1	Prospective cohort	serious <sup>a</sup>	no serious inconsistency	no serious indirectness	none	none	adjusted OR: 1.14 (1.04, 1.26)	MODERATE
<b>BMI (dichotomous-unclear) for predicting NAFLD</b>								
1	Prospective cohort	low	no serious inconsistency	no serious indirectness	none	none	adjusted HR: 1.22 (1.13, 1.32)	HIGH

(a) Multivariable logistic regression analysis adjusted for age, not adjusted for  $\geq 3$  key covariates, no blinding.

### 3.3.1.1 Metabolic syndrome

**Table 16: Risk factor (metabolic syndrome) for NAFLD (adults)**

Quality assessment							Adjusted effects	Quality
Number of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Pooled effect with 95% CIs [if meta-analysed] or effect and 95% CI in single study	
<b>Metabolic syndrome (lee 2010) for predicting NAFLD</b>								
1	Prospective cohort	low	no serious inconsistency	no serious indirectness	none	none	adjusted HR: 5.91 (3.93, 8.89)	HIGH
<b>Metabolic syndrome (SPELIOTES) for predicting NAFLD</b>								
1	Prospective cohort	serious <sup>a</sup>	no serious inconsistency	no serious indirectness	none	none	adjusted OR: 1.95 (1.48, 2.57)	MODERATE

Quality assessment							Adjusted effects	Quality
Number of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Pooled effect with 95% CIs [if meta-analysed] or effect and 95% CI in single study	
<b>Metabolic syndrome (HAMABE) for predicting NAFLD</b>								
1	Prospective cohort	serious <sup>b</sup>	no serious inconsistency	no serious indirectness	none	none	adjusted OR: 2.99 (1.62, 5.52)	MODERATE

1 (a) Multivariable logistic regression analysis adjusted for diabetes, triglycerides and hypertension, no blinding.

2 (b) Multivariable logistic regression analysis adjusted for age, no blinding.

### 3 5.3.2 Risk factors for NASH

4 No clinical evidence was identified.

### 5 5.3.3 Risk factors for fibrosis

6 No clinical evidence was identified.

7

## 1 **5.4 Economic evidence**

### 2 **5.4.1 Published evidence**

3 No relevant economic evaluations were identified.

4 See also the economic article selection flow chart in Appendix F.

### 5 **5.4.2 New cost-effectiveness analysis**

6 Original cost-effectiveness modelling was undertaken for this question. A summary of the modelling  
7 work and an evidence statement summarising the results of the analysis can be found in Chapter 6.  
8 The full analysis can be found in Appendix N.

9 The following risk factors were considered in the analysis:

- 10 • high triglycerides ( $\geq 1.5$  g/litre)
- 11 • low HDL-cholesterol (<400 mg/litre for men, <500 mg/litre for women)
- 12 • metabolic syndrome (NCEP criteria)
- 13 • obesity (BMI $\geq 30$ )
- 14 • type 2 diabetes (glycaemia $\geq 1.1$  g/litre)
- 15 • wide waist circumference ( $\geq 102$  cm for men,  $\geq 88$  cm for women)

## 16 **5.5 Evidence statements**

### 17 **5.5.1 Clinical**

#### 18 **5.5.1.1 Prognostic variables as risk factors for NAFLD**

##### 19 **Waist circumference**

- 20 • High quality evidence from 2 cohort studies with multivariable analysis suggested waist  
21 circumference to be a predictor of NAFLD in adults, with an adjusted HR of 1.08 (1.06, 1.10) and  
22 an adjusted OR of 1.08 (1.06, 1.10).
- 23 • There was no evidence for children and young people.

##### 24 **Hypertension**

- 25 • Moderate to low quality evidence from 4 cohort studies, with multivariable analysis, showed  
26 hypertension and blood pressure were not significant predictors of NAFLD in a general, obese and  
27 non-obese adult population. Adjusted HR's were 0.99 (0.72, 1.36), 1.01 (1.0, 1.02) and 1 (0.99,  
28 1.01) for BP (general population), diastolic BP (non-obese population) and systolic BP (non-obese  
29 population) respectively. Adjusted OR's reported were 0.9 (0.64, 1.27) and 1.18 (0.93, 1.48) for  
30 hypertension (general population) and BP (mixed obese and non-obese population) respectively  
31 • There was no evidence for children and young people.

##### 32 **Triglycerides**

- 33 • There was some evidence suggesting that adults with high triglycerides may be at higher risk of  
34 NAFLD from 5 cohort studies with multivariable analysis. High quality evidence from 1 study  
35 reported an adjusted HR of 2.1 (1.52, 2.9) and high to moderate quality evidence from 4  
36 prospective cohort studies reported an adjusted HR of 1.21 (1.07, 1.37) and adjusted ORs of 1.38  
37 (1.18, 1.61), 1.25 (1.19, 1.31) and 1.41 (1.11, 1.8).

- 1 • There was no evidence for children and young people.
- 2 **HDL-cholesterol**
- 3 • There was some evidence suggesting that adults with lower HDL-cholesterol may be at higher risk
- 4 of NAFLD from 2 cohort studies with multivariable analysis. High quality evidence from 1 study
- 5 suggested that low HDL cholesterol was predictive of NAFLD with an adjusted HR of 0.57 (0.34,
- 6 0.96), along with low quality evidence from another study reported an adjusted OR of 0.82 (0.55,
- 7 1.24). However, 1 study of low quality suggested low HDL was protective of NAFLD with an
- 8 adjusted HR of 1.23 (0.91, 1.66).
- 9 • There was no evidence for children and young people.
- 10 **Diabetes**
- 11 • Moderate quality evidence from 1 study of 3529 adults, with multivariable analysis, suggested
- 12 type 2 diabetes as a risk factor for NAFLD reporting an adjusted OR of 1.64 (1.11, 2.42).
- 13 • There was no evidence for children and young people.
- 14 **Age**
- 15 • High to moderate quality evidence from 4 cohort studies, with multivariable analysis, showed age
- 16 was not a significant predictor of NAFLD in adults. Three studies reported adjusted ORs of 0.95
- 17 (0.94, 0.97), 1.03 (1.02, 1.04) and 0.99 (0.98, 1.0); and 1 study reported adjusted HR of 0.98 (0.97,
- 18 0.99).
- 19 • There was no evidence for children and young people.
- 20 **BMI**
- 21 • High to moderate quality evidence from 3 cohort studies, with multivariable analysis, suggests
- 22 some evidence that adults with a high BMI may be at risk of NAFLD reporting adjusted HRs of 2.46
- 23 (1.88, 3.22) and 1.22 (1.13, 1.32); and an adjusted OR of 1.14 (1.04, 1.26).
- 24 There was no evidence for children and young people.
- 25 **Metabolic syndrome (combination of risk factors)**
- 26 • There was some high to moderate quality evidence suggesting that adults with metabolic
- 27 syndrome may be at higher risk of NAFLD from 3 cohort studies, with multivariable analysis. Two
- 28 high quality studies reported adjusted ORs of 1.95 (1.48, 2.57) and 2.99 (1.62, 5.52) and 1 study
- 29 reported a HR of 5.91 (3.93, 8.89).
- 30 There was no evidence for children and young people.
- 31 **3.5.5.1.2 Prognostic variables as risk factors for NASH or fibrosis**
- 32 There was no evidence in adults or children and young people to determine the risk factors for NASH
- 33 or fibrosis.
- 34 **5.5.2 Economic**
- 35 • One original cost-utility analysis found that testing for NAFLD was cost-effective compared to no
- 36 testing at a cost-effectiveness threshold of £20,000 per QALY for all retest frequencies and NAFLD
- 37 prevalence's investigated. Retesting at a frequency of 5 years was cost-effective compared to
- 38 other frequencies. This analysis was assessed as directly applicable with minor limitations.
- 39

## 1 5.6 Recommendations and link to evidence

<b>Recommendation</b>	<b>1. Suspect non-alcoholic fatty liver disease (NAFLD) in people who have:</b> <ul style="list-style-type: none"> <li>• type 2 diabetes or</li> <li>• metabolic syndrome.</li> </ul>
<b>Research recommendation</b>	<b>1. What are the prognostic factors for the development of NAFLD or NASH in children and young people?</b>
Relative values of different prognostic measures and outcomes	<p>The GDG agreed that diagnosis of NAFLD and diagnosis of NASH and fibrosis were the most informative outcomes for this review. However, no cohort study evidence was identified for the outcome diagnosis of NASH and fibrosis.</p>
Trade-off between clinical benefits and harms	<p>The GDG concluded that the evidence identified within this part of the review demonstrated that waist circumference, type 2 diabetes mellitus, increased triglycerides, low HDL-cholesterol, and metabolic syndrome appeared to be predictive factors for NAFLD in adults; with metabolic syndrome being the single most strongly predictive factor. It was noted that metabolic syndrome seemed to be predictive of NAFLD in adults, regardless of whether people had all components of the syndrome or only certain elements of it (irrespective of which combination of elements they were). The GDG noted that, whilst there was some association between increased BMI in adults and NAFLD, the strength of this association varied significantly between studies. There was no compelling evidence that hypertension or age were predictive of NAFLD in adults.</p> <p>The GDG decided that the risk factors that merited inclusion in cost modelling as predictive factors for NAFLD for adults were type 2 diabetes mellitus, high triglycerides, high BMI, low HDL-cholesterol, wide waist circumference and the presence of metabolic syndrome. The GDG concluded that the lack of any cohort study evidence for risk factors in children and young people meant that it would not be possible to model risks in this population; therefore only adults were considered in the economic model. However, the GDG agreed that there was no specific reason to suggest that these risk factors would differ in a younger population and agreed to extrapolate the evidence from adult populations to make a recommendation for all age groups. A research recommendation for further research on risk factors for NAFLD in children and young people was considered appropriate to confirm this assumption.</p> <p>This review also looked for predictive factors for NASH and severe fibrosis. This is because a major aim of both primary and secondary care is to identify the smaller number of 'high risk' people with NAFLD who merit further intervention (because they also have NASH or significant fibrosis) from the large numbers of people within the general population with 'simple' steatosis. However, no evidence was identified on predictive factors for these conditions and the GDG agreed that it was unable to make a recommendation on whether the presence of any specific risk factors might warrant testing for NASH or severe fibrosis.</p>
Trade-off between net clinical effects and costs	<p>No relevant published economic evaluations were identified.</p> <p>An original cost-utility analysis was conducted for this guideline to address the questions in this review and also Chapters 6, 7 and 8. As described above, no economic analysis was conducted relating to children and young people under 18 years.</p> <p>The risk factor groups with the highest prevalence of NAFLD were people with metabolic syndrome (54%) and people with type 2 diabetes (53%). As explained in further detail in Chapter 6, the original economic analysis compared the cost-</p>

## NAFLD

### Risk factors for NAFLD

	<p>effectiveness of 8 diagnostic tests with 2 no testing strategies, and found the fatty liver index (FLI) was the most cost-effective of the diagnostic tests. The analysis found that FLI was cost-effective compared to no testing (with no treatment) for adults with type 2 diabetes or metabolic syndrome at all frequencies of retesting investigated (1–6 years) at a cost-effectiveness threshold of £20,000 per QALY.</p> <p>For adults with a high BMI (46% prevalence of NAFLD), high triglycerides (46%), low HDL-cholesterol (36%), or wide waist circumference (36%), testing using FLI was also cost-effective compared to no testing at all retesting frequencies investigated. However, given that routine testing for NAFLD will be a new activity and conscious of the number of people involved, the GDG agreed that testing for NAFLD should be prioritised to those groups (people with type 2 diabetes or metabolic syndrome) at highest risk of having or developing NAFLD. The GDG further noted that people with any of the other, individual, risk factors, would themselves be at risk of developing metabolic syndrome or type 2 diabetes over the coming years. At the point that they do develop one of those conditions they would then become eligible for NAFLD testing.</p> <p>See Chapter 6 for recommendations on the diagnostic test for NAFLD to be used.</p>
Quality of evidence	<p>The clinical studies included in this review were cohort studies based on adult populations that adjusted for 3 or more confounders listed in the review protocol. The quality of the majority of these study outcomes ranged from a modified GRADE rating of moderate to low. Downgrading of evidence was predominantly due to the high risk of bias in some studies due to the lack blinding, as well as the imprecise nature of the results. Evidence of a high GRADE rating was seen for some of the evidence included; for the prognostic factors waist circumference, triglycerides, low HDL-cholesterol, age, BMI and metabolic syndrome.</p> <p>The economic study included in this review was of high quality, being directly applicable and with minor limitations.</p>
Other considerations	<p><b>Research recommendation</b></p> <p>The GDG made a research recommendation to elucidate the prognostic factors for NAFLD and NASH in children and young people.</p>

## 6 Diagnosis of NAFLD

### 6.1 Introduction

Historically, the presence of NAFLD has been suspected in those presenting with abnormal liver blood tests or evidence of fatty changes on ultrasound. However, the full spectrum of NAFLD (from simple steatosis to steatohepatitis, cirrhosis and liver-related morbidity) can also be present with normal liver tests.

Early detection of NAFLD may be useful to identify those with potentially silent progressive fatty liver disease. Diagnostic practice varies widely and includes clinical, biochemical and radiographic tests. Currently, liver biopsy remains the gold standard for NAFLD diagnosis but is impractical as a diagnostic tool because it is invasive and expensive. As such, there is a need for highly sensitive and specific diagnostic tests that can be commonly used by clinicians in primary, secondary and tertiary care.

The aim of this review is to objectively evaluate existing invasive and non-invasive tests to accurately diagnose NAFLD in adults, young people and children. The outcome will facilitate development of a practical diagnostic pathway.

Hepatic steatosis at 5% or more is the accepted histological definition of grade 1 steatosis<sup>87</sup>; steatosis at less than 5% is considered normal. Steatosis at 30% is the accepted lower limit where steatosis can be detected reliably by ultrasound (currently the most commonly used diagnostic test for fatty liver).

In addition to the imaging techniques assessed by these guidelines, fatty liver can also be detected using computed tomography (CT). Fat has a lower attenuation than water using X-ray based techniques; this makes the liver appear darker on images and, by measuring the radiodensity, fat can be quantified (in Hounsfield units). Through its widespread diagnostic use, CT has become the largest source of radiation to many populations, and with the high prevalence of fatty liver in the West there would be the potential to significantly add to this radiation burden. Given that fatty liver usually has a benign clinical course and that there are alternative imaging techniques without radiation, it was decided that it would be inappropriate to potentially recommend a technique that would significantly add to the population radiation dose. On this basis, CT was not formally evaluated as a technique for the detection or quantification of fat within the liver; this is consistent with the principles of the European Committee of Radiation Risk.<sup>69</sup>

### 6.2 Review question: What is (are) the appropriate investigation(s) for diagnosing NAFLD in adults, young people and children?

For full details see review protocol in Appendix C.

**Table 17: Characteristics of review question**

<b>Population</b>	Adults (18 years and over), children and young people (aged >5 to <18)
<b>Target condition</b>	Steatosis $\geq 5\%$ and $\geq 30\%$ (acknowledging that non-alcoholic fatty liver disease (NAFLD) is a clinical diagnosis characterized by hepatic steatosis in the absence of a history of significant alcohol use or other known liver disease).
<b>Index tests</b>	<ul style="list-style-type: none"> <li>• Alanine transaminase (ALT)</li> <li>• Aspartate aminotransferase (AST)</li> <li>• Controlled attenuation parameter (CAP)</li> <li>• Fatty liver index</li> </ul>

## Diagnosis of NAFLD

	<ul style="list-style-type: none"> <li>• Gamma-glutamyl transferase (GGT)</li> <li>• MRI/MRS</li> <li>• NAFLD liver fat score</li> <li>• Steatotest</li> <li>• Ultrasound</li> <li>• Combination of the above tests</li> </ul>
<b>Reference standard</b>	Liver biopsy
<b>Statistical measures (outcomes)</b>	Diagnostic accuracy measures: <ul style="list-style-type: none"> <li>• Sensitivity</li> <li>• Specificity</li> <li>• Positive/Negative predictive value</li> <li>• Positive/Negative likelihood ratio</li> <li>• ROC curve of AUC</li> </ul>
<b>Study design</b>	Diagnostic accuracy cohorts – prospective or retrospective designs where raw data are reported, or enough data are reported to calculate 2x2 table.

### 1 6.3 Clinical evidence

2 Thirty-eight studies were included in the review.<sup>20,25,29,30,35,36,38,50,54,70,78,79,88,91,96,98,107,112-114,117,119,138,140,145,165-167,173,190,200,204,205,208-211,219,222</sup>  
 3 Evidence from these are summarised in the clinical  
 4 evidence profiles below (Table 19, Table 20, Table 21 and Table 22). See also the study selection flow  
 5 chart in Appendix E, sensitivity/specificity plots and diagnostic meta-analysis plots in Appendix K,  
 6 study evidence tables in Appendix H and exclusion list in Appendix M.

7 Papers reported diagnostic accuracy for a variety of tests; controlled attenuation parameter (CAP),  
 8 fatty liver index (FLI), magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS),  
 9 NAFLD liver fat score, Steatotest and ultrasound, using multiple different thresholds. No papers  
 10 relevant to the review protocol were identified for alanine transaminase (ALT), aspartate  
 11 aminotransferase (AST) or gamma-glutamyl transferase (GGT). Many papers used the NAFLD activity  
 12 score (NAS)<sup>87</sup> to grade steatosis on biopsy (by assessing the percentage of hepatocytes containing  
 13 lipid droplets) S0: less than 5%, S1: 5-33%, S2: 34-66%, S3: greater than 66%. However, this was not  
 14 universally used across all papers. Details of individual steatosis grading systems are available in  
 15 Table 18.

#### 16 **Diagnosing steatosis ≥5%**

17 Twenty-five papers investigated tests for diagnosing steatosis ≥5%. Five papers presented evidence  
 18 for controlled attenuation parameter (CAP),<sup>30,54,113,119,173</sup> 2 papers for the Fatty Liver Index (FLI),<sup>20,50</sup> 9  
 19 papers for different types of MRI,<sup>29,98,112,117,140,167,190,204,219</sup> 4 papers for MRS,<sup>98,204,205,219</sup> 1 for the NAFLD  
 20 liver fat score,<sup>50</sup> 1 for Steatotest<sup>91</sup> and eight for ultrasound.<sup>35,38,78,96,204,208,210,211</sup>

#### 21 **Diagnosing steatosis ≥30%**

22 Twenty-seven papers investigated tests for diagnosing steatosis ≥30, ≥33 or ≥34%. These papers are  
 23 pooled under the heading of diagnosing steatosis ≥30% (as the GDG agreed that these 3 different  
 24 cut-offs all captured the concept of fat affecting approximately a third of the liver). Nine papers  
 25 presented evidence for controlled attenuation parameter (CAP),<sup>30,36,54,107,119,165,166,173,209</sup> 2 papers for  
 26 the Fatty Liver Index (FLI),<sup>36,50</sup> 4 papers for different types of MRI,<sup>98,112,140,190</sup> 3 papers for MRS,<sup>88,98,200</sup>  
 27 1 for the NAFLD liver fat score,<sup>50</sup> 2 for the Steatotest,<sup>36,91</sup> and ten for  
 28 ultrasound.<sup>70,78,79,96,114,138,145,208,210,222</sup>



1 **Table 18: Summary of studies included in the review**

Study	Index test(s)	Population	Diagnosis of interest	Comments
Borman 2013 <sup>20</sup> n = 250	Fatty liver index (FLI)	Chronic liver disease and BMI $\geq 28$ kg/m <sup>2</sup>	Steatosis $\geq 5\%$	Validation study FLI cut-off 79 (maximum sens, spec) Kleiner grading (NAS)
Chiang 2014 <sup>29</sup> n = 63	MRIdealfat fraction	Pre-transplant liver donors	Fatty liver $\geq 5\%$	Type of MRI calculation: iterative decomposition of water and fat with echo asymmetry and least squares estimation MRI cut off 3.42 One-off grading system used: <5%, 5-10%, 11-15%, >15%
Chon 2014 <sup>30</sup> n = 135	CAP	Chronic liver disease	Steatosis $\geq 5\%$ Steatosis $\geq 34\%$	CAP cut-off 250, 299 decibel-milliwatts (dB/m) (maximum sens, spec) Kleiner grading (NAS)
Dasarathy 2009 <sup>35</sup> n = 73	Ultrasound	Clinical suspicion of abnormal liver function or liver disease	Macrovesicular fat $\geq 5\%$	Reports for sens&spec for $\geq 30\%$ steatosis but not enough data to calculate 2x2 table. One-off grading system used: <5%, 5-35%, 35-65%, >65%
de Lédinghen 2012 <sup>36</sup> n = 112	CAP FLI Steatotest	Chronic liver disease	Steatosis $\geq 34\%$	CAP cut-off 311 dB/m (maximum accuracy) FLI cut-off 93.9 (maximum accuracy) Steatotest cut-off 0.94 (maximum accuracy) One-off grading system used: <10%, 11-33%, 34-66%, >67%
de Moura Almeida 2008 <sup>38</sup> n = 105	Ultrasound	BMI $\geq 35$ kg/m <sup>2</sup>	Steatosis $\geq 5\%$	One-off grading system used: <5%, 5-25%, 25-50%, 50-75% >75%
Fedchuk 2014 <sup>50</sup> n = 324	FLI NAFLD-liver fat score	Clinical or ultrasound suspicion of NAFLD	Steatosis >5% Steatosis >33%	FLI cut-off 60, 82 (maximum sens, spec) NAFLD-LFS cut-off 0.16 (maximum sens, spec) Kleiner grading (NAS)
Ferraioli 2014 <sup>54</sup> n = 109	CAP	Chronic viral hepatitis	Steatosis $\geq 5\%$ Steatosis $\geq 34\%$	CAP cut off 219, 296 dB/m (maximum sens, spec) Kleiner grading (NAS)
Hepburn 2005 <sup>70</sup> n = 122	Ultrasound	Hepatitis C	Steatosis >30%	One-off grading system used: <2%, 2-10%, 10-30%, 30-60% >60%
Jun 2014 <sup>78</sup> n = 3869	Ultrasound	Living liver donor candidates	Steatosis $\geq 5\%$ Steatosis $\geq 30\%$	One-off grading system used: <5%, 5-15%, 15-30%, >30%
Junior 2012 <sup>79</sup>	Ultrasound	Gastric bypass	Steatosis >33%	One-off grading system used: any degree (unclear threshold), <33%

## NAFLD

### Diagnosis of NAFLD

Study	Index test(s)	Population	Diagnosis of interest	Comments
n = 259				
Koelblinger 2012 <sup>88</sup> n = 35	MRS	Hepatic surgery	Steatosis ≥30%	MRS cut-off 2.7% One-off grading system used: <5%, 5-30%, <30%
Lassailly 2011 <sup>91</sup> n = 288	Steatotest	Bariatric surgery	Steatosis ≥5% Steatosis >33%	Steatotest cut-off 0.38, 0.69 Kleiner grading (NAS)
Lee 2007 <sup>96</sup> n = 589	Ultrasound	Living liver donor candidates	Steatosis ≥5% Steatosis >30%	One-off grading system used: <5%, 5-30%, >60%
Lee 2010 <sup>98</sup> n = 161	MRI-DE MRS	Living liver donor candidates	Steatosis ≥5% Steatosis ≥30%	MRI cut-off 4.0, 6.5 MRS cut-off 2.6, 7.7 One-off grading system used: <5%, 5-30%, >60%
Lupsor-Platon 2015 <sup>107</sup> n = 201	CAP	Different diffuse chronic liver diseases	Steatosis ≥ 34%	CAP cut-off 285 (maximum sens, spec)
Marsman 2011 <sup>112</sup> n = 36	MRI %RSID	Colorectal liver metastases after neoadjuvant chemotherapy	Macrovesicular steatosis >5% Macrovesicular steatosis >33%	MRI % relative signal intensity decrease (RSID) cut-off unclear Kleiner grading (NAS)
Masaki 2013 <sup>113</sup> n = 155	CAP	Suspected chronic liver disease	Steatosis ≥5%	CAP cut off 232.5dB/m (maximum sens, spec) Kleiner grading (NAS)
Mathiesen 2002 <sup>114</sup> n = 165	Ultrasound	Abnormalities of liver transaminases	Steatosis ≥33%	One-off grading system: <33%, 33-66%, >66%
Mennesson 2009 <sup>117</sup> n = 40	MRI fat water ratio	Incidentally discovered elevation of liver enzymes	Steatosis ≥5%	Fat-water ratio cut-off >0 Kleiner grading (NAS)
Myers 2012 <sup>119</sup> n = 153	CAP	Chronic liver disease and BMI ≥28 kg/m <sup>2</sup>	Steatosis ≥5% Steatosis >33%	CAP cut off 289 and 288 dB/m Kleiner grading (NAS)
Palmentieri 2006 <sup>138</sup> n = 216	Ultrasound	Suspected liver disease	Steatosis ≥30%	One-off grading system: <2%, 3-29%, 30-49%, >50%
Paparo 2015 <sup>140</sup> n = 77	MRI (PDFF)	Chronic hepatitis C	Steatosis ≥5% Steatosis ≥ 34%	MRI proton density fat fraction (PDFF) 6.87 and 11.08 (maximum sens, spec)
Perez 2007 <sup>145</sup> n = 131	Ultrasound	Chronic liver disease	Steatosis >33%	One-off grading system: <33%, 33-66%, >66%
Sasso 2010 <sup>166</sup> n = 115	CAP	Chronic liver disease	Steatosis ≥34%	CAP cut off 259.4 dB/m One-off grading system: <10%, 11-33%, 34-66%, >66%

## NAFLD

### Diagnosis of NAFLD

Study	Index test(s)	Population	Diagnosis of interest	Comments
Sasso 2012 <sup>165</sup> n = 615	CAP	Chronic hepatitis C	Steatosis $\geq 34\%$	CAP cut off 233 dB/m One-off grading system: <10%, 11-33%, 34-66%, >66%
Schwimmer 2015 <sup>167</sup> n = 174 (children)	MRI (PDFF)	Children with liver biopsy performed	Steatosis $\geq 5\%$	MRI proton density fat fraction (PDFF) cut off 6.4% NASH CRN grading
Shen 2014 <sup>173</sup> n = 152	CAP	Suspected NAFLD or chronic hepatitis B	Steatosis $\geq 5\%$ Steatosis $\geq 34\%$	CAP cut off 250, 285 dB/m Kleiner grading (NAS)
Tang 2015 <sup>190</sup> n = 89	MRI (PDFF)	Adults with suspected NAFLD	Steatosis $\geq 5\%$ Steatosis $\geq 33\%$	MRI proton density fat fraction (PDFF) 6.4 and 22.1 (maximum sens, spec)
Urdzik 2012 <sup>200</sup> n = 35	MRS	Colorectal liver metastasis	Steatosis $\geq 33\%$	MRS cut-off 10.2% Kleiner grading (NAS)
van Werven 2010 <sup>204</sup> n = 46	MRI fat fraction MRS Ultrasound	Various indications for liver resection	Macrovesicular hepatic fat content – steatosis $\geq 5\%$	MRI cut-off fat-fraction 1.5% MRS cut-off 1.8% Kleiner grading (NAS)
van Werven 2011 <sup>205</sup> n = 38	MRS	Gastric bypass	Macrovesicular steatosis $\geq 5\%$	MRS cut-off 5.7% Kleiner grading (NAS)
Wang 2013 <sup>210</sup> n = 175	Ultrasound	Chronic hepatitis	Steatosis $\geq 5\%$ Steatosis $\geq 30\%$	Hepatorenal contrast ratio 4 and 7 cut-off One-off grading system: <5%, 5-9%, 10-19%, 20-29%, >30%
Wang 2014 <sup>208</sup> n = 171	Ultrasound	Hepatitis	Steatosis >5% Steatosis $\geq 34\%$	Kleiner grading (NAS)
Wang 2014 <sup>209</sup> n = 88	CAP	Chronic hepatitis B	Steatosis $\geq 34\%$	CAP cut off 230 dB/m One-off grading system: <10%, 11-33%, 34-66%, >67%
Webb 2009 <sup>211</sup> n = 111	Ultrasound	Chronic liver disease	Steatosis $\geq 5\%$	Optimal hepatorenal sonographic cut-off 1.49 One-off grading system: <5%, 5-25%, 25-60%, >60%
Wu 2014 <sup>219</sup> n = 60	MRI-DE MRI-TE MRS	Hepatic tumour and liver resection	Steatosis $\geq 5\%$	Reported results separately for DE-MRI (double-echo chemical-shift gradient-echo) and TE-MRI (triple-echo). DE-MRI cut-off 11.08% TE-MRI cut-off 5.35% MRS cut-off 4.73% Kleiner grading (NAS)
Yajima 1983 <sup>222</sup> n = 45	Ultrasound	Liver disease	Fatty change >30%	One-off grading system: >30%



Index Test (Threshold)	No of studies	n	Risk of bias	Inconsistency	Indirectness	Imprecision	Sensitivity % (median/ range/ 95% CI)	Specificity % (median/ range/ 95% CI)	Quality
MRI PDFF at 6.4 threshold									
MRI %RSID at -0.74 threshold	1	36	Serious <sup>a</sup>	-	None	Serious <sup>d</sup>	87 (66, 97)	69 (39, 91)	LOW
MRI-TE at 5.35 threshold	1	60	Serious <sup>a</sup>	-	None	Serious <sup>d</sup>	93 (66, 100)	96 (85, 99)	LOW
<b>Magnetic resonance spectroscopy (MRS)</b>									
MRS at 0-5 threshold range <i>Pooled meta-analysis data</i>	3	265	Serious <sup>a</sup>	No serious inconsistency	None	Very serious <sup>d</sup>	86 (63, 98)	82 (59, 95)	LOW
MRS at 5.7 threshold	1	38	Serious <sup>a</sup>	-	None	Serious <sup>d</sup>	85 (62, 97)	94 (70, 100)	LOW
<b>NAFLD liver fat score (NAFLD-LFS)</b>									
NLFS at 0.16 threshold	1	324	Very serious <sup>a</sup>	-	None	Serious <sup>d</sup>	65 (59, 70)	87 (60, 98)	VERY LOW
<b>Steatotest</b>									
Steatotest at 0.38 threshold	1	288	Very serious <sup>a</sup>	-	None	Serious <sup>d</sup>	87 (82, 91)	50 (33, 67)	VERY LOW
<b>Ultrasound</b>									
Ultrasound with no specified threshold <i>Pooled meta-analysis data</i>	6	4836	Very serious <sup>a</sup>	Very serious <sup>b</sup>	None	Very serious <sup>d</sup>	64 (48, 78)	87 (76, 94)	VERY LOW
Ultrasound hepatorenal contrast at 4.0 threshold	2	286	Very serious <sup>a</sup>	Serious <sup>b</sup>	None	Serious <sup>d</sup>	82 (74, 89)	63 (50, 74)	VERY LOW
Ultrasound hepatorenal contrast at 1.49 threshold							100 (92, 100)	91 (81, 97)	

Note: The assessment of the evidence quality was conducted with emphasis on test sensitivity as this was the primary measure discussed in decision making. If data were available from 3 or more studies, a diagnostic meta-analysis was performed and the pooled sensitivity and specificity result presented

(a) Risk of bias was assessed using the QUADAS-II checklist. Evidence quality was downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias.

(b) Inconsistency was assessed by inspection of the sensitivity forest plots, or diagnostic meta-analysis plots across studies, using the point estimates and confidence intervals. Particular attention was placed on values above or below 50% (diagnosis based on chance alone) and the 95% threshold set by the GDG (the threshold above which would be acceptable to recommend a test). The evidence was downgraded by 1 increment if the individual studies varied across 2 areas (for example 50-95% and 95-100%) and by 2 increments if the individual studies varied across 3 areas (for example 0-50%, 50-95% and 95-100%). Reasons for heterogeneity between studies could include the use of thresholds that were not pre-specified.

(c) Indirectness was assessed using the QUADAS-II checklist items referring to applicability. Evidence quality was downgraded by 1 increment if the majority of the evidence was at serious indirectness, and downgraded by 2 increments if the majority of the evidence was at very serious indirectness.

- (d) The judgement of precision was based on visual inspection of the confidence region in the diagnostic meta-analysis if a diagnostic meta-analysis was conducted. Where a diagnostic meta-analysis was not conducted, imprecision was assessed according to the range of point estimates. As a rule of thumb a range of 0-20% of differences in point estimates of sensitivity was considered not imprecise, 20-40% serious, and >40% very serious imprecision. Imprecision was assessed on the primary measure for decision making.
- (e) The GDG decided it was inappropriate to pool these 3 studies to obtain diagnostic meta-analysis summary sensitivity and specificity points due to the difference in scanners used to obtain the readings (1.5T versus 3T). Therefore, the sensitivity and specificity data are reported separately.

**Table 20: Clinical evidence profile: Clinical evidence profile (AUC): Diagnostic tests for steatosis ≥5%**

Index Test	No of studies	n	Risk of bias	Inconsistency	Indirectness	Imprecision	Area under the curve, median (range)	Quality
ALT	No evidence							
AST	No evidence							
CAP	5	704	Serious <sup>a</sup>	Serious <sup>b</sup>	None	None	88 (67, 97)	LOW
FLI	2	574	Very serious <sup>a</sup>	Serious <sup>b</sup>	None	Serious <sup>d</sup>	67 (59, 76) 83 (72, 91)	VERY LOW
GGT	No evidence							
MRI	8	730	Very serious <sup>a</sup>	Serious <sup>b</sup>	None	Serious <sup>d</sup>	93 (82, 100)	VERY LOW
MRS	4	305	Very serious <sup>a</sup>	Serious <sup>b</sup>	None	Serious <sup>d</sup>	91 (78, 97)	VERY LOW
NAFLD-LFS	1	324	Very serious <sup>a</sup>	-	None	None	80 (69, 88)	LOW
Steatotest	No evidence							
Ultrasound	4	405	Very serious <sup>a</sup>	Serious <sup>b</sup>	None	Serious <sup>d</sup>	77 (69, 100)	VERY LOW

- (a) Risk of bias was assessed using the QUADAS-II checklist. Author reported AUC are less informative than having the raw data or sensitivity and specificity data at a cut-off threshold.
- (b) Inconsistency was assessed by inspection of the AUC values for each index test across studies, using the point estimates and confidence intervals. Particular attention was placed on values above or below 50% (diagnosis based on chance alone) and the 95% threshold set by the GDG (the threshold above which would be acceptable to recommend a test). The evidence was downgraded by 1 increment if the individual studies varied across 2 areas (for example 50-95% and 95-100%) and by 2 increments if the individual studies varied across 3 areas (for example 0-50%, 50-95% and 95-100%).
- (c) Indirectness was assessed using the QUADAS-II checklist items referring to applicability.
- (d) The judgement of precision was based on the median AUC value and its 95% CI. Particular attention was placed on values above or below 50% (diagnosis based on chance alone) and the 95% threshold set by the GDG (the threshold above which would be acceptable to recommend a test). As a rule of thumb a range of 0-20% of differences in point estimates were considered not imprecise, 20-40% serious, and >40% very serious imprecision. Imprecision was assessed on the primary measure for decision making.

**Table 21: Clinical evidence profile (SENSITIVITY and SPECIFICITY): Diagnostic tests for steatosis  $\geq 30\%$** 

Index Test (Threshold)	No of studies	n	Risk of bias	Inconsistency	Indirectness	Imprecision	Sensitivity % (median/ range/ 95% CI)	Specificity % (median/ range/ 95% CI)	Quality
<b>Alanine transaminase (ALT)</b>									
No evidence									
<b>Aspartate aminotransferase (AST)</b>									
No evidence									
<b>Controlled attenuation parameter (CAP)</b>									
CAP at 200-249 threshold	2	786	Serious <sup>a</sup>	No serious inconsistency	None	Serious <sup>d</sup>	87 (78, 94) 83 (63, 95)	74 (70, 78) 78 (66, 87)	LOW
CAP at 250-299 threshold <i>Pooled meta-analysis data</i>	6	782	Serious <sup>a</sup>	Very serious <sup>b</sup>	None	Serious <sup>d</sup>	82 (68, 92)	83 (71, 91)	VERY LOW
CAP at 300+ threshold	1	112	Serious <sup>a</sup>	-	None	Serious <sup>d</sup>	58 (39, 75)	94 (86, 98)	LOW
<b>Fatty liver index (FLI)</b>									
FLI at 93.9 threshold	2	436	Very serious <sup>a</sup>	Very serious <sup>b</sup>	None	Very serious <sup>d</sup>	27 (13, 46)	96 (89, 99)	VERY LOW
FLI at 82 threshold							59 (52, 66)	69 (61, 77)	
<b>Gamma glutamyltransferase (GGT)</b>									
No evidence									
<b>Magnetic resonance imaging (MRI)</b>									
MRI-DE at 6.5 threshold	1	161	Serious <sup>a</sup>	-	None	Very serious <sup>d</sup>	91 (59, 100)	94 (89, 97)	VERY LOW
MRI PDFF at 11.08 threshold	2	166	Serious <sup>a</sup>	Serious <sup>b</sup>	None	Very serious <sup>d</sup>	88 (47, 100)	88 (78, 95)	VERY LOW
MRI PDFF at 22.1 threshold							64 (48, 78)	96 (85, 99)	
MRI %RSID at 19.22 threshold	1	36	Serious <sup>a</sup>	-	None	Very serious <sup>d</sup>	78 (40, 97)	100 (87, 100)	VERY LOW
<b>Magnetic resonance spectroscopy (MRS)</b>									
MRS at 2.7 threshold	3	231	Serious <sup>a</sup>	Serious <sup>b</sup>	None	Very serious <sup>d</sup>	100 (74, 100)	87 (66, 97)	VERY LOW
MRS at 7.7 threshold							73 (39, 94)	79 (72, 86)	
MRS at 10.2 threshold							100 (66, 100)	92 (75, 99)	

Index Test (Threshold)	No of studies	n	Risk of bias	Inconsistency	Indirectness	Imprecision	Sensitivity % (median/ range/ 95% CI)	Specificity % (median/ range/ 95% CI)	Quality
<b>NAFLD liver fat score (NAFLD-LFS)</b>									
NAFLD LFS at 0.16 threshold	1	324	Very serious <sup>a</sup>	-	None	None	78 (72, 84)	59 (51, 68)	LOW
<b>Steatotest</b>									
Steatotest at 0.94 threshold	2	400	Very serious <sup>a</sup>	Very serious <sup>b</sup>	None	Serious <sup>d</sup>	9 (2, 24)	42 (33, 50)	VERY LOW
Steatotest at 0.69 threshold							42 (33, 50)	79 (72, 85)	
<b>Ultrasound</b>									
Ultrasound with no specified threshold	9	5554	Very serious <sup>a</sup>	Very serious <sup>b</sup>	None	Serious <sup>d</sup>	79 (59, 91)	85 (77, 92)	VERY LOW
<i>Pooled meta-analysis data</i>									
Ultrasound (hepatorenal contrast) with 7 threshold	1	175	Serious <sup>a</sup>	-	None	Serious <sup>d</sup>	86 (67, 96)	85 (78, 90)	LOW

Note: The assessment of the evidence quality was conducted with emphasis on test sensitivity as this was the primary measure discussed in decision making. If data were available from 3 or more studies, a diagnostic meta-analysis was performed and the pooled sensitivity and specificity result presented.

- (a) Risk of bias was assessed using the QUADAS-II checklist. Evidence quality was downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias.
- (b) Inconsistency was assessed by inspection of the sensitivity forest plots, or diagnostic meta-analysis plots across studies, using the point estimates and confidence intervals. Particular attention was placed on values above or below 50% (diagnosis based on chance alone) and the 95% threshold set by the GDG (the threshold above which would be acceptable to recommend a test). The evidence was downgraded by 1 increment if the individual studies varied across 2 areas (for example 50-95% and 95-100%) and by 2 increments if the individual studies varied across 3 areas (for example 0-50%, 50-95% and 95-100%). Reasons for heterogeneity between studies could include the use of thresholds that were not pre-specified.
- (c) Indirectness was assessed using the QUADAS-II checklist items referring to applicability. Evidence quality was downgraded by 1 increment if the majority of the evidence was at serious indirectness, and downgraded by 2 increments if the majority of the evidence was at very serious indirectness.
- (d) The judgement of precision was based on visual inspection of the confidence region in the diagnostic meta-analysis if a diagnostic meta-analysis was conducted. Where a diagnostic meta-analysis was not conducted, imprecision was assessed according to the range of point estimates. As a rule of thumb a range of 0-20% of differences in point estimates of sensitivity was considered not imprecise, 20-40% serious, and >40% very serious imprecision. Imprecision was assessed on the primary measure for decision making – sensitivity.
- (e) The quoted specificity value is the value associated with the median sensitivity (the primary measure) in order to maintain paired values; sensitivity was the primary measure discussed in decision making.



**Table 22: Clinical evidence profile (AUC): Diagnostic tests for steatosis  $\geq 30\%$** 

Index Test	No of studies	n	Risk of bias	Inconsistency	Indirectness	Imprecision	Area under the curve, median (range)	Quality
ALT	No evidence							
AST	No evidence							
CAP	8	1479	Serious <sup>a</sup>	Serious <sup>b</sup>	None	Very serious <sup>d</sup>	86 (69, 100)	VERY LOW
FLI	2	436	Very serious <sup>a</sup>	None	None	Serious <sup>d</sup>	71 (59, 83) 65 (59, 71)	VERY LOW
GGT	No evidence							
MRI	3	327	Serious <sup>a</sup>	Serious <sup>b</sup>	None	Serious <sup>d</sup>	95 (85, 100)	VERY LOW
MRS	2	196	Serious <sup>a</sup>	Serious <sup>b</sup>	None	None	91 (85, 95) 98 (95, 100)	LOW
NAFLD-LFS	1	574	Serious <sup>a</sup>	-	None	None	72 (66, 77)	MODERATE
Steatotest	2	400	Very serious <sup>a</sup>	None	None	Serious <sup>d</sup>	73 (61, 84) 70 (63, 75)	VERY LOW
Ultrasound	1	175	Serious <sup>a</sup>	-	None	None	93 (88, 97)	MODERATE

(a) Risk of bias was assessed using the QUADAS-II checklist. Author reported AUC are less informative than having the raw data or sensitivity and specificity data at a cut-off threshold.

(b) Inconsistency was assessed by inspection of the AUC values for each index test across studies, using the point estimates and confidence intervals. Particular attention was placed on values above or below 50% (diagnosis based on chance alone) and the 95% threshold set by the GDG (the threshold above which would be acceptable to recommend a test). The evidence was downgraded by 1 increment if the individual studies varied across 2 areas (for example 50-95% and 95-100%) and by 2 increments if the individual studies varied across 3 areas (for example 0-50%, 50-95% and 95-100%).

(c) Indirectness was assessed using the QUADAS-II checklist items referring to applicability.

(d) The judgement of precision was based on the median AUC value and its 95% CI. Particular attention was placed on values above or below 50% (diagnosis based on chance alone) and the 95% threshold set by the GDG (the threshold above which would be acceptable to recommend a test). The evidence was downgraded by 1 increment if the confidence interval varied across 2 areas (for example 50-95% and 95-100%) and by 2 increments if the confidence interval varied across 3 areas (for example 0-50%, 50-95% and 95-100%).

## 1 **6.4 Economic evidence**

### 2 **6.4.1 Published evidence**

3 No relevant economic evaluations were identified.

4 See also the economic article selection flow chart in Appendix F.

### 5 **6.4.2 Unit costs**

6 See Table 61 in Appendix N.

### 7 **6.4.3 New cost-effectiveness analysis**

8 Original cost-effectiveness modelling was undertaken for this question. A summary is included here.  
9 An evidence statement summarising the results of the analysis can be found below. The full analysis  
10 can be found in Appendix N.

#### 11 **6.4.3.1 Aim and structure**

12 The ultimate aim of the health economic model was to determine the most cost-effective diagnostic  
13 test to detect steatosis 5% and whom to test (according to specific risk factors). Within the scope of  
14 the model was also to examine the cost-effectiveness of the various retest frequencies for every risk  
15 factor group. For these purposes a lifetime health state transition (Markov) model was constructed,  
16 following the NICE reference case,<sup>126</sup> which depicted the patient pathway of liver disease from the  
17 development of early steatosis to liver transplant.

18 The diagnostic strategies compared were:

- 19 • CAP at 200–249
- 20 • fatty liver index at 60
- 21 • MRI PDFF at 6.87
- 22 • MRS at 0-5
- 23 • liver fat score at 0.16
- 24 • Steatotest at 0.38
- 25 • ultrasound
- 26 • liver biopsy
- 27 • no test – no monitoring
- 28 • no test – monitor all.

29 The population was adults with suspected NAFLD, categorised into the following subgroups:

- 30 • Obese (BMI $\geq$ 30)
- 31 • Wide waist circumference ( $\geq$ 102cm for men,  $\geq$ 88cm for women)
- 32 • Diabetes (Glycaemia $\geq$ 110mg/dl)
- 33 • Low HDL (<40mg/dl men, <50mg/dl women)
- 34 • High triglycerides ( $\geq$ 150mg/dl)
- 35 • Metabolic syndrome (NCEP criteria)

36 The model used diagnostic accuracy data from studies identified in the present guideline review. Test  
37 costs were obtained from published literature and GDG sources. Health states costs were

## Diagnosis of NAFLD

constructed under GDG guidance specifically for the purposes of the model. Utilities and transition probabilities were mostly obtained from published literature and through extrapolations from other liver diseases where there was a lack of evidence. The model was built probabilistically to take account of the uncertainty around input parameter point estimates.

Cost-effectiveness was defined by the value of the net monetary benefit (NMB) attributed to every test. The decision rule applied is that the comparator with the highest NMB is the most cost-effective option at the specified £20,000 per extra QALY threshold.

#### 6.4.3.2 Results

Testing for steatosis 5% was considered cost-effective at a £20,000 threshold for all retest frequencies. This varied depending on the specified retest frequency. Irrespective of the risk factor examined, the 5-year retest frequency delivered the highest NMB benefit for FLI (first ranking test). In all combinations of risk factor and retest frequency the testing strategies had the following ranking (specific figures apply to people with type 2 diabetes at a 5 year retest frequency).

Test	Mean cost (£)	Mean QALYs	NMB (£) at £20,000/QALY	Rank
CAP at 200–249	7,588	15.39	300,140	7
FLI at 60	6,658	15.36	300,497	1
MRI PDFF at 6.87	6,704	15.35	300,370	4
MRS at 0-5	7,277	15.38	300,305	5
Ultrasound	6,793	15.36	300,410	2
LFS at 0.16	6,507	15.34	300,383	3
Steatotest at 0.38	7,544	15.38	300,147	6
Liver biopsy	8,127	15.40	299,842	9
No test – treat all	7,932	15.39	299,953	8
No test – no treatment	3,902	15.18	299,764	10

Among the 8 diagnostic tests compared, FLI ranked first carrying the best combination of test unit costs and diagnostic accuracy. Ultrasound ranked second having lower sensitivity (64% against FLI's 76%) and noticeably higher test unit costs. LFS closely followed ultrasound with a slightly lower NMB. MRI and MRS ranked fourth and fifth across all tests having the highest diagnostic accuracy but for a considerably higher test unit cost. Most of the aforementioned tests had similarly wide 95% confidence intervals ranking from first to eighth.

In the deterministic sensitivity analysis FLI remained first in 17 out of the 27 tested scenarios. MRI was second in most scenarios. LFS remained third in all scenarios apart from where the FLI diagnostic sensitivity was set at its low CI (ranked second). The no test – all negative strategy ranked first in the scenarios where 58 years was set as the starting age and the scenarios where the transition probabilities representing the liver disease progression were reduced by 50%.

## 6.5 Evidence statements

### 6.5.1 Clinical

#### Diagnosing steatosis ≥5%

- No evidence was identified to determine the diagnostic accuracy of ALT, AST or GGT as separate tests.
- Low quality evidence from 2 studies which could not be pooled showed sensitivities of 91% (79-98) and 87% (75-95; and specificities of 52% (39-64) and 77% (68-85) for CAP using thresholds between 200-249. Very low quality evidence from a diagnostic meta-analysis of 3 studies (n=440)

## Diagnosis of NAFLD

- 1 showed a pooled sensitivity of 76% (47-94) and a pooled specificity of 87% (65-97) for CAP used at  
 2 a threshold between 250-300. The median AUC from these 5 studies was 88 with a range across  
 3 study confidence intervals of 67 to 97.
- 4 • Low quality evidence from 2 studies (n=574) showed sensitivities of 81% (75-86) and 76% (71-81)  
 5 and specificities of 49% (36-63) and 87% (60-98) for FLI using thresholds of 79 and 60. The AUC  
 6 from these 2 studies were 67 and 83 with confidence intervals ranging from 59 to 91.
  - 7 • Low quality evidence from 2 studies showed MRI-DE used at thresholds of 4.0 or 11.08 had  
 8 sensitivities of 77% (64-87) and 86% (57-98), and specificities of 87% (79-93) and 78% (64-89).  
 9 Very low quality evidence from 2 studies showed that calculating the fat fraction using MRI with  
 10 thresholds of 3.42 and 1.5 had sensitivities of 100% (78-100) and 90% (70-99), and specificities of  
 11 77% (63-88) and 91% (71-99). Moderate quality evidence from 1 study looking at the fat water  
 12 ratio of < 0 on MRI found sensitivity of 97% (84-100) and specificity of 86% (42-100). Very low  
 13 quality evidence from 3 studies (including the only identified study in children and young people)  
 14 using MRI PDFF at thresholds of 6.87 and 6.4 found sensitivities of 68% (60-75), 87% (70-96) and  
 15 86% (76-92) and specificities of 96% (79-100), 98% (88-100) and 83% (36-100). The lowest of  
 16 these accuracy readings came from the study in children and young people. Low quality evidence  
 17 from 1 study using %RSID on MRI at a threshold of -0.74 found sensitivity of 87% (66-97) and  
 18 specificity of 69% (39-91). Low quality evidence from 1 study on MRI-TE at 5.35 found sensitivity  
 19 of 93% (66-100) and specificity of 96% (85-99). The median AUC from 8 of the 9 studies was 93  
 20 with a range across study confidence intervals of 82 to 100.
  - 21 • Low quality evidence from a diagnostic meta-analysis of 3 studies (n=265) showed a pooled  
 22 sensitivity of 86% (63-98) and a pooled specificity of 82% (59-95) for MRS at a threshold range  
 23 within 0-5. Low quality evidence from 1 study (n=38) using a higher threshold of 5.7 found a  
 24 sensitivity of 85% (62-97) and a specificity of 94% (70-100). The median AUC from these 4 studies  
 25 was 91 with a range across study confidence intervals of 78 to 97.
  - 26 • Very low quality evidence from 1 study (n=324) showed a sensitivity of 65% (59-70) and a  
 27 specificity of 87% (60-98) for the NAFLD-LFS at a threshold of 0.16. The AUC from this study was  
 28 80 (69-88).
  - 29 • Very low quality evidence from 1 study (n=288) showed a sensitivity of 87% (82-91) and a  
 30 specificity of 50% (33-67) for Steatotest at a threshold of 0.38. This study did not report AUC data.
  - 31 • Very low quality evidence from a diagnostic meta-analysis of 6 studies (n=4836) showed a pooled  
 32 sensitivity of 64% (48-78) and a pooled specificity of 87% (76-94) for ultrasound. Very low quality  
 33 evidence from 2 studies using the hepatorenal contrast ratio of 4.0 or 1.49 found sensitivities of  
 34 82% (74-89) and 100% (92-100) and specificities of 63% (50-74) and 91% (81-97). The median AUC  
 35 from 4 of these studies that reported AUC data was 77 with a range across study confidence  
 36 intervals of 69 to 99.
- 37 **Diagnosis steatosis  $\geq 30\%$**
- 38 • No evidence was identified to determine the diagnostic accuracy of ALT, AST or GGT as separate  
 39 tests.
  - 40 • Low quality evidence from 2 studies (n=786) using a CAP threshold between 200-249 found  
 41 sensitivities of 87% (78-94) and 83% (63-95) and specificities of 74% (70-78) and 78% (66-87). Very  
 42 low quality evidence from a diagnostic meta-analysis of 6 studies (n=782) showed a pooled  
 43 sensitivity of 82% (68-92) and a pooled specificity of 83% (71-91) for CAP at a threshold of 250-  
 44 299. Low quality evidence from 1 study using a higher threshold of 311 found a sensitivity of 58%  
 45 (39-75) and a specificity of 94% (86-98). The median AUC from these eight studies was 86 with a  
 46 range across study confidence intervals of 69 to 100.
  - 47 • Very low quality evidence from 2 studies (n=436) showed sensitivities of 27% (13-46) and 59%  
 48 (52-66) and specificities of 96% (89-99) and 69% (61-77) for FLI at thresholds of 93.9 and 82. The  
 49 AUC from these 2 studies were 65 and 71 with confidence intervals ranging from 59 to 83.

## Diagnosis of NAFLD

- 1 • Very low quality evidence from 1 study (n=161) showed sensitivity of 91% (59-100) and specificity  
2 of 94% (89-97) for MRI-DE with a threshold of 6.5. Very low quality evidence from 2 studies  
3 (n=166) looking at MRI PDFF with thresholds of 11.08 and 22.1 showed sensitivities of 88% (47-  
4 100) and 64% (48-78) and specificities of 88% (78-95) and 96% (85-99). Very low quality evidence  
5 from 1 study (n=36) looking at %RSID on MRI at a threshold 19.22 found a sensitivity of 78% (40-  
6 97) and a specificity of 100% (87-100). The mean AUC from 3 studies which reported AUC data  
7 was 95 (85-100).
- 8 • Very low quality evidence from 3 studies (n=231) looking at MRS that could not be pooled due to  
9 high variation in thresholds (2.7, 7.7 and 10.2) showed a sensitivities of 100% (74-100), 73% (39-  
10 94) and 100% (66-100) and specificities of 87% (66-97), 79% (72-86) and 92% (75-99). The AUC  
11 from 2 of the 3 studies were 91 and 98 with confidence intervals ranging from 85 to 100.
- 12 • Very low quality evidence from 1 study (n=324) showed a sensitivity of 78% (72-84) and a  
13 specificity of 59% (51-68) for the NAFLD-LFS at 0.16 threshold. The AUC from this study was 72  
14 (66-77).
- 15 • Very low quality evidence from 2 studies (n=400) showed sensitivities of 9% (2-24) and 42% (33-  
16 50) and specificities of 42% (33-50) and 79% (72-85) for Steatotest at thresholds of 0.94 and 0.69.  
17 The AUC from these 2 studies were 70 and 73 with confidence intervals ranging from 61 to 84.
- 18 • Very low quality evidence from a diagnostic meta-analysis of 9 studies (n=5554) showed a pooled  
19 sensitivity of 79% (59-91) and a pooled specificity of 85% (77-92) for ultrasound when no  
20 threshold was specified. Low quality evidence from 1 study (n=175) son hepatorenal contrast  
21 using ultrasound with a threshold of 7 showed a sensitivity of 86% (67-96) and a specificity of 85%  
22 (78-90). Only 1 study reported AUC and this was 93 (88-97).

23 **6.5.2 Economic**

- 24 • One original cost-utility analysis that compared 10 different diagnostic strategies to detect NAFLD  
25 found that FLI ranked first compared to the following diagnostic strategies at a retest frequency of  
26 5 years, using relevant thresholds for each test, with reference to a cost-effectiveness threshold  
27 of £20,000 per QALY gained:
- 28 o ultrasound
  - 29 o NAFLD liver fat score
  - 30 o MRI PDFF
  - 31 o MRS
  - 32 o SteatoTest
  - 33 o CAP
  - 34 o no test – no treatment
  - 35 o liver biopsy
  - 36 o no test – treat all.

37 This analysis was assessed as directly applicable with minor limitations.

38

39

## 1 6.6 Recommendations and link to evidence

<p><b>Recommendations</b></p>	<ol style="list-style-type: none"> <li>2. Take an alcohol history to rule out alcohol-related liver disease. See also NICE's <a href="#">cirrhosis</a> guideline<sup>a</sup>.</li> <li>3. Do not use routine liver blood tests to rule out NAFLD.</li> <li>4. Consider testing adults for NAFLD if: <ul style="list-style-type: none"> <li>• they have type 2 diabetes or metabolic syndrome and</li> <li>• alcohol-related liver disease has been ruled out.</li> </ul> </li> <li>5. Use the fatty liver index (FLI) test if testing adults for NAFLD.</li> <li>6. Diagnose adults with NAFLD if: <ul style="list-style-type: none"> <li>• they have an FLI score of 60 or above and</li> <li>• other suspected causes of fatty liver have been ruled out.</li> </ul> </li> <li>7. Consider retesting adults for NAFLD using FLI every 5 years if they have: <ul style="list-style-type: none"> <li>• an FLI score of less than 60 and</li> <li>• type 2 diabetes or metabolic syndrome.</li> </ul> </li> <li>8. Test children and young people for NAFLD using ultrasound if they: <ul style="list-style-type: none"> <li>• have type 2 diabetes or metabolic syndrome and</li> <li>• do not misuse alcohol.</li> </ul> </li> <li>9. Diagnose children and young people with NAFLD if: <ul style="list-style-type: none"> <li>• they have fatty liver on ultrasound and</li> <li>• other suspected causes of fatty liver have been ruled out.</li> </ul> </li> <li>10. Retest children and young people for NAFLD using ultrasound every 3 years if they have: <ul style="list-style-type: none"> <li>• a normal ultrasound and</li> <li>• type 2 diabetes or metabolic syndrome.</li> </ul> </li> </ol>
<p><b>Research recommendation</b></p>	<p><b>2. Which non-invasive tests most accurately diagnose NAFLD and advanced liver fibrosis in children and young people?</b></p>
<p>Relative values of different diagnostic measures and outcomes</p>	<p>The GDG evaluated the evidence for both diagnostic tests assessing for at least 5% steatosis, as well as those assessing for at least 30% steatosis. The threshold of greater than or equal to 5% steatosis was selected because at least 5% of hepatocytes containing fat on a liver biopsy sample is the conventional histological diagnostic criterion for hepatic steatosis. Greater than or equal to 30% steatosis was selected as it is broadly accepted that this is the threshold at which hepatic steatosis may generally be observed on ultrasonography; the conventional means by which fatty liver has typically been identified. The GDG observed that whilst certain chronic</p>

<sup>a</sup> The NICE cirrhosis guideline is currently out for consultation

## Diagnosis of NAFLD

	<p>liver pathologies may occur in a patchy fashion throughout the organ and therefore may potentially be missed on a liver biopsy (for example, regenerative cirrhotic nodules), people with NAFLD tend to have hepatic steatosis distributed reasonably evenly throughout the organ, meaning that liver biopsy is still widely accepted as the diagnostic 'gold standard' for NAFLD.</p> <p>No studies were identified that used liver blood test measurements alone as a diagnostic test. However, the GDG noted that liver enzyme measurements form part of 3 of the diagnostic tests under evaluation in this review (FLI, NAFLD-LFS, and SteatoTest). Evidence was identified and reviewed for all 3 of these tests.</p>
Trade-off between clinical benefits and harms	<p>The GDG noted that only 1 of the identified studies (which looked at the effectiveness of MRI) had been performed in children or young people. The likely explanation for this is that very few of the diagnostic techniques under investigation in this review have been validated within cohorts of children and young people with NAFLD. In addition, there is a high threshold to carry out liver biopsy to diagnose this condition in children and young people due to its invasiveness. In this age group this procedure is therefore mainly carried out if there is diagnostic doubt or if there is concern about more advanced disease. Therefore, it is unlikely that studies matching the review protocol with liver biopsy as the reference standard would be widely conducted in this younger population.</p> <p>Members of the GDG noted that, at present, the imaging tests included within this review may be difficult to access within primary care, with even ultrasound not always being easily accessible. Furthermore, the GDG expressed some concerns about the interpretation of results of these imaging tests; for example, the GDG noted a wide range of practice in the means by which fatty liver is identified by clinicians performing ultrasound, as there is no universally accepted definition on what exactly constitutes a diagnosis of steatosis on ultrasound.</p> <p>The GDG also expressed concerns about certain practicalities regarding non-imaging diagnostic tests. For example, NAFLD-LFS includes measurement of fasting insulin, and this is not a test typically performed routinely within primary care.</p> <p>The GDG concluded that the identified studies provided evidence for all 4 of the imaging techniques under review (CAP, MRI, MRS, and abdominal ultrasound) as being sufficiently effective tests for detecting both <math>\geq 5\%</math> and <math>\geq 30\%</math> steatosis in adults. This justified their inclusion within cost-effectiveness modelling. The opinion of the GDG was that MRI and MRS appeared to be the most accurate imaging techniques for diagnosing NAFLD in adults (for example, MRI and MRS were the only diagnostic tests under review with evidence for an AUC <math>\geq 90\%</math> at both <math>\geq 5\%</math> and <math>\geq 30\%</math> steatosis), with MRI and MRS appearing to be of similar efficacy to each other. However, the GDG noted that MRS is still largely a research tool.</p> <p>The GDG also reviewed the evidence for non-imaging based diagnostic tests for NAFLD in adults. Of these, it appeared that the FLI test was the most effective; however, the GDG noted that different studies showed variable specificity for the FLI test in diagnosing <math>\geq 5\%</math> steatosis, and that FLI appeared to demonstrate very high specificity but more limited sensitivity in diagnosing <math>\geq 30\%</math> steatosis. On balance, however, it was agreed that the FLI test should be included within cost modelling, using a threshold of 60 or above to denote presence of NAFLD.</p> <p>The GDG felt that SteatoTest and NAFLD-LFS appeared to be much less effective tests for diagnosing NAFLD in adults (noting the low specificity of SteatoTest and limited sensitivity of NAFLD-LFS in detecting <math>\geq 5\%</math> steatosis, along with the poor sensitivity of SteatoTest and low specificity of NAFLD-LFS in detecting <math>\geq 30\%</math> steatosis). Nevertheless, despite these concerns, the GDG concluded that the SteatoTest and NAFLD-LFS tests still, overall, had sufficient sensitivity and specificity to merit inclusion within the cost modelling.</p> <p>The results of the original economic model demonstrated that FLI was the most cost-effective test to use to diagnose NAFLD in adults who had type 2 diabetes or metabolic syndrome. A threshold of FLI <math>&gt;60</math> was felt the most appropriate one by the</p>

## Diagnosis of NAFLD

	<p>GDG, as this was the score that generated maximum sensitivity for the diagnosis of hepatic steatosis in the reviewed literature.<sup>50</sup> Ultrasound was the next most cost-effective option after FLI.</p> <p>It was noted that all evidence for FLI was from an adult population. The GDG expressed concern that this test was not validated in children and young people and as waist circumference (1 of the 3 components of the FLI) is not a reliable predictor of NAFLD in children and young people, agreed that it was not appropriate to extrapolate the evidence from the adult population for this test. Ultrasound is the next most cost-effective option and the GDG agreed it was widely accepted as an appropriate diagnostic tool for children and young people as there was no clinical reason to believe that the performance would differ in a younger population. The GDG therefore recommended that ultrasound should be used as the preferred diagnostic test for NAFLD in children and young people. It was agreed that as the health benefits of identifying NAFLD in children, where present, would extend over a longer time-horizon than adults, this test should be offered to children in which NAFLD is suspected.</p> <p>The GDG was informed by evidence from the review in Chapter 5 on risk factors for NAFLD and the economic model for the frequency of retesting for presence of NAFLD in those who had a negative FLI result in adults, or ultrasound in children and young people. It was agreed that it was appropriate to consider retesting adults with NAFLD and the aforementioned risk factors every 5 years, as there was evidence that this was both clinically and cost-effective. However, there was concern that children and young people are rapidly developing and experiencing hormonal changes which may affect their risk of developing NAFLD. Furthermore, type and volume of food intake and type and frequency of physical activity undertaken changes immensely in younger people over short periods of time. For these reasons, the GDG agreed that a recommendation for retesting every 3 years in children and young people was warranted, based on expert opinion, so as not to miss the development of NAFLD.</p>
Trade-off between net clinical effects and costs	<p>No relevant published economic evaluations were identified.</p> <p>Original cost-utility analysis was conducted for this guideline to address the questions in this review and also Chapters 5, 7 and 8. No economic analysis was conducted relating to children and young people under 18 years due to a lack of data on the diagnostic accuracy of these tests in under 18s.</p> <p>This analysis found that FLI was the most cost-effective of the 8 diagnostic tests and 2 non-testing strategies being compared for adults, followed by ultrasound, LFS and MRI. The GDG noted that the cost-effectiveness of all the tests was similar, as the overall difference in future health (in QALYs) for a person following the addition of testing with one or other of these different tests was small. A probabilistic sensitivity analysis showed that 5 of the 8 tests (along with not testing and not treating anyone for NAFLD) could be the preferred strategy within the bounds of 95% confidence. The probabilistic sensitivity analysis conducted showed FLI was the preferred option in 34% of simulations for metabolic syndrome with 5 years retesting, with MRI being preferred in 20% and no testing being most cost-effective in 22%.</p> <p>The model showed that the difference in the cost-effectiveness of different retesting intervals was small, but 5-yearly retesting was favoured for the base case (ICERS for people with type 2 diabetes: £15,682 per QALY gained for 5-yearly retesting compared to 6-yearly retesting, but £32,861 per QALY gained for 4-yearly testing compared to 5-yearly testing; with similar figures for metabolic syndrome).</p> <p>The GDG noted that the cost of conducting FLI is very small, and the difference in costs between strategies largely consists of the treatments given and additional further tests undertaken by people after they are diagnosed with NAFLD. The average health benefit per person is also small. However, the model does assume in the no testing strategy that not only are people not tested at the start, but they will not be tested for NAFLD, advanced fibrosis or cirrhosis at any later stage, and they will not need to receive any treatment (and so incur any cost) unless and until they</p>



reach the stage of symptomatic decompensated cirrhosis. This is likely to be a cautious assumption, diminishing the effectiveness of testing compared to no testing.

The GDG also considered the practical feasibility of offering different diagnostic tests to all those with metabolic syndrome or type 2 diabetes. The GDG noted that FLI could be easily conducted by GPs in primary care, without referring individuals to secondary care for initial testing. In contrast, ultrasound is not routinely accessible in many primary care practices, and so a recommendation to use ultrasound for diagnosis would require the referral of a very large number of people to secondary services. Since such services do not currently have spare ultrasound capacity, this would require a large upfront increase in ultrasound equipment and personnel in order to fulfil such a recommendation. MRI has the same disadvantages, but more so, as an upfront increase in capacity would be even more expensive. In addition, it is likely that some people would either be unwilling to be referred or would not take up their appointment in secondary care, and so a strategy where consultation and testing can be conducted in a GP surgery within a single visit is likely to maximise the number of people taking up the offer of diagnostic testing. Therefore, not only is FLI the most cost-effective of the diagnostic tests, it would also be the easiest to practically implement.

The GDG explored the robustness of the results of the original economic analysis by conducting extensive sensitivity analyses.

The base case assumes a very modest benefit from a lifestyle modification programme (see Chapter 13), involving a benefit to quality of life during the year of the intervention, but no lasting benefit. The effect of not offering lifestyle modification was modelled, and testing was still preferred to no testing.

In the base case it was not assumed that people on the no testing strategy would have fewer primary care appointments, as given their underlying condition (for example, type 2 diabetes) it was assumed that they would be seeing their GP regularly in any case. However this was tested by adding in the cost of an additional appointment in each testing cycle for people receiving diagnostic tests. This made a small difference to overall costs but did not alter the order of ranking of the strategies.

The GDG also noted the relatively high proportion of deaths of people in the model from liver-related causes. The GDG believed this is consistent with recent studies following up the causes of death of people with NAFLD,<sup>13,45,232</sup> but was aware that this is a higher death rate than is typically reported in national mortality statistics. The GDG believed that this is likely to be due to systematic underreporting of liver problems as a cause of death, combined with a higher rate of death from liver-related causes in people with type 2 diabetes than in the general population (2.5 times the average rate<sup>37</sup>), and the fact that deaths from liver-related causes continue to rise, whilst deaths from other causes (notably cardiovascular disease) continue to fall: this model predicts that deaths from liver-related causes will continue to rise in future. The GDG was also aware that people with NAFLD typically have higher risk of death from cardiovascular causes than the general population (HR 1.55 according to 1 recent study<sup>45</sup>). As the rates of other (not liver-related) death in this model were taken from the general (age-related) population, these may underestimate the risk of other-cause death. To test the possible impact of these factors, sensitivity analyses were undertaken decreasing liver-related mortality rates; increasing other-cause mortality rates; decreasing the progression of people from each stage of NAFLD or fibrosis to the next, thus lowering the number of people with cirrhosis and so dying from cirrhosis; and combinations of these. Only when the transition from advanced fibrosis to cirrhosis was decreased by half did no testing become preferable to testing.

Finally, the GDG noted that the age for starting the model was set at 45 in the base case, in line with the average age of people receiving diagnostic tests in the studies included in the clinical review for accuracy of the diagnostic tests. However, this may

Diagnosis of NAFLD

	<p>be lower than would be expected for people with metabolic syndrome or type 2 diabetes. The NICE Type 2 diabetes guideline NG28 used a diagnosis age of 57.8 years for type 2 diabetes. If the starting age is increased in the economic model, testing (using FLI) becomes decreasingly cost-effective compared to no testing, and crosses the threshold of £20,000 per QALY at almost exactly 57.8 years. The ICER for FLI compared to no testing at 58 years is £20,176. If additional variations are made to the model favouring no testing (such as increasing the number of GP appointment or removing the effect of lifestyle modification), then that increases this ICER further, and makes FLI less cost-effective. In considering these analyses, the GDG noted that testing is cost-effective at a threshold of £20,000 per QALY under the base case conditions it pre-specified, but not under all sensitivity analyses, in particular if the average age of people when first tested was to be increased to 58 or higher. As a result the GDG cannot be absolutely sure if a strategy of testing everyone with type 2 diabetes or metabolic syndrome for NAFLD would be cost-effective for those specific populations. Therefore, the GDG recommends that testing for NAFLD should be considered for adults in these groups. When testing for NAFLD is undertaken, FLI should be used as the preferred diagnostic test. It was agreed that retesting should be considered every 5 years for adults with a negative test result if they still have metabolic syndrome or type 2 diabetes.</p>
<p>Quality of evidence</p>	<p>Many of the included studies included large numbers of people with NAFLD, although the quality of the assessed evidence was all low or very low by GRADE criteria. Much of the evidence was assessed as being at serious or very serious risk of bias due to issues with patient selection, unclear reporting on whether the index test results were interpreted without knowledge of biopsy findings, lack of pre-specified thresholds for the index tests and unclear timing between index test and biopsy. Further adding to the downgrading of the evidence was the imprecision around the effects and heterogeneity of results.</p> <p>In addition, the GDG observed that identified studies used a range of thresholds to maximise diagnostic accuracy within their study populations, with the thresholds rarely pre-specified. This may reflect that some of the diagnostic methods being assessed are relatively new technologies, which operators are still learning to use and for which normal ranges have not yet fully been defined. The following ranges of thresholds were used for each test:</p> <ul style="list-style-type: none"> <li>• When diagnosing steatosis ≥5%: CAP: 219–289 dB/m (median 250); FLI: 60–79; MRI: 0–5.7 % (median 3.42); MRS: 1.8–4.73 (median 2.6); NAFLD-LFS: 0.16; SteatoTest: 0.38; ultrasound: unclear threshold interpretations.</li> <li>• When diagnosing steatosis ≥30%: CAP: 230–311 dB/m (medians 285 and 288); FLI: 82–93.9; MRI: 6.5 %; MRS: 2.7–10.2 (median 7.7); NAFLD-LFS: 0.16; SteatoTest: 0.69–0.94; ultrasound: unclear threshold interpretations.</li> </ul> <p>The economic study included in this review was of high quality, being directly applicable and with minor limitations.</p>
<p>Other considerations</p>	<p>The FLI formula is publicly available and is calculated as:</p> $FLI\ score = \left( \frac{e^{0.953 \times \log_e(\text{triglycerides}) + 0.139 \times BMI + 0.718 \times \log_e(\text{ggt}) + 0.053 \times \text{waist circumference} - 15.745}}{1 + e^{0.953 \times \log_e(\text{triglycerides}) + 0.139 \times BMI + 0.718 \times \log_e(\text{ggt}) + 0.053 \times \text{waist circumference} - 15.745}} \right) \times 100$ <p>Although there are many causes for steatosis and consequently a potentially wide differential diagnosis in practice, the principal differential is between primary, metabolic syndrome-related NAFLD and alcohol-related liver disease. Discriminating these is reliant upon a detailed history and seeking corroboration from family members where available to ensure that any history of occult excessive alcohol consumption is excluded. An arbitrary threshold for ethanol consumption of &lt;20 g/day for women and &lt;30 g/day for men is adopted to sustain a diagnosis of NAFLD. For people with abnormal liver blood tests and either suspected or confirmed fatty liver, alternative causes must be excluded with a detailed drug history and laboratory tests for chronic viral hepatitis (HBVsAg and HCV serology),</p>

autoimmune liver disease (ANA, AMA, SMA, LKM1 antibodies, immunoglobulins) and other treatable metabolic diseases (haemochromatosis, Wilson's disease, coeliac disease, alpha-1 antitrypsin deficiency). The GDG agreed that it would be expected that clinicians using these guidelines would apply their clinical discretion regarding the appropriate degree of further investigation for possible alternate causes for the finding of fatty liver based on the specific clinical scenario, before confirming a diagnosis of NAFLD.

The GDG discussed the issue of the role of liver blood tests in assessing for presence of NAFLD. Specifically, the GDG noted that even though NAFLD is a very common cause of abnormal liver blood tests, published data have demonstrated that the majority of people with NAFLD (more than 70%) in fact have normal serum liver enzyme levels.<sup>21</sup> The GDG's shared experience was that many clinicians have the misperception that the finding of a person having normal liver blood tests is incompatible with them having NAFLD. The GDG agreed it was important to emphasise in the recommendations that clinicians should not rely on liver blood tests to rule out NAFLD.

The GDG noted that although alcohol-related liver disease is considered to be rare in children and young people, the risks of alcohol intake should still be considered in a paediatric population and should be part of the clinical consultation; therefore hazardous drinking should be taken into account when diagnosing NAFLD.

#### **Research recommendation**

The GDG made a high-priority research recommendation to identify the most accurate non-invasive tests to diagnose NAFLD in children and young people. See Appendix P for further details.

# 7 Diagnosing the severity of NAFLD

## 7.1 Introduction

Whilst it is clear that NAFLD is common within the general population, this generally causes little in the way of morbidity or mortality. Problems arise with the development of inflammation and fibrosis. It is important to be able to assess the severity of the disease process; in particular, it is essential to be able to assess the amount of fibrosis present, as this is the best predictor of prognosis. The GDG was particularly interested in the utility of diagnostic tools to identify patients with advanced fibrosis as recent studies have demonstrated that it is only patients with this degree of fibrosis that suffer long term liver-related morbidity and mortality. Historically, assessment of severity has been done using liver biopsy, an invasive procedure which carries its own risks.

The aim of this review is to assess the utility of available diagnostic tools in terms of being able to classify the various stages of NAFLD, in particular NASH and advanced fibrosis.

## 7.2 Review question: Which assessment tool is most accurate in identifying the severity or stage of NAFLD?

For full details see review protocol in Appendix A.

**Table 23: Characteristics of review question**

<b>Population</b>	Adults, children and young people with NAFLD
<b>Target condition</b>	NASH Any fibrosis ( $\geq$ F1) Advanced fibrosis ( $\geq$ F3)
<b>Index tests</b>	<p>For NASH</p> <ul style="list-style-type: none"> <li>• Cytokeratin-18</li> <li>• AST/ALT ratio</li> <li>• ALT</li> <li>• Ferritin</li> <li>• NASH test</li> </ul> <p>For fibrosis</p> <ul style="list-style-type: none"> <li>• Blood tests               <ul style="list-style-type: none"> <li>○ ALT</li> <li>○ AST/ALT ratio</li> <li>○ AST-to-platelet ratio index (APRI)</li> <li>○ BARD score</li> <li>○ Enhanced liver fibrosis (ELF) test</li> <li>○ Ferritin</li> <li>○ Fibrosis 4 (FIB4)</li> <li>○ Fibrometer</li> <li>○ Fibrotest</li> <li>○ NAFLD fibrosis score</li> </ul> </li> <li>• Imaging techniques               <ul style="list-style-type: none"> <li>○ Acoustic radiation force impulse imaging (ARFI)</li> <li>○ Diffusion weighted magnetic imaging</li> </ul> </li> </ul>

## Diagnosing the severity of NAFLD

	<ul style="list-style-type: none"> <li>○ MRI</li> <li>○ MRS</li> <li>○ MR elastography</li> <li>○ Shear wave elastography</li> <li>○ Transient elastography</li> </ul>
<b>Reference standard</b>	Liver biopsy
<b>Outcomes</b>	Sensitivity Specificity ROC curve or area under the curve (AUC)
<b>Study design</b>	Prospective and retrospective cohorts

### 1 7.3 Clinical evidence

2 Fifty-six studies were included in the review.<sup>3,5,11,12,31,34,39</sup>  
 3 33,41,51,53,56,58,59,77,81,82,84,86,89,90,99,105,106,108,110,111,115,129,131,132,139,141,143,146,147,152,153,155,159,170,174,180,187,206,213-  
 4 215,221,225-229,231

5 Evidence from these is summarised in the clinical evidence profile below (Table 25).  
 6 See also the study selection flow chart in Appendix E, sensitivity and specificity forest plots and area  
 7 under the curve plots in Appendix K, study evidence tables in Appendix H and exclusion list in  
 8 Appendix M.

8 We searched for cross sectional studies and cohort studies (including both retrospective and  
 9 prospective analyses) assessing the diagnostic accuracy of a range of tests that employ serum  
 10 biomarkers, indexes and scores and imaging tests to identify whether NASH or fibrosis are present  
 11 (as indicated by the reference standard of liver biopsy) in people under investigation for the severity  
 12 of NAFLD.

13 A variety of index tests were used at very wide ranging thresholds (see columns 2 and 5 in Table 24  
 14 for further detail). Studies may report sensitivity and specificity values at a pre-specified published  
 15 cut-off threshold, or they may determine the optimal threshold from a ROC analysis. This resulted in  
 16 a range of thresholds being reported for some index tests. In addition to reporting the sensitivity and  
 17 specificity of a test at a particular cut-off threshold, some individual studies also report the AUC from  
 18 a ROC analysis for each index test investigated. Where available, the median AUC value with the  
 19 range of AUC values from all the studies for each index test was summarised in the clinical evidence  
 20 profiles.

21 Eighteen studies reported diagnostic test accuracy for diagnosing NASH. The thresholds used in all  
 22 tests were rarely pre-specified and varied widely. Evidence was found on the following tests: ALT at  
 23 thresholds ranging from 19 to 100; cytokeratin 18 (CK 18) [M30 fragment] at thresholds ranging from  
 24 121 to 670; CK 18 [M65 fragment] at thresholds ranging from 244 to 1183; and ferritin at thresholds  
 25 ranging from 160 to 240. No studies were identified on the diagnostic accuracy for AST/ALT ratio or  
 26 NASH test.

27 Ten studies reported diagnostic test accuracy for diagnosing any fibrosis (greater than or equal to  
 28 F1). Evidence was found on the following tests: enhanced liver fibrosis score (ELF) at thresholds of -  
 29 0.207 and 9.28; Ferritin at thresholds ranging from 208 to 600; magnetic resonance elastography  
 30 (MRE) at a threshold of 3.02; NAFLD fibrosis score at thresholds of -1.455 and 0.676; and transient  
 31 elastography at thresholds ranging from 4.3 to 7.4. No studies were identified on the diagnostic  
 32 accuracy for ALT, AST-to-platelet ratio index (APRI), acoustic radiation force imaging (ARFI), AST/ALT  
 33 ratio, BARD score, fibrosis 4 (FIB4), Fibrometer, Fibrotest, MRI, MRS, shear wave elastography.

34 Thirty-nine studies reported diagnostic test accuracy for diagnosing advanced fibrosis (greater than  
 35 or equal to F3). There was again a very wide range of thresholds used that were often not pre-

## Diagnosing the severity of NAFLD

specified. However for a certain number of these tests (BARD, FIB4, NAFLD fibrosis score) much of the evidence is based on previously published and commonly agreed thresholds. This allowed for a high proportion of the evidence to be meta-analysed and presented in a pooled format. Evidence was found on the following tests: APRI at thresholds ranging from 0.5 to 1 (predominantly published threshold of 1); ARFI at thresholds of 1.77 and 4.24; AST/ALT ratio at thresholds ranging from 0.67 to 1.6 (predominantly agreed lower threshold of 0.8 and higher threshold of 1); BARD at a threshold of 2; ELF at thresholds ranging from -3.37 to 10.51; Ferritin at thresholds ranging from 200 to 600; FIB4 at thresholds ranging from 1.3 to 3.25 (many utilising commonly published thresholds of 1.3, 2.67 and 3.25); Fibrotest at thresholds ranging from 0.3 to 0.7; MRE at thresholds of 3.64 and 4.15; NAFLD fibrosis score at thresholds ranging from -2.16 to 0.735 (most papers utilising published thresholds of -1.455 and 0.676); transient elastography using the M probe at thresholds ranging from 7.1 to 12 and using the XL probe at thresholds ranging from 5.7 to 9.3. One study reported the diagnostic accuracy of a combined panel of ELF plus NAFLD fibrosis score at thresholds of -0.2826 and 0.0033. No studies were identified on the diagnostic accuracy for ALT, Fibrometer, MRS or shear wave elastography. One study was identified on the diagnostic accuracy of MRI, but the GDG decided to exclude the evidence for this particular test based on the subjective nature of the diagnostic criteria (for more information please see the discussion in Section 7.6).

**Table 24: Summary of studies included in the review**

Study	Index test(s)	Population	Diagnosis of interest	Thresholds
Adams 2011 <sup>3</sup>	APRI BARD FIB4 Fibrotest	People with biopsy-proven NAFLD	Advanced fibrosis	0.54 2.0 1.54 0.47 Determined according to highest Youden's index
Aida 2014 <sup>5</sup>	CK 18 [M30]	People with biopsy-proven NAFLD	NASH	270 U/L Determined as optimal cut off
Angulo 2007 <sup>12</sup>	NAFLD fibrosis score	People with biopsy-proven NAFLD	Advanced fibrosis	≤1.455 and >0.676 Determined by optimising NPV and PPV
Angulo 2014 <sup>11</sup>	Ferritin	People with biopsy-proven NAFLD	Any fibrosis Advanced fibrosis	>1 x ULN (300ng/ml in men, 200 ng/ml in women) >1.5 x ULN >2 x ULN Determined by logistic regression as optimising rule in and rule out.
Chan 2014 <sup>25</sup>	ALT CK 18 [M30]	Adults with biopsy-proven NAFLD	NASH	53, 67 and 100 293, 432, and 474 Determined according to highest overall accuracy and maximising sensitivity and specificity.
Cichoż-Lach 2012 <sup>31</sup>	BARD NAFLD fibrosis score	People with biopsy-proven NAFLD	Advanced fibrosis	2.0 -1.455 and >0.676 Thresholds based on previously published cut-offs
Cui 2015 <sup>33</sup>	2D MRE FIB4	Adults with biopsy-proven NAFLD	Advanced fibrosis	3.64 1.30 and 2.67

## NAFLD

### Diagnosing the severity of NAFLD

Study	Index test(s)	Population	Diagnosis of interest	Thresholds
				Thresholds based on previously published cut-offs
Cusi 2014 <sup>34</sup>	CK 18 [M30]	Overweight/obese people with biopsy-proven NAFLD	NASH	212 U/L Determined according to highest Youden's index
Demir 2013 <sup>39</sup>	AST/ALT ratio BARD NAFLD fibrosis score	People with biopsy-proven NAFLD	Advanced fibrosis	≤0.8 and ≥1 2 ≤-1.455 and >0.676 Thresholds based on previously published cut-offs
Dvorak 2014 <sup>41</sup>	CK 18 [M30 and M65] ALT  APRI AST/ALT ratio ELF FIB4 NALFD fibrosis score	People with biopsy-proven NAFLD	NASH  Advanced fibrosis	211 and 234 [M30] 790 and 750 [M65] 1.02 microkat/l (60 U/L)  0.65 0.67 -3.37 1.51 -2.16 No information about how cut-offs determined.
Feldstein 2009 <sup>53</sup>	CK 18 [M30]	Adults with biopsy-proven NAFLD	NASH	216 and 287 U/L Thresholds based on minimising false positive and false negative rates.
Feldstein 2013 <sup>51</sup>	CK 18 [M30]	Children with biopsy-proven NAFLD	NASH	218, 233, and 268 U/L Determined by maximising sensitivity >90%, specificity >90% and Youden's index
Goh 2015 <sup>56</sup>	AST/ALT ratio BARD NAFLD fibrosis score	People with biopsy-proven NAFLD	Advanced fibrosis	0.8 2 ≤-1.455 and >0.676 Not specifically stated but presumably based on previously published cut-offs.
Grigorescu 2012 <sup>58</sup>	CK 18 [M65]	People with biopsy-proven NAFLD	NASH	≥340 U/L No information on how threshold determined. Presumed to be optimal accuracy.
Guha 2008 <sup>59</sup>	ELF ELF + NAFLD fibrosis score	People with biopsy-proven NAFLD	Any fibrosis Advanced fibrosis	-0.2070 0.3576 -0.2826 (combined panel) 0.0033 (combined panel) Unclear how thresholds determined. Presumed to be optimal accuracy.
Joka 2012 <sup>77</sup>	CK 18 [M30 and M65]	People with biopsy-proven NAFLD	NASH	149.5 U/L

## NAFLD

### Diagnosing the severity of NAFLD

Study	Index test(s)	Population	Diagnosis of interest	Thresholds
				386.0 U/L Unclear how thresholds determined. Presumed to be optimal accuracy.
Kawanura 2013 <sup>81</sup>	APRI BARD FIB4	People with biopsy-proven NAFLD	Advanced fibrosis	0.98 2 2.67 Thresholds determined from previously published cut-offs.
Khosravi 2011 <sup>82</sup>	ALT	People with biopsy-proven NAFLD	Advanced fibrosis	0.88 Unclear how threshold determined. Presumed to be optimal accuracy.
Kim 2013 <sup>86</sup>	CK 18 [M30] Ferritin	People with biopsy-proven NAFLD	NASH	235.5 U/L 160 nanogram/ml Unclear how thresholds determined. Presumed to be optimal accuracy.
Kim 2013 <sup>84</sup>	MR elastography	People with biopsy-proven NAFLD	Advanced fibrosis	4.15 kPa Threshold based on optimal accuracy.
Kruger 2011 <sup>89</sup>	APRI AST/ALT ratio	People with biopsy-proven NAFLD	Advanced fibrosis	0.98 0.8 Threshold based on optimal accuracy.
Kumar 2013 <sup>90</sup>	TE	People with biopsy-proven NAFLD	Any fibrosis Advanced fibrosis	4.3, 6.1 and 7.3 kPa 7.8, 9.0 and 11.2 kPa Determined by maximising sensitivity >90%, specificity >90% and Youden's index.
Lee 2013 <sup>99</sup>	BARD	People with biopsy-proven NAFLD	Advanced fibrosis	≥2 Range presented. Based on previously published thresholds used in this review.
Loomba 2014 <sup>105</sup>	MR elastography	People with biopsy-proven NAFLD	Any fibrosis Advanced fibrosis	3.02 and 3.64 kPa Thresholds chosen to maximise specificity ≥90%
Lupsor 2010 <sup>106</sup>	TE	People with biopsy-proven NASH	Any fibrosis Advanced fibrosis	5.3 and 10.4 kPa Thresholds based on maximum sum of sensitivity and specificity
Mahadeva 2013 <sup>108</sup>	APRI TE	People with biopsy-proven NASH	Advanced fibrosis	0.5 7.10 kPa Cut-offs determined by highest Youden's index
Malik 2009 <sup>110</sup>	CK 18 [M30]	People with biopsy-proven NAFLD	NASH	300 U/L Threshold chosen for optimal accuracy



## NAFLD

### Diagnosing the severity of NAFLD

Study	Index test(s)	Population	Diagnosis of interest	Thresholds
Manousou 2011 <sup>111</sup>	Ferritin	People with biopsy-proven NAFLD	NASH	240 nanogram/ml Unclear how threshold determined. Presumed to be optimal accuracy.
McPherson 2010 <sup>115</sup>	APRI AST/ALT ratio BARD FIB4 NAFLD fibrosis score	People with biopsy-proven NAFLD	Advanced fibrosis	1 0.8 and 1 2 1.30 and 3.25 -1.455 and 0.676 Thresholds based on published cut-offs
Neuschwander-Tetri 2010 <sup>129</sup>	ALT	People with biopsy-proven NAFLD	NASH	Conservative: 19 U/L women and 30 U/L men Upper limit: 40 U/L Unclear how threshold determined.
Nobili 2008 <sup>132</sup>	TE	Children and young people with biopsy-proven NASH	Any fibrosis Advanced fibrosis	5.1 and 10.2 kPa Thresholds based on optimal accuracy
Nobili 2009 <sup>131</sup>	ELF	Children and young people with biopsy-proven NAFLD	Any fibrosis Advanced fibrosis	9.28 and 10.51 Thresholds based on optimal accuracy: minimising FP and FNs
Palmeri 2011 <sup>139</sup>	ARFI	People with biopsy-proven NAFLD	Advanced fibrosis	4.24 kPa Threshold based on optimal accuracy
Papatheodoridis 2010 <sup>141</sup>	CK 18 [M30]	People with biopsy-proven NAFLD	NASH	225 U/L 250 U/L 300 U/L Unclear how threshold determined.
Pathik 2015 <sup>143</sup>	APRI AST/ALT ratio NAFLD fibrosis score TE	Adults with fatty liver on ultrasound	Advanced fibrosis	1 1.6 -1.455 and 0.676 12 kPa Presumably from previously published cut-offs.
Perez-Gutierrez 2013 <sup>146</sup>	APRI AST/ALT ratio BARD FIB4 NAFLD fibrosis score	People with biopsy-proven NAFLD	Advanced fibrosis	1 0.8 2 3.25 0.676 Unclear how threshold determined. Presumed based on published cut-offs
Petta 2011 <sup>147</sup>	TE	People with biopsy-proven NAFLD	Advanced fibrosis	8.75 kPa Threshold based on optimal accuracy

## NAFLD

### Diagnosing the severity of NAFLD

Study	Index test(s)	Population	Diagnosis of interest	Thresholds
Qureshi 2008 <sup>152</sup>	NAFLD fibrosis score	Obese people with biopsy-proven NAFLD	Any fibrosis Advanced fibrosis	-1.455 and 0.676 Unclear how determined. Presumably from previously published cut-offs.
Raszeja-Wyszomirska 2010 <sup>153</sup>	BARD	People with biopsy-proven NAFLD	Advanced fibrosis	2 Threshold based on published cut-off
Ratziu 2006 <sup>155</sup>	Fibrotest	People with biopsy-proven NAFLD	Advanced fibrosis	0.30 and 0.70 Unclear how thresholds determined. Presumed to be maximising sensitivity and specificity.
Ruffillo <sup>159</sup>	BARD NAFLD fibrosis score	People with biopsy-proven NAFLD	Advanced fibrosis	2 1.455 and 0.676 Thresholds determined from previously published cut-offs.
Shah 2009 <sup>170</sup>	BARD FIB4	People with biopsy-proven NAFLD	Advanced fibrosis	2 1.30 and 2.67 Unclear how thresholds determined. Presumed to be maximising PPV and NPV.
Shen 2012 <sup>174</sup>	CK 18 [M30 and M65]	People with biopsy-proven NAFLD	NASH	203, 338 and 670 U/L 501, 790 and 1183 U/L Determined by maximising sensitivity >90%, specificity >90% and Youden's index
Sookoian 2009 <sup>180</sup>	ALT	People with biopsy-proven NAFLD	NASH	22 U/L Based on optimal discrimination.
Sumida 2012 <sup>187</sup>	APRI AST/ALT ratio BARD FIB4 NAFLD fibrosis score	People with biopsy-proven NAFLD	Advanced fibrosis	1 0.8 and 1 2 1.45 and 3.25 -1.455 and 0.676 Based on previously published cut-offs
Verma 2013 <sup>206</sup>	ALT	People with biopsy-proven NAFLD	NASH	35 and 70 IU/L Unclear how thresholds decided. Presumed to be discriminating between rule in and rule out.
Wong 2008 <sup>215</sup>	NAFLD fibrosis score	People with NAFLD	Advanced fibrosis	-1.455 and 0.676 Based on previously published cut-offs
Wong 2010 <sup>214</sup>	TE	People with biopsy-proven NAFLD	Advanced fibrosis	7.9, 8.7 and 9.6 kPa Determined by maximising sensitivity >90%, specificity >90% and highest Youden's index

## NAFLD

### Diagnosing the severity of NAFLD

Study	Index test(s)	Population	Diagnosis of interest	Thresholds
Wong 2012 <sup>213</sup>	TE	People with biopsy-proven NAFLD	Advanced fibrosis	M probe: 7.9, 8.7 and 9.6 kPa XL probe: 5.7, 7.2 and 9.3 kPa Determined by maximising sensitivity >90%, specificity >90% and highest Youden's index
Xun 2012 <sup>221</sup>	APRI AST/ALT ratio BARD FIB4 NAFLD fibrosis score	People with biopsy-proven NAFLD	Advanced fibrosis	0.5, and 1 0.8 and 1 2 1.3, 2.67 and 3.25 -1.455 and 0.676 Unclear how thresholds decided. Presumed to be based on previously published cut-offs
Yilmaz 2007 <sup>225</sup>	CK 18 [M30 and M65]	People with NAFLD	NASH	121.6 IU/L 243.82 IU/L Cut-offs determined with statistical software. Perhaps maximising specificity.
Yoneda 2008 <sup>227</sup>	TE	People with biopsy-proven NAFLD	Any fibrosis Advanced fibrosis	5.90 kPa 9.80 kPa Unclear how thresholds were determined.
Yoneda 2010 <sup>228</sup>	ARFI TE	People with biopsy-proven NAFLD	Advanced fibrosis	1.77 m/s 9.9 kPa Unclear how thresholds were determined.
Yoneda 2013 <sup>226</sup>	AST/ALT ratio BARD FIB4 NAFLD fibrosis score	People with biopsy-proven NAFLD with AST levels ≤40 IU/L	Advanced fibrosis	0.8 and 0.975 2 and 3 2.67 and 1.659 0.676 and 0.735 Thresholds determined by published cut-offs and then re-setup on highest Youden's index
Yoneda 2015 <sup>229</sup>	Ferritin	People with biopsy-proven NAFLD	Any fibrosis Advanced fibrosis	208.8 nanogram/ml 301.0 nanogram/ml Unclear how thresholds were determined. Presumed to be optimal accuracy.
Younossi 2011 <sup>231</sup>	CK 18 [M30]	People with biopsy-proven NAFLD	NASH	200.543, 272.924 and 537.062 Determined by maximising sensitivity >90%, specificity >90% and the optimal threshold to minimise the Euclidian distance on the ROC curve.

**Table 25: Clinical evidence profile (SENSITIVITY and SPECIFICITY): Diagnostic tests for NASH**

Index test (Threshold)	Number of studies	n	Risk of bias	Inconsistency	Indirectness	Imprecision	Sensitivity % (median/ range/ 95% CI)	Specificity % (median/ range/ 95% CI)	Quality
<b>ALT</b>									
ALT at 19 threshold	1	695	very serious <sup>a</sup>	-	none	no serious imprecision	99 (97, 100)	8 (5, 12)	LOW
ALT at 22 threshold	1	101	very serious <sup>a</sup>	-	none	no serious imprecision	97 (88, 100)	24 (12, 40)	LOW
ALT at 35 threshold	1	222	very serious <sup>a</sup>	-	none	no serious imprecision	89 (77, 96)	30 (23, 37)	LOW
ALT at 40 threshold	1	695	very serious <sup>a</sup>	-	none	no serious imprecision	86 (82, 89)	32 (27, 38)	LOW
ALT at 53 threshold	1	93	serious <sup>a</sup>	-	none	serious imprecision <sup>d</sup>	79 (64, 91)	41 (28, 55)	LOW
ALT at 60 threshold	1	56	very serious <sup>a</sup>	-	none	serious imprecision <sup>d</sup>	71 (54, 85)	61 (36, 83)	VERY LOW
ALT at 67 threshold	1	93	serious <sup>a</sup>	-	none	serious imprecision <sup>d</sup>	72 (55, 85)	59 (45, 72)	LOW
ALT at 70 threshold	1	222	very serious <sup>a</sup>	-	none	serious imprecision <sup>d</sup>	50 (36, 64)	61 (53, 68)	VERY LOW
ALT at 100 threshold	1	93	serious <sup>a</sup>	-	none	serious imprecision <sup>d</sup>	41 (26, 58)	80 (66, 89)	LOW
<b>AST/ALT ratio</b>									
No evidence identified									
<b>Cytokeratin 18 [M30]</b>									
CK 18 [M30] at 121 threshold	1	83	very serious <sup>a</sup>	-	none	serious imprecision <sup>d</sup>	60 (44, 74)	97 (86, 100)	VERY LOW
CK 18 [M30] at 149 threshold	1	22	very serious <sup>a</sup>	-	none	serious imprecision <sup>d</sup>	100 (74, 100)	80 (44, 97)	VERY LOW

Index test (Threshold)	Number of studies	n	Risk of bias	Inconsistency	Indirectness	Imprecision	Sensitivity % (median/ range/ 95% CI)	Specificity % (median/ range/ 95% CI)	Quality
CK 18 [M30] at 200-249 threshold range	9	1307	very serious <sup>a</sup>	serious inconsistency <sup>b</sup>	none	very serious imprecision <sup>d</sup>	77 (51, 97) <sup>e</sup>	66 (19, 96) <sup>e</sup>	VERY LOW
CK 18 [M30] at 250-300 threshold range	8	839	very serious <sup>a</sup>	serious inconsistency <sup>b</sup>	none	serious imprecision <sup>d</sup>	65 (53, 76) <sup>e</sup>	91 (82, 97) <sup>e</sup>	VERY LOW
CK 18 [M30] at 338 threshold	1	147	very serious <sup>a</sup>	-	none	serious imprecision <sup>d</sup>	67 (54, 78)	60 (49, 71)	VERY LOW
CK 18 [M30] at 432 threshold	1	93	serious <sup>a</sup>	-	none	serious imprecision <sup>d</sup>	56 (40, 72)	63 (49, 76)	LOW
CK 18 [M30] at 474 threshold	1	93	serious <sup>a</sup>	-	none	serious imprecision <sup>d</sup>	44 (28, 60)	65 (51, 77)	LOW
CK 18 [M30] at 537 threshold	1	79	very serious <sup>a</sup>	-	none	serious imprecision <sup>d</sup>	28 (15, 44)	87 (73, 96)	VERY LOW
CK 18 [M30] at 670 threshold	1	147	very serious <sup>a</sup>	-	none	serious imprecision <sup>d</sup>	25 (15, 36)	90 (81, 95)	VERY LOW
<b>Cytokeratin 18 [M65]</b>									
CK 18 [M65] at 244 threshold	1	83	very serious <sup>a</sup>	-	none	serious imprecision <sup>d</sup>	69 (53, 82)	82 (66, 92)	VERY LOW
CK 18 [M65] at 340 threshold	1	79	very serious <sup>a</sup>	-	none	serious imprecision <sup>d</sup>	80 (67, 89)	65 (41, 85)	VERY LOW
CK 18 [M65] at 386 threshold	1	22	very serious <sup>a</sup>	-	none	very serious imprecision <sup>d</sup>	75 (43, 95)	70 (35, 93)	VERY LOW
CK 18 [M65] at 501 threshold	1	147	very serious <sup>a</sup>	-	none	no serious imprecision	91 (82, 97)	35 (24, 46)	LOW
CK 18 [M65] at 750 threshold	1	56	very serious <sup>a</sup>	-	none	serious imprecision <sup>d</sup>	79 (63, 90)	83 (59, 96)	VERY LOW
CK 18 [M65] at 790 threshold	1	147	very serious <sup>a</sup>	-	none	serious imprecision <sup>d</sup>	62 (50, 74)	71 (59, 80)	VERY LOW
CK 18 [M65] at 1183 threshold	1	147	very serious <sup>a</sup>	-	none	serious	32 (21, 44)	90 (81, 95)	VERY LOW

Index test (Threshold)	Number of studies	n	Risk of bias	Inconsistency	Indirectness	Imprecision	Sensitivity % (median/ range/ 95% CI)	Specificity % (median/ range/ 95% CI)	Quality
						imprecision <sup>d</sup>			
<b>Ferritin</b>									
Ferritin at 160 threshold	1	108	very serious <sup>a</sup>	-	none	serious imprecision <sup>d</sup>	70 (58, 81)	59 (42, 74)	VERY LOW
Ferritin at 240 threshold	1	111	very serious <sup>a</sup>	-	none	no serious imprecision	91 (81, 96)	70 (55, 83)	LOW
<b>NASH test</b>									
No evidence identified									

- 11 (a) Risk of bias was assessed using the QUADAS-2 checklist. Evidence quality was downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2  
12 increments if the majority of the evidence was at very high risk of bias.
- 13 (b) Inconsistency was assessed by inspection of the sensitivity and specificity forest plots (based on the primary measure), using the point estimates and confidence intervals. Particular  
14 attention was placed on values above or below 50% (diagnosis based on chance alone) and the threshold set by the GDG (the threshold above which would be acceptable to recommend a  
15 test). The evidence was downgraded by 1 increment if the individual studies varied across 2 areas (50–90% and 90–100%) and by 2 increments if the individual studies varied across 3  
16 areas (0–50%, 50–90% and 90–100%).
- 17 (c) Indirectness was assessed using the QUADAS-2 checklist items referring to applicability.
- 18 (d) The judgement of precision was based on visual inspection of the confidence region in the diagnostic meta-analysis if a diagnostic meta-analysis was conducted. Where a diagnostic  
19 meta-analysis was not conducted imprecision was assessed according to the range of the confidence interval. As a rule of thumb (after discussion with the GDG) a range of 0–20% of  
20 differences in confidence interval around sensitivity was considered not imprecise, 20–40% serious imprecisions, and >40% very serious imprecision. Imprecision was assessed on the  
21 primary measure for decision-making.
- 22 (e) The judgement of precision was based on visual inspection of the confidence region in the diagnostic meta-analysis if a diagnostic meta-analysis was conducted. Where a diagnostic  
23 meta-analysis was not conducted imprecision was assessed according to the range of the confidence interval. As a rule of thumb (after discussion with the GDG) a range of 0–20% of  
24 differences in confidence interval around sensitivity was considered not imprecise, 20–40% serious imprecisions, and >40% very serious imprecision. Imprecision was assessed on the  
25 primary measure for decision-making.



Index test (Threshold)	Number of studies	n	Risk of bias	Inconsistency	Indirectness	Imprecision	Sensitivity % (median/ range/ 95% CI)	Specificity % (median/ range/ 95% CI)	Quality
No evidence identified									
<b>APRI</b>									
No evidence identified									
<b>AST/ALT ratio</b>									
No evidence identified									
<b>BARD</b>									
No evidence identified									
<b>ELF</b>									
ELF at -0.207 threshold	1	192	very serious <sup>a</sup>	-	none	no serious imprecision	61 (51, 70)	80 (69, 88)	LOW
ELF at 9.28 threshold	1	112	serious <sup>a</sup>	-	none	no serious imprecision	88 (78, 94)	81 (65, 92)	MODERATE
<b>Ferritin</b>									
Ferritin at 208.8 threshold	1	1202	very serious <sup>a</sup>	-	none	no serious imprecision	49 (46, 52)	70 (63, 76)	LOW
Ferritin at 1 x upper normal limit (200 women, 300 men)	1	1014	serious <sup>a</sup>	-	none	no serious imprecision	37 (33, 41)	76 (71, 80)	MODERATE
Ferritin at 1.5 x upper normal limit (200 women, 300 men)	1	1014	serious <sup>a</sup>	-	none	no serious imprecision	22 (19, 25)	89 (85, 92)	MODERATE
Ferritin at 2 x upper normal limit (200 women, 300 men)	1	1014	serious <sup>a</sup>	-	none	no serious imprecision	13 (11, 16)	95 (92, 97)	MODERATE
<b>FIB4</b>									
No evidence identified									
<b>Fibrometer</b>									
No evidence identified									
<b>Fibrotest</b>									



Index test (Threshold)	Number of studies	n	Risk of bias	Inconsistency	Indirectness	Imprecision	Sensitivity % (median/ range/ 95% CI)	Specificity % (median/ range/ 95% CI)	Quality
No evidence identified									
<b><u>NAFLD fibrosis score</u></b>									
NAFLD fibrosis score at -1.455 threshold	1	331	very serious <sup>a</sup>	-	none	no serious imprecision	77 (70, 82)	50 (41, 60)	LOW
NAFLD fibrosis score at 0.676 threshold	1	331	very serious <sup>a</sup>	-	none	no serious imprecision	28 (22, 35)	93 (87, 97)	LOW
<b><u>Imaging tests</u></b>									
<b><u>ARFI</u></b>									
No evidence identified									
<b><u>Diffusion weighted imaging</u></b>									
No evidence identified									
<b><u>MR elastography</u></b>									
MRE at 3.02 threshold	1	117	very serious <sup>a</sup>	-	none	serious imprecision <sup>d</sup>	55 (43, 67)	91 (78, 97)	VERY LOW
<b><u>MRI</u></b>									
No evidence identified									
<b><u>MRS</u></b>									
No evidence identified									
<b><u>Shear wave elastography</u></b>									
No evidence identified									
<b><u>Transient elastography [M probe]</u></b>									
TE [M] at 4.3 threshold	1	120	serious <sup>a</sup>	-	none	no serious imprecision	93 (86, 97)	22 (9, 40)	MODERATE
TE [M] at 5.1 threshold	1	50	serious <sup>a</sup>	-	none	no serious imprecision	97 (87, 100)	91 (59, 100)	MODERATE
TE [M] at 5.3 threshold	1	72	serious <sup>a</sup>	-	none	no serious	95 (82, 99)	77 (60, 90)	MODERATE

Index test (Threshold)	Number of studies	n	Risk of bias	Inconsistency	Indirectness	Imprecision	Sensitivity % (median/ range/ 95% CI)	Specificity % (median/ range/ 95% CI)	Quality
TE [M] at 5.9 threshold	1	97	very serious <sup>a</sup>	-	none	imprecision no serious imprecision	86 (76, 93)	89 (65, 99)	LOW
TE [M] at 6.1 threshold	1	120	serious <sup>a</sup>	-	none	no serious imprecision	78 (68, 86)	69 (50, 84)	MODERATE
TE [M] at 7.3 threshold	1	120	serious <sup>a</sup>	-	none	serious imprecision <sup>d</sup>	58 (47, 68)	91 (75, 98)	LOW

- (a) Risk of bias was assessed using the QUADAS-2 checklist. Evidence quality was downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias.
- (b) Inconsistency was assessed by inspection of the sensitivity and specificity forest plots (based on the primary measure), using the point estimates and confidence intervals. Particular attention was placed on values above or below 50% (diagnosis based on chance alone) and the threshold set by the GDG (the threshold above which would be acceptable to recommend a test). The evidence was downgraded by 1 increment if the individual studies varied across 2 areas (50–90% and 90–100%) and by 2 increments if the individual studies varied across 3 areas (0–50%, 50–90% and 90–100%).
- (c) Indirectness was assessed using the QUADAS-2 checklist items referring to applicability.
- (d) The judgement of precision was based on visual inspection of the confidence region in the diagnostic meta-analysis if a diagnostic meta-analysis was conducted. Where a diagnostic meta-analysis was not conducted imprecision was assessed according to the range of confidence intervals. As a rule of thumb (after discussion with the GDG) a range of 0–20% of differences in confidence interval around sensitivity was considered not imprecise, 20–40% serious imprecisions, and >40% very serious imprecision. Imprecision was assessed on the primary measure for decision-making.

**Table 28: Clinical evidence profile (AUC): Diagnostic tests for any fibrosis**

Index test	Number of studies	n	Risk of bias	Inconsistency	Indirectness	Imprecision	Area under the curve, median (range of CIs)	Quality
<b>Blood tests</b>								
ALT	No evidence identified							
APRI	No evidence identified							
AST/ALT ratio	No evidence identified							

Index test	Number of studies	n	Risk of bias	Inconsistency	Indirectness	Imprecision	Area under the curve, median (range of CIs)	Quality
BARD	No evidence identified							
ELF	2	304	very serious <sup>a</sup>	serious inconsistency <sup>b</sup>	none	serious imprecision <sup>d</sup>	0.76 (0.69-0.97) <sup>e</sup>	VERY LOW
Ferritin	2	2215	very serious <sup>a</sup>	no serious inconsistency	none	no serious imprecision	0.55 (0.52-0.62) <sup>e</sup>	LOW
FIB4	No evidence identified							
Fibrometer	No evidence identified							
Fibrotest	No evidence identified							
NAFLD fibrosis score	1	331	AUC not reported					
<b>Imaging tests</b>								
ARFI	No evidence identified							
Diffusion weighted imaging	No evidence identified							
MR elastography	1	117	very serious <sup>a</sup>		none	assessment not possible	0.838 (no CIs reported)	VERY LOW
MRI	No evidence identified							
MRS	No evidence identified							
Shear wave elastography	No evidence identified							
Transient elastography	4	339	serious <sup>a</sup>	serious inconsistency <sup>b</sup>	none	serious imprecision <sup>d</sup>	0.879 (0.75-0.99) <sup>e</sup>	VERY LOW

1

(a) Risk of bias was assessed using the QUADAS-2 checklist.

2

(b) Inconsistency was assessed by inspection of the AUC values for each index test across studies, using the point estimates and confidence intervals. Particular attention was placed on values above or below 50% (diagnosis based on chance alone) and the threshold of 90% set by the GDG (the threshold above which would be acceptable to recommend a test). The evidence was downgraded by 1 increment if the individual studies varied across 2 areas (50–90% and 90–100%) and by 2 increments if the individual studies varied across 3 areas (0–50%, 50–90% and 90–100%).

3

4

5

6

(c) Indirectness was assessed using the QUADAS-2 checklist items referring to applicability.

7

(d) The judgement of precision was based on the median AUC value and its 95% CI. The evidence was downgraded by 1 increment if the CI varied across 2 areas (50–90% and 90–100%) and by 2 increments if the individual studies varied across 3 areas (0–50%, 50–90% and 90–100%).

8

9

(e) This is a conservative estimate as the lower of 2 possible median values.

**Table 29: Clinical evidence profile (SENSITIVITY and SPECIFICITY): Diagnostic tests for advanced fibrosis**

Index test (Threshold)	Number of studies	n	Risk of bias	Inconsistency	Indirectness	Imprecision	Sensitivity % (median/ range/ 95% CI)	Specificity % (median/ range/ 95% CI)	Quality
<b>Blood tests</b>									
<b>ALT</b>									
No evidence identified									
<b>APRI</b>									
APRI at 0.5 threshold	2	283	serious <sup>a</sup>	serious inconsistency <sup>b</sup>	none	serious imprecision <sup>d</sup>	52 (33, 71) 79 (58, 93)	82 (74, 89) 50 (41, 59)	VERY LOW
APRI at 0.54 threshold	1	242	very serious <sup>a</sup>	-	none	serious imprecision <sup>d</sup>	72 (58, 83)	77 (71, 83)	VERY LOW
APRI at 0.65 threshold	1	56	very serious <sup>a</sup>	-	none	very serious imprecision <sup>d</sup>	65 (38, 86)	67 (50, 81)	VERY LOW
APRI at 0.98-1 threshold <i>Pooled meta-analysis data</i>	7	1342	very serious <sup>a</sup>	very serious inconsistency <sup>b</sup>	none	very serious imprecision <sup>d</sup>	56 (37, 74)	85 (77, 90)	VERY LOW
<b>AST/ALT ratio</b>									
AAR at 0.67 threshold	1	56	very serious <sup>a</sup>	-	none	very serious imprecision <sup>d</sup>	65 (38, 86)	67 (50, 81)	VERY LOW
AAR at 0.8 threshold <i>Pooled meta-analysis data</i>	8	2189	very serious <sup>a</sup>	very serious inconsistency <sup>b</sup>	none	very serious imprecision <sup>d</sup>	68 (51, 83)	62 (47, 76)	VERY LOW
AAR at 0.88 threshold	1	147	very serious <sup>a</sup>	-	none	very serious imprecision <sup>d</sup>	88 (47, 100)	80 (72, 86)	VERY LOW
AAR at 0.975 threshold	1	235	very serious <sup>a</sup>	-	none	serious imprecision <sup>d</sup>	79 (63, 90)	70 (63, 78)	VERY LOW
AAR at 1 threshold <i>Pooled meta-analysis data</i>	4	1139	very serious <sup>a</sup>	very serious inconsistency <sup>b</sup>	none	very serious imprecision <sup>d</sup>	47 (23, 72)	88 (77, 95)	VERY LOW
AAR at 1.6 threshold	1	110	very serious <sup>a</sup>	-	none	serious	79 (63, 90)	100 (95, 100)	VERY LOW

Index test (Threshold)	Number of studies	n	Risk of bias	Inconsistency	Indirectness	Imprecision	Sensitivity % (median/ range/ 95% CI)	Specificity % (median/ range/ 95% CI)	Quality
						imprecision <sup>d</sup>			
<b><u>BARD</u></b>									
BARD at 2 threshold <i>Pooled meta-analysis data</i>	14	3336	very serious <sup>a</sup>	very serious inconsistency <sup>b</sup>	none	serious imprecision <sup>d</sup>	79 (69, 88)	61 (49, 72)	VERY LOW
<b><u>ELF</u></b>									
ELF at -3.37 threshold	1	56	very serious <sup>a</sup>	-	none	serious imprecision <sup>d</sup>	88 (64, 99)	97 (87, 100)	VERY LOW
ELF at 0.3576 threshold	1	192	very serious <sup>a</sup>	-	none	serious imprecision <sup>d</sup>	80 (65, 90)	90 (84, 94)	VERY LOW
ELF at 10.51 threshold	1	112	serious <sup>a</sup>	-	none	serious imprecision <sup>d</sup>	100 (63, 100)	98 (93, 100)	LOW
<b><u>ELF + NADLF fibrosis score</u></b>									
Combined panel at -0.2826 threshold	1	192	very serious <sup>a</sup>	-	none	no serious imprecision	91 (78, 97)	96 (91, 98)	LOW
Combined panel at 0.0033 threshold	1	192	very serious <sup>a</sup>	-	none	serious imprecision <sup>d</sup>	89 (75, 96)	99 (95, 100)	VERY LOW
<b><u>Ferritin</u></b>									
Ferritin at 301 threshold	1	1201	very serious <sup>a</sup>	-	none	no serious imprecision	33 (28, 39)	75 (72, 87)	LOW
Ferritin at 1 x upper normal limit (200 women, 300 men)	1	1014	serious <sup>a</sup>	-	none	no serious imprecision	41 (35, 47)	70 (67, 73)	MODERATE
Ferritin at 1.5 x upper normal limit (200 women, 300 men)	1	1014	serious <sup>a</sup>	-	none	no serious imprecision	27 (22, 33)	84 (81, 87)	MODERATE
Ferritin at 2 x upper normal limit (200 women, 300 men)	1	1014	serious <sup>a</sup>	-	none	no serious imprecision	16 (12, 21)	92 (90, 94)	MODERATE
<b><u>FIB4</u></b>									
FIB4 at 1.3 threshold	4	940	very serious <sup>a</sup>	no serious inconsistency	none	very serious imprecision <sup>d</sup>	77 (56, 91)	68 (51, 82)	VERY LOW

Index test (Threshold)	Number of studies	n	Risk of bias	Inconsistency	Indirectness	Imprecision	Sensitivity % (median/ range/ 95% CI)	Specificity % (median/ range/ 95% CI)	Quality
<i>Pooled meta-analysis data</i>									
FIB4 at 1.45 threshold	1	576	very serious <sup>a</sup>	-	none	no serious imprecision	91 (81, 96)	64 (60, 68)	LOW
FIB4 at 1.51 threshold	1	56	very serious <sup>a</sup>	-	none	very serious imprecision <sup>d</sup>	71 (44, 90)	77 (61, 98)	VERY LOW
FIB4 at 1.54 threshold	1	242	very serious <sup>a</sup>	-	none	serious imprecision <sup>d</sup>	74 (60, 85)	87 (81, 91)	VERY LOW
FIB4 at 1.659 threshold	1	235	very serious <sup>a</sup>	-	none	serious imprecision <sup>d</sup>	89 (75, 97)	71 (64, 77)	VERY LOW
FIB4 at 2.67 threshold <i>Pooled meta-analysis data</i>	5	1050	very serious <sup>a</sup>	very serious inconsistency <sup>b</sup>	none	very serious imprecision <sup>d</sup>	45 (23, 70)	95 (88, 98)	VERY LOW
FIB4 at 3.25 threshold <i>Pooled meta-analysis data</i>	4	1101	very serious <sup>a</sup>	serious inconsistency <sup>b</sup>	none	very serious imprecision <sup>d</sup>	38 (15, 65)	95 (87, 99)	VERY LOW
<b><u>Fibrometer</u></b>									
No evidence identified									
<b><u>Fibrotest</u></b>									
Fibrotest at 0.3 threshold	2	267	very serious <sup>a</sup>	no serious inconsistency	none	serious imprecision <sup>d</sup>	95 (75, 100) 88 (62, 98)	71 (63, 78) 69 (58, 79)	VERY LOW
Fibrotest at 0.47 threshold	1	242	very serious <sup>a</sup>	-	none	serious imprecision <sup>d</sup>	60 (46, 74)	90 (85, 94)	VERY LOW
Fibrotest at 0.7 threshold	2	263	very serious <sup>a</sup>	no serious inconsistency	none	very serious imprecision <sup>d</sup>	25 (9, 49) 33 (10, 65)	97 (93, 99) 99 (93, 100)	VERY LOW
<b><u>NAFLD fibrosis score</u></b>									
NAFLD fibrosis score at -2.16 threshold	1	56	very serious <sup>a</sup>	-	none	very serious imprecision <sup>d</sup>	76 (50, 93)	69 (52, 83)	VERY LOW
NAFLD fibrosis score at -1.455 threshold	11	2576	very serious <sup>a</sup>	very serious inconsistency <sup>b</sup>	none	serious imprecision <sup>d</sup>	77 (62, 89)	73 (57, 86)	VERY LOW

Index test (Threshold)	Number of studies	n	Risk of bias	Inconsistency	Indirectness	Imprecision	Sensitivity % (median/ range/ 95% CI)	Specificity % (median/ range/ 95% CI)	Quality
<i>Pooled meta-analysis data</i>									
NAFLD fibrosis score at 0.676 threshold	13	3039	very serious <sup>a</sup>	very serious inconsistency <sup>b</sup>	none	very serious imprecision <sup>d</sup>	41 (20, 64)	95 (90, 98)	VERY LOW
<i>Pooled meta-analysis data</i>									
NAFLD fibrosis score at 0.735 threshold	1	235	very serious <sup>a</sup>	-	none	serious imprecision <sup>d</sup>	68 (51, 82)	88 (83, 92)	VERY LOW
<b>Imaging tests</b>									
<b>ARFI</b>									
ARFI at 1.77 threshold	1	54	very serious <sup>a</sup>	-	none	serious imprecision <sup>d</sup>	100 (69, 100)	91 (78, 97)	VERY LOW
ARFI at 4.24 threshold	1	135	very serious <sup>a</sup>	-	none	serious imprecision <sup>d</sup>	90 (76, 97)	89 (81, 95)	VERY LOW
<b>Diffusion weighted imaging</b>									
No evidence identified									
<b>MR elastography</b>									
MRE at 3.64 threshold	2	219	very serious <sup>a</sup>	no serious inconsistency	none	serious imprecision <sup>d</sup>	86 (65, 97) 89 (67, 99)	91 (83, 96) 90 (82, 96)	VERY LOW
MRE at 4.15 threshold	1	142	very serious <sup>a</sup>	-	none	serious imprecision <sup>d</sup>	85 (71, 94)	93 (86, 97)	VERY LOW
<b>MRI</b>									
No evidence identified									
<b>MRS</b>									
No evidence identified									
<b>Shear wave elastography</b>									
No evidence identified									
<b>Transient elastography [M probe]</b>									

Index test (Threshold)	Number of studies	n	Risk of bias	Inconsistency	Indirectness	Imprecision	Sensitivity % (median/ range/ 95% CI)	Specificity % (median/ range/ 95% CI)	Quality
TE [M] at 7.1 threshold	1	131	very serious <sup>a</sup>	-	none	serious imprecision <sup>d</sup>	69 (49, 85)	67 (57, 76)	VERY LOW
TE [M] at 7.8-7.9 threshold <i>Pooled meta-analysis data</i>	3	522	very serious <sup>a</sup>	no serious inconsistency	none	very serious imprecision <sup>d</sup>	91 (74, 98)	73 (47, 90)	VERY LOW
TE [M] at 8.7-9 threshold <i>Pooled meta-analysis data</i>	4	668	very serious <sup>a</sup>	no serious inconsistency	None	very serious imprecision <sup>d</sup>	82 (65, 93)	81 (67, 92)	VERY LOW
TE [M] at 9.6-9.9 threshold <i>Pooled meta-analysis data</i>	4	553	very serious <sup>a</sup>	serious inconsistency <sup>b</sup>	none	very serious imprecision <sup>d</sup>	78 (58, 93)	87 (74, 95)	VERY LOW
TE [M] at 10.2 threshold	1	50	serious <sup>a</sup>	-	none	very serious imprecision <sup>d</sup>	100 (48, 100)	100 (92, 100)	VERY LOW
TE [M] at 10.4 threshold	1	72	serious <sup>a</sup>	-	none	very serious imprecision <sup>d</sup>	100 (48, 100)	97 (90, 100)	VERY LOW
TE [M] at 11.2 threshold	1	120	serious <sup>a</sup>	-	none	serious imprecision <sup>d</sup>	70 (50, 86)	92 (85, 97)	LOW
TE [M] at 12 threshold	1	110	very serious <sup>a</sup>	-	none	serious imprecision <sup>d</sup>	89 (75, 97)	81 (70, 89)	VERY LOW
<b><u>Transient elastography [XL probe]</u></b>									
TE [XL] at 5.7 threshold	1	184	very serious <sup>a</sup>	-	none	no serious imprecision	91 (80, 97)	54 (45, 63)	LOW
TE [XL] at 7.2 threshold	1	184	very serious <sup>a</sup>	-	none	serious imprecision <sup>d</sup>	78 (64, 88)	78 (70, 85)	VERY LOW
TE [XL] at 9.3 threshold	1	184	very serious <sup>a</sup>	-	none	serious imprecision <sup>d</sup>	57 (43, 71)	90 (84, 95)	VERY LOW

- 1 (a) Risk of bias was assessed using the QUADAS-2 checklist. Evidence quality was downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2
- 2 increments if the majority of the evidence was at very high risk of bias.
- 3 (b) Inconsistency was assessed by inspection of the sensitivity and specificity forest plots (based on the primary measure), using the point estimates and confidence intervals. Particular
- 4 attention was placed on values above or below 50% (diagnosis based on chance alone) and the threshold set by the GDG (the threshold above which would be acceptable to recommend a
- 5 test). The evidence was downgraded by 1 increment if the individual studies varied across 2 areas (50–90% and 90–100%) and by 2 increments if the individual studies varied across 3
- 6 areas (0–50%, 50–90% and 90–100%).



(c) Indirectness was assessed using the QUADAS-2 checklist items referring to applicability.

(d) The judgement of precision was based on visual inspection of the confidence region in the diagnostic meta-analysis if a diagnostic meta-analysis was conducted. Where a diagnostic meta-analysis was not conducted imprecision was assessed according to the range of confidence intervals. As a rule of thumb (after discussion with the GDG) a range of 0–20% of differences in confidence intervals around sensitivity was considered not imprecise, 20–40% serious imprecisions, and >40% very serious imprecision. Imprecision was assessed on the primary measure for decision-making.

**Table 30: Clinical evidence profile (AUC): Diagnostic tests for advanced fibrosis**

Index test	Number of studies	n	Risk of bias	Inconsistency	Indirectness	Imprecision	Area under the curve, median (range of CIs)	Quality
<b>Blood tests</b>								
ALT	No evidence identified							
APRI	7	1378	very serious <sup>a</sup>	no serious inconsistency	none	serious imprecision <sup>d</sup>	0.74 (0.40-0.86)	VERY LOW
AST/ALT ratio	9	1910	very serious <sup>a</sup>	no serious inconsistency	none	very serious imprecision <sup>d</sup>	0.79 (0.44-0.91)	VERY LOW
BARD	12	2835	very serious <sup>a</sup>	no serious inconsistency	none	serious imprecision <sup>d</sup>	0.70 (0.51-0.92) <sup>e</sup>	VERY LOW
ELF	3	360	very serious <sup>a</sup>	no serious inconsistency	none	serious imprecision <sup>d</sup>	0.97 (0.51-1.00)	VERY LOW
ELF + NAFLD fibrosis score	1	192	very serious <sup>a</sup>	-	none	no serious imprecision	0.98 (0.96-1)	LOW
Ferritin	2	2215	very serious <sup>a</sup>	no serious inconsistency	none	no serious imprecision	0.55 (0.52-0.60) <sup>e</sup>	LOW
FIB4	9	2277	very serious <sup>a</sup>	no serious inconsistency	none	serious imprecision <sup>d</sup>	0.86 (0.50-0.95)	VERY LOW
Fibrometer	No evidence identified							
Fibrotest	3	509	very serious <sup>a</sup>	serious inconsistency <sup>b</sup>	none	serious imprecision <sup>d</sup>	0.81 (0.64-0.96)	VERY LOW
NAFLD fibrosis score	11	2331	very serious <sup>a</sup>	serious inconsistency <sup>b</sup>	none	very serious imprecision <sup>d</sup>	0.81 (0.49-0.99)	VERY LOW

Index test	Number of studies	n	Risk of bias	Inconsistency	Indirectness	Imprecision	Area under the curve, median (range of CIs)	Quality
<b>Imaging tests</b>								
ARFI	2	189	very serious <sup>a</sup>	no serious inconsistency	none	assessment not possible	0.90 (no CIs reported) <sup>e</sup>	VERY LOW
Diffusion weighted imaging	No evidence identified							
MR elastography	3	361	very serious <sup>a</sup>	no serious inconsistency	none	no serious imprecision	0.94 (0.90-0.98)	LOW
MRS	No evidence identified							
Shear wave elastography	No evidence identified							
Transient elastography [M]	10	1182	very serious <sup>a</sup>	serious inconsistency <sup>b</sup>	none	serious imprecision <sup>d</sup>	0.91 (0.66-1.00) <sup>e</sup>	VERY LOW
Transient elastography [XL]	1	184	very serious <sup>a</sup>	-	none	serious imprecision <sup>d</sup>	0.85 (0.79-0.91)	VERY LOW

1 (a) Risk of bias was assessed using the QUADAS-2 checklist.

2 (b) Inconsistency was assessed by inspection of the AUC values for each index test across studies, using the point estimates and confidence intervals. Particular attention was placed on  
3 values above or below 50% (diagnosis based on chance alone) and the threshold of 90% set by the GDG (the threshold above which would be acceptable to recommend a test). The  
4 evidence was downgraded by 1 increment if the individual studies varied across 2 areas (50–90% and 90–100%) and by 2 increments if the individual studies varied across 3 areas (0–50%,  
5 50–90% and 90–100%).

6 (c) Indirectness was assessed using the QUADAS-2 checklist items referring to applicability.

7 (d) The judgement of precision was based on the median AUC value and its 95% CI. The evidence was downgraded by 1 increment if the CI varied across 2 areas (50–90% and 90–100%) and  
8 by 2 increments if the individual studies varied across 3 areas (0–50%, 50–90% and 90–100%).

9 (e) The judgement of precision was based on the median AUC value and its 95% CI. The evidence was downgraded by 1 increment if the CI varied across 2 areas (50–90% and 90–100%) and  
10 by 2 increments if the individual studies varied across 3 areas (0–50%, 50–90% and 90–100%).

## 7.4 Economic evidence

### 7.4.1 Published literature

No economic evaluations were identified for diagnostic tests for NASH.

Two economic evaluations were identified for diagnostic tests for fibrosis: 1 cost-per-correct diagnosis analysis that compared transient elastography with liver biopsy<sup>184</sup> and 1 cost-per-correct diagnosis analysis that compared a variety of imaging and blood tests with liver biopsy.<sup>32</sup> These are summarised in the economic evidence profile below (Table 31) and the economic evidence tables in Appendix I. See also the economic article selection flow chart in Appendix F.

**Table 31: Economic evidence profile: diagnostic tests for fibrosis**

Study	Applicability	Limitations	Other comments	Incremental cost	Incremental effects	Cost-effectiveness	Uncertainty
Crossan 2015 <sup>32</sup> (UK)	Partially applicable <sup>(a)</sup>	Potentially serious limitations <sup>(b)</sup>	<ul style="list-style-type: none"> <li>Cost per correct TP and TN diagnosis analyses.</li> <li>Study compared the diagnostic accuracy and costs of various imaging tests and serum markers in a hypothetical cohort of 1000 NAFLD patients with suspected liver fibrosis.</li> </ul>	Details in Table 32 and Table 33 below.			No sensitivity analysis conducted. No confidence intervals reported.
Steadman 2013 <sup>184</sup> (Canada)	Partially applicable <sup>(c)</sup>	Potentially serious limitations <sup>(d)</sup>	<ul style="list-style-type: none"> <li>Cost per correct TP diagnosis analysis.</li> <li>Comparing the diagnostic accuracy and costs of transient elastography with liver biopsy in a hypothetical cohort of 1000 NAFLD patients with fibrosis.</li> </ul>	£205 (favours transient elastography)	242 extra correct diagnoses (favours liver biopsy)	<u>Cost per additional correct diagnosis:</u> £846 (95% CI: £277–2,237)	Changes in sensitivity, specificity and prevalence have a significant effect on the resulting cost per correct diagnosis

Note: Abbreviations: TN: true negatives; TP: true positives.

(a) No costs or health outcomes following diagnosis were considered in the model.

(b) The time horizon is not long enough to capture all the effects, no sensitivity analysis conducted and no confidence interval were reported.

(c) Differences in healthcare system may make results less applicable to UK, no health outcomes following diagnosis were considered in the model.

(d) Transient elastography diagnostic accuracy estimates were informed by observational data.

1

**Table 32: Crossan 2015<sup>32</sup> – Incremental analysis: true positives**

Interventions		True positives	Cost per test	Cost per 1000	Compared with	Incremental cost per correct diagnosis (TP) <sup>(a)</sup> (£/correct diagnosis gained)
1	NFS + TE	15	£55.95	£55,950	7	Dominated
2	FIB-4 (high cut-off)	71	£4.40	£4,400	7	Dominated
3	Fibrotest + TE	74	£94.60	£94,600	7	Dominated
4	NFS (high cut-off)	75	£4.95	£4,950	7	Dominated
5	APRI	76	£4.05	£4,050	7	Dominated
6	Fibrotest (high cut-off)	76	£43.60	£43,600	7	Dominated
7	AST-ALT (high cut-off)	88	£0.90	£900	16	Dominated
8	NFS all	134	£20.85	£20,850	16	Dominated
9	AST-ALT (low cut-off)	149	£0.90	£900	16	Dominated
10	Fib-4 all	149	£21.09	£21,090	16	Dominated
11	ELF	151	£108.00	£108,000	16	Dominated
12	NFS (low cut-off)	151	£4.95	£4,950	16	Dominated
13	TE	155	£51.00	£51,000	16	Dominated
14	Fibrotest all	158	£59.31	£59,310	16	Dominated
15	Fib-4 (low cut-off)	159	£4.40	£4,400	16	Dominated
16	BAARD	160	£0.90	£900	No test	£5.63
17	NFS + ELF (high cut-off)	164	£112.95	£112,950	18	Dominated
18	Fibrotest (low cut-off)	169	£43.60	£43,600	16	£4,744.44
19	ARFI	170	£51.00	£51,000	18	£7,400.00
20	NFS + ELF all	171	£114.81	£114,810	22	Dominated
21	MRE	172	£199.00	£199,000	22	Dominated
22	NFS + ELF (low cut-off)	172	£112.95	£112,950	19	£30,975.00
23	Liver biopsy	189	£956.61	£956,610	22	£49,627.06

2 (a) Each test compared with next best alternative

**Table 33: Crossan 2015<sup>32</sup> – Incremental analysis: true negatives**

Interventions		True negatives	Cost per test	Cost per 1000	Compared with	Incremental cost per correct diagnosis (TN) <sup>(a)</sup> (£/correct diagnosis gained)
1	BAARD	491	£0.90	£900	11	Dominated
2	NFS (low cut-off)	535	£4.95	£4,950	11	Dominated
3	AST-ALT (low cut-off)	568	£0.90	£900	11	Dominated
4	Fibrotest (low cut-off)	593	£43.60	£43,600	11	Dominated
5	Fib-4 (low cut-off)	603	£4.40	£4,400	11	Dominated
6	APRI	668	£4.05	£4,050	11	Dominated
7	TE	681	£51.00	£51,000	11	Dominated
8	MRE	715	£199.00	£199,000	11	Dominated
9	ARFI	726	£51.00	£51,000	11	Dominated

3

Interventions		True negatives	Cost per test	Cost per 1000	Compared with	Incremental cost per correct diagnosis (TN) <sup>(a)</sup> (£/correct diagnosis gained)
10	ELF	730	£108.00	£108,000	11	Dominated
11	AST-ALT (high cut-off)	740	£0.90	£900	No test	£1.22
12	Fib-4 all	754	£21.09	£21,090	18	Dominated
13	NFS + ELF (low cut-off)	778	£112.95	£112,950	18	Dominated
14	Fibrotest (high cut-off)	779	£43.60	£43,600	18	Dominated
15	NFS all	780	£20.85	£20,850	18	Dominated
16	Fibrotest + TE	780	£94.60	£94,600	18	Dominated
17	Fibrotest all	783	£59.31	£59,310	18	Dominated
18	FIB-4 (high cut-off)	783	£4.40	£4,400	11	£81.40
19	NFS (high cut-off)	786	£4.95	£4,950	18	£183.33
20	NFS + TE	795	£55.95	£55,950	19	£5,666.67
21	NFS + ELF all	805	£114.81	£114,810	22	Dominated
22	NFS + ELF (high cut-off)	805	£112.95	£112,950	20	£5,700.00
23	Liver biopsy	811	£956.61	£956,610	22	£140,610.00

1 (a) Each test compared with next best alternative

## 2 7.4.2 Unit costs

3 See Table 61 in Appendix N.

## 4 7.4.3 New cost-effectiveness analysis

5 Original cost-effectiveness modelling was undertaken for this question. A summary is included here.  
6 An evidence statement summarising the results of the analysis can be found below. The full analysis  
7 can be found in Appendix N.

### 7.4.3.1 Aim and structure

9 The ultimate aim of the health economic model was to determine the most cost-effective diagnostic  
10 test to detect advanced fibrosis ( $\geq$ F3) and whom to test (according to specific risk factors). Within the  
11 scope of the model was also to examine the cost-effectiveness of the various retest frequencies for  
12 every risk factor group. For these purposes a lifetime health state transition (Markov) model was  
13 constructed, following the NICE reference case,<sup>126</sup> which depicted the patient pathway of liver  
14 disease from the development of early steatosis to liver transplant.

15 The diagnostic strategies compared were:

- 16 • APRI at 0.98–1
- 17 • ARFI at 4.24
- 18 • AST/ALT at 0.8
- 19 • BARD at 2
- 20 • ELF at 10.51
- 21 • Ferritin at 2x
- 22 • FIB4 at 1.45

- 1 • Fibrotest at 0.47
- 2 • MRE at 4.15
- 3 • NAFLD fibrosis score at 0.676
- 4 • TE (M probe) at 7.8–7.9
- 5 • TE (XL) at 5.7
- 6 • No test – no monitoring
- 7 • No test – monitor all.

8 The population was adults with suspected NAFLD, categorised into the following subgroups:

- 9 • NAFLD, base case prevalence
- 10 • NAFLD and type 2 diabetes
- 11 • NAFLD and hypertension
- 12 • NAFLD and BMI $\geq$ 30
- 13 • NAFLD and metabolic syndrome.

14 The model used diagnostic accuracy data from studies identified in the present clinical review. Test  
15 costs were obtained from published literature and GDG sources. Health states costs were  
16 constructed under GDG guidance specifically for the purposes of the model. Utilities and transition  
17 probabilities were mostly obtained from published literature and through extrapolations from other  
18 liver diseases where there was a lack of evidence. The model was built probabilistically to take  
19 account of the uncertainty around input parameter point estimates.

20 Cost-effectiveness was defined by the value of the net monetary benefit (NMB) attributed to every  
21 test. The decision rule applied is that the comparator with the highest NMB is the most cost-effective  
22 option at the specified £20,000 per extra QALY threshold.

### 23 4.3.2 Results

24 Testing for advanced fibrosis was considered cost-effective at a £20,000 threshold for all risk factor  
25 subgroups and retest frequencies run through the model. Across the different retest frequencies the  
26 NMB of the first ranked test was greatest at a 3-year retest frequency. The latter finding was found  
27 to be sensitive to changes in the starting age of the model.

28 Among the 15 diagnostic strategies included in the model, ELF ranked first having the highest  
29 diagnostic accuracy across the compared tests but also the second highest test unit costs. ARFI and  
30 MRE followed in terms of ranking having the next best diagnostic accuracies after ELF. FibroTest and  
31 NFS followed in fourth and fifth positions both having high specificity and low sensitivity; TE in  
32 contrast had high sensitivity and low specificity and ranked slightly lower. There was considerable  
33 uncertainty in the results with all strategies having wide 95% confidence intervals apart from ARFI (1  
34 to 6).

35 The results in Table 34 below relate to the base case prevalence retested every 3 years. Rankings  
36 were mostly similar across all combinations, only differing slightly after the third position.

37 **Table 34: Advanced fibrosis test ranking**

Test	Mean cost (£)	Mean QALYs	NMB (£) at £20,000/QALY	Rank
APRI at 0.98–1	10,184	13.68	263,403	7
ARFI at 4.24	10,142	13.71	264,060	2
AST/ALT at 0.8	11,280	13.71	262,996	10
BARD at 2	11,350	13.72	263,105	9

Test	Mean cost (£)	Mean QALYs	NMB (£) at £20,000/QALY	Rank
ELF at 10.51	9,632	13.70	264,301	1
Ferritin at 2x	9,206	13.58	262,433	13
FIB4 at 1.45	11,295	13.73	263,277	8
Fibrotest at 0.47	9,949	13.68	263,596	4
MRE at 4.15	10,259	13.70	263,751	3
NFS at 0.676	9,208	13.64	263,541	5
TE (M) at 7.8–7.9	11,056	13.72	263,426	6
TE (XL) at 5.7	11,685	13.73	262,964	11
Liver biopsy	11,543	13.68	262,071	14
No test – monitor all	12,319	13.75	262,641	12
No test – monitor nobody	7,563	13.48	261,939	15

- 1 In the deterministic sensitivity analysis, the rankings did not seem to be sensitive to changes in ELF's  
2 cost but they changed in favour of ARFI when ELF's sensitivity was set to its low CI. Removing the  
3 drug intervention or reducing its effectiveness by 1/3 had a negative effect on the cost effectiveness  
4 of testing with the 'no test – no monitoring' strategy ranking first. ARFI consistently ranked second  
5 (or higher) apart from when the progression rate to cirrhosis was decreased by 50% and in the  
6 aforementioned scenarios with the drug intervention.

## 1 7.5 Evidence statements

### 2 7.5.1 Clinical

#### 3 Diagnosing NASH

- 4 • No evidence was identified to determine the accuracy of AST/ALT ratio or NASH test for  
5 diagnosing NASH.
- 6 • Five studies provided mostly low quality evidence for the diagnostic accuracy of ALT at 9 different  
7 thresholds ranging from 19 to 100. As the threshold increased the sensitivity decreased from 99%  
8 (97-100) to 41% (26-58), and the specificity increased from 8% (5-12) to 80% (66-89).
- 9 • Twelve studies provided mostly very low quality evidence for the diagnostic accuracy of CK18  
10 (M30 fragment) at 24 different thresholds ranging from 121 to 670. The sensitivities ranged from  
11 100% (74-100) to 25% (15-36). Specificities ranged from 97% (86-100) to 60% (49-71).
- 12 • Five studies provided mostly very low quality evidence for the diagnostic accuracy of CK18 (M65  
13 fragment) at 7 different thresholds ranging from 244 to 1183. Sensitivities ranged from 91% (82-  
14 97) to 32% (21-44). Specificities ranged from 35% (24-46) to 90% (81-95).
- 15 • Two studies provided evidence for the diagnostic accuracy of ferritin. Very low quality evidence  
16 for the threshold of 160 showed a sensitivity of 70% (58-81) and specificity of 59% (42-74). Low  
17 quality evidence for the threshold of 240 showed a sensitivity of 90% (81-96) and specificity of  
18 70% (55-83).

#### 19 Diagnosing any fibrosis ( $\geq$ F1)

- 20 • No evidence was identified to determine the accuracy of ALT, APRI, AST/ALT ratio, BARD, FIB4,  
21 Fibrometer, Fibrotest, ARFI, diffusion weighted imaging, MRI, MRS, or shear wave elastography  
22 for diagnosing any fibrosis ( $\geq$ F1).
- 23 • Two studies provided evidence for the diagnostic accuracy of ELF. Low quality evidence from 1  
24 study for the threshold of -0.207 showed a sensitivity of 61% (51-70) and a specificity of 80 (69-  
25 88). Moderate quality evidence from a second study for the threshold of 9.28 showed a sensitivity  
26 of 88% (78-94) and a specificity of 81% (65-92).
- 27 • Two studies provided evidence for the diagnostic accuracy of ferritin. Low quality evidence from 1  
28 study for the threshold of 208.8 showed a sensitivity of 49% (46-52) and a specificity of 70% (63-  
29 76). Moderate quality evidence from a second study for thresholds ranging from 1 x the upper  
30 normal limit to 2 x the upper normal limit showed sensitivities decreasing as the thresholds  
31 increased, and specificities increasing with the thresholds increasing. The upper normal limit is  
32 200 for women and 300 for men. At the upper normal limit sensitivity was 37% (33-41) and  
33 specificity was 76% (71-80). Sensitivity decreased to 13% (11-16) with an increase of the threshold  
34 and specificity increased to 95% (92-97).
- 35 • One paper provided low quality evidence for the diagnostic accuracy of the NAFLD fibrosis score.  
36 At the threshold of -1.455, sensitivity was 77% (70-82) and specificity was 50% (41-60). When the  
37 threshold increased to 0.676, sensitivity decreased to 28% (22-35) and specificity increased to  
38 93% (87-97).
- 39 • One study provided very low quality evidence for the diagnostic accuracy of MR elastography. At  
40 a threshold of 3.02, sensitivity was 55% (43-67) and specificity was 91% (78-97).
- 41 • Four studies provided mostly moderate quality evidence for the diagnostic accuracy of transient  
42 elastography (with an M probe) at 6 different thresholds ranging from 4.3 to 7.3 kPa. Sensitivities  
43 ranged from 97% (87-100) to 58% (47-68). Specificities ranged from 22% (9-40) to 91% (75-98).



**Diagnosing advanced fibrosis ( $\geq$ F3)**

- No evidence was identified to determine the accuracy of ALT, Fibrometer, diffusion weighted imaging, MRI, MRS, or shear wave elastography for diagnosing advanced fibrosis ( $\geq$ F3).
- Meta-analysis data from 7 studies (n=1342) provided very low quality evidence for a pooled sensitivity of 56% (37-74) and pooled specificity of 85% (77-90) when using APRI with a threshold ranging from 0.98 to 1 to diagnose advanced fibrosis. Four more studies provided very low quality evidence for APRI used with a variety of lower thresholds. Two studies provided very low quality evidence for the threshold of 0.5 with sensitivities of 52% (33-71) and 79% (58-93) and specificities of 82% (74-89) and 50% (41-59). Another study provided very low quality evidence for a threshold of 0.54 with a sensitivity of 72% (58-83) and specificity of 77% (71-83). And the fourth study provided very low quality evidence for a threshold of 0.65 with a sensitivity of 65% (38-86) and specificity of 67% (50-81).
- Meta-analysis data from eight studies (n=2189) provided very low quality evidence for a pooled sensitivity of 68% (51-83) and a specificity of 62% (47-76) when using the AST/ALT ratio at a threshold of 0.8. Four studies provided very low quality evidence for using AST/ALT ratio at a higher threshold of 1, suggesting a pooled sensitivity of 47% (23-72) and a pooled specificity of 88% (77-95). Four single studies each presented very low quality evidence for 4 other thresholds. One used a threshold of 0.67 and showed a sensitivity of 65% (38-86) and a specificity of 67% (50-81). Another used a threshold of 0.88 and showed a sensitivity of 88% (47-100) and a specificity of 80% (72-86). The third used a threshold of 0.975 and showed a sensitivity of 79% (63-90) and a specificity of 70% (63-78). The fourth used the highest threshold of 1.6 and showed a sensitivity of 79% (63-90) and a specificity of 100% (95-100).
- Meta-analysis data from 14 studies (n=3336) provided very low quality evidence for a pooled sensitivity of 79% (69-88) and a pooled specificity of 61% (49-72) when using the BARD score at a threshold of 2 to diagnose advanced fibrosis.
- Three single studies provided evidence for 3 different ELF thresholds to diagnose advanced fibrosis. Very low quality evidence from 1 study for the lowest threshold of -3.37 suggested a sensitivity of 88% (64-99) and a specificity of 97% (87-100). Very low quality evidence from 1 study for a threshold of 0.3576 suggested a sensitivity of 80% (65-90) and a specificity of 90% (84-94). Low quality evidence from 1 study for a high threshold of 10.51 suggested the best sensitivity of 100% (63-100) and the best specificity of 98% (93-100).
- One study provided evidence for a combined panel of the ELF and NAFLD fibrosis score used at 2 different thresholds. Low quality evidence for the lower threshold of -0.2826 suggested a sensitivity of 91% (78-97) and a specificity of 96% (91-98). Very low quality evidence for a higher threshold of 0.0033 suggested a slightly lower sensitivity of 89% (75-96) and a specificity of 99% (95-100).
- Two studies provided evidence for the diagnostic accuracy of ferritin. Low quality evidence from 1 study for the threshold of 301 showed a sensitivity of 33% (28-39) and a specificity of 75% (72-87). Moderate quality evidence from a second study for thresholds ranging from 1 x the upper normal limit to 2 x the upper normal limit showed sensitivities decreasing as the thresholds increased, and specificities increasing with the thresholds increasing. The upper normal limit is 200 for women and 300 for men. At the upper normal limit sensitivity was 41% (35-47) and specificity was 70% (67-73). Sensitivity decreased to 16% (12-21) with an increase of the threshold and specificity increased to 92% (90-94).
- Ten studies provided evidence for FIB4 at a range of 7 different thresholds. Meta-analysis data from 4 studies (n=940) provided very low quality evidence for a pooled sensitivity of 77% (56-91) and a pooled specificity of 68% (51-82) when using a low threshold of 1.3. Meta-analyses of studies concentrating on higher thresholds provided low quality evidence for a threshold of 2.67 (5 studies, n=1050) with a pooled sensitivity of 45% (23-70) and a pooled specificity of 95% (88-

- 98); and very low quality evidence for a threshold of 3.25 (4 studies, n=1101) with a pooled sensitivity of 38% (15-65) and a pooled specificity of 95% (87-99). Four single studies presented evidence at 4 other different thresholds between the low and high thresholds covered by the meta-analyses. From these, the highest specificity reported was 91% (81-96) with a linked specificity of 64% (60, 68), this was low quality evidence from a single study for the threshold of 1.45 (n=576).
- Two papers from the same study group reported on low and high thresholds for Fibrotest. Very low quality evidence from these studies suggested sensitivities of 95% (75-100) and 88% (62-98) and specificities of 71% (63-78) and 69% (58-79) when using a threshold of 0.3. Very low quality evidence from these studies also suggested sensitivities of 25% (9-49) and 33% (10-65) and specificities of 97% (93-99) and 99% (93-100) when using a threshold of 0.7. Very low quality evidence from a single study suggested a sensitivity of 60% (46-74) and a specificity of 90 (85-94) when using a mid-range threshold of 0.47.
  - Meta-analysis of 11 studies (n=2576) provided very low quality evidence for NAFLD fibrosis score at a low threshold of -1.455 with a pooled sensitivity of 77% (62-89) and a pooled specificity of 73% (57-86). Meta-analysis of 13 studies (n=3039) provided very low quality evidence for NAFLD fibrosis score at a high threshold of 0.676 with a pooled sensitivity of 41% (20-64) and a pooled specificity of 95% (90-98). One study also provided very low quality evidence for a lower threshold of -2.16 with a sensitivity of 76% (50-93) and a specificity of 69% (52-83). Another single study provided very low quality evidence for a higher threshold of 0.735 with a sensitivity of 68% (51-82) and a specificity of 88% (83-92).
  - Two studies investigated the diagnostic accuracy for ARFI, each used different thresholds. One smaller study (n=54) provided very low evidence for a low threshold of 1.77 with a sensitivity of 100% (69-100) and a specificity of 91% (78-97). The other study (n=135) provided very low quality evidence for a high threshold of 4.24 with a sensitivity of 90% (76-97) and a specificity of 89% (81-95).
  - Three studies investigated the diagnostic accuracy for MR elastography (MRE), using 2 different thresholds. Two studies (n=219) provided very low evidence for a threshold of 3.64 with sensitivity ranging from 86-89% (65-99) and specificity ranging from 90-91% (82-96). The other study (n=142) provided very low quality evidence for a threshold of 4.15 with a sensitivity of 85% (71-94) and a specificity of 93% (86-97).
  - Ten studies investigated the diagnostic accuracy of transient elastography (using the M probe) for 13 different thresholds ranging from 7.1 to 12. Within this wide range, some studies were grouped together to form tighter ranges of thresholds to make meta-analysis possible. One study using a threshold of 7.1 provided very low quality evidence for a sensitivity of 69% (49-85) and a specificity of 67% (57-76). Meta-analysis of 3 studies (n=522) provided very low quality evidence for a threshold 7.8-7.9 with a pooled sensitivity of 91% (74-98) and a pooled specificity of 73% (47-90). Meta-analysis of 4 studies (n=668) provided very low quality evidence for a threshold 8.7-9 with a pooled sensitivity of 82% (65-93) and a pooled specificity of 81% (67-92). Meta-analysis of 4 studies (n=553) provided very low quality evidence for a threshold 9.6-9.9 with a pooled sensitivity of 78% (58-93) and a pooled specificity of 87% (74-95). One study using a threshold of 10.2 provided very low quality evidence for a sensitivity of 100% (48-100) and a specificity of 100% (92-100). One study using a threshold of 10.4 provided very low quality evidence for a sensitivity of 100% (48-100) and a specificity of 97% (90-100). One study using a threshold of 11.2 provided low quality evidence for a sensitivity of 70% (50-86) and a specificity of 92% (85-97). One study using a threshold of 12 provided very low quality evidence for a sensitivity of 89% (75-97) and a specificity of 81% (70-89).
  - One study provided evidence for transient elastography using the XL probe at 3 different thresholds. Low quality evidence for a threshold of 5.7 showed a sensitivity of 91% (80-97) and a specificity of 54 (45-63). Very low quality evidence for a threshold of 7.2 showed a sensitivity of

1 78% (64-88) and a specificity of 78 (70-85). Very low quality evidence for a threshold of 9.3  
2 showed a sensitivity of 57% (43-71) and a specificity of 90 (84-95).

### 3 7.5.2 Economic

- 4 • One cost analysis that compared 23 strategies for testing adults with NAFLD for advanced fibrosis  
5 found that:
- 6 o BAARD had an incremental cost of £5.63 per additional TP correct diagnosis when compared to  
7 no testing.
  - 8 o FibroTest (low cut-off) had an incremental cost of £4,744 per additional TP correct diagnosis  
9 when compared to BAARD.
  - 10 o ARFI had an incremental cost of £7,400 per additional TP correct diagnosis when compared to  
11 FibroTest (low cut-off).
  - 12 o All other options were either dominated by the tests above or have an incremental cost of  
13 over £30,000 per additional correct TP correct diagnosis when compared to ARFI.
  - 14 o AST-ALT ratio (high cut-off) had an incremental cost of £1.22 per additional TN correct  
15 diagnosis when compared to no testing.
  - 16 o FIB-4 (high cut-off) had an incremental cost of £81.40 per additional TN correct diagnosis when  
17 compared to AST-ALT (high cut-off).
  - 18 o NFS (high cut-off) had an incremental cost of £183.33 per additional TN correct diagnosis when  
19 compared to FIB-4 (high cut-off).
  - 20 o A combination of NFS and transient elastography had an incremental cost of £5,667 per  
21 additional TN correct diagnosis when compared to NFS (high cut-off).
  - 22 o A combination of NFS and ELF (high cut-off) had an incremental cost of £5,700 per additional  
23 TN correct diagnosis when compared to NFS and transient elastography.
  - 24 o All other options were either dominated by the tests above or had an incremental cost of over  
25 £100,000 per additional correct TN correct diagnosis when compared to NFS and ELF.
- 26 This analysis was assessed as partially applicable with potentially serious limitations.
- 27 • One cost analysis that compared liver biopsy and transient elastography for testing adults with  
28 NAFLD for advanced fibrosis found that liver biopsy had an incremental cost of £846 per  
29 additional correct TP diagnosis when compared to transient elastography. This analysis was  
30 assessed as partially applicable with potentially serious limitations.
  - 31 • One original cost-utility analysis that compared 15 strategies for testing adults with NAFLD for  
32 advanced fibrosis, with a retest frequency of 3 years, found that ELF ranked first compared to the  
33 following diagnostic strategies, using relevant thresholds for each test, with reference to a cost-  
34 effectiveness threshold of £20,000 per QALY gained:
    - 35 o ARFI
    - 36 o MRE
    - 37 o FibroTest
    - 38 o NAFLD fibrosis score
    - 39 o transient elastography (M probe)
    - 40 o APRI
    - 41 o FIB-4
    - 42 o BARD
    - 43 o AST-ALT ratio
    - 44 o transient elastography (XL probe)
    - 45 o no test – monitor all

Diagnosing the severity of NAFLD

- 1 o ferritin
- 2 o liver biopsy
- 3 o no test – monitor nobody.
- 4 This analysis was assessed as directly applicable with minor limitations.

5 **7.6 Recommendations and link to evidence**

<b>Recommendations</b>	<p><b>11. Use the enhanced liver fibrosis (ELF) test to test people for advanced liver fibrosis if NAFLD has been diagnosed (either by targeted case-finding as in recommendations 4 and 8 or by incidental findings).</b></p> <p><b>12. Diagnose people with advanced liver fibrosis and refer them to a relevant specialist in hepatology, if they have:</b></p> <ul style="list-style-type: none"> <li>• an ELF score of 10.51 or above and</li> <li>• NAFLD.</li> </ul>
<b>Research recommendations</b>	<p><b>3. Which non-invasive tests most accurately identify non-alcoholic steatohepatitis (NASH) in people with non-alcoholic fatty liver disease (NAFLD)?</b></p> <p><b>4. Which non-invasive tests most accurately diagnose NAFLD and advanced liver fibrosis in children and young people?</b></p>
Relative values of different diagnostic measures and outcomes	<p>For decision-making, the GDG focused on diagnostic accuracy measures including the sensitivity and specificity of the tests for a diagnosis of NASH, any fibrosis and advanced fibrosis. It was noted that the data would be fed into the health economic model, in order to identify the most cost-effective test, or sequence of tests, for the diagnosis of advanced fibrosis. The GDG agreed that, for a condition such as NAFLD with advanced fibrosis (where early identification is essential for effective management), it was crucial to have a highly sensitive test, especially early on in the patient pathway if multiple tests are used. This is because a sensitive test will result in few people with advanced fibrosis being missed (few false negative results). The GDG noted that the cut-off threshold used to define a positive test can vary and assessed the accuracy of the tests at a variety of published thresholds. A threshold set to increase the sensitivity of the test will consequently reduce the specificity. The GDG also discussed the importance of a specific test. A specific test will result in very few NAFLD patients without advanced fibrosis being incorrectly labelled (false positive results). This is particularly important if the results of the test determine people that would then have an invasive, dangerous or costly procedure or treatment.</p>
Trade-off between clinical benefits and harms	<p>The GDG was interested in the performance of blood tests and imaging tests in the diagnosis of NASH, any fibrosis, or advanced fibrosis in people known to have NAFLD. The GDG was not interested in the performance of these tests as screening tools in the general population. Therefore, test performance was assessed from studies matching the intended NAFLD population.</p> <p><b>Diagnostic tests for NASH:</b></p> <p>No evidence was identified for the performance of AST/ALT ratio or the NASH test in the diagnosis of NASH. The GDG considered that the evidence reviewed for certain assessment tools – namely ALT and keratin 18 [M30 fragment] – demonstrated limited efficacy for the diagnosis of NASH and would not be recommended as tests. Therefore, the evidence would not be considered within the economic model. Specifically, although both of these tests demonstrated a general trend towards an</p>

improvement in sensitivity (to the detriment of specificity) as the threshold values changed between studies (and vice versa), the mean AUC of approximately 0.6 for ALT studies and 0.75 for keratin 18 [M30 fragment] studies led the GDG to conclude that neither were suitable for further consideration. The identified studies evaluating ferritin as an assessment tool for NASH showed only moderate sensitivity and specificity, and a mean AUC of 0.6. Nevertheless, the GDG noted that this is a readily available, relatively cheap assay that has not been fully assessed within this context, and concluded that a research recommendation (for studies assessing the utility of ferritin – as well as other laboratory tests) in making the diagnosis of NASH was justified.

The GDG felt that the identified evidence regarding keratin 18 [M65 fragment] once again demonstrated a marked trade-off between sensitivity and specificity among different studies, and a wide range of threshold values; nevertheless, it also noted the acceptable mean AUC of 0.81. The GDG noted the biological plausibility of why measurement of this protein may be expected to be a useful diagnostic tool for NASH. On balance, the GDG concluded that the evaluated evidence was not strong enough to recommend keratin 18 [M65] outright as a diagnostic test for NASH, but, as already described, a research recommendation was justified for studies evaluating novel biomarkers as diagnostic tests for NASH.

**Diagnostic tests for any fibrosis (≥F1):**

The quantity of evidence identified for this part of review was more limited than that relevant to the other sections. Although relevant studies were found for the ELF test, ferritin, NAFLD fibrosis score, MR elastography and transient elastography, none were available for ALT, APRI, AST/ALT ratio, BARD, FIB4, fibrometer, FibroTest, ARFI, diffusion weighted imaging, MRI, MRS or shear wave elastography.

The GDG noted that the available evidence was, at best only moderate quality, and once again observed that very different threshold values were applied between studies for the same test. In addition, members of the GDG questioned the benefit of attempting to identify all people with any fibrosis, as some evidence suggests that it is only those adults, children and young people with NAFLD and who have advanced fibrosis (greater than or equal to F3) who merit the closest monitoring and who are at greatest risk for the complications of NAFLD.<sup>44,45,179</sup> As such, the GDG concluded that no assessment tools from this part of the review could be recommended for use based on this evidence, and hence were not included in the economic modelling.

**Diagnostic tests for advanced fibrosis (≥F3):**

Overall, much more evidence was identified for this part of the review; however, no relevant evidence was identified for ALT, ARFI, fibrometer, diffusion-weighted imaging or MRS. Both blood tests and imaging-based tests were reviewed. The majority of the evidence was from populations with biopsy-proven NAFLD, except 1 study which included people with ultrasound-diagnosed NAFLD.

Evidence was found which evaluated the efficacy of a number of laboratory-based tests. Pooled meta-analysis data for APRI (at thresholds of between 0.98 and 1.0) demonstrated sensitivity of 53% but specificity of 85%; the high specificity led the GDG to conclude that APRI potentially could be considered for use. The included studies assessing AST/ALT ratio only showed moderate sensitivity and specificity with an AUC of 0.79, however, the GDG observed that this test is widely available and modestly priced, so concluded that it could still be considered as an option. The review of those studies evaluating BARD concluded that, although only a modest AUC and specificity was demonstrated on pooled meta-analysis data, higher levels of sensitivity were reported. The 3 studies evaluating ELF (including data from children and young people) all demonstrated high sensitivity and high specificity (with AUC of 0.97), suggesting a promising option. One study looked at a combined panel of the ELF with the NAFLD fibrosis score which similarly demonstrated high sensitivity and specificity (with AUC 0.98) and was also agreed as promising. Despite noting that those included studies that evaluated ferritin all demonstrated low sensitivities, the

Diagnosing the severity of NAFLD

	<p>GDG felt that this still merited further consideration because, although the test is reasonably priced and widely available, the GDG was interested in seeing if the performance of the low sensitivities within the economic model may warrant a ‘do not use’ recommendation. The GDG noted that studies assessing FIB-4, in which a threshold value was used that maximised specificity, tended to be those with the lowest sensitivities, but that on balance, this test could be considered, focusing on those studies which exhibited high sensitivities based on the thresholds assessed. Those studies evaluated for the NAFLD fibrosis score tended to show high sensitivity at the lower threshold and high specificity at the higher threshold (as the test was designed to do), and the GDG agreed that this would also be a possible test to consider for modelling. The GDG expressed concerns about FibroTest, as the exact algorithm to generate the test score is not widely available, and financial support for 2 of the studies included in the review had been obtained from the manufacturer of the test; nevertheless, some promising data independent from the manufacturer were also identified.<sup>3</sup></p> <p>Studies were also identified for ultrasound-based assessment tools. The GDG noted that both studies reviewed for ARFI displayed high sensitivity and specificity, with an AUC of 0.90. With the promising results but limited amount of evidence investigating this imaging technique, the GDG felt this may warrant a research recommendation. The evaluated evidence for transient elastography demonstrated both high sensitivities and specificities (tending to be higher in studies using the M probe than the XL probe – although this may reflect the fact that the M probe is a more established technology), and the AUC was 0.93 for M-probe studies; the GDG agreed that, if considered, the assumption is that the test is performed according to the manufacturer’s instructions using the most appropriate probe in each person.</p> <p>Finally, evidence was reviewed for magnetic resonance-based assessment tools. The identified studies including MR elastography demonstrated high sensitivity and specificity. The identified study including MRI was not felt suitable for further assessment by the GDG, as the criteria used in this study to identify those with NAFLD and advanced fibrosis were felt to be subjective and non-reproducible.</p> <p>All of the above tests considered to demonstrate potentially promising results were included within an original economic model to consider the cost-effectiveness. When taking the results of the economic model and clinical evidence into account, the GDG agreed that the ELF test was the most clinically and cost-effectiveness option and should be recommended for use in both adults and children and young people. The GDG agreed that a figure of ELF test score &gt;10.51 would be used to presume F3 orF4 fibrosis, as this was the threshold used in the largest study using ELF evaluated within this review.</p>
<p>Trade-off between net clinical effects and costs</p>	<p>Two relevant published economic evaluations were identified for this review.</p> <p>Crossan 2015 compared 23 different diagnostic tests, or combinations of tests, and sought to evaluate the cost of identifying each true positive with NAFLD, and the cost of identifying each true negative without NAFLD. In the true positive results, BAARD was found to cost £5.63 per diagnosis compared with no test, and to dominate 15 more expensive but less effective tests. The only tests more effective than BAARD did so at excessive cost per additional correct diagnosis. The cost-per-true negative results showed that the AST/ALT ratio cost £1.22 per correct diagnosis compared to no test and dominated 10 less effective tests. FIB-4 (with a high cut-off) gave an additional 43 correct diagnoses per 1000 people at a cost of £81.40 per additional correct diagnosis. No test or combination did well in diagnosing both true positives and true negatives. This analysis did not take into account the difference in future health or future healthcare costs resulting from using the different tests, and so the GDG was unable to draw any conclusions from it on which test would be most cost-effective from the perspective of the NHS as a whole. The GDG also noted the lack of confidence intervals and absence of sensitivity analysis in this evaluation.</p> <p>Steadman 2013 was another cost-per-diagnosis study, which compared transient</p>

## Diagnosing the severity of NAFLD

	<p>elastography to liver biopsy in a cohort of people with NAFLD. It found that liver biopsy was more accurate, at a cost of £846 per additional (true positive) correct diagnosis. However, the GDG could not reach a conclusion on whether £846 is a cost-effective price per correct diagnosis as the study design meant that, again, there was no information on the future health benefits and future additional health costs or savings from using a more or less accurate diagnostic test. Additional limitations of this study included the use of observational data regarding the efficacy of transient elastography in diagnosing advanced NAFLD.</p> <p>An original cost-utility analysis was conducted for this guideline to address the cost-effectiveness of diagnostic tests for advanced fibrosis in adults, alongside the review questions in Chapters 5, 6 and 8.</p> <p>This analysis found that, given a retesting frequency of 3 years (see Chapter 8), ELF was the highest ranking of the 13 tests compared at a cost-effectiveness threshold of £20,000 per QALY gained, followed by ARFI. Given the uncertainty in the data used, it is not certain that ELF was more cost-effective than ARFI, but it was placed first in 73% of probabilistic simulations. ELF and ARFI were the only 2 tests that could be ranked first within the 95% confidence intervals for ranking order.</p> <p>Although ELF and ARFI were agreed by the GDG to be both clinically and potentially cost-effective options for assessing the severity of disease in people with NAFLD, the GDG also discussed practical reasons why the ELF test would be the better choice. Specifically, given that it is anticipated that most severity testing for people with NAFLD could be undertaken in primary care, it would be more practical if the test used to assess severity is a blood test that can be easily sent from a general practitioner's surgery rather than an imaging test that is not currently available outside of secondary care.</p> <p>The GDG therefore concluded that ELF is both the most cost-effective and the most appropriate test for advanced fibrosis in adults with NAFLD and should be offered to people with NAFLD.</p> <p>No original economic analysis was conducted on the cost-effectiveness of diagnostic testing for NASH or for any-stage fibrosis in adults, as the GDG judged that none of the tests for those conditions have yet been proven to be sufficiently clinically effective to be considered as options.</p> <p>No economic analysis was conducted relating to diagnosing NASH, any fibrosis or advanced fibrosis in children and young people under 18 years due to a lack of data on the diagnostic accuracy of these tests in under 18s.</p>
Quality of evidence	<p>Many of the included studies were of low or very low quality by GRADE criteria. Much of the evidence was assessed as being at serious or very serious risk of bias due to issues with patient selection, unclear reporting on whether the index test results were interpreted without knowledge of biopsy findings, lack of pre-specified thresholds for the index tests and unclear timing between index test and biopsy. Imprecision around the effects further added to the downgrading of the evidence.</p> <p>Studies may report sensitivity and specificity values at a pre-specified published cut-off threshold, or they may determine the optimal threshold from a ROC analysis. This resulted in a range of thresholds being reported for some index tests. If all the sensitivity and specificity values from the range of cut-off thresholds are pooled together, this can result in an overestimation of the diagnostic accuracy in comparison to another index test where sensitivity and specificity values are only reported for 1 cut-off threshold. The GDG noted that a very wide range of threshold values was used between different studies for many of the assessment tools under evaluation within this review, with a number of reasons becoming apparent to justify this. Firstly, in some cases, assessment tools represent newer technologies for which normal and pathological ranges have not yet been fully defined. Secondly, in many cases, the use of a threshold value for a particular assessment tool that provided a high sensitivity was often at the compromise of a reduction in specificity (and vice-versa); as such, the performance of different threshold values had been evaluated</p>

## Diagnosing the severity of NAFLD

	<p>even for the same assessment tool to attempt to ascertain the most acceptable balance between sensitivity and specificity. The GDG expressed concerns that so many of the identified studies failed to define normal or abnormal threshold values a priori, and also that threshold values were so hugely variable between different studies evaluating the same assessment tool.</p> <p>One study initially considered for inclusion investigated MRI using a threshold narratively described by the authors as “diffuse irregularity of the surface of the liver”. The GDG subsequently agreed to exclude this paper on the basis that the criterion described in this study to identify those with NAFLD and advanced fibrosis was felt to be subjective, not adequately quantified and non-reproducible in a way that could easily be explained if required within a recommendation.</p> <p>The 2 published economic studies included in this review were assessed as partially applicable with potentially serious limitations. As cost analyses only, the GDG were unable to draw conclusions based on their results. The original economic analysis conducted for this question was assessed as directly applicable and with minor limitations.</p>
Other considerations	<p>The GDG noted that at present, many cases of NAFLD are identified incidentally (for example, abdominal imaging requested to investigate abdominal pain incidentally detects fatty liver) rather than through targeted case-finding as recommended in Chapter 6. The GDG emphasised that regardless of the means by which the diagnosis of NAFLD has been made, all affected people should undergo a severity assessment through the pathway described in these recommendations.</p> <p>It was agreed by the GDG that all people who have been identified as having an ELF test of at least 10.51 (and therefore presumed to have F3 or F4 fibrosis) should be referred to the care of a specialist in hepatology (or a paediatric hepatologist as appropriate). The GDG agreed that these are the people with NAFLD who need closest monitoring (given their potential development of complications of chronic liver disease), and also the people most likely to be considered for pharmacotherapy for the condition. These aspects of assessment and management of the condition were universally agreed by the GDG to be best suited to secondary care, and specifically a specialist in hepatology (either an adult or paediatric specialist, as appropriate).</p> <p>The GDG also noted that hepatocellular carcinoma (HCC) has been recognised to occur in people with NAFLD without cirrhosis. However, given that the incidence of HCC in people with NAFLD without cirrhosis appears to be substantially lower than those with NAFLD with associated cirrhosis<sup>230</sup> (for whom surveillance for HCC is recommended in the draft NICE Cirrhosis guideline<sup>120</sup>), the GDG felt that it was outside of its remit to provide further guidance on this issue.</p> <p><b>Research recommendations</b></p> <p>The GDG made high-priority research recommendations to identify the most accurate non-invasive tests to diagnose NASH in people of all ages, and to diagnose advanced fibrosis in children and young people. See Appendix P for further details.</p>



## 1 8 Monitoring NAFLD progression

### 2 8.1 Introduction

3 There is no guidance on the frequency with which people with NAFLD without fibrosis should be seen  
4 in clinic, and hence there is wide variation in clinical practice. This latter group constitutes a  
5 substantial number of people, and thus standardisation of their follow-up has the potential to  
6 significantly reduce unnecessary clinic appointments.

### 7 8.2 Review question: How often should we monitor adults, young 8 people and children with NAFLD or NASH (with or without fibrosis) 9 to determine the risk of disease progression?

10 For full details see review protocol in Appendix C.

11 **Table 35: Characteristics of review question**

<b>Population</b>	<ul style="list-style-type: none"> <li>• Adults with NAFLD (18 years and over)</li> <li>• Young people with NAFLD (11 years or older and younger than 18 years), children with NAFLD (younger than 11 years)</li> </ul>
<b>Prognostic variable under consideration</b>	Progression of NAFLD stage
<b>Confounding factors</b>	Factors independently associated with prognostic variable: <ul style="list-style-type: none"> <li>• Waist circumference</li> <li>• BMI</li> <li>• Raised triglycerides</li> <li>• Low HDL-cholesterol</li> <li>• Type 2 diabetes</li> <li>• Hypertension</li> <li>• Age</li> </ul>
<b>Outcomes</b>	Rate of: <ul style="list-style-type: none"> <li>• Progression from NAFLD to NASH</li> <li>• Progression from NASH to NASH with fibrosis</li> <li>• Progression from NASH with fibrosis to cirrhosis</li> </ul>
<b>Study design</b>	Prospective and retrospective cohorts Randomised trials (if appropriate) Systematic reviews of the above

### 12 8.3 Clinical evidence

13 Fifteen studies were included in the review that reported serial liver biopsies in populations of  
14 people with NAFLD.<sup>4,24,44,48,49,52,64,66,71,73,116,137,181,195,212</sup> Evidence from these are summarised in the  
15 clinical evidence profile below. See also the study selection flow chart in Appendix E, forest plots in  
16 Appendix K, GRADE tables in appendix J, study evidence tables in Appendix H and exclusion list in  
17 Appendix M.

1 **No studies were identified that used a multivariate analysis of the progression rate, therefore**  
2 **other study designs were considered for inclusion. Five of the reported studies were**  
3 **retrospective longitudinal in design,**<sup>4,52,71,116,137</sup> **whilst 10 were prospective**  
4 **observational.**<sup>181,195 24,44,48,49,64,66,73,212</sup> **There was a wide range in the time between repeat**  
5 **biopsies, ranging from 1 to 15 years amongst the studies. One included study reported**  
6 **on a population of children and young adults,**<sup>71</sup> **whilst the remaining studies featured**  
7 **adult populations only. Six of the studies were from European**  
8 **populations,**<sup>44,48,116,137,181,195</sup> **5 from the USA,**<sup>4,49,52,66,71</sup> **and 4 from Asian countries:**  
9 **Japan,**<sup>64</sup> **China**<sup>73,212</sup> **and Malaysia.**<sup>24</sup> **As few studies provided enough data to meta-**  
10 **analyse progression rate, a sixteenth study was included in the review.**<sup>179</sup> **This study**  
11 **featured a systematic review and meta-analysis of progression rate for those people**  
12 **who had no fibrosis at baseline using information gathered from contacting some of the**  
13 **authors of some of the papers in this review. Therefore, where possible, the additional**  
14 **data has been added to the current review to provide a suggested fibrosis progression**  
15 **rate across papers. A summary of this information is available in Table 37. Additionally,**  
16 **we investigated whether the included studies also identified factors that may predict**  
17 **fibrosis progression. Seven studies used a multivariate analysis to assess which factors**  
18 **at baseline or follow up predicted a progression of fibrosis.**<sup>4,24,44,64,116,181,212</sup> **The summary**  
19 **from these is found in Table 36: Summary of studies included in the review**  
20  
21  
22

**Table 36: Summary of studies included in the review**

Reference	Risk of bias	Number of participants			Duration of follow up, mean (SD/range)	Change in fibrosis score n (%)			Fibrosis regression rate (SD/95%CI) stages/year		
		NAFLD (total n)	NAFL	NASH		Progress ≥1 stage	Stable	Regress ≥1 stage	NAFLD	NAFL	NASH
<b>Papers with enough data supported by Singh 2014 to analyse progression rate (adult population)</b>											
Adams 2005 <sup>4</sup>	serious <sup>a</sup>	103	7	96	3.2 years (3.0)	38 (37%)	35 (34%)	30 (29%)	Total cohort (regardless of baseline fibrosis status):		
									0.02 (0.66)	0.19 (0.20)	0.014 (0.69)
									Baseline no fibrosis: <sup>b</sup>		
									0.31 (0.21, 0.41)	-	-
Ekstedt 2012 <sup>44</sup>	very serious <sup>a</sup>	68	67	1	13.8 years (1.2)	12 (18%)	54 (82%)	0	Baseline no fibrosis: <sup>b</sup>		
									0.06 (0.04, 0.08)	0.06 (0.04, 0.08)	-
Evans 2002 <sup>48</sup>	serious <sup>a</sup>	7	0	7	8.2 years (5.5-11.9)	4 (57%)	3 (43%)	0	Baseline no fibrosis: <sup>b</sup>		
									0.09 (-0.01, 0.19)	-	0.09 (-0.01, 0.19)
Fassio 2004 <sup>49</sup>	serious <sup>a</sup>	22	0	22	5.3 years (2.7)	7 (32%)	11 (50%)	4 (18%)	Baseline no fibrosis: <sup>b</sup>		
									0.25 (0.04, 0.46)	-	0.25 (0.04, 0.46)
Hui 2005 <sup>73</sup>	serious <sup>a</sup>	17	3	14	6.1 years (3.8-8.0)	9 (53%)	8 (47%)	0	Baseline no fibrosis: <sup>b</sup>		
									0.10 (0.03, 0.18)	0.06 (-0.05, 0.16)	0.12 (0.03, 0.21)
McPherson	serious <sup>a</sup>	108	27	81	6.6 years	45 (42%)	43 (40%)	20 (18%)	Total cohort (regardless of baseline		

Reference	Risk of bias	Number of participants			Duration of follow up, mean (SD/range)	Change in fibrosis score n (%)			Fibrosis regression rate (SD/95%CI) stages/year		
		NAFLD (total n)	NAFL	NASH		Progress ≥1 stage	Stable	Regress ≥1 stage	NAFLD	NAFL	NASH
2015 <sup>116</sup>					(1.3- 22.6)				fibrosis status):		
									0.08 (0.25)	-	-
Pais 2013 <sup>137</sup>	no serious	70	25	45	3.7 years (2.1)	20 (29%)	30 (42%)	20 (29%)	Baseline no fibrosis: <sup>b</sup>		
									0.19 (0.06, 0.31)	0.19 (0.06, 0.31)	-
Teli 1995 <sup>195</sup>	serious <sup>a</sup>	12	12	0	11.6 years (1.5-15)	1 (8%)	11 (92%)	0	Baseline no fibrosis: <sup>b</sup>		
									0.01 (-0.01, 0.03)	0.01 (-0.01, 0.03)	-
Wong 2010 <sup>212</sup>	no serious	52	35	17	3.0 years	12 (27%)	25 (48%)	13 (25%)	Baseline no fibrosis: <sup>b</sup>		
									0.18 (0.09, 0.26)	0.15 (0.06, 0.24)	0.28 (0.07, 0.49)
<b>Papers with change in fibrosis score only (no progression rate data; adult population)</b>											
Chan 2014 <sup>24</sup>	serious <sup>a</sup>	35	11	24	6.4 years (0.8)	18 (46%)	17 (44%)	4 (10%)	-	-	-
Feldstein 2005 <sup>52</sup>	serious <sup>a</sup>	39	5	34	22 (13) months	22 (56%)	17 (44%)	0	-	-	-
Hamaguchi 2010 <sup>64</sup>	serious <sup>a</sup>	39	22	17	1.0-8.5 years	12 (31%)	16 (41%)	11 (28%)	-	-	-
Harrison 2003 <sup>66</sup>	serious <sup>a</sup>	22	0	22	5.7 years (1.4-15.7)	7 (32%)	11 (50%)	4 (18%)	-	-	-
Sorrentino 2010 <sup>181</sup>	serious <sup>a</sup>	132	NR	NR	6.4 years (5-8.3)	45 (34%)	76 (58%)	11 (8%)	-	-	-
<b>Papers with change in fibrosis score only (no progression rate data; child and young adult population)</b>											
H A- Kader 2008 <sup>71</sup>	very serious <sup>a</sup>	18	NR	NR	28 months (median)	7 (39%)	8 (44%)	3 (17%)	-	-	-

(b) Fibrosis progression rates taken from Singh 2014<sup>178,179</sup>

### 8.3.1 Fibrosis progression rate

**Table 37: Fibrosis progression rates depending on NAFLD status at baseline**

Quality assessment							Pooled effect with 95% CIs (stages/year)	Corresponding time to progress one fibrosis stage	Quality
Number of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other			
<b>Fibrosis progression rate for all people with NAFLD and no fibrosis at baseline<sup>a</sup></b>									
8	Cohorts	serious <sup>b</sup>	very serious inconsistency <sup>c</sup>	no serious indirectness	no serious imprecision	none	0.12 (0.07, 0.18)	8.3 years	VERY LOW
<b>Fibrosis progression rate for all people with NAFL (no NASH) and no fibrosis at baseline<sup>a</sup></b>									
5	Cohorts	serious <sup>b</sup>	very serious inconsistency <sup>c</sup>	no serious indirectness	no serious imprecision	none	0.07 (0.02, 0.12)	14.3 years	VERY LOW
<b>Fibrosis progression rate for all people with NASH (no NASH) and no fibrosis at baseline<sup>a</sup></b>									
4	Cohorts	serious <sup>b</sup>	no serious inconsistency	no serious indirectness	no serious imprecision	none	0.13 (0.07, 0.19)	7.7 years	MODERATE
<b>Fibrosis progression rate for all people with NAFLD (regardless of fibrosis status at baseline)</b>									
2	Cohorts	serious <sup>b</sup>	no serious inconsistency	no serious indirectness	serious imprecision <sup>d</sup>	none	0.07 (-0.39, 0.53)	14.3 years	LOW

(a) Fibrosis progression rates taken from Singh 2014<sup>178,179</sup>

(b) Downgraded by 1 increment if the majority of the evidence had serious limitations, and downgraded by 2 increments if the majority of the evidence had very serious limitations.

(c) Downgraded by 2 increments because the point estimates vary widely across studies, heterogeneity  $I^2 > 80\%$ . This may be due to widely varying times between paired biopsies.

(d) 95% CI crosses the null line.

### 8.3.2 Risk factors for change in NAFLD histology

**Table 38: Factors measured at baseline that were associated with fibrosis progression or regression**

Quality assessment	Pooled effect with 95%	Quality
--------------------	------------------------	---------

Number of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	CI's [if meta-analysed] or effect and 95% CI in single study	Quality
<b>HOMA IR Score<sup>a</sup> &gt;10 at baseline for predicting NAFLD progression</b>								
1 <sup>b</sup>	Prospective cohort	serious <sup>c</sup>	no serious inconsistency	no serious indirectness	none	none	Adjusted OR: 1.9 (1.61, 12.1)	Moderate
<b>Lobular deposition of fibronectin&gt;1 at baseline for predicting NAFLD progression</b>								
1 <sup>b</sup>	Prospective cohort	serious <sup>c</sup>	no serious inconsistency	no serious indirectness	none	none	Adjusted OR: 14.1 (6.9, 32.3)	Moderate
<b>Incidence of hypertension at baseline for predicting NAFLD progression</b>								
1 <sup>b</sup>	Prospective cohort	serious <sup>c</sup>	no serious inconsistency	no serious indirectness	none	none	Adjusted OR: 4.8 (2.7, 18.2)	Moderate
<b>FIB4 score at follow up for predicting NAFLD progression</b>								
1 <sup>b</sup>	Prospective cohort	serious <sup>c</sup>	no serious inconsistency	no serious indirectness	none	none	Adjusted OR: 2.1 (1.1, 3.9)	Moderate

(a)  $HOMA-IR = (\text{fasting serum insulin level } \mu U/l \times \text{plasma glucose level } \text{mmol/l}) / 22.5$ .

(b) Adjusted in multivariate analysis for sex, age, BMI at baseline, presence of Mallory hyaline, hepatocyte ballooning, the grade of portal and lobular inflammation (grades 2 and 3 were combined), baseline HOMA IR, the grade of steatosis, diagnosis of NASH at baseline.

(c) Downgraded by 1 increment if the majority of the evidence had serious limitations, and downgraded by 2 increments if the majority of the evidence have very serious limitations.

**Table 39: Factors measured at follow up that were associated with fibrosis progression or regression**

Quality assessment							Pooled effect with 95% CI's [if meta-analysed] or effect and 95% CI in single study	Quality
Number of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations		
<b>Increase in HbA1C<sup>a</sup> from baseline for predicting NAFLD regression (for each 1% increase)</b>								
1 <sup>b</sup>	Prospective cohort	serious <sup>h</sup>	no serious inconsistency	no serious indirectness	none	none	Adjusted HR: 0.18 (0.05, 0.59)	Moderate
<b>Treatment with insulin for predicting NAFLD regression</b>								
1 <sup>c</sup>	Prospective	serious <sup>h</sup>	no serious	no serious	none	none	Adjusted HR: 8.59	Moderate

Quality assessment							Pooled effect with 95% CIs [if meta-analysed] or effect and 95% CI in single study	Quality
Number of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations		
	cohort		inconsistency	indirectness			(1.20, 61.59)	
<b>Presence of type 2 diabetes at follow up for predicting NAFLD progression</b>								
1 <sup>d</sup>	Retrospective cohort	serious <sup>h</sup>	no serious inconsistency	no serious indirectness	none	none	Adjusted OR: 6.25 (1.88, 20)	Moderate
<b>Change in waist circumference from baseline for predicting NAFLD progression (each 1 cm increment)</b>								
1 <sup>e</sup>	Prospective cohort	no serious risk	no serious inconsistency	no serious indirectness	none	none	Adjusted OR: 1.3 (1.1, 1.5)	High
<b>Change in Low density lipoprotein-cholesterol level from baseline for predicting NAFLD progression (for each 1 mmol/l increment)</b>								
1 <sup>f</sup>	Prospective cohort	no serious risk	no serious inconsistency	no serious indirectness	none	none	Adjusted OR: 2.7 (1.2, 6.1)	High
<b>FIB4 score at follow up for predicting NAFLD progression</b>								
1 <sup>g</sup>	Prospective cohort	serious <sup>h</sup>	no serious inconsistency	no serious indirectness	none	none	Adjusted OR: 3.1 (1.4, 6.8)	Moderate

1 (a) HbA1c - Glycated Haemoglobin.

2 (b) Adjusted in multivariate analysis for age, gender, BMI, treatment with insulin, baseline HbA1C levels

3 (c) Adjusted in multivariate analysis for age, gender, BMI, baseline HbA1C level, change in HbA1C levels

4 (d) Adjusted in multivariate analysis for platelet count, GGT (Gamma-glutamyl transpeptidase), AST/ALT ratio (alanine aminotransferase ratio/ Aspartate transaminase), FIB4 score (FIB4 age = [years] × AST [IU/L]/platelet count [expressed as platelets × 109/L] × (ALT/2[IU/L]), NAFLD progression score (NAFLD score = -1.675 + 0.037 × age (years) + 0.094 × BMI (kg/m<sup>2</sup>) + 1.13 × diabetes (yes = 1, no = 0) + 0.99 × AST/ALT ratio - 0.013 × platelet (×109/l) - 0.66 × albumin (g/dl)

7 (e) Adjusted in multivariate analysis using changes in BMI, ALT and low density lipoprotein-cholesterol level

8 (f) Adjusted in multivariate analysis using changes in BMI, ALT and waist circumference

9 (g) Adjusted in multivariate analysis for platelet count, GGT (Gamma-glutamyl transpeptidase), AST/ALT ratio, NAFLD progression score (NAFLD score = -1.675 + 0.037 × age (years) + 0.094 × BMI (kg/m<sup>2</sup>) + 1.13 × diabetes (yes = 1, no = 0) + 0.99 × AST/ALT ratio - 0.013 × platelet (×109/l) - 0.66 × albumin (g/dl)

11 (h) Downgraded by 1 increment if the majority of the evidence had serious limitations, and downgraded by 2 increments if the majority of the evidence had very serious limitations

1 The following studies did not report OR/HR but did provide information on multivariate analysis in  
 2 the narrative or in forms not possible to extract into GRADE.

3 **Table 40: Multivariate analysis of factors associated with fibrosis progression**

Reference	Risk of bias	Confounders included in analysis	Factors reported
Adams 2005 <sup>4</sup>	High risk	AST/ALT ratio Age Steatosis grade BMI Diabetes Fibrosis stage at baseline	Significant factors: <ul style="list-style-type: none"> <li>• Diabetes-regression coefficient 0.39, SE 0.01, p value =0.005</li> <li>• Early fibrosis stage- regression coefficient -0.22, SE 0.06, p value 0.001</li> <li>• BMI regression coefficient 0.04, SE 0.01, p value 0.008</li> </ul> Non-significant factors: <ul style="list-style-type: none"> <li>• AST/ALT ratio: regression coefficient -0.16, SE 0.13, p value 0.2</li> <li>• Steatosis grade: regression coefficient 0.10, SE 0.08, p value 0.2</li> <li>• Age regression coefficient 0.01, SE 0.01, p value 0.1</li> </ul>
Chan 2014 <sup>24</sup>	High risk	Age Male gender Elevated ALT AST Y-GT	No significant factors identified
Ekstedt 2012 <sup>44</sup>	High risk	Steatosis grade Portal inflammation Hepatocellular ballooning Mallory bodies Portal fibrosis stage Perisinoidal fibrosis stage NAS	No significant factors identified.
Mcperson 2014 <sup>116</sup>	High risk	<u>Factors at baseline</u> Platelet count AST/ALT ratio FIB-4 score	Platelet count and AST/ALT were not significant on multivariate analysis.
		<u>Factors at follow-up</u> Type 2 diabetes Platelet count GGT AST/ALT ratio FIB 4 score NAFLD fibrosis score	Platelet count, GGT, AST/ALT ratio and NAFLD fibrosis score were not significant on multivariate analysis.
Wong 2010 <sup>212</sup>	Low risk	Changes in BMI Waist circumference Low density lipoprotein level ALT level	Change in BMI and ALT level were not significant on multivariate analysis.



## 1 **8.4 Economic evidence**

### 2 **8.4.1 Published literature**

3 No relevant economic evaluations were identified.

4 See also the economic article selection flow chart in Appendix F.

### 5 **8.4.2 Unit costs**

6 See Table 61 in Appendix N.

### 7 **8.4.3 New cost-effectiveness analysis**

8 Original cost-effectiveness modelling was undertaken to determine the most cost-effective  
 9 frequency of testing for advanced fibrosis. A summary of the modelling work and an evidence  
 10 statement summarising the results of the analysis can be found in Chapter 7. The full analysis can be  
 11 found in Appendix N.

12 The model examined multiple monitoring frequency scenarios from 1 to 6 years.

## 13 **8.5 Evidence statements**

### 14 **8.5.1 Clinical**

- 15 • No relevant evidence was identified that specifically addressed the question of how often people  
 16 with NAFLD or NASH should be monitored to determine risk for disease progression. However  
 17 when adding further evidence from a supplementary meta-analysis paper that contacted review  
 18 authors for additional data some information on fibrosis progression rates could be calculated.  
 19 Very low quality evidence from 8 studies suggested that those with any form of NAFLD progress  
 20 0.12 (0.07-0.18) fibrosis stages per year. Very low quality evidence from 5 studies suggest that  
 21 those with NALF only and no NASH progress 0.07 (0.02-0.12) fibrosis stages per year and  
 22 moderate quality evidence from 4 studies suggested those with NASH progress at a rate of 0.13  
 23 (0.07-0.19) stages per year. Low quality evidence from two studies that did not take into account  
 24 fibrosis stage at baseline suggested that people with any form of NAFLD progress at a rate of 0.07  
 25 (-0.39, 0.53) stages per year.
- 26 • Moderate quality evidence from 2 cohort studies suggested that the presence at baseline of high  
 27 HOMA IR score, lobular deposition of fibronectin >1, hypertension and high FIB4 score were  
 28 associated with fibrosis progression in people with NAFLD.
- 29 • Moderate quality evidence from 2 cohort studies suggested a strong association between insulin  
 30 treatment and diabetes at follow-up with the progression of fibrosis. However there are large  
 31 confidence intervals around these effects. Moderate to high quality evidence from 3 cohort  
 32 studies suggested weaker associations between an increase of HbA1c from baseline, increase in  
 33 waist circumference, change in low LDL-cholesterol and a high FIB4 score at follow up and the  
 34 progression of NAFLD.

### 35 **8.5.2 Economic**

- 36 • One original cost-utility analysis found that testing adults with NAFLD for advanced fibrosis was  
 37 cost-effective compared to no testing under all fibrosis prevalence's and retest frequencies  
 38 investigated at a cost-effectiveness threshold of £20,000 per QALY gained. Retesting at a

- 1 frequency of 3 years was cost-effective compared to other frequencies. This analysis was assessed  
 2 as directly applicable with minor limitations.

### 3 8.6 Recommendations and link to evidence

<b>Recommendations</b>	<p><b>13. Retest adults with NAFLD and an ELF score of less than 10.51 for advanced liver fibrosis using ELF every 3 years.</b></p> <p><b>14. Retest children and young people with NAFLD and an ELF score of less than 10.51 for advanced liver fibrosis using ELF every 2 years.</b></p> <p><b>15. Monitor adults and young people over 16 with NAFLD and advanced liver fibrosis for cirrhosis in line with NICE's <a href="#">cirrhosis guideline</a><sup>b</sup>.</b></p>
<b>Research recommendation</b>	<b>5. How often should children and young people with NAFLD or NASH be monitored to determine risk of disease progression?</b>
Relative values of different outcomes	The GDG considered that the rate of progression related to the baseline severity of NAFLD would be the most informative outcome. However, from the evidence identified, very few studies provided comprehensive data on the differential progression of disease in people with different stages of NAFLD over the course of the study. No studies were identified that used multivariate analysis of the progression rate. However, the addition of a pre-existing systematic review and meta-analysis with additional data provided by selected study authors (while not presented in a transparent enough fashion for us to use as raw data) did provide some indication of suggested progression rates based on those people with no fibrosis at baseline. Additionally, some of the identified studies did provide data regarding clinical, biochemical and histological factors associated with NAFLD progression (including multivariate analysis). The GDG agreed that these outcomes were important, as identifying risk factors associated with more rapid disease progression could inform the GDG's decisions regarding the interval at which monitoring should occur in people with NAFLD possessing that risk factor.
Trade-off between clinical benefits and harms	<p>The identified evidence for risk factors associated with NAFLD progression was reviewed by the GDG. The GDG noted that the risk factor with the most evidence for an association between its presence and progression of disease was type 2 diabetes mellitus or insulin resistance. Included studies demonstrated both type 2 diabetes mellitus and HOMA-IR were greater than 10 as risk factors for fibrosis progression. Similarly, evidence also demonstrated both a negative change in HbA1c and lack of need for the prescription of insulin as risk factors for fibrosis regression. The GDG noted that the association between a reduction in HbA1c and fibrosis regression in people with NAFLD was observed even in people without diabetes.</p> <p>The GDG also noted the evidence for FIB-4 score being a risk factor for fibrosis progression, both when FIB-4 was measured at the start of the study or at follow up. On review of the other identified studies, the GDG agreed that there was compelling evidence that hypertension and high LDL-cholesterol at the start of monitoring were also risk factors for fibrosis progression. The GDG also concluded that an increase in waist circumference by more than 1 cm over the course of monitoring was also a risk factor for fibrosis progression, noting that the risk appeared to increase linearly for every centimetre of waist circumference gained during follow-up.</p> <p>The GDG noted the evidence from 1 study suggesting that lobular deposition of fibronectin greater than 1 on liver biopsy at baseline increased the risk of progressive</p>

<sup>b</sup> The NICE cirrhosis guideline is currently out for consultation

Monitoring NAFLD progression

	<p>fibrosis in people with NAFLD approximately 14-fold. However, the GDG also discussed the considerable degree of subjectivity that exists in quantifying fibronectin deposition, and the considerable practical difficulties in performing immunohistochemistry on liver biopsies in order to assay fibronectin levels at all. As such, the GDG concluded that fibronectin deposition should not be considered further.</p> <p>The GDG was informed by the economic model about how frequently people should be monitored for advanced fibrosis and whether those with risk factors should be monitored more frequently. It was, however, noted that the presence of risk factors did not affect the cost-effectiveness of retesting and the GDG agreed that all people with NAFLD and a negative ELF test should be retested every 3 years, irrespective of presence of the risk factors for progression identified within this review.</p> <p>The GDG raised concern regarding only retesting children and young people every 3 years. It was noted that the growth and development changes occurring in this age group, including hormonal changes and lifestyle factors, may have an impact on the progression of NAFLD. Although it was acknowledged that there is no conclusive evidence of a more rapid rate of progression in this age group, the GDG agreed that expert opinion was that progression may be more rapid and more frequent testing was warranted. A consensus recommendation was therefore agreed to retest children every 2 years.</p>
<p>Trade-off between net clinical effects and costs</p>	<p>No relevant published economic evaluations were identified.</p> <p>Original cost-utility analysis was conducted for this guideline to address the cost-effectiveness of different frequencies of monitoring of NAFLD progression in adults, alongside the review questions in Chapters 5, 6 and 7. As noted in Chapter 7, no diagnostic tests were identified with sufficient clinical accuracy to be considered for testing for NASH or any stage fibrosis, and so no economic modelling was conducted on such tests. The modelling instead looked at the cost-effectiveness of regular testing for advanced fibrosis. As discussed in Chapter 7, the GDG judged ELF to be the most cost-effective and practical diagnostic test for advanced fibrosis in adults with NAFLD. By varying the frequency of retesting, the economic analysis considered which retesting intervals could be cost-effective at a cost-effectiveness threshold of £20,000 per QALY gained. This identified that retesting every 3 years was cost-effective compared to retesting every 4 years (ICER: £17,740 for the base case).</p> <p>The GDG also noted that the accuracy and so cost-effectiveness of ELF were underestimated in the model, as the sensitivity was decreased from 100% to 94% to avoid the technical constraints that prevent using a perfect 100% in a model (see N.2.3.3.1), and so if anything these results are in fact slightly biased against ELF.</p> <p>An analysis was also conducted to examine if it was cost-effective to retest adults with NAFLD and risk factors for advanced fibrosis (such as hypertension) at a different frequency from those with NAFLD, but without additional risk factors. This showed that a shorter retest frequency than for the base case was not cost-effective even with additional risk factors. See Appendix N for more detail on these results.</p> <p>The GDG concluded that monitoring for progression to advanced fibrosis should be offered every 3 years to all adults with NAFLD, however diagnosed and with any combination of risk factors.</p> <p>No economic analysis was conducted relating to children and young people under 18 years due to a lack of data on the diagnostic accuracy of any tests for NASH or fibrosis in under 18s.</p>
<p>Quality of evidence</p>	<p>Both retrospective longitudinal and prospective observational studies were included, of which 1 study included children and young people as participants.</p> <p>No studies that used multivariate analysis of the progression rate were identified. Therefore it was difficult to account for the possible differences of treatment effectiveness between the studies and the large variation in timelines. Only 1 identified study had defined the interval between liver biopsies a priori<sup>30</sup> (with this</p>

	<p>study biopsying participants after 3 years); other studies repeated biopsies at time points as variable as between 1 and 15 years after the original biopsy, with the length of clinical follow-up also varying considerably between different studies.</p> <p>The evidence for possible progression rates ranges from very low to moderate quality. There is a serious risk of bias associated with the evidence for each NAFLD, NAFL and NASH population. Contributing to this risk of bias assessment is that some of the evidence was summary effect measures calculated within a systematic review that was informed by unpublished information from various original study authors. Therefore the raw data was not provided for assessment and analysis. Due to limitations in the available evidence on appropriate length of surveillance periods, when considering retesting frequencies the GDG based their recommendations heavily on the outcomes of the cost-effectiveness analysis associated with the previous diagnosis and severity chapters (as discussed in the trade-off between net clinical effects and costs section above). Although there was some evidence for progression rates for people with NASH, no diagnostic tests were identified with sufficient clinical accuracy to be recommended for diagnosing NASH. Therefore the GDG could not recommend a frequency for testing for NASH.</p> <p>The identified evidence on risk factors for progression was mostly moderate quality on GRADE assessment. This was based on the risk of bias assessment for the fibrosis progression section of the review. This was due to many of the papers being at high risk for attrition bias with very low re-biopsy rates and at high risk for detection bias with short follow up times that limit the chances for outcomes to be observed. For the risk factors associated with NAFLD progression the impression and risk of bias were assessed.</p> <p>The GDG expressed concerns about some of the threshold values used in studies evaluating risk factors for fibrosis progression; for instance, the study of Sorrentino 2010<sup>181</sup> assessed for HOMA-IR greater than 10 as being a risk factor. This is an extremely high level of insulin resistance, and much higher than that typically found in many people with type 2 diabetes mellitus or metabolic syndrome.</p> <p>The GDG described additional concerns regarding the inclusion of studies where liver biopsy frequency had not been defined a priori. Specifically, all but 1 of the included studies described cohorts of people with NAFLD where repeat liver biopsies had not been performed routinely at a fixed time interval, but had principally been undertaken because of a concern regarding clinical deterioration (for example, derangement of liver enzymes, or development of features of metabolic syndrome). Such cohorts may therefore potentially represent the more severe end of the clinical spectrum because they aroused clinical concern and may overestimate the true progression rate of people with NAFLD meaning they may not be fully representative of the true natural history of the condition.</p> <p>The economic study included in this review was of high quality, being directly applicable and with minor limitations.</p>
Other considerations	<p>The GDG noted the recommendation from the draft NICE Cirrhosis guideline<sup>120</sup> that adults with NAFLD and known advanced fibrosis should be tested for cirrhosis, and retested every 2 years if negative. The GDG noted that the Cirrhosis guideline applies to young people and adults aged 16 years and over, and therefore agreed it was appropriate for all people with NAFLD aged 16 or over to be monitored in line with this guidance.</p> <p><b>Research recommendation</b></p> <p>The GDG made a research recommendation to elucidate how frequently children and young people should be monitored for progression of NAFLD to advanced fibrosis.</p>

# 9 Extra-hepatic conditions

## 9.1 Introduction

Over the last decade, it has been shown that the clinical burden of NAFLD is not only confined to liver-related morbidity and mortality. There is now a growing body of evidence that NAFLD is a multisystem disease. The evidence is beginning to support the concept of NAFLD as a disease affecting several extra hepatic organs and regulatory pathways that is associated with other extra-hepatic chronic diseases, such as type 2 diabetes, cardiovascular disease, cardiac disease, chronic kidney disease, sleep apnoea, colorectal cancer, osteoporosis, psoriasis, and various endocrinopathies such as polycystic ovary syndrome.

The major focus of research during the last decade has involved studying associations between NAFLD and type 2 diabetes, and NAFLD and cardiovascular disease. Research has involved studying NAFLD as a risk factor for type 2 diabetes and studying whether improvements in NAFLD alters risk for developing type 2 diabetes. In studying associations between NAFLD and extra-hepatic complications it is important to assess the independence of NAFLD as a risk factor for extra-hepatic complications and to also assess the strength of NAFLD as a risk factor for each extra-hepatic disease.

To date, there is no guidance to advise current clinical practice as to whether people with NAFLD and type 2 diabetes or NAFLD and cardiovascular disease should be managed differently from people with NAFLD alone, who do not have evidence of type 2 diabetes or CVD. If the presence of NAFLD and co-existing extra-hepatic diseases altered disease progression of the extra-hepatic disease (for example, diabetes), treatments for NAFLD or for type 2 diabetes might be altered or intensified. Additionally, there is no guidance at present as to whether the presence of NAFLD should influence current clinical practice in assessing risk of NAFLD-associated extra-hepatic diseases such as type 2 diabetes or cardiovascular disease. If the presence of NAFLD alters risk prediction for these extra-hepatic conditions then risk reduction measures for type 2 diabetes and cardiovascular disease might be implemented earlier in people who have pre-existing NAFLD.

There is current uncertainty regarding the strength and independence of associations between NAFLD and extra-hepatic complications, and there is also uncertainty as to whether people with the combination of NAFLD and extra-hepatic complications should be managed or treated differently. This review aims to address that uncertainty.

## 9.2 Review question: Should a diagnosis of NAFLD in adults, young people and children prompt assessment for additional extra-hepatic conditions and, if so, which?

For full details see review protocol in Appendix C.

**Table 41: Characteristics of review question**

<b>Population</b>	Adults (18 years and over), young people (11 years or older to younger than 18 years) and children (younger than 11 years and older than 5 years) with NAFLD.
<b>Prognostic variable</b>	Presence of NAFLD
<b>Confounding factors</b>	Critical confounders: <ul style="list-style-type: none"> <li>• BMI</li> <li>• Gender</li> </ul>

## Extra-hepatic conditions

	<ul style="list-style-type: none"> <li>• Age</li> <li>• Diabetes (needs to be adjusted for only because it's a risk factor for CVD).</li> </ul> <p>Important confounders:</p> <ul style="list-style-type: none"> <li>• Metabolic syndrome</li> <li>• Blood pressure.</li> </ul>
<b>Outcomes</b>	<p>Critical:</p> <ul style="list-style-type: none"> <li>• Cardiovascular disease (MI, stroke, TIA, angina, PAD, hypertension)</li> <li>• Type 2 diabetes</li> <li>• Colorectal cancer</li> <li>• Dyslipidaemia (hypertriglyceridemia).</li> </ul> <p>Important:</p> <ul style="list-style-type: none"> <li>• Polycystic ovarian syndrome (PCOS) for adults and young people</li> <li>• Chronic kidney disease (CKD)</li> <li>• Obstructive sleep apnoea syndrome</li> <li>• Vitamin D levels</li> <li>• Obesity</li> <li>• Insulin resistance.</li> </ul>
<b>Study design</b>	Prospective and retrospective cohorts with multivariate analysis that adjust for $\geq 3$ of the above confounders in their model.

### 1 9.3 Clinical evidence

2 Twenty-seven studies were included in the review.<sup>15,26,27,46,72,74,76,80,83,92,95,100,118,142,144,148,149,160,176,189,191-</sup>  
3 <sup>194,216,223,224</sup> Evidence from these are summarised in the clinical evidence profile below (Table 42). See  
4 also the study selection flow chart in Appendix E, forest plots in Appendix K, study evidence tables in  
5 Appendix H and exclusion list in Appendix M.

6 We searched for prospective, retrospective cohort or case-control studies investigating the  
7 association of NAFLD with the development of certain extra-hepatic conditions. A wide variety of  
8 predominantly prospective studies were identified (see details in Table 42). Some studies included  
9 specialised populations such as those who had diabetes, or those who had already undergone certain  
10 tests (coronary angiogram), although most studies came from large databases of healthy individuals  
11 involved in regular medical health check-ups. While we searched for evidence in covering adults,  
12 children and young people, the evidence identified was from adult populations. The GDG felt that  
13 since the disease process of primary NAFLD in children and young people is thought to be the same  
14 as that in adults, there is no reason to expect that extra-hepatic conditions would be different in  
15 children and young people with NAFLD to adults with the condition. Some studies utilised the same  
16 large data set but analysed them slightly differently (1 gender only, based on different definitions of  
17 NAFLD, or using different measures of adjusted effect [HR, OR, or RR]). All studies conducted a  
18 multivariable analysis, but different variables were analysed in each of the studies. Common  
19 confounders considered in multivariable analysis were age, BMI or waist circumference, gender, pre-  
20 existing conditions such as diabetes and hypertension, blood pressure, triglycerides and cholesterol.  
21 The majority of studies identified NAFLD as the prognostic risk factor by using ultrasound to diagnose  
22 fatty liver and then confirm NAFLD by excluding other causes (such as alcohol, viral hepatitis).  
23 However, sometimes the confirmation of NAFLD specifically as opposed to hepatic steatosis (fatty  
24 liver) in general was unclear. In these cases the clinical evidence summary tables in this section and  
25 the forest plots in Appendix K have been labelled accordingly. Some studies also used ultrasound plus  
26 other measures, such as liver enzyme levels or NAFLD fibrosis score. Where studies used ultrasound  
27 to grade fatty liver as mild or moderate to severe and then compare these 'levels of severity' to no

## NAFLD

### Extra-hepatic conditions

---

1 fatty liver, only the latter comparison is included in this review, as the guideline committee agreed  
2 that ultrasound alone is insufficient to adequately grade steatosis.

3 Twelve studies were identified looking at NAFLD and cardiovascular risk. One on atrial fibrillation in  
4 people with diabetes, 5 on cardiovascular events in general (2 of which were in people with  
5 diabetes), 2 on cardiovascular mortality, 1 on coronary artery disease (within a highly selected and  
6 therefore slightly indirect population of those already clinically indicated for coronary angiogram)  
7 and 3 on hypertension. Two studies were identified looking at NAFLD and colorectal cancer. However  
8 1 of these was development of colorectal adenoma (not specifically cancer) so was graded as indirect  
9 evidence. Nine studies were identified for NAFLD and diabetes. These were predominantly drawing  
10 from large databases of Korean and Japanese employee health checks. Four studies were identified  
11 for NAFLD and the development of chronic kidney disease. Three of these were with people with  
12 diabetes. No evidence was found on NAFLD and the development of dyslipidaemia, obstructive sleep  
13 apnoea syndrome, polycystic ovarian syndrome, obesity, insulin resistance or the effect on vitamin D  
14 levels.

**Table 42: Summary of studies included in the review**

Study	Population	Analysis	Prognostic variable	Confounders	Outcome	Limitations
<b>Protocol extra-hepatic condition: Cardiovascular disease (critical)</b>						
El Azeem 2013 <sup>46</sup>	People with normal kidney function  n = 747	Logistic regression	NAFLD: Fatty liver by ultrasound and exclusion of those with history of alcohol.	Age, gender, weight, BMI, WC, smoking, systolic BP, diastolic BP, anti-hypertensive, FBG, HbA1c, duration of DM, insulin therapy, cholesterol, triglycerides, ALT, AST, metabolic syndrome.	Cardio vascular events ( $\beta$ ) during 3 year follow up.  Defined as CHD, ischemic stroke, cerebral haemorrhage.	Unclear patient selection, unclear outcome reporting (exponential beta coefficient with unclear 95% CI only).
Lau 2010 <sup>92</sup>	German population registry  n = 2417	Linear and logistic regression	NAFLD: Fatty liver on ultrasound and increased ALT.	Age, sex, WC, BMI, DM, alcohol consumption, antihypertensive medication.  No exclusion of alcohol but sensitivity analysis on alcohol consumption did not obtain statistical significance.	Development of hypertension (OR) during the 5 year follow up.	Unclear attrition. Unclear inter-rater reliability. Some baseline population already on antihypertensive medication.
Lazo 2011 <sup>95</sup>	National Health and Nutrition Examination Study and Mortality follow-up study, USA  n = 11269	Cox proportional hazards	NAFLD: moderate to severe hepatic steatosis on ultrasound with normal liver enzymes.  NASH: moderate to severe hepatic steatosis on	Sex, age, race or ethnicity, smoking status, BMI, education, alcohol consumption, physical activity, hypertension, diabetes and raised GGT levels	Cardiovascular-related death	Unclear how patients were identified and included in the study. Unclear attrition between prognostic risk factor groups.



Study	Population	Analysis	Prognostic variable	Confounders	Outcome	Limitations
			ultrasound with increased levels of liver enzymes.			
Morling 2015 <sup>118</sup>	Older population with type 2 diabetes  n = 663	Cox proportional hazards	NAFLD: hepatic steatosis on ultrasound without excess alcohol or use of hepatotoxic medication and a negative liver screen	Age, gender, duration of diabetes, treatment for diabetes, lipid-lowering drugs, blood pressure-lowering drugs, deprivation, smoking, excess alcohol consumption, BMI, systolic BP, diastolic BP, HbA1c, HDL-cholesterol, total cholesterol, eGFR	Incident cardiovascular disease	Unclear if NAFLD results reported or just those for steatosis only. Unclear recruitment and attrition.
Perazzo 2014 <sup>144,144</sup>	Dyslipidaemia and type 2 diabetes  n = 2312	Cox proportional hazards	Advanced fibrosis: FibroTest >0.48  Severe steatosis: SteatoTest >0.69	Age, gender, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, SBP, DBP, tobacco and alcohol consumption, presence of diabetes, as well as HbA1c and for those with Type 2 diabetes also adjusted for treatment factors.	Cardiovascular-related death	Unclear how patients recruited (consecutive or random). Unclear attrition between prognostic risk factor groups. Unclear final mortality numbers, but there is a possibility that there could be <10 events per variable.
Pickhardt 2014 <sup>148</sup>	Abdominal CT examinations  n = 1050	Logistic regression	NAFLD: hepatic steatosis on CT and exclusion of alcohol abuse.	BMI, obesity, elevated liver enzymes.  No age or gender in MVA however they are similar at	Cardiovascular events (OR) during 7 year follow up.  Defined as MI, cerebrovascular	Unclear use of raters in prognostic variable and consideration of variability.

Study	Population	Analysis	Prognostic variable	Confounders	Outcome	Limitations
				baseline.	accident, TIA, and coronary bypass graft or stent.	
Pisto 2014 <sup>149</sup>	Hypertensive and age-match and sex-matched controls  n = 988	Cox regression	Hepatic steatosis at ultrasound.	Fat content, age, gender, LDL cholesterol, smoking, alcohol, systolic BP, BMI, QUICKI.	Cardio vascular events (HR) during 17 year follow up.  Defined as CHD or stroke.	DM and heavy drinkers not included in MVA. Authors' state (no data supplied) that sensitivity analyses excluding these people did not affect the results.
Ryoo 2014 <sup>160</sup>	Korean male employee health check-ups  n = 22090	Cox proportional hazards	Fatty liver on ultrasound and exclusion of drinkers >20 g/day	Age, BMI, triglycerides, serum creatinine, AST, ALT, GGT, smoking, exercise, diabetes	Development of hypertension (HR) over 3.5 years of follow up.	Unclear attrition reporting based on baseline group membership
Sung 2014 <sup>189</sup>	Korean employee health check-ups  n = 11448	Logistic regression	Fatty liver by ultrasound. Stratified into 4 groups based on combination of fatty liver status at baseline and follow-up (no-no [reference group]; no-yes; yes-no; yes-yes).	Ade, sex, BMI, alcohol consumption, smoking status, exercise, systolic BP, diabetes, GGT, HOMA-IR	Development of hypertension (OR) over 5 year follow up.	Difference in baseline alcohol consumption and they do not exclude heavy drinkers. Adjusted for in MVA but no results reported.
Targher 2007 <sup>191</sup>	People with type 2 diabetes  n = 2103	Cox proportional hazards	NAFLD: hepatic steatosis on ultrasound and excluding alcohol	Age, sex, smoking, diabetes duration, HbA1c, LDL-cholesterol, medications, metabolic	Cardio vascular events (HR) during 3 year follow up.	Indirect population: includes 10% people who drank >20 g/day and baseline info not

Study	Population	Analysis	Prognostic variable	Confounders	Outcome	Limitations
			abuse and other known causes.	syndrome.	Defined as MI, ischemic stroke, coronary revascularisation or cardiovascular death.	available and not included in MVA. BMI not included in MVA however sensitivity analysis (data not supplied) states that when individual components of MetS were adjusted for there was almost identical results.
Targher 2013 <sup>193</sup>	People with type 2 diabetes  n = 400	Cox regression	NAFLD: hepatic steatosis on ultrasound and excluding alcohol abuse and other known causes.	Age, sex, hypertension, 10-year Framingham heart study AF risk (age, sex, BMI, SBP, hypertension treatment, ECG PR interval, and history of heart failure)	Atrial fibrillation or atrial flutter (OR) at 10 year follow up.	Less than 10 outcomes per variable means an unstable analysis
Wong 2011 <sup>216</sup>	Adults with clinical indication for coronary angiogram  n = 612	Logistic regression	Fatty liver on ultrasound and exclusion of drinkers >20 g/day	Fatty liver, age, gender, diabetes, WC, fasting glucose, HDL-cholesterol, ALT.  BMI, and blood pressure were not significant at univariate level so were not included at MVA.	Development of coronary artery disease (OR) at 20-22 months follow up	Short follow-up time, no attrition information supplied.
<b>Protocol extra-hepatic condition: Colorectal cancer (critical)</b>						
Huang 2013 <sup>72</sup>	Taiwanese employee health	Logistic regression	NAFLD: Fatty liver by ultrasound and	Age, BMI, gender, NAFLD, smoking, hypertension,	Development of colorectal adenoma	No attrition information

Study	Population	Analysis	Prognostic variable	Confounders	Outcome	Limitations
	check-ups  n = 1522		exclusion of drinkers >20 g/day	diabetes, metabolic syndrome.	(OR) at 3 year follow up.	reported. Unclear inter-rater reliability. Indirect outcome: not specifically development of colorectal cancer (precursor lesion).
Lee 2012 <sup>100</sup>	Korean women health checks  n = 5517	Cox proportional hazards	Fatty liver by ultrasound	Age, BMI, blood pressure, cholesterol, triglycerides, NAFLD, smoking, cardiometabolic risk factors.	Development of colorectal neoplasm (RR) during 7 year follow up.	Unclear definition of NAFLD specifically, no alcohol information supplied and not entered into MVA, No attrition data supplied. Less than 10 events per variable is a risk for unstable analysis.
<b>Protocol extra-hepatic condition: Diabetes (critical)</b>						
Bae 2011 <sup>15</sup>	Korean employee health check-ups  n = 7849	Cox proportional hazards	NAFLD: Hepatic steatosis by ultrasound and exclusion of drinkers >20 g/day	Age, sex, BMI, triglyceride. HDL cholesterol, systolic BP, smoking status, physical activity, alcohol intake, coexisting IFG.	Development of diabetes (HR) at 4 year follow up	Unclear patient selection, retrospective design, unclear variability of assessors.
Change 2013 <sup>26</sup>	Korean employee health check-ups  n = 38291	Cox proportional hazards	NAFLD: Hepatic steatosis by ultrasound and exclusion of drinkers >20 g/day and NAFLD fibrosis score (low versus high).	Age, BMI, sex, smoking, alcohol intake, exercise, family history of DM, other metabolic markers such as cholesterol, triglycerides, HOMA-IR & hsCRP	Development of diabetes (HR) at 5 year follow up	Unclear patient selection, unclear attrition reporting based on baseline group membership
Imamura 2014 <sup>74</sup>	Japanese health	Logistic regression	NAFLD: Fatty liver by	Age, BMI, Hypertension,	Development of	Unclear patient

Study	Population	Analysis	Prognostic variable	Confounders	Outcome	Limitations
	check-ups n = 3545		ultrasound and limited to subjects who are hepatitis virus negative and not on medication for hypertension and dyslipidaemia	Dyslipidaemia, fatty liver and results presented according to gender.	diabetes (OR) at 5 year follow up	selection, retrospective design, unclear variability of assessors.
Kasturiratne 2013 <sup>80</sup>	Sri Lankan health study cohort n = 1857	Cox proportional hazards	NAFLD: Hepatic steatosis by ultrasound and lack of alcohol consumption	Age, sex, BMI, WC, hypertension, dyslipidaemia, ALT, family history of DM.	Development of diabetes (HR) at 3 year follow up.	Unclear patient selection, unclear attrition and inclusion of confounders in MVA, unclear variability of assessors.
Kim 2008 <sup>83</sup>	Korean medical checks n = 6069	Logistic regression	NAFLD: Fatty liver on ultrasound and exclusion of frequent drinkers.	Age, sex, BMI, family history of DM, smoking, blood pressure, fasting glucose, ALT, HDL cholesterol, triglyceride levels, sonographer.	Development of diabetes (RR) at 5 year follow up.	Unclear patient selection, no definition for alcohol intake and NAFLD status, no attrition information.
Park 2013 <sup>142</sup>	Korean male health check-ups n = 25232	Cox proportional hazards	NAFLD: Hepatic steatosis by ultrasound and exclusion of drinkers >20 g/day	Age, WC, HDL-cholesterol, triglycerides, systolic BP, HOMA-IR, serum creatinine, family history of diabetes, exercise, metabolic syndrome.	Development of diabetes (HR) at 5 year follow up.	BMI not included in MVA (although WC a proxy), unclear patient selection, unclear variability of assessors.
Shibata 2007 <sup>176</sup>	Japanese male health check-ups n = 3189	Cox proportional hazards	NAFLD: fatty liver on ultrasound and exclusion of drinkers >20 g/day	Age, BMI	Development of diabetes (HR) during 4 years of follow-up	Unclear patient selection, unclear patient selection, unclear variability of assessors, unclear

Study	Population	Analysis	Prognostic variable	Confounders	Outcome	Limitations
						baseline status.
Yamada 2010 <sup>223</sup>	Japanese health checks  n = 12375	Logistic regression	Fatty liver on ultrasound.	Age, BMI, alcohol drinking, smoking, family history of diabetes, fatty liver. Results reported separately by gender.	Development of type 2 diabetes or impaired fasting glucose (OR) over 5 year follow up.	Indirect outcome, unclear patient selection, daily drinkers not excluded from MVA.
Yamazaki 2015 <sup>224</sup>	Japanese health checks  n = 3074	Logistic regression	NAFLD: Fatty liver on ultrasound after exclusion of hepatitis B, C and ethanol intake >20 g/day  Focus on reduction in NAFLD between baseline and follow-up.	Age, sex, BMI, impaired fasting glucose, family history of diabetes, dyslipidaemia, hypertension and physical exercise.	Incidence of type 2 diabetes over 10 years.	Unclear patient selection, retrospective design, unclear variability of assessors.
<b>Protocol extra-hepatic condition: Chronic kidney disease (important)</b>						
Chang 2008 <sup>27</sup>	Korean employee health check-ups (non-diabetic and non-hypertensive)  n = 8329	Cox proportional hazards	NAFLD: Hepatic steatosis by ultrasound and exclusion of drinkers >20 g/day	Age, NAFLD, obesity, eGFR, HDL cholesterol, triglycerides, hypertension	Development of CKD (RR) at 4 year follow up.	Unclear attrition reporting based on baseline group membership, unclear variability of assessors.
Jenks 2014 <sup>76</sup>	Older adults with type 2 diabetes  n = 601	Linear regression	NAFLD: Hepatic steatosis by ultrasound in absence of other cause (viral, alcohol)	Age, sex, BMI, duration of diabetes, HbA1c, systolic BP.	Development of CKD (RR) at 3 year follow up.	Unclear attrition based on baseline group membership. Unclear specific confounders entered into MVA.

Study	Population	Analysis	Prognostic variable	Confounders	Outcome	Limitations
Targher 2008 <sup>194</sup>	People with type 2 diabetes  n = 1760	Cox proportional hazards	NAFLD by ultrasound and exclusion of other common causes	Age, gender, BMI, WC, blood pressure, smoking, diabetes, HbA1c, lipid, antihypertensive, antiplatelet.	Development of CKD (HR) at 6.5 year follow up.	No information on baseline status of those lost to follow up, no patient selection information, unclear variability of assessors.
Targher 2014 <sup>192</sup>	People with type 1 diabetes  n = 261	Cox proportional hazards	NAFLD: Hepatic steatosis by ultrasound and exclusion of secondary causes	Age, sex, duration of diabetes, BMI, HbA1c, hypertension, eGFR, serum triglycerides	Development of CKD (HR) at 12 year follow up.	No attrition information. Some baseline differences not adjusted for in MVA (BP and metabolic syndrome).

**Table 43: Clinical evidence summary: NAFLD as a risk factor for developing cardiovascular disease (CRITICAL protocol outcome)**

Quality assessment							Adjusted effects	Quality
Number of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Pooled effect with 95% CIs [if meta-analysed] or effect and 95% CI in single study	
<b>NAFLD vs. no NAFLD for predicting atrial fibrillation [people with diabetes]</b>								
1	Cohort study	serious <sup>a</sup>	-	no serious indirectness	no serious imprecision	none	adjusted OR: 4.96 (1.40, 17.57)	MODERATE
<b>Hepatic steatosis vs. no hepatic steatosis for predicting risk of cardiovascular events (MI, cerebrovascular accident, TIA, coronary bypass)</b>								
1	Cohort study	very serious <sup>a</sup>	-	no serious indirectness	serious <sup>c</sup>	none	adjusted OR: 1.11 (0.55, 2.23)	VERY LOW
<b>Fat content vs. no fat content for predicting cardiovascular events (coronary heart disease event or stroke)</b>								
1	Cohort study	serious <sup>a</sup>	-	no serious indirectness	serious <sup>c</sup>	none	adjusted HR: 1.49 (0.97, 2.29)	LOW
<b>Hepatic steatosis vs. no hepatic steatosis for predicting cardiovascular disease events (MI, ischemic stroke, coronary revascularisation, or cardiovascular death) [people with diabetes]</b>								
2	Cohort studies	very serious <sup>a</sup>	very serious inconsistency <sup>d</sup>	no serious indirectness	no serious imprecision	none	adjusted HR: 1.58 (1.07, 2.33)	VERY LOW
<b>NAFLD vs. no NAFLD for predicting cardiovascular-related death</b>								
1	Cohort study	very serious <sup>a</sup>	-	no serious indirectness	serious <sup>c</sup>	none	adjusted HR: 0.86 (0.67, 1.11)	VERY LOW
<b>NASH vs. no NASH for predicting cardiovascular-related death</b>								
1	Cohort study	very serious <sup>a</sup>	-	no serious indirectness	serious <sup>c</sup>	none	adjusted HR: 0.59 (0.29, 1.20)	VERY LOW
<b>Advanced fibrosis vs. no advanced fibrosis for predicting cardiovascular-related death [people with dyslipidaemia and/or type 2 diabetes]</b>								
1	Cohort study	very serious <sup>a</sup>	-	no serious indirectness	serious <sup>c</sup>	none	adjusted HR: 1.24 (0.27, 5.77)	VERY LOW
<b>Advanced fibrosis vs. no advanced fibrosis for predicting cardiovascular-related death [people with type 2 diabetes]</b>								



Quality assessment							Adjusted effects	Quality
1	Cohort study	very serious <sup>a</sup>	-	no serious indirectness	serious <sup>c</sup>	none	adjusted HR: 1.26 (0.06, 8.31)	VERY LOW
<b>Severe steatosis vs. no severe steatosis for predicting cardiovascular-related death [people with dyslipidaemia and/or type 2 diabetes]</b>								
1	Cohort study	very serious <sup>a</sup>	-	no serious indirectness	serious <sup>c</sup>	none	adjusted HR: 2.27 (0.75, 6.89)	VERY LOW
<b>Severe steatosis vs. no severe steatosis for predicting cardiovascular-related death [people with type 2 diabetes]</b>								
1	Cohort study	very serious <sup>a</sup>	-	no serious indirectness	serious <sup>c</sup>	none	adjusted HR: 1.46 (0.21, 10.27)	VERY LOW
<b>Fatty liver vs. no fatty liver for predicting coronary artery disease [people having coronary angiogram]</b>								
1	Cohort study	very serious <sup>a</sup>	-	serious indirectness <sup>b</sup>	no serious imprecision	none	adjusted OR: 2.13 (1.46, 3.11)	VERY LOW
<b>Fatty liver + increased ALT vs. no fatty liver + normal ALT for predicting hypertension</b>								
1	Cohort study	very serious <sup>a</sup>	-	no serious indirectness	no serious imprecision	none	adjusted OR: 1.70 (1.20, 2.41)	LOW
<b>Persistent fatty liver vs. no fatty liver for predicting hypertension</b>								
1	Cohort study	very serious <sup>a</sup>	-	no serious indirectness	no serious imprecision	none	adjusted OR: 1.29 (1.07, 1.56)	LOW
<b>Developing fatty liver vs. no fatty liver for predicting hypertension</b>								
1	Cohort study	very serious <sup>a</sup>	-	no serious indirectness	no serious imprecision	none	adjusted OR: 1.59 (1.30, 1.94)	LOW
<b>Resolution of fatty liver vs. no fatty liver for predicting hypertension</b>								
1	Cohort study	very serious <sup>a</sup>	-	no serious indirectness	serious <sup>c</sup>	none	adjusted OR: 1.04 (0.78, 1.39)	VERY LOW
<b>NAFLD vs. no NAFLD for predicting hypertension [men only]</b>								
1	Cohort study	serious <sup>a</sup>	-	no serious indirectness	serious <sup>c</sup>	none	adjusted HR: 1.14 (1.00, 1.30)	LOW

1

(a) Downgraded by 1 increment if the majority of the evidence had serious limitations, and downgraded by 2 increments if the majority of the evidence had very serious limitations.

2

(b) The majority of the evidence had indirect population.

(c) 95% CI crosses the null line.

(d) Downgraded by 2 increments because the point estimates vary widely across studies, heterogeneity  $I^2=58\%$ ,  $p=0.02$ . This may be due to consideration of different confounders in the analysis of the 2 studies.

**Table 44: Clinical evidence summary: NAFLD as a risk factor for developing colorectal cancer (CRITICAL protocol outcome)**

Quality assessment							Adjusted effects	Quality
Number of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Pooled effect with 95% CIs [if meta-analysed] or effect and 95% CI in single study	
<b>Fatty liver vs. no fatty liver for predicting colorectal cancer [women only]</b>								
1	Cohort study	very serious <sup>a</sup>	-	no serious indirectness	no serious imprecision	none	adjusted RR: 3.80 (1.02, 14.16)	LOW
<b>NAFLD vs. no NAFLD for predicting colorectal adenoma</b>								
1	Cohort study	very serious <sup>a</sup>	-	serious indirectness <sup>b</sup>	no serious imprecision	none	adjusted OR: 1.45 (1.07, 1.97)	VERY LOW

(a) Downgraded by 1 increment if the majority of the evidence had serious limitations, and downgraded by 2 increments if the majority of the evidence had very serious limitations.

(b) The majority of the evidence had indirect outcomes.

**Table 45: Clinical evidence summary: NAFLD as a risk factor for developing diabetes (CRITICAL protocol outcome)**

Quality assessment							Adjusted effects	Quality
Number of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Pooled effect with 95% CIs [if meta-analysed] or effect and 95% CI in single study	
<b>NAFLD vs. no NAFLD for predicting diabetes</b>								
2	Cohort studies	very serious <sup>a</sup>	no serious inconsistency	no serious indirectness	no serious imprecision	none	adjusted HR: 1.42 (1.19, 1.70)	LOW
<b>Fatty liver vs. no fatty liver for predicting diabetes</b>								
1	Cohort study	very serious <sup>a</sup>	-	no serious indirectness	no serious imprecision	none	adjusted RR: 2.29 (1.13, 4.64)	LOW
<b>NAFLD vs. no NAFLD for predicting diabetes [men only]</b>								

Quality assessment							Adjusted effects	Quality
2	Cohort studies	very serious <sup>a</sup>	very serious inconsistency <sup>b</sup>	no serious indirectness	no serious imprecision	none	adjusted HR: 3.23 (1.04, 9.98)	VERY LOW
<b>NAFLD vs. no NAFLD for predicting diabetes [men only]</b>								
2	Cohort studies	serious <sup>a</sup>	no serious inconsistency	no serious indirectness	no serious imprecision	none	adjusted OR: 2.01 (1.47, 2.76)	MODERATE
<b>NAFLD vs. no NAFLD for predicting diabetes [women only]</b>								
2	Cohort studies	serious <sup>a</sup>	no serious inconsistency	no serious indirectness	no serious imprecision	none	adjusted OR: 2.25 (1.24, 4.07)	MODERATE
<b>NAFLD + low NFS vs. no NAFLD and low NFS for predicting diabetes</b>								
1	Cohort study	very serious <sup>a</sup>	-	no serious indirectness	no serious imprecision	none	adjusted HR: 1.81 (1.61, 2.03)	LOW
<b>NAFLD + high NFS vs. no NAFLD and low NFS for predicting diabetes</b>								
1	Cohort study	very serious <sup>a</sup>	-	no serious indirectness	no serious imprecision	none	adjusted HR: 3.84 (2.93, 5.03)	LOW
<b>NAFLD + high NFS vs. NAFLD + low NFS for predicting diabetes</b>								
1	Cohort study	serious <sup>a</sup>	-	no serious indirectness	no serious imprecision	none	adjusted HR: 2.38 (1.84, 3.08)	MODERATE
<b>Improvement in NAFLD vs. sustained NAFLD for predicting diabetes</b>								
1	Cohort study	serious <sup>a</sup>	-	no serious indirectness	no serious imprecision	none	adjusted OR: 0.27 (0.12, 0.61)	MODERATE
<b>Fatty liver vs. no fatty liver for predicting diabetes or impaired fasting glucose [men only]</b>								
1	Cohort study	very serious <sup>a</sup>	-	serious indirectness <sup>c</sup>	no serious imprecision	none	adjusted OR: 1.90 (1.56, 2.31)	VERY LOW
<b>Fatty liver vs. no fatty liver for predicting diabetes or impaired fasting glucose [women only]</b>								
1	Cohort study	very serious <sup>a</sup>	-	serious indirectness <sup>c</sup>	no serious imprecision	none	adjusted OR: 2.15 (1.53, 3.02)	VERY LOW

(b) Downgraded by 2 increments because the point estimates vary widely across studies, heterogeneity  $I^2=85\%$ ,  $p=0.04$ . This may be due to consideration of different confounders in the analysis of the 2 studies.

(c) The majority of the evidence had indirect outcomes.

**Table 46: Clinical evidence summary: NAFLD as a risk factor for developing chronic kidney disease (IMPORTANT protocol outcome)**

Quality assessment							Adjusted effects	Quality
Number of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Pooled effect with 95% CIs [if meta-analysed] or effect and 95% CI in single study	
<b>NAFLD vs. no NAFLD for predicting chronic kidney disease [men only]</b>								
1	Cohort study	very serious <sup>a</sup>	-	no serious indirectness	no serious imprecision	none	adjusted RR: 1.44 (1.12, 1.85)	LOW
<b>NAFLD vs. no NAFLD for predicting chronic kidney disease [people with type 2 diabetes]</b>								
1	Cohort study	very serious <sup>a</sup>	-	no serious indirectness	serious <sup>b</sup>	none	adjusted RR: 1.01 (0.49, 2.08)	VERY LOW
<b>NAFLD vs. no NAFLD for predicting chronic kidney disease [people with type 1 diabetes]</b>								
1	Cohort study	serious <sup>a</sup>	-	no serious indirectness	no serious imprecision	none	adjusted HR: 2.02 (1.08, 3.78)	MODERATE
<b>NAFLD vs. no NAFLD for predicting chronic kidney disease [people with type 2 diabetes]</b>								
1	Cohort study	very serious <sup>a</sup>	-	no serious indirectness	no serious imprecision	none	adjusted HR: 1.49 (1.10, 2.02)	LOW

(a) Downgraded by 1 increment if the majority of the evidence had serious limitations, and downgraded by 2 increments if the majority of the evidence had very serious limitations.

(b) 95% CI crosses the null line.

## 1 9.4 Economic evidence

### 2 9.4.1 Published literature

3 No relevant economic evaluations were identified.

4 See also the economic article selection flow chart in Appendix F.

### 5 9.4.2 Unit costs

6 See Table 89 in Appendix O.

## 7 9.5 Evidence statements

### 8 9.5.1 Clinical

#### 9 Cardiovascular risk

- 10 • Moderate quality evidence from 1 study suggests that people with diabetes and NAFLD are at  
11 higher risk for developing atrial fibrillation than those without NAFLD (adjusted OR 4.96, 95% CI  
12 1.40-17.57). Three cohort studies investigated NAFLD as a risk factor for cardiovascular events.  
13 Very low and low quality evidence suggests that the presence of hepatic steatosis or fat content  
14 are not a risk factor for cardiovascular events such as myocardial infarction, cerebrovascular  
15 accident, transient ischemic attack, coronary bypass, coronary heart disease or stroke (adjusted  
16 OR 1.11, 95% CI 0.55-2.23 and adjusted HR 1.49, 95% CI 0.97-2.29). Very low quality evidence  
17 from 2 studies suggests that for those with diabetes, having hepatic steatosis is a risk factor for  
18 myocardial infarction, ischemic stroke, coronary revascularisation or cardiovascular death  
19 compared to those with diabetes and no hepatic steatosis (adjusted HR 1.58, 95% CI 1.07-2.33).  
20 Two papers investigated aspects of NAFLD as a risk factor for cardiovascular death. Very low  
21 quality evidence from 1 study suggests that neither NAFLD nor NASH put people at increased risk  
22 for cardiovascular-related death (adjusted HR 0.86, 95% CI 0.67-1.11 and adjusted HR 0.59, 95% CI  
23 0.29-1.20). Very low quality evidence from another study involving people with dyslipidaemia  
24 and/or type 2 diabetes also suggests that advanced fibrosis or severe steatosis are not an  
25 increased risk factor for cardiovascular-related death (adjusted HR 1.24, 95% CI 0.27-5.77,  
26 adjusted HR 1.26, 95% CI 0.06-8.31, adjusted HR 2.27, 95% CI 0.75-6.89, and adjusted HR 1.46,  
27 95% CI 0.21-10.27). Very low quality evidence from 1 study in a highly selected indirect population  
28 of people having coronary angiogram suggests that those with fatty liver are at an increased risk  
29 for developing coronary artery disease compared to those without fatty liver (adjusted OR 2.13,  
30 95% CI 1.46-3.11). Low quality evidence from 1 study suggests that fatty liver and increase ALT  
31 levels are a risk factor for developing hypertension compared to those with no fatty liver and  
32 normal ALT levels (adjusted OR 1.70, 95% CI 1.20-2.41). Low quality evidence from 1 study  
33 suggests that those with persistent fatty liver (at both baseline and follow-up) and those who  
34 developed fatty liver between baseline and follow-up are at increased risk for developing  
35 hypertension compared to those without fatty liver at baseline or follow-up (adjusted OR 1.29,  
36 95% CI 1.07-1.56 and adjusted OR 1.59, 95% CI 1.30-1.94), however those who had fatty liver at  
37 baseline and experienced resolution of fatty liver by follow-up are not at increased risk for  
38 developing hypertension (adjusted OR 1.04, 95% CI 0.78-1.39). Low quality evidence from a third  
39 study in men only also suggests that those with NAFLD are not at increased risk for developing  
40 hypertension compared to men without NAFLD (adjusted HR 1.14, 95% CI 1.00-1.03).

#### 41 Diabetes

1 • Low quality evidence from 2 studies suggests that people with NAFLD are at increased risk for  
 2 developing diabetes (adjusted HR 1.42, 95% CI 1.19-1.70). Similar low quality evidence from 1  
 3 study suggests that people with fatty liver are at increased risk for developing diabetes (adjusted  
 4 RR 2.29, 95% CI 1.13-4.64). Very low quality evidence from 2 studies suggests that NAFLD is a risk  
 5 factor for developing diabetes in a male only population (adjusted HR 3.23, 95% CI 1.04-9.98).  
 6 Moderate quality evidence from 2 more cohort studies also suggests that NAFLD is a risk factor  
 7 for developing diabetes for men (adjusted OR 2.01, 95% CI 1.47-2.76) and for women (adjusted  
 8 OR 2.25, 95% CI 1.24-4.07). Low quality evidence from 1 study looking at the presence of NAFLD  
 9 in combination with fibrosis score suggests that both those with NAFLD and a low NAFLD fibrosis  
 10 score and NAFLD with an intermediate-high fibrosis score are at increased risk for developing  
 11 diabetes compared to those with no NAFLD (adjusted HR 1.81, 95% CI 1.61-2.03 and adjusted HR  
 12 3.84, 95% CI 2.93-5.03), and that those with NAFLD and an intermediate-high NFS are at an  
 13 increased risk for developing diabetes compared to those with NAFLD and a low NFS score  
 14 (adjusted HR 2.38, 95% CI 1.84-3.08). Moderate quality evidence from 1 study suggests that  
 15 reduction of NAFLD is associated with a reduced risk of type 2 diabetes compared to those with  
 16 sustained NAFLD (adjusted OR 0.27, 95% CI 0.12-0.61). Very low quality evidence from 1 study  
 17 suggests that men and women with fatty liver are at an increased risk for developing the indirect  
 18 outcome of diabetes or impaired fasting glucose compared to men and women without fatty liver  
 19 (adjusted OR 1.90, 95% CI 1.56-2.31, and adjusted OR 2.15, 95% CI 1.53-3.02).

#### 20 **Colorectal cancer**

21 • Low quality evidence from 1 retrospective cohort study shows that women with fatty liver have  
 22 an increased risk of developing colorectal cancer, although the small event numbers lead to a  
 23 large confidence interval around the effect (adjusted RR 3.80, 95%CI 1.02-14.16). Very low quality  
 24 evidence from 1 cohort study shows that people with NAFLD have an increased risk for  
 25 developing the indirect outcome of colorectal adenoma (adjusted OR 1.45, 95% CI 1.07-1.97).

#### 26 **Chronic kidney disease**

27 • Low quality evidence from 1 study shows that men with NAFLD have an increased risk for  
 28 developing chronic kidney disease (adjusted OR 1.44, 95%CI 1.12-1.85). Two studies were  
 29 identified looking at NAFLD in people with type 2 diabetes. Very low quality evidence from 1 of  
 30 these studies suggests there is no difference in risk between those with NAFLD and those without  
 31 (adjusted RR 1.01, 95% CI 0.49-2.08). However, low quality evidence from the other study  
 32 suggests that those with NAFLD and diabetes are at an increased risk for developing CKD  
 33 compared to those with diabetes and no NAFLD (adjusted HR 1.49, 95%CI 1.10-2.02). Moderate  
 34 quality evidence from 1 cohort study in people with type 1 diabetes suggests that in this  
 35 population, having NAFLD does increase your risk for CKD (adjusted HR 2.02, 95%CI 1.08-3.78).  
 36 • There was no evidence identified on whether people with NAFLD are at an increased risk for  
 37 developing dyslipidaemia, obstructive sleep apnoea, PCOS, obesity, or insulin resistance, or having  
 38 an independent effect on vitamin D levels.

#### 39 **9.5.2 Economic**

40 • No relevant economic evaluations were identified.

### 41 **9.6 Recommendations and link to evidence**

<b>Recommendations</b>	<b>16. Be aware that NAFLD is a risk factor for type 2 diabetes, hypertension and chronic kidney disease.</b>
	<b>17. Be aware that in people with type 2 diabetes, NAFLD is a risk factor for atrial fibrillation, myocardial infarction, ischemic stroke and</b>

	<b>cardiovascular death.</b>
<b>Research recommendation</b>	<b>6. Is NAFLD a risk factor for the development of colorectal cancer?</b>
Relative values of different outcomes	The GDG agreed that the outcomes that were critical to decision-making were the risks of cardiovascular disease (including myocardial infarction, stroke, transient ischaemic attack, angina, peripheral arterial disease and hypertension), type 2 diabetes, colorectal cancer and dyslipidaemia (focusing particularly on hypertriglyceridaemia). Studies that reported cardiovascular events and those that reported mortality attributable to cardiovascular disease were agreed to be suitable for inclusion. The GDG agreed to include data concerning occurrence of colorectal adenomas as well as data reporting colorectal malignancies.
Trade-off between clinical benefits and harms	<p><b>Cardiovascular disease:</b></p> <p>A single prospective cohort study reported that people with NAFLD and diabetes had a significantly increased risk of atrial fibrillation. Although only a single study, the GDG considered the apparent strength of association – coupled with the large number of participants within the study (400 people) – was sufficient for them to conclude that NAFLD with diabetes is an independent risk factor for atrial fibrillation, after adjusting for age, sex, hypertension, electrocardiographic LVH and PR interval, and 10-year Framingham Heart Study-derived AF risk score.</p> <p>Although the evidence shows that NAFLD is independently associated with an approximate doubling of risk of cardiovascular disease, the GDG noted that none of the identified evidence evaluating whether cardiovascular-related mortality alone is a complication of NAFLD identified a positive association. This finding was maintained whether NASH or severe fibrosis were present or not, and regardless of the presence or absence of dyslipidaemia or diabetes. The GDG also noted that the evidence reviewed was of very low quality by GRADE criteria. However, the GDG noted a large prospective cohort study - which included more than 2000 people - reported data consistent with NAFLD with diabetes as being an independent risk factor for cardiovascular events (which were measured in different ways including incidence of specific events such as myocardial infarction or stroke; need for certain interventions such as coronary revascularisation or carotid endarterectomy; or as cardiovascular-related mortality). The conclusion of the GDG was that the identified evidence was strong enough to conclude that co-morbid NAFLD and diabetes (and possibly not NAFLD by itself) is an independent risk factor for cardiovascular disease when adjusting for combinations of fat content, age, gender, LDL cholesterol, smoking, alcohol consumption, systolic blood pressure, BMI, QUICKI (quantitative insulin sensitivity check index), diabetes, elevated liver enzymes, smoking, diabetes duration, HbA1c, medications, and metabolic syndrome. However, to date more evidence is needed in people without diabetes as a co-morbid condition, since cohort studies in people without diabetes have lower cardiovascular event rates than studies in which diabetes is a co-morbid condition. Thus, existing studies may be underpowered to study the association between NAFLD and cardiovascular disease in people who do not have diabetes.</p> <p>The GDG also reviewed the data for whether NAFLD is a risk factor for hypertension. Evidence was identified, consistent with NAFLD in combination with a raised ALT, as being an independent risk factor for hypertension when adjusted for age, sex, waist circumference, BMI, diabetes mellitus, average daily alcohol consumption and the use of anti-hypertensive medication. Similarly, data from a retrospective cohort of more than 11,000 people showed that the development of NAFLD (or the continued presence of NAFLD) over 5 years of follow-up was associated with the development of hypertension, but that this association no longer held for people whose fatty liver resolved over the course of follow-up. The GDG agreed that the reviewed evidence was sufficient to conclude that NAFLD is a significant risk factor for the development of hypertension.</p>

	<p><b>Colorectal cancer:</b></p> <p>The GDG noted the data from a retrospective cohort of more than 5,000 people with fatty liver disease demonstrated that fatty liver disease may increase the risk of colorectal cancer in women (this was an all-female cohort, rather than evidence that the risk only exists for women). Similarly, the GDG noted evidence for NAFLD appearing to cause a small increase in colonic adenomas. The GDG concluded that the available evidence was suggestive of an association between NAFLD and colorectal cancer, but insufficient for them to conclude that NAFLD was an independent risk factor for colorectal cancer when adjusted for age, BMI, gender, smoking, hypertension, diabetes mellitus, blood pressure, fasting glucose, total cholesterol, triglycerides, HDL-cholesterol and metabolic syndrome. Nevertheless, given that this evidence was from large populations and reported the same direction of effect, the GDG felt there were sufficient grounds to make a research recommendation for further studies to investigate whether NAFLD is a risk factor for colorectal cancer.</p> <p><b>Diabetes:</b></p> <p>The GDG noted that all of the identified evidence for this part of the review question was consistent with NAFLD being an independent risk factor for diabetes when controlling for other possible confounders. This risk was similar for both men and women. People with NAFLD with a high NAFLD fibrosis score were at a higher risk of diabetes than those who did not have a high fibrosis score. The GDG agreed with the conclusion that NAFLD is an independent risk factor for diabetes when adjusting for combinations of age, sex, BMI, triglyceride, HDL cholesterol, systolic BP, smoking status, physical activity, alcohol intake, coexisting IFG, hypertension, dyslipidaemia, ALT, HOMA-IR, serum creatinine and family history of diabetes mellitus.</p> <p><b>Chronic kidney disease (CKD):</b></p> <p>The GDG noted the contradictory results from studies assessing the relationship between NAFLD and CKD, with the evidence from certain data sets consistent with NAFLD being a risk factor for CKD, whilst other data did not support this. However, the GDG also noted the higher quality of evidence of the data supporting this relationship, including lower imprecision, compared to the data suggestive of no relationship. On balance, the GDG concluded that there was sufficient evidence to conclude that NAFLD is an independent risk factor for CKD when adjusting for age, sex, duration of diabetes, BMI, HbA1c, hypertension, smoking, eGFR, serum triglycerides, obesity, and HDL cholesterol.</p> <p><b>Other extra-hepatic conditions:</b></p> <p>No evidence was identified to support or refute whether people with NAFLD have a different risk of developing dyslipidaemia, obstructive sleep apnoea, polycystic ovarian syndrome, obesity, insulin resistance or different vitamin D levels, compared to people without NAFLD.</p>
Trade-off between net clinical effects and costs	<p>No relevant economic evaluations were identified.</p> <p>The GDG considered the economic implications of this review. Any recommendations leading to a greater number of people being referred for additional assessment (and hence possible subsequent care) would have the potential to give rise to additional costs, but also resultant benefits to health. The GDG did not think it appropriate to recommend that any specific people should receive additional assessment or care as a result of these considerations, but instead recommended that clinicians be aware of the additional risk posed by NAFLD for the named conditions. This will then be taken into account when clinicians assess people for these conditions in line with the existing NICE recommendations for those</p>



## Extra-hepatic conditions

	<p>conditions. As the existing NICE recommendations are based on cost-effectiveness evidence, the GDG are confident that any additional treatment arising as a result of such assessments would be cost-effective.</p>
Quality of evidence	<p>For this review question, evidence was identified from cohort and case-control studies using multivariate analysis. The quality of evidence was variable, with the majority of the evidence rated as low or very low quality by GRADE criteria. Much of the downgrading was due to the serious or very serious risk of bias in the evidence due to issues around patient selection, and unclear attrition reporting. Some evidence was also at higher risk of bias due to lack of transparency for multivariable analysis strategies. However, the number of participants in included studies was often very large, and participant follow-up had often been over a long period of time. Heterogeneity was noted between studies both in the means of diagnosing NAFLD, and in defining some of the outcomes measures; for example, variability in the definition of 'cardiovascular events' which contributed to the difficulty in evaluating studies that use different thresholds for what constitutes the occurrence of such events (with respect of analysis of dichotomous outcomes) . However, the definition of these terms in all of the included studies was felt to be sufficient to still be of clinical relevance towards decision-making.</p>
Other considerations	<p>The GDG noted that NICE guidelines already exist for the assessment and management of extra-hepatic conditions reviewed within this question (for example, NICE guideline CG180 on atrial fibrillation, NICE guideline CG182 on chronic kidney disease, and NICE guideline CG131 on colorectal cancer). As such, the GDG agreed that it was outside of its remit to recommend an assessment pathway for those in whom these extra-hepatic conditions are suspected, but that this review question should serve as a reminder to clinicians who have made a diagnosis of NAFLD to consider whether assessment for such extra-hepatic conditions may be appropriate.</p> <p>The GDG noted that all of the included evidence related to adults only. However, the GDG felt that since the disease process of primary NAFLD in children and young people is thought to be the same as that in adults, there is no reason to expect that extra-hepatic conditions would be different in children and young people with NAFLD to adults with the condition and therefore the recommendation should apply to all.</p> <p><b>Research recommendation</b></p> <p>The GDG made a research recommendation to investigate if NAFLD is a risk factor for developing colorectal cancer.</p>

# 10 Weight reduction interventions

## 10.1 Introduction

Whilst weight reduction is commonly recommended in primary care for a host of co-morbidities including NAFLD, achieving and maintaining weight loss remains challenging for the majority of overweight or obese people. It is generally assumed, but not proven, that weight loss may help to reverse NAFLD, particularly as weight loss can lead to a preferential reduction in central abdominal fat compared to subcutaneous fat. This review seeks to determine whether there is evidence to support the assumption that weight loss would reverse NAFLD.

## 10.2 Review question: What is the clinical and cost-effectiveness of dietary interventions for weight reduction for adults, young people and children with NAFLD compared with standard care?

For full details see review protocol in Appendix A.

**Table 47: PICO characteristics of review question**

<b>Population</b>	<ul style="list-style-type: none"> <li>Adults with NAFLD (18 years and over)</li> <li>Young people with NAFLD (11 years or older and younger than 18 years) and children with NAFLD (younger than 11 years)</li> </ul>
<b>Interventions</b>	<ul style="list-style-type: none"> <li>Very low calorie diet (VLCD) (meal replacement/Extreme restriction)</li> <li>Calorie restriction (pooled):               <ul style="list-style-type: none"> <li>Low fat</li> <li>Low carbohydrate</li> <li>High protein</li> <li>Percentage fat (comparing percentages)</li> <li>Percentage carbohydrate (comparing percentages)</li> <li>Percentage protein (comparing percentages)</li> </ul> </li> </ul>
<b>Comparison</b>	No intervention, standard care (for example, advice) or control
<b>Outcomes</b>	<p><b>Critical outcomes:</b></p> <ul style="list-style-type: none"> <li>Progression of NAFLD as assessed by:               <ul style="list-style-type: none"> <li>Liver biopsy</li> <li>MRI/MRS</li> <li>Ultrasound (absence of steatosis only)</li> <li>The Enhanced Liver Fibrosis (ELF) score</li> <li>Transient elastography</li> <li>NAFLD fibrosis score</li> </ul> </li> <li>Quality of life (for example CLDQ, EQ-5D)</li> <li>Serious adverse events</li> </ul> <p><b>Important outcomes:</b></p> <ul style="list-style-type: none"> <li>Weight loss</li> <li>Liver function tests (for example ALT levels, ALT/AST ratio)</li> <li>Adverse events</li> </ul>
<b>Study design</b>	RCTs, systematic reviews of RCTs If no RCTs or SRs identified, comparative prospective cohort studies

### 10.3 Clinical evidence

No relevant clinical studies were identified comparing very low calorie diets or calorie restriction diets with standard care.

### 10.4 Economic evidence

No relevant economic evaluations were identified.

See also the economic article selection flow chart in Appendix F.

### 10.5 Evidence statements

#### 10.5.1 Clinical

No relevant clinical studies were identified.

#### 10.5.2 Economic

No relevant economic evaluations were identified.

### 10.6 Recommendations and link to evidence

Recommendation	18. Manage overweight and obesity in people with NAFLD in line with the recommendations on physical activity and diet in NICE's <a href="#">obesity guideline</a> .
Relative values of different outcomes	<p>The GDG agreed that the outcomes that were critical to decision-making were progression of NAFLD, quality of life and occurrence of serious adverse events. The GDG considered weight loss, liver function test and adverse events to be important outcomes.</p> <p>No relevant clinical studies were identified for inclusion within the review.</p>
Trade-off between clinical benefits and harms	<p>The lack of relevant clinical studies meant that the GDG was unable to make a recommendation based upon this review. However, the GDG specifically noted that the absence of relevant clinical evidence should not be misinterpreted as evidence that weight reduction interventions in themselves are of no clinical effectiveness in the management of NAFLD. The GDG agreed that weight reduction advice is now widely viewed by clinicians as part of routine care for people with NAFLD, explaining in part why the evidence base for weight reduction interventions, in comparison to no intervention or standard care, is so limited.</p>
Trade-off between net clinical effects and costs	<p>No economic evidence was identified relevant to dietary interventions alone. The costs of dietary interventions would fall upon people with NAFLD as consumers, with the exception of initial counselling sessions to inform people on appropriate dietary changes and, later, sessions to encourage them to continue. If these sessions are brief, or contained within standard primary care consultations, then their cost will be modest. Consequently, if a dietary intervention was clinically effective, with evidence that people can adhere to it, and with modest initial consultation costs, it would also be likely to be cost-effective from the perspective of the NHS.</p> <p>However, given that no clinical evidence has been found to demonstrate that specific dietary interventions are clinically effective, we cannot say that any specific dietary intervention will necessarily be cost-effective at a cost-effectiveness threshold of £20,000 per QALY gained.</p>

## NAFLD

### Weight reduction interventions

	The cost-effectiveness of dietary interventions when adopted as part of a broader lifestyle intervention is considered in the review of lifestyle interventions (Chapter 13).
Quality of evidence	No randomised controlled trials or prospective cohort studies were identified that were relevant for inclusion. Whilst other literature relevant to the review question was identified (for example, conference abstracts), these were below the standard of evidence specified in the protocol.
Other considerations	<p>The GDG noted that there are studies that examine diet in combination with other lifestyle interventions. These are assessed in Chapter 13.</p> <p>The GDG noted the guidance already published by NICE regarding weight loss in overweight and obese children, young people and adults (including PH47, PH53 and CG189), and agreed that the multi-component approach to management made in these recommendations is relevant and applicable to overweight and obese children, young people and adults with NAFLD. CG189 provides specific recommendations for management and therefore the GDG agreed to cross-refer to these recommendations.</p>

1

2

# 11 Dietary modification and supplements

## 11.1 Introduction

Given both the absence of any pharmacological interventions specifically licensed at present for the treatment of NAFLD – as well as concerns about the difficulties in complying with lifestyle interventions – there is great interest in alternative therapeutic strategies for the condition. One such strategy focuses on dietary modifications or supplements, with a number of different interventions that have a robust scientific rationale for being of potential clinical benefit having now been evaluated in clinical trials. This review question sought to review the clinical and cost-effectiveness of these dietary interventions.

These interventions take a number of different forms:

- **Omega-3 fatty acids:** Typical Western diets are associated with a significant increase in the ratio of omega-6 fatty acid consumption compared to omega-3 fatty acids. The potential consequences of this include impaired regulation of hepatic and adipose function (predisposing to hepatic fat deposition) as well as increased production of pro-inflammatory arachidonic acid-derived eicosanoids (which may predispose to steatohepatitis). Given that omega-3 fatty acid supplementation is well-recognised to improve both hypertriglyceridaemia and insulin sensitivity (as well as conveying systemic anti-inflammatory effects), it has been proposed that omega-3 fatty acid supplementation may slow down or even reverse hepatic steatosis and/or steatohepatitis.
- **Probiotics and prebiotics:** People with NAFLD appear to have an alteration in the composition of their gut microbiota and increased intestinal permeability in comparison to healthy people without the condition. Whether this acts as a cause of NAFLD, consequence or is purely incidental remains unclear; however, there is increasing evidence for interaction between the gut microbiota and the host metabolism, as well as recognition that a consequence of intestinal permeability may be increased exposure of the liver to potentially pro-inflammatory gut-derived microbial products. Together, this suggests that the gut-liver axis may directly influence the onset and progression of NAFLD. By extension, it has been proposed that modulation of the gut microbiota (by means including probiotics (defined as live micro-organisms that are proposed to convey a health benefit to the host when ingested) or prebiotics (non-digestible food components that promote the growth or activity of micro-organisms within the gut that may convey a health benefit to the host)) may slow down or reverse hepatic fat deposition and/or steatohepatitis.

Other dietary modifications that may also influence the onset and/or progression of NAFLD (including caffeine, alcohol and fructose) are evaluated in separate review questions within this guideline.

## 11.2 Review question: What is the clinical and cost-effectiveness of dietary modifications or supplements for adults, young people and children with NAFLD compared with standard care?

For full details see review protocol in Appendix A.

**Table 48: PICO characteristics of review question**

Population	<ul style="list-style-type: none"> <li>• Adults with NAFLD (18 years and over)</li> <li>• Young people with NAFLD (11 years or older and younger than 18 years), and children</li> </ul>
------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

## Dietary modification and supplements

	with NAFLD (younger than 11 years) [NB adults and children pooled for Omega-3 fatty acids, but separate for probiotics and fibre/prebiotics]
Intervention(s)	<b>Supplements:</b> <ul style="list-style-type: none"> <li>• Omega-3 fatty acids</li> <li>• Probiotics</li> <li>• Fibre/prebiotic</li> </ul>
Comparison(s)	No intervention, standard care (for example advice) or control
Outcomes	<b>Critical outcomes:</b> <ul style="list-style-type: none"> <li>• Progression of NAFLD as assessed by: <ul style="list-style-type: none"> <li>○ Liver biopsy</li> <li>○ MRI/MRS</li> <li>○ Ultrasound (absence of steatosis only)</li> <li>○ The Enhanced Liver Fibrosis (ELF) score</li> <li>○ Transient elastography</li> <li>○ NAFLD fibrosis score</li> </ul> </li> <li>• Quality of life (for example CLDQ, EQ-5D)</li> <li>• Serious adverse events</li> </ul> <b>Important outcomes:</b> <ul style="list-style-type: none"> <li>• Weight loss</li> <li>• Liver function tests (for example, ALT, AST, ALT/AST ratio)</li> <li>• Adverse events</li> </ul>
Study design	RCTs Systematic reviews of RCTs If no RCTs or SRs identified, prospective cohort studies

### 11.3 Clinical evidence

2 Twelve studies were identified that were relevant to the review protocol (1 study is reported in 2  
3 separate papers).<sup>9,10,14,47,75,130,162,168,169,182,201,218</sup> Three RCTs assessed probiotics in adults,<sup>10,47,218</sup> and 2  
4 in children.<sup>9,201</sup> Four studies assessed omega-3 fatty acids in adults.<sup>14,162,168,169,182</sup> and 3 in  
5 children.<sup>75,130,135,136</sup> The diagnostic tests used to identify participants with NAFLD varied between the  
6 studies (Table 49).

7 Only 1 of the papers identified for omega 3 fatty acids in children provided information in the format  
8 that could be quality assessed using GRADE. The remaining evidence was provided in graphical  
9 format in 1 paper, and median and IQR for another. Therefore, in order to include more evidence on  
10 this comparison in the review, the author was contacted to provide the data from the graphs.<sup>130</sup>

11 No studies were identified that assessed fibre intake or prebiotics. Further details of the included  
12 studies are detailed in Table 49. See also the study selection flow chart in Appendix E, study evidence  
13 tables in Appendix H, forest plots in Appendix K, GRADE tables in Appendix J and excluded studies list  
14 in Appendix M.

**Table 49: Summary of studies included in the review**

Study	Population	Intervention	Comparison	Follow-up	Outcomes	Study diagnosis of people with NAFLD
Alisi 2014 <sup>9</sup> RCT	n=48 Children and young people (<18 years)	<i>VSL#3</i> – a mixture of 8 probiotic strains ( <i>Streptococcus thermophilus</i> , bifidobacteria [ <i>B. breve</i> , <i>B. infantis</i> , <i>B. longum</i> ], <i>Lactobacillus acidophilus</i> , <i>L. plantarum</i> , <i>L. paracasei</i> , and <i>L. delbrueckii</i> subsp. <i>Bulgaricus</i> )	Placebo	4 months	ALT BMI  NAFLD progression was measured by ultrasound only so this particular outcome data was excluded from this review	Combination of physical findings at examination, elevated ALT levels of unknown origin and ultrasonographic evidence of hepatic steatosis as well as histological evaluation of liver biopsy at baseline only.
Aller 2011 <sup>10</sup> RCT	n=30 Adults	<i>Streptococcus thermophilus</i> and <i>Lactobacillus delbrueckii</i> subsp. <i>bulgaricus</i> ( <i>Lactobacillus bulgaricus</i> ), 1 tablet per day 500 million <i>Lactobacillus bulgaricus</i> and <i>Streptococcus thermophilus</i>	Placebo: 120 mg starch	3 months	ALT AST Weight	Percutaneous liver biopsy
Argo 2015 <sup>14</sup> RCT	n=34 Adults	n-3 polyunsaturated fatty acids 3000 mg/day	Placebo	12 months	NAFLD progression; NAS, % liver fat (from MRI) ALT Weight	Biopsy demonstrating steohepatitis, defined as steatosis with inflammation, hepatocellular ballooning and/or fibrosis.
Elsamparast 2014 <sup>47</sup> RCT	n=52 Adults	<i>Streptococcus thermophilus</i> and <i>Lactobacillus delbrueckii</i> subsp. <i>bulgaricus</i> ( <i>Lactobacillus bulgaricus</i> ). Synbiotic capsule: 200 million of 7 strains of friendly bacteria ( <i>Lactobacillus casei</i> , <i>Lactobacillus rhamnosus</i> , <i>Streptococcus thermophilus</i> , <i>Bifidobacterium breve</i> , <i>Lactobacillus acidophilus</i> , <i>Bifidobacterium longum</i> and <i>Lactobacillus bulgaricus</i> ) and prebiotic (fructooligosaccharide) and probiotic cultures (magnesium stearate [mineral and vegetable source]) and a	Placebo (maltodextrin)	28 weeks	NAFLD progression; transient elastography fibrosis score ALT AST Serious adverse events	Steatosis on ultrasound associated with persistently raised ALT >50 U/L for 6 months

Study	Population	Intervention	Comparison	Follow-up	Outcomes	Study diagnosis of people with NAFLD
		vegetable capsule (hydroxypropyl methyl cellulose); twice daily				
Janczyk 2015 <sup>75</sup>	N=64 Children and young people aged 11-18	Omega-3 fatty acids (docosahexaenoic acid and eicosapentainoic acid, 450-1300 mg/day)	Placebo	6 months	ALT* AST* Weight loss zBMI* Adverse events	Ultrasound or liver histology consistent with NAFLD/nonalcoholic steatohepatitis
Nobili 2013 <sup>130</sup> RCT	n=60 Children and young people aged <18	Omega-3 fatty acids DHA 250 mg/day DHA 500 mg/day	Placebo	2 years	ALT and BMI presented in graphical format – author contacted to provide raw data.	Liver biopsy
Pacifico 2015 <sup>135</sup> RCT	n=51 Children and young people aged <18	Omega-3 fatty acids DHA 250 mg/day	Placebo	6 months	NAFLD progression • Percentage decrease of MRI hepatic fat fraction  ALT BMI	MRI and liver biopsy
Sanyal 2014 <sup>162</sup> RCT	n=243 Adults	Omega-3 fatty acids, EPA-E 1800 mg/ day and EPA-E2700 mg/day*	Placebo	12 months	NAFLD progression; • Proportion of responders (NAS ≤3 with fibrosis unchanged and a ≥2 decrease in NAS with fibrosis unchanged) • Proportion meeting criteria (NAS ≤3 with fibrosis unchanged) • Proportion meeting	Liver biopsy



Study	Population	Intervention	Comparison	Follow-up	Outcomes	Study diagnosis of people with NAFLD
		* outcomes for both doses were combined for the purposes of this review (there was no heterogeneity on original separate dose results)			criteria ( $\geq 2$ decrease in NAS with fibrosis unchanged) NAFLD progression; NAS Body weight AST ALT Serious adverse events Severe adverse events	
Spadaro 2008 <sup>182</sup> RCT	n=40 Adults	Omega-3 fatty acids; polyunsaturated fatty acid 2 g/day	Standard care. AHA recommended diet	6 months	NAFLD progression; ALT AST	Increase in ALT levels for $\geq 6$ months before the study, ultrasonography demonstrating fatty liver
Scorletti 2014 <sup>168,169</sup> RCT	n=103 Adults	DHA plus EPA (Omacor); 4 g/day (1 g of Omacor contains 460 mg of EPA and 380 mg of DHA as ethyl esters)	Placebo; 4 g per day of olive oil	15 to 18 months	NAFLD progression; MRI NAFLD progression; NAFLD fibrosis score ALT AST	Histological confirmation by liver biopsy, imaging evidence by MRS, ultrasound or CT
Vajro 2011 <sup>201</sup> RCT	n=20 Children and young adults (< 18 years)	<i>Lactobacillus</i> GG 12 billion CFU/ day	Placebo	8 weeks	ALT	Liver ultrasound (bright liver) and liver enzyme tests
Wong 2013 <sup>218</sup> RCT	n=20 Adults	<i>Lactobacillus delbrueckii</i> subsp. <i>bulgaricus</i> ( <i>Lactobacillus bulgaricus</i> ). <i>Lactobacillus plantarum</i> , <i>L. bulgaricus</i> , <i>L. acidophilus</i> , <i>L. rhamnosus</i> and <i>Bifidobacterium bifidum</i> ; 1 x 10 g sachet contained 200 million probiotic cultures and 3 g fructo-oligosaccharides (prebiotics), cellulose, magnesium stearate,	Standard care Lifestyle advice: lose weight, reduce fat intake and exercise at	6 months	NAFLD progression; MRS hepatic triglyceride content ALT AST Any adverse event	Liver biopsy

Study	Population	Intervention	Comparison	Follow-up	Outcomes	Study diagnosis of people with NAFLD
		silica and milk; 1 sachet twice a day	least 3 times per week			

(a) DHA; docosahexaenoic acid.

(b) EPA; ethyleicosapentanoic acid.

(c) NAS: NAFLD activity score.

(d) PUFA: n-3 long chain polyunsaturated fatty acids.

\*median and IQR reported only.

**Table 50: Clinical evidence summary: probiotics versus placebo or usual care**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with Probiotic versus placebo or usual care (95% CI)
NAFLD progression; MRS hepatic triglyceride content (adults), $\geq 3$ months to $<12$ months	20 (1 study)	⊕⊕⊕⊖ MODERATE <sup>a</sup> due to imprecision	-	The mean MRS liver fat (%) in the control group was 22.6	The mean NAFLD progression; MRS hepatic triglyceride content (adults), $\geq 3$ months to $<12$ months in the intervention groups was 6.8 lower (13.59 to 0.01 lower)
NAFLD progression; transient elastography fibrosis score (adults), $\geq 3$ months to $<12$ months	52 (1 study)	⊕⊕⊕⊕ HIGH	-	The mean transient elastography fibrosis score in the control group was 7.9	The mean NAFLD progression; transient elastography fibrosis score (adults), $\geq 3$ months to $<12$ months in the intervention groups was 2.21 lower (3 to 1.42 lower)
ALT (U/l) (adults), $\geq 3$ months to $<12$ months	100 (3 studies)	⊕⊕⊕⊕ HIGH	-	The mean ALT (U/l) in the control group was 61.8	The mean ALT (U/l) (adults), $\geq 3$ months to $<12$ months in the intervention groups was 17.68 lower (20.13 to 15.24 lower)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with Probiotic versus placebo or usual care (95% CI)
ALT (U/l) (children / young people), ≥3 months to <12 months	84 (2 studies)	⊕⊕⊕⊖ MODERATE <sup>b</sup> due to risk of bias	-	The mean ALT (U/l) in the control group was 61.6	The mean ALT (U/l) (children / young people), ≥3 months to <12 months in the intervention groups was 17.66 lower (26.89 to 8.43 lower)
AST (U/l) (adults), ≥3 months to <12 months	100 (3 studies)	⊕⊕⊖⊖ LOW <sup>c</sup> due to inconsistency	-	The mean AST (U/l) in the control group was 51.0	The mean AST (U/l) (adults), ≥3 months to <12 months in the intervention groups was 21.01 lower (24.04 to 17.97 lower)
Weight loss (BMI) (adults), ≥3 months to <12 months	28 (1 study)	⊕⊕⊕⊖ MODERATE <sup>a</sup> due to imprecision	-	The mean weight (BMI) in the control group was 88.9	The mean weight loss (BMI) (adults), ≥3 months to <12 months in the intervention groups was 3.6 higher (14.8 to 7.6 higher)
Weight loss (BMI) (children / young people), ≥3 months to <12 months	64 (1 study)	⊕⊕⊕⊖ MODERATE <sup>a</sup> due to imprecision	-	The median weight (BMI) in the control group was 32	The mean weight loss (BMI) (children / young people), ≥3 months to <12 months in the intervention groups was 0.8 lower (1.6 lower to 0 higher)
Any adverse event (adults), ≥3 months to <12 months	20 (1 study)	⊕⊕⊖⊖ LOW <sup>a</sup> due to imprecision	RR 1 (0.34 to 2.93)	400 per 1000	0 fewer per 1000 (from 264 fewer to 772 more)
Serious adverse event (adults), ≥3 months to <12 months	52 (1 study)	⊕⊕⊕⊖ MODERATE <sup>a</sup> due to imprecision	Not estimable due to no events occurring	Not estimable due to no events occurring	-

(a) Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.  
 (b) Downgraded by 1 increment if the majority of evidence was at high risk of bias or 2 increments if the majority of evidence was at very high risk of bias.  
 (c) Heterogeneity,  $I^2=91$ ,  $p<0.0001$ .

**Table 51: Clinical evidence summary: omega-3 fatty acids versus placebo or usual care**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with Omega-3 fatty acids (95% CI)
NAFLD progression; MRS liver fat (%) (adults), $\geq 12$ months	137 (2 studies)	⊕⊕⊖⊖ LOW <sup>ab</sup> due to risk of bias, imprecision	-	The mean MRS liver fat (%) in the control group was 15.85	The mean NAFLD progression; MRS liver fat (%) (adults), $\geq 12$ months in the intervention groups was 3.56 lower (6.86 to 0.27 lower)
NAFLD progression; liver fibrosis score (adults), $\geq 12$ months	103 (1 study)	⊕⊖⊖⊖ VERY LOW <sup>a</sup> due to risk of bias, imprecision	-	The mean NAFLD liver fibrosis score in the control group was 9.0	The mean NAFLD progression; liver fibrosis score (adults), $\geq 12$ months in the intervention groups was 0.1 higher (0.43 lower to 0.63 higher)
NAFLD progression; composite of NAS $\leq 3$ /fibrosis unchanged and/or NAS decrease $\geq 2$ / fibrosis unchanged (adults), combined omega 3 doses (1800 mg/day and 2700 mg/day), $\geq 12$ months	174 (1 study)	⊕⊕⊖⊖ LOW <sup>b</sup> due to imprecision	RR 0.9 (0.6 to 1.35)	400 per 1000	40 fewer per 1000 (from 160 fewer to 140 more)
NAFLD progression; NAS $\leq 3$ /fibrosis unchanged (adults), combined omega 3 doses (1800 mg/day and 2700 mg/day), $\geq 12$ months	174 (1 study)	⊕⊕⊖⊖ LOW <sup>b</sup> due to imprecision	RR 0.88 (0.57 to 1.36)	364 per 1000	44 fewer per 1000 (from 156 fewer to 131 more)
NAFLD progression; NAS decrease $\geq 2$ / fibrosis unchanged (adults), combined omega 3 doses (1800 mg/day and 2700 mg/day), $\geq 12$ months	174 (1 study)	⊕⊕⊖⊖ LOW <sup>b</sup> due to imprecision	RR 0.87 (0.54 to 1.4)	327 per 1000	43 fewer per 1000 (from 151 fewer to 131 more)
NAFLD progression; % decrease in MRI	51	⊕⊕⊕⊖	-	The mean % reduction	The mean % reduction in MRI

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with Omega-3 fatty acids (95% CI)
hepatic fat fraction (children / young adults), ≥3 months to <12 months	(1 study)	MODERATE <sup>a</sup> due to imprecision		in MRI hepatic fat fraction in the control group was 22.6% reduction	hepatic fat fraction (children / young people) in the intervention groups was 30.8 more (6.22 to 55.38 more)
ALT (U/l) (adults), ≥3 months to <12 months	36 (1 study)	⊕⊕⊖⊖ LOW <sup>bc</sup> due to indirectness, imprecision	-	The mean ALT levels (U/l) in the control group was 59.7	The mean ALT (U/l) (adults), ≥3 months to <12 months in the intervention groups was 16 lower (31.71 to 0.29 lower)
ALT (U/l) (adults), ≥12 months	137 (2 studies)	⊕⊕⊕⊕ HIGH	-	The mean ALT levels (U/l) in the control group was 50.65	The mean ALT (U/l) (adults), ≥12 months in the intervention groups was 2.39 lower (12.39 lower to 7.6 higher)
ALT (U/l) (children and young people) ≥3 months to <12 months*	51 (1 study)	⊕⊕⊕⊖ MODERATE <sup>a</sup> due to imprecision	-	The mean ALT levels (U/l) in the control group was 45	The mean ALT (U/l) (children and young people), ≥12 months in the intervention groups was 18 lower (28.08 to 7.92 lower)
AST (U/l) (adults), ≥3 months to <12 months	36 (1 study)	⊕⊕⊕⊖ MODERATE <sup>c</sup> due to indirectness	-	The mean AST levels (U/l) in the control group was 26.7	The mean AST (U/l) (adults), ≥3 months to <12 months in the intervention groups was 0.2 higher (5.42 lower to 5.82 higher)
AST (U/l) (adults), ≥12 months	103 (1 study)	⊕⊕⊕⊕ HIGH	-	The mean AST levels (U/l) in the control	The mean AST (U/l) (adults), ≥12 months in the intervention groups

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with Omega-3 fatty acids (95% CI)
				group was 34.1	was 4.1 higher (4.6 lower to 12.8 higher)
AST (U/l) (children and young people) $\geq 3$ months to <12 months	64 (1 study)	*	-	-	Not estimable (median and IQR reported only)
Weight (kg) (adults)	34 (1 study)	⊕⊕⊕⊖ LOW <sup>b</sup> due to imprecision	-	The mean weight (kg) in the control group was 88.8	The mean weight (kg) (adults) in the intervention groups was 4.9 higher (8.43 lower to 18.23 higher)
BMI/zBMI (children and young people)*	51 (1 study)	⊕⊕⊕⊖ LOW <sup>b</sup> due to imprecision	-	The mean final BMI (kg/m <sup>2</sup> ) in the control group was 27.2	The final BMI (kg/m <sup>2</sup> ) (children and young people) in the intervention groups was 0.1 higher (2.53 lower to 2.73 higher)
Weight reduction (children / young people), $\geq 3$ months to <12 months >5% reduction	64 (1 study) 6 months	⊕⊕⊕⊖ LOW <sup>b</sup> due to imprecision	RR 0.81 (0.29 to 2.28)	206 Weight loss per 1000	39 fewer Weight loss per 1000 (from 146 fewer to 264 more)
BMI reduction (children / young people), $\geq 3$ months to <12 months >5% reduction	64 (1 study) 6 months	⊕⊕⊕⊖ MODERATE <sup>b</sup> due to imprecision	RR 2.72 (1.08 to 6.83)	147 Weight loss per 1000	253 more Weight loss per 1000 (from 12 more to 857 more)
Any adverse event (adults), combined omega 3 doses (1800 mg/day and 2700 mg/day), $\geq 12$ months	243 (1 study)	⊕⊕⊕⊕ HIGH	RR 0.88 (0.81 to 0.96)	947 per 1000	114 fewer per 1000 (from 38 fewer to 180 fewer)
Any adverse event (children and young people), mild abdominal discomfort, $\geq 3$ months to <12 months	64 (1 study) 6 months	⊕⊕⊕⊖ LOW <sup>b</sup> due to imprecision	RR 1.13 (0.07 to 17.34)	29 per 1000	4 more per 1000 (from 27 fewer to 474 more)
Serious adverse events (adults), combined omega 3 doses (1800 mg/day and 2700	243 (1 study)	⊕⊕⊕⊖ LOW <sup>b</sup>	RR 1.16 (0.43 to 3.14)	67 per 1000	11 more per 1000 (from 38 fewer to 143 more)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with Omega-3 fatty acids (95% CI)
mg/day), ≥12 months		due to imprecision			
Severe adverse event (adults), combined omega 3 doses (1800 mg/day and 2700 mg/day), ≥12 months	243 (1 study)	⊕⊕⊖⊖ LOW <sup>b</sup> due to imprecision	RR 1.47 (0.66 to 3.27)	93 per 1000	44 more per 1000 (from 32 fewer to 212 more)

\*Data from additional studies that could not be assessed for quality in GRADE are described in Table 52 and Table 53.

(a) Downgraded by 1 increment if the majority of evidence was at high risk of bias or 2 increments if the majority of evidence was at very high risk of bias.

(b) Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

(c) Downgraded by 1 increment due to indirect intervention (omega-3 fatty acid intervention was not purified).

**Table 52: Sanyal 2014<sup>162</sup> results table for outcomes reporting median (25th percentile, 75th percentile)**

Outcome	EPA-E 1800 mg//day (n=55)	EPA-E 2700 mg/day (n=64)	Placebo (n=55)	Risk of bias
NAS	-1.0 (-2.0, 0)	-1.0 (-2.0, 0)	-1.0 (-2.0, 0)	Low risk of bias*
Body weight (kg)	0.5 (-3.0, 3.2)	0.0 (-3.7, 2.5)	-1.0 (-2.7, 1.8)	Low risk of bias*
AST (IU/l)	-6.5 (-21.5, 11.3)	-2 (-18.3, 14.8)	-8 (-25, 0)	Low risk of bias*
ALT (IU/l)	-5.5 (-23.5, 13.3)	-5.5 (-24.8, 25.5)	-20 (-42, 3)	Low risk of bias*

(a) EPA: Ethyleicosapentanoic acid.

(b) NAS: NAFLD activity score

(c) Values represent median (25th percentile, 75th percentile)

\*Low risk of bias, no indirectness in population, intervention or outcome, no inconsistency. Imprecision not able to be estimated.

**Table 53: Janczyk 2015<sup>75</sup> results table for outcomes reporting median (IQR) Omega-3 versus placebo in children and young people**

Outcome	Omega 3 (30)	Placebo (n=34)	Risk of bias
ALT (U/L)	48.5 (31-62)	53.5 (39-99)	Low risk of bias *
AST (U/L)	28 (25-36)	39 (27-55)	Low risk of bias *
BMI z-score	2.4 (1.4-3.2)	2.4 (1.9-3.4)	Low risk of bias *

\*Low risk of bias, no indirectness in population, intervention or outcome, no inconsistency. Imprecision not able to be estimated.

## 11.4 Economic evidence

### 11.4.1 Published literature

3 No relevant economic evaluations were identified.

4 See also the economic article selection flow chart in Appendix F.

### 11.4.2 Unit costs

6 See Table 90 in Appendix O.

## 11.5 Evidence statements

### 11.5.1 Clinical

#### 9 Probiotics versus usual care or placebo

- 10 • In terms of NAFLD progression, moderate quality evidence suggested that probiotics had a  
11 beneficial effect in the reduction of the percentage of liver fat measured by MRS in adults over a  
12 period of equal to or greater than 3 to less than 12 months, and high quality evidence showed  
13 lower transient elastography fibrosis scores in those who were treated with probiotics compared  
14 with placebo controls.
- 15 • High to moderate quality evidence suggested that probiotic treatment for equal to or greater than  
16 3 to less than 12 months has a beneficial effect on ALT levels in both adults and children and  
17 young people. Low quality evidence also suggested a clinical benefit for probiotic treatment on  
18 AST levels in adults when compared to placebo or usual care.
- 19 • Moderate quality evidence suggested a small benefit of probiotics over placebo on weight loss in  
20 children and young people at equal to or greater than 3 to less than 12 months, although no  
21 benefit on weight loss was seen in adults.
- 22 • Moderate quality evidence suggested no difference in adverse events between the probiotic  
23 treatment groups or placebo groups in adults.

#### 24 Omega-3 fatty acids versus usual care or placebo

- 25 • In terms of NAFLD progression, although the majority of evidence indicated some advantage of  
26 omega-3 fatty acids over placebo in adults, the imprecision of these effects was too large to allow  
27 conclusions to be drawn about clinical benefit or harm. The quality of evidence ranged from low  
28 to very low. Some advantage of omega-3 fatty acids was seen from low quality evidence in adults  
29 after treatment for greater than 12 months compared to placebo. Moderate quality evidence  
30 suggested a clinically important reduction in percentage of hepatic fat fraction content on MRI  
31 with omega 3 fatty acids in children compared to placebo after equal to or greater than 3 to less  
32 than 12 months of treatment.
- 33 • There was some low quality evidence for omega-3 fatty acids lowering the levels of ALT in adults  
34 after equal to or greater than 3 to less than 12 months of treatment compared to usual care.  
35 Despite a similar trend being observed for adults after greater than 12 month's treatment, the  
36 imprecision of the effect was too large to allow conclusions to be drawn about clinical benefit or  
37 harm. Moderate quality evidence suggested a clinically important difference in final ALT levels in  
38 children and young people who had omega 3 fatty acids compared to placebo after equal to or  
39 greater than 3 to less than 12 months of treatment.



Dietary modification and supplements

- 1 • There were similar small improvements in AST and less adverse events with omega-3 fatty acids in  
 2 adults when treated for longer than 12 months. The evidence also suggested greater BMI and  
 3 more serious adverse events, however the imprecision of the effects were again too large to allow  
 4 clinical conclusions to be drawn. The evidence ranged from high to low quality. Moderate to low  
 5 quality evidence suggested no difference clinical benefit in terms of weight loss in children and  
 6 young people. There was some evidence of benefit for reduction in BMI when considered as a  
 7 dichotomous outcome of reduction of >5% but not when considered as continuous final BMI  
 8 values. However, there is high quality evidence that fewer adverse events reported in adults  
 9 receiving omega-3 fatty acids treatment for greater than 12 months than placebo. Low quality  
 10 evidence suggested no difference in the adverse event of mild abdominal discomfort between  
 11 treatment and control groups of children and young people.

12 **11.5.2 Economic**

- 13 • No relevant economic evaluations were identified.

14 **11.6 Recommendations and link to evidence**

<b>Recommendations</b>	<p>19. Explain to adults with NAFLD that there is some evidence that the following probiotics could be effective for reducing liver fat content and liver fibrosis:</p> <ul style="list-style-type: none"> <li>• <i>Bifidobacterium bifidum</i></li> <li>• <i>Bifidobacterium breve</i></li> <li>• <i>Bifidobacterium infantis</i></li> <li>• <i>Bifidobacterium longum</i></li> <li>• <i>Lactobacillus acidophilus</i></li> <li>• <i>Lactobacillus casei</i></li> <li>• <i>Lactobacillus delbrueckii bulgaricus</i></li> <li>• <i>Lactobacillus paracasei</i></li> <li>• <i>Lactobacillus plantarum</i></li> <li>• <i>Lactobacillus rhamnosus</i></li> <li>• <i>Streptococcus thermophilus</i>.</li> </ul> <p>20. Explain to children and young people with NAFLD, and their parents or carers, that there is no evidence that probiotics reduce liver fat content and liver fibrosis.</p> <p>21. Do not offer omega-3 fatty acids to adults with NAFLD because there is not enough evidence to recommend their use.</p> <p>22. Explain to children and young people with NAFLD, and their parents or carers, that there is some evidence that the omega-3 fatty acid docosahexaenoic acid reduces liver fat content and alanine aminotransferase levels but the clinical significance of these changes is uncertain.</p>
<b>Research recommendation</b>	<p>7. What is the clinical and cost-effectiveness of using probiotics or prebiotics to treat NAFLD in adults, young people and children?</p>

Relative values of different outcomes	<p>The GDG agreed that the outcomes that were critical to decision-making were progression of NAFLD, quality of life and occurrence of serious adverse events. Of these, progression of NAFLD as measured by liver biopsy was considered of greatest value for decision-making (with several studies using a composite of NAS <math>\leq 3</math> and fibrosis unchanged, or NAS decrease <math>\geq 2</math> and fibrosis unchanged as the primary outcomes). The GDG agreed that other outcomes described within the identified evidence were also of clinical relevance; specifically, improvements in MRS intrahepatic triglyceride and improvements in transient elastography scores. Reduction in liver enzyme values and loss of weight were both agreed to be appropriate potential surrogate markers for improvement in NAFLD (and therefore considered as important outcomes), as were non-serious adverse events.</p>
Trade-off between clinical benefits and harms	<p><b>Probiotics:</b></p> <p>Five RCTs were identified investigating the clinical effectiveness of probiotic use in people with NAFLD (2 of which included children and young people). All of these studies defined the probiotic formulation administered, and it was agreed that these were clinically appropriate formulations in each case. The meta-analyses of the 3 adult studies demonstrated improvements in several outcomes without the occurrence of notable adverse events; however, the GDG also noted that the magnitude of improvement in outcome measures tended to be so modest that their clinical significance was unclear. The GDG considered that the studies reviewed, that included children and young people with NAFLD, overall suggested a clinically relevant reduction in liver enzyme values in the treatment arm, but no significant improvements in any other of the reported outcomes. The GDG also noted that a higher rate of non-specific gastrointestinal side effects would have been expected with probiotics, but this was not evident from this review.</p> <p>Overall, the GDG's interpretation of the reviewed evidence was that probiotics may have benefit for minimising progression of NAFLD in adults, but that there is currently no evidence (from the limited data available) that probiotics may slow NAFLD progression in children and young people. They observed that there was no evidence of probiotic use causing notable adverse events in people with NAFLD of any age. However, the GDG agreed that further research in this area is warranted, on a number of grounds. Firstly, there is a clear scientific rationale for why probiotics and manipulation of the gut microbiota may be effective in the treatment of NAFLD in children, young people and adults. Secondly, the identified studies were small and of variable quality, yet still provided some promising data suggesting that NAFLD progression may be slowed through the use of probiotics, which merited consideration of larger and more robust studies within this area.</p> <p><b>Omega-3 fatty acids:</b></p> <p>All studies had defined the form of omega-3 fatty acid administered apart from 1; the GDG viewed these results with caution, as the exact nature of the intervention was unclear. It was also noted that some people in the control arm in this study had been identified as using omega-3 fatty acids, and that there was variable adherence within the intervention arm; this may have minimised observation of the full potential benefits of the omega-3 fatty acid intervention. It was noted that investigators in some studies had sought to define adherence by study participants to the intervention (for example by measurement of erythrocyte percentage DHA and EPA enrichment by gas chromatography). The GDG agreed that the 4 studies considered assessing the effect of omega-3 fatty acids on NAFLD progression in adults with NAFLD<sup>14,162,168,169,182</sup> did not overall demonstrate any significant improvements in clinically relevant outcomes. A slight decrease in adverse events and an even smaller increase in serious or severe adverse events was reported in adults with NAFLD randomised to receiving omega-3 supplements compared to the control group, but these differences were not large enough to be clinically important. The GDG also observed that regression analysis in the Scorletti et al, 2014 study demonstrated that DHA (but not EPA) was independently associated with a</p>

## Dietary modification and supplements

	<p>decrease in liver fat percentage (as measured by MRS), but that the primary endpoint of progression of NAFLD as measured by liver biopsy was no different whether people with NAFLD were given omega-3 fatty acid supplements either containing DHA or without.</p> <p>The GDG also considered 3 studies assessing NAFLD progression in children with the condition treated with omega-3 fatty acids. There was some evidence of clinically relevant reductions in hepatic fat fraction (as assessed by MRI) and ALT in children and young people with NAFLD who were treated with DHA for 6 months.</p> <p>Collectively, the GDG concluded that there was insufficient evidence from the reviewed evidence for omega-3 fatty acids to be recommended at present to adults with NAFLD as a treatment to slow NAFLD progression. Whilst there was some supportive evidence for omega-3 fatty acids (specifically, DHA) slowing progression of NAFLD in children and young people with the condition, the GDG felt that as this was from a single study - with a relatively small cohort size – it was insufficient to allow the GDG to fully recommend DHA as therapy for children and young people with NAFLD, and agreed to a conclusion that DHA appears to have some effectiveness in this role.</p> <p><b>Other dietary interventions:</b></p> <p>No studies were identified relevant for inclusion regarding the other dietary interventions of fibre or prebiotics. As such, the GDG were unable to make any specific recommendations regarding such interventions.</p>
Trade-off between net clinical effects and costs	<p>No economic evidence was identified relating to any of the dietary supplements considered in this review.</p> <p>The GDG noted that the probiotic VSL#3 (containing sachets of lyophilised lactic acid bacteria) is listed within the BNF, and could therefore potentially be prescribed by clinicians. The GDG considered that further research into the role of probiotics as a dietary intervention in the management of NAFLD or other conditions may result in further probiotic products entering into the BNF in the future. As such, the research recommendation made by the GDG may potentially have future cost implications for the NHS in terms of probiotic prescriptions. These implications would need to be considered when this advice is next updated.</p> <p>The GDG is not recommending that omega-3 fatty acid preparations should either be prescribed by clinicians or bought over-the-counter by people with NAFLD, and so there are no economic considerations relating to these products.</p>
Quality of evidence	<p><b>Probiotics:</b></p> <p>The GDG noted that the number of identified studies was small and included only small numbers of participants, with variable degrees of follow-up. The information given within the identified studies regarding the means taken to assess compliance with the intervention was often limited. For these reasons and the imprecision associated with the effects, the majority of evidence was rated as low to moderate quality. A high quality GRADE rating was observed for 2 outcomes; NAFLD progression assessed by transient elastography fibrosis score and ALT levels in adults at <math>\geq 3</math> to 12 months.</p> <p><b>Omega-3 fatty acids:</b></p> <p>The majority of the evidence was rated as low risk of bias as the identified RCTs were overall well-designed, adequately powered studies with appropriate outcomes that together gave sufficient data to allow meaningful conclusions to be reached regarding the clinical efficacy of this intervention. However, the imprecision associated with the effects for many outcomes lead to the majority of evidence being rated as moderate quality. A high-quality GRADE rating was observed for 3 outcomes; ALT levels, AST levels and adverse events for adults at <math>\geq 12</math> months.</p>
Other considerations	<b>Research recommendation</b>

## NAFLD

### Dietary modification and supplements

The GDG made a high-priority research recommendation to investigate the clinical and cost-effectiveness of probiotics and prebiotics to treat NAFLD. See Appendix P for further details.

1

# 12 Exercise interventions

## 12.1 Introduction

Exercise and/or exercise-related behaviours forms a part of the current treatment offered for NAFLD, especially in the absence of approved pharmaceutical agents. However, the field of evidence around exercise and NAFLD is relatively new in comparison to more established conditions, such as type 2 diabetes or heart disease.

The aim of this review is to define objectively the individual effect of exercise on liver fat and biomarkers of liver health in adults, young people and children with NAFLD.

## 12.2 Review question: What is the clinical and cost-effectiveness of exercise programmes for adults, young people and children with NAFLD compared with standard care?

For full details see review protocol in Appendix A.

**Table 54: PICO characteristics of review question**

Population	<ul style="list-style-type: none"> <li>Adults with NAFLD (18 years and over)</li> <li>young people with NAFLD (11 years or older and younger than 18 years)</li> <li>children with NAFLD (younger than 11 years)</li> </ul>
Intervention(s)	Exercise including: <ul style="list-style-type: none"> <li>Aerobic exercise or cardio-exercise</li> <li>Resistance exercise or repeated muscle contraction (strength, anaerobic endurance)</li> <li>High intensity training (alternate intense anaerobic and recovery)</li> <li>General everyday physical activity</li> <li>Reducing sedentary time</li> </ul>
Comparison(s)	No intervention, control or sham
Outcomes	<p><b>Critical outcomes:</b></p> <ul style="list-style-type: none"> <li>Progression of NAFLD as assessed by:               <ul style="list-style-type: none"> <li>Liver biopsy</li> <li>MRI/MRS</li> <li>Ultrasound (absence of steatosis only)</li> <li>The Enhanced Liver Fibrosis (ELF) score</li> <li>Transient elastography</li> <li>NAFLD fibrosis score</li> </ul> </li> <li>Quality of life (for example, CLDQ, EQ-5D)</li> <li>Serious adverse events</li> </ul> <p><b>Important outcomes:</b></p> <ul style="list-style-type: none"> <li>Liver function tests (for example, ALT and AST levels, ALT/AST ratio)</li> <li>Weight</li> <li>Adverse events</li> </ul>
Study design	RCTs Systematic reviews of RCTs

	If no RCTs or SRs identified, prospective cohort studies

### 112.3 Clinical evidence

2 Six RCTs were identified (Table 55) in adults.<sup>42,60-62,151,185,186,196,197,234,236</sup> Three compared aerobic  
 3 exercise to standard care or no treatment,<sup>42,151,185,186</sup> 2 compared resistance exercise with standard  
 4 care or a stretching control,<sup>60-62,234,236</sup> and 1 compared high intensity exercise with usual care.<sup>196,197</sup>  
 5 No studies were identified in young people and children aged less than 12 years. The study diagnosis  
 6 of NAFLD for the inclusion of participants varied and is detailed in Table 56. Also the study selection  
 7 flow chart in Appendix E, study evidence tables in Appendix H, forest plots in Appendix K, GRADE  
 8 tables in Appendix J and excluded studies list in Appendix M.

9

**Table 55: Summary of studies included in the review**

Study	Population	Intervention	Comparison	Follow-up	Outcomes	Study diagnosis of people with NAFLD
Eckard 2013 <sup>42</sup> USA RCT	n=20 adults (18 years and over)	n=9 aerobic exercise; 20-60 min, 4-7 times per week, 18 step program including warm up, exercise bike, walking on treadmill, various arm and leg stretches, and gradual cool-down	n=11 standard care	6 months	NAFLD progression with liver biopsy NAS (range 0 to 8) Liver function test; ALT Liver function test; AST Weight	Liver biopsy
Hallsworth 2011 <sup>60-62</sup> UK RCT	n=21 adults (18 years and over)	n=11 resistance exercise; repeated muscle contraction performed 3 times per week (biceps curl; calf raise; triceps press; chest press; seated hamstrings curl; shoulder press; leg extension and lateral pull down) for between 45 and 60 min	n=10 standard care	8 weeks	NAFLD progression; <sup>1</sup> H-MRS intrahepatic lipid CH <sub>2</sub> -water (%) Liver function test; ALT Weight	NAFLD fibrosis scoring system
Pugh 2013 <sup>151</sup> UK RCT	n=13 adults (18 years and over)	n=7 aerobic exercise; 3 times per week of moderate-intensity aerobic exercise training for 30 min, increased to 5 times per week	n=6 usual care	16 weeks	NAFLD progression; <sup>1</sup> H-MRS intrahepatic lipid CH <sub>2</sub> -water (%) Liver function test; ALT Liver function test; AST Weight	ALT levels >41 U/l for at least 6 months in the presence of an echobright liver on abdominal ultrasonography
Sullivan 2012 <sup>185,186</sup> UK RCT	n=18 adults (18 years and over)	n=12 aerobic exercise; 30-60 min, 5 times per week at 45-55% of VO <sub>2</sub> peak	n=6 no treatment	16 weeks	NAFLD progression; MRS intrahepatic triglyceride (%) Liver function test; ALT Weight	MRS intrahepatic triglyceride content >10%
Thoma 2013 <sup>196,197</sup> UK RCT	n=29 adults (18 years and over)	n=15 high intensity exercise; alternate intense anaerobic (cycle ergometer-based) and recover (90 sec passive recovery and 60 seconds band resisted upper body exercise) 3 times per week	n=14 usual care	12 weeks	NAFLD progression; <sup>1</sup> H-MRS intrahepatic lipid CH <sub>2</sub> -water (%) Liver function test; ALT Liver function test; AST	>5% liver fat and NAFLD fibrosis score maximum of ≤-1.455

Study	Population	Intervention	Comparison	Follow-up	Outcomes	Study diagnosis of people with NAFLD
					Weight	
Zelber-Sagi 2014 <sup>234,236</sup> Israel RCT	n=56 adults (18 years and over)	n=33 resistance exercise resistance training performed in a community setting, 40 min, 3 times per week,	n=23 home stretching routine lasting 20 min, 3 time per week	3 months	Liver function test; ALT Liver function test; AST Weight	Ultrasound

**Table 56: Clinical evidence summary: exercise versus control**

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with exercise (95% CI)
NAFLD progression; MRS intrahepatic lipid CH2-water / intrahepatic triglyceride (%),(adults), ≥3 months to <12 months	74 (4 studies)	⊕⊖⊖⊖ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision	-	The mean NAFLD progression (MRS) in the control group was 16.6	The mean NAFLD progression; MRS intrahepatic lipid CH2-water / intrahepatic triglyceride (%) in the intervention groups was 2.67 lower (4.87 to 0.46 lower)
NAFLD progression; liver biopsy NAS (range 0 to 8), (adults), ≥3 months to <12 months	20 (1 study)	⊕⊖⊖⊖ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision	-	The mean NAFLD progression; (liver biopsy) in the control group was 3.3	The mean NAFLD progression; liver biopsy NAS (range 0 to 8) in the intervention groups was 0.4 lower (1.76 lower to 0.96 higher)
ALT levels (U/l); RCT	155 (6 studies)	⊕⊖⊖⊖ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision	-	The mean ALT levels (U/l) in the control group was 45.50	The mean ALT levels (U/l) in the intervention groups was 3.07 lower (7.03 lower to 0.9 higher)
AST levels (U/l), (adults), ≥3 months to <12 months	54 (3 studies)	⊕⊖⊖⊖ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision	-	The mean AST levels (U/l) in the control group was 36.5	The mean AST levels (U/l) in the intervention groups was 5.56 lower (12.88 lower to 1.76 higher)



Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with exercise (95% CI)
Weight (kg); Aerobic exercise, (adults), ≥3 months to <12 months	29 (2 studies)	⊕⊕⊕⊕ VERY LOW <sup>a,b,c</sup> due to risk of bias, inconsistency, imprecision	-	The mean weight (kg) in the control group was 98.45	The mean weight (kg) in the intervention groups was 3.65 lower (21.63 lower to 14.33 higher)
Weight (kg); High intensity exercise(adults), ≥3 months to <12 months	23 (1 study)	⊕⊕⊕⊕ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision	-	The mean weight (kg) in the control group was 90.1	The mean weight (kg) in the intervention groups was 1.6 lower (11.26 lower to 8.06 higher)
Weight (kg); Resistance exercise, (adults), ≥3 months to <12 months	83 (2 studies)	⊕⊕⊕⊕ LOW <sup>a</sup> due to risk of bias	-	The mean weight (kg) in the control group was 94.6	The mean weight (kg) in the intervention groups was 0.71 lower (1.36 to 0.06 lower)

(a) Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias.

(b) Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

(c) Heterogeneity,  $I^2=74%$ ,  $p=0.05$ , unexplained by subgroup analysis.

1  
2  
3  
4  
5

## 12.4 Economic evidence

No relevant economic evaluations were identified.

See also the economic article selection flow chart in Appendix F.

## 12.5 Evidence statements

### 12.5.1 Clinical

#### NAFLD progression

- Very low quality evidence from 4 RCTs (n=74) demonstrated an overall clinical benefit of exercise on NAFLD progression, as determined by MRS intrahepatic lipids, when compared to usual care and no treatment in adults at equal to or greater than 3 to less than 12 months. Very low quality evidence from a single RCT (n=20) demonstrated no clinically important benefit of exercise on NAFLD progression, as determined by the NAFLD activity score, when compared to usual care in adults at equal to or greater than 3 to less than 12 months, although the direction of effect favoured exercise.

#### Liver function tests (ALT and AST levels)

- Very low quality evidence from 6 RCTs (n=155) demonstrated no overall clinical benefit of exercise on ALT levels when compared to usual care, home stretching and no treatment in adults at equal to or greater than 3 to less than 12 months, although the direction of effect favoured exercise. Similarly, very low quality evidence from 3 RCTs (n=54) demonstrated no overall clinical benefit of exercise on AST levels when compared to usual care in adults at equal to or greater than 3 to less than 12 months, although the direction of effect favoured exercise.

#### Weight

- An overall clinical benefit of resistance exercise was seen on weight loss in adults when compared to usual care and home stretching from 2 RCTs (n=83) at equal to or greater than 3 to less than 12 months (low quality evidence). Very low quality evidence from 2 RCTs (n=29) comparing aerobic exercise to usual care and no treatment and a single RCT (n=23) comparing high intensity exercise to usual care showed no clinically important benefit on weight loss in adults at equal to or greater than 3 to less than 12 months, although the direction of effect favoured exercise.

### 12.5.2 Economic

- No relevant economic evaluations were identified.

## 12.6 Recommendations and link to evidence

Recommendation	<b>23. Explain to people with NAFLD that there is some evidence that exercise reduces liver fat content.</b>
Relative values of different outcomes	The GDG agreed that the outcomes that were critical to decision-making were progression of NAFLD, quality of life and occurrence of serious adverse events. Of these, progression of NAFLD (as measured by liver biopsy) was the most important outcome. The GDG agreed that other outcomes described within the identified evidence could also be considered to be of clinical relevance. In particular, improvements in MRS intrahepatic lipid or triglyceride, and reduction in liver enzyme values were all agreed to be appropriate potential surrogate markers for

## Exercise interventions

	<p>improvement in NAFLD and therefore considered as important outcomes. The GDG noted that the degree of improvement of such surrogate markers that could be defined as clinically important would depend upon the baseline values rather than purely the absolute reduction in those receiving an intervention.</p>
Trade-off between clinical benefits and harms	<p>The identified studies employed a variety of different exercise interventions (aerobic exercise, resistance exercise, and high intensity exercise) and used a range of different outcome measures, as already described. The GDG agreed that physical activity and exercise produced moderate effects on the liver independent of weight change in children, young people and adults with NAFLD. However, studies were short term and in small numbers of participants. The GDG agreed that advice regarding increasing levels of physical activity and exercise generated health benefits beyond NAFLD and should be supported. It was noted that exercise in isolation of dietary modification does not result in weight loss. Furthermore, none of the included studies reported dietary habits of the participants and therefore it was considered unsurprising that a clinically important difference in weight loss was not demonstrated in this review.</p>
Trade-off between net clinical effects and costs	<p>No economic evidence was identified relevant to exercise interventions alone. Referring people with NAFLD to exercise programmes involving supervision by healthcare or exercise professionals would lead to costs to the NHS. However, the GDG is not recommending the use of any interventions involving a supervised exercise programme alone.</p> <p>The cost-effectiveness of exercise interventions when adopted as part of a broader lifestyle intervention is considered in the review of lifestyle interventions (Chapter 13).</p>
Quality of evidence	<p>The GDG noted that only a relatively small number of relevant studies were identified (with no appropriate studies including children or young people) and the number of people recruited into the studies tended to be low. The majority of the evidence was of very low quality as assessed by GRADE criteria. This was due to the lack of blinding, presence of selection bias and incomplete outcome reporting due to the high number of drop outs in some of the included studies, resulting in a high or very high risk of bias rating. Additionally, the imprecise nature of the results extracted and analysed in this review further downgraded the GRADE quality rating. The GDG observed that the exercise interventions were provided for a relatively short time (typically 12 weeks, with a maximum of 6 months) and also commented that very few of the studies described the actions taken to ensure that study participants were compliant with an exercise intervention.</p>
Other considerations	<p>The GDG noted the short duration of exercise interventions used in the identified studies; however, the GDG recommended exercise as a lifelong behavioural change, as the health benefits of exercise extend far beyond the short term.</p> <p>The GDG noted that there are studies that examine exercise in combination with other lifestyle interventions, which is more reflective of current practice. These are assessed in Chapter 13.</p> <p>The GDG agreed it was important to not discourage people from exercise. There is existing guidance published by NICE regarding exercise in overweight and obese children, young people and adults (including PH47, PH53 and CG189). The GDG agreed that the recommendations in these guidelines are relevant and applicable to overweight and obese children, young people and adults with NAFLD and that there was no reason why people with NAFLD should follow different advice. The GDG particularly emphasised the point described in CG189 (recommendation 1.6.1) that exercise provides health benefits even without weight loss, including reduced risks of type 2 diabetes mellitus and of cardiovascular disease.</p>

# 13 Lifestyle modification

## 13.1 Introduction

Lifestyle modification, encompassing diet, physical activity and/or exercise-related behaviours, is currently the primary recommended treatment for NAFLD, especially in the absence of approved pharmaceutical agents. However, the field of evidence around lifestyle and NAFLD is relatively new in comparison to more established conditions, such as type 2 diabetes or heart disease.

The aim of this review is to define objectively the individual and combined effects of diet, exercise and behaviour modification on liver fat, inflammation and fibrosis and upon biomarkers of liver health in adults, young people and children with NAFLD. This information will support clinical care teams and commissioners in providing effective support pathways for people with NAFLD. This objective review will also highlight areas which need additional attention to assist in evolving continually improving care going forward.

## 13.2 Review question: What is the clinical and cost-effectiveness of lifestyle modification programmes for diet and exercise interventions for adults, young people and children with NAFLD compared with diet alone, exercise alone or standard care?

For full details see review protocol in Appendix A.

**Table 57: PICO characteristics of review question**

<b>Population</b>	<ul style="list-style-type: none"> <li>Adults with NAFLD (18 years and over)</li> <li>Young people with NAFLD (11 years or older and younger than 18 years), and children with NAFLD (younger than 11 years)</li> </ul>
<b>Interventions</b>	<ul style="list-style-type: none"> <li>Combine any diet with any exercise</li> <li>Diet and exercise and additional lifestyle modification (for example, cognitive behavioural therapy, behaviour managed programmes, psychological intervention for parents, family therapy)</li> </ul>
<b>Comparisons</b>	<ul style="list-style-type: none"> <li>No intervention</li> <li>standard care (for example, advice)</li> <li>Diet only</li> <li>Exercise only</li> <li>Diet and exercise versus diet, exercise and lifestyle modification</li> </ul>
<b>Outcomes</b>	<p><b>Critical outcomes:</b></p> <ul style="list-style-type: none"> <li>Progression of NAFLD as assessed by:               <ul style="list-style-type: none"> <li>Liver biopsy</li> <li>MRI/MRS</li> <li>Ultrasound (absence of steatosis only)</li> <li>The Enhanced Liver Fibrosis (ELF) score</li> <li>Transient elastography</li> <li>NAFLD fibrosis score</li> </ul> </li> <li>Quality of life (for example CLDQ, EQ-5D)</li> <li>Serious adverse events</li> </ul>

	<b>Important outcomes:</b> <ul style="list-style-type: none"> <li>• Weight</li> <li>• Liver function tests (for example, ALT, AST levels, ALT/AST ratio)</li> <li>• Adverse events</li> </ul>
<b>Study design</b>	RCTs, systematic reviews of RCTs, prospective cohort studies

### 113.3 Clinical evidence

2 Seven studies were included in the review: 4 RCTs<sup>8,42,150,217</sup> and 3 prospective cohort studies,<sup>28,157,199</sup>  
3 these are summarised in Table 58 below. Evidence from these studies is summarised in Table 59  
4 below. See also the study selection flow chart in Appendix E, study evidence tables in Appendix H,  
5 forest plots in Appendix K, GRADE tables in Appendix J and excluded studies list in Appendix M.  
6

**Table 58: Summary of studies included in the review**

Study	Population	Intervention	Comparison	Follow up	Outcomes	Study diagnosis of people with NAFLD
Al-Jiffri 2013 <sup>8</sup> (RCT)	n=100 Adults (≥18 years)	Exercise: aerobic treadmill-based program was set to 65–75% of the maximum heart rate according to modified Bruce protocol. The program consisted of 5 minutes warm-up on the treadmill, 30 minutes training and 5 minutes cool down. Three times a week for 3 weeks. Diet: Interview-based food survey by dietician to specify previous food habits and possible anomalies to dietary behaviour. The prescribed low calories diet was balanced with 15% protein, 30–35% fat and 50–55% carbohydrate to give a total of 1200 kcal daily for 2 months.	Diet: Interview-based food survey by dietician to specify previous food habits and possible anomalies to dietary behaviour. The prescribed low calories diet was balanced with 15% protein, 30–35% fat and 50–55% carbohydrate to give a total of 1200 kcal daily for 2 months.	3 months	ALT AST	Elevated AST or ALT levels and liver biopsy
Chen 2008 <sup>28</sup> (prospective cohort)	n=54 Adults (≥18 years)	Participants given guidance on a low-calorie balanced diet with a suggested daily calorie intake of 25 kcal/IBW, the range of daily calorie intake was 1200–1500 kcal. They also participated in a high-intensity stationary bicycle exercise program at a frequency of 1 hour twice a week for 10 weeks. They kept a record of a diet diary and monitored by a dietician. Exercises were performed under a professional instructor.	Control population – no details given Exercise population - Aerobic exercise/ cardio-exercise. High intensity stationary bicycle program at a frequency of 1 hour twice a week	10 weeks	AST ALT Weight	Ultrasound
Eckard 2013 <sup>42</sup> (RCT)	n=56 Adults	Intervention 1: Low-fat diet and moderate exercise- attended	Comparator 1: Aerobic exercise: 20–60 minutes	6 months	NAFLD activity	Liver biopsy

Study	Population	Intervention	Comparison	Follow up	Outcomes	Study diagnosis of people with NAFLD
	(≥18 years)	specialised nutrition classes conducted by a registered dietician, given an individualised nutrition prescription, received education on an exercise program for weight loss, initial class was taught by an exercise physiologist who started each participant on an individualised exercise program. Intervention 2: Moderate-fat/low-processed carbohydrate diet and moderate exercise: attended specialised nutrition classes conducted by a registered dietician, given an individualised nutrition prescription, received education on an exercise program for weight loss, initial class was taught by an exercise physiologist who started each participant on an individualised exercise program.	4 to 7 days/week, 18 step program including warm-up, exercise bike, walking on treadmill, various arm and leg stretches and gradual cool down with exercise ramped over 6 weeks. Concomitant care: standard care and dietician support Comparator 2: standard care. Concomitant care: dietician support		score ALT AST Weight	
Promrat 2010 <sup>150</sup>	N= 31 Adults (≥18 years)	Any diet plus any exercise plus any behavioural therapy- Participants were seen in small groups (3-5 members) conducted by nutritionist/health educator, Diet: participants assigned a calorie goal based on their starting weight and a daily fat gram goal designed to produce a 25% fat diet. Exercise: unsupervised exercise, that is, walking, bicycling, aerobic dance, and strength training, aim to do 10,000 steps per day with goal of 200 minutes per week of moderate-intensity	Control- Participants attended small group sessions providing basic education about NASH and about principles of healthy eating, physical activity, and weight control led by a Master's-level nutritionist/ health educator. Concomitant care: Participants allowed to	48 weeks	NAS score Fat Parenchymal inflammation Ballooning injury Fibrosis	Liver biopsy

Study	Population	Intervention	Comparison	Follow up	Outcomes	Study diagnosis of people with NAFLD
		physical activity by 6 months. Behaviour: participants self-monitored their eating and exercise days, records reviewed weekly by the therapist. Concomitant care: Participants allowed to start medication for hyperglycemia. Participant's already taking thiazolidinediones or metformin had to be on a stable regimen. Diabetics allowed to take insulin or sulfonylureas.	start medication for hyperglycemia. Participant's already taking thiazolidinediones or metformin had to be on a stable regimen. Diabetics allowed to take insulin or sulfonylureas			
Reinehr 2009 <sup>157</sup> (prospective cohort study)	n=152 Young people and children (<18 years)	Any diet plus any exercise plus any behavioural therapy: Physical activity, nutrition advice (fat and sugar reduced diet with 15% protein, 55% carbohydrate, 30% fat and 5% sugar) and behavioural therapy including individual psychological care of the child and their family	Control: 15 minute presentation as to a suitable diet, necessary physical exercise and behaviour patterns, they were given nutrition advice with written information and recipes	12 months	NAFLD prevalence (ultrasound) ALT AST	Ultrasound
Ueno 1997 <sup>199</sup> (prospective cohort)	n=24 (≥18 years)	Diet and exercise: In-patient study: patients admitted into hospital for 1 month to undergo restricted diet and exercise therapy, they then followed the same therapy regimen at home for the subsequent 2 months. Diet: 25 kcal/kg ideal body weight of conventional diet, with 3 meals/day provided (20% protein, 30% fat and 50% carbohydrate). Exercise: walking 3000 steps/day for 3 days, thereafter adding 500 steps every 3 days until 10,000 steps reached, then jogging for	Control: Patients carried out their ordinary diet and lifestyle - aims of study described to patients	2 months	ALT AST	Fatty liver on ultrasound tomography



Study	Population	Intervention	Comparison	Follow up	Outcomes	Study diagnosis of people with NAFLD
Wong 2013 <sup>217</sup> (RCT)	n= 154 (≥18 years)	20 minutes twice a day  Any diet plus any exercise plus Dietician-led lifestyle modification (diet plus exercise and behavioural therapy): Attending diet consultation sessions weekly in the first 4 months, and monthly then on. First session the dietician carried out a complete behavioural assessment, follow up sessions included individualised menu plans with a varied diet emphasising fruit and vegetable, moderate carbohydrate, low-fat, low-glycaemic index and low calorific products in appropriate portions and increased proteins. Participants given a booklet on food portion size exchange and tips for eating out, and another listing low-GI food options and meal plans. Weekly food record kept to assess adherence. Patients also encouraged to see an exercise instructor who designed suitable exercise regimes for each patient: moderate intensity aerobic exercise for 30 minutes, 3–5 days a week. The intensity of the exercise was gradually increased to 30 minutes every day.	Usual care: patients encouraged to reduce carbohydrate and fat intake and exercise at least 3 times per week, 30 minutes per session	12 months	Liver stiffness (transient elastography ) MRS Intrahepatic triglyceride % ALT AST	Screening with proton-magnetic resonance spectroscopy ( <sup>1</sup> H-MRS)

**Table 59: Clinical evidence profile: lifestyle modification (any diet plus any exercise plus behavioural modification) versus control (RCTs) <12 months**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with Lifestyle modification versus control (RCT) (<12 months) (95% CI)
NAS (0-8, final value) Scale from: 0 to 8.	28 (1 study) 48 weeks	⊕⊕⊖⊖ LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean nas (0-8, final value) in the control groups was 4.9	The mean nas (0-8, final value) in the intervention groups was 0.5 lower (1.3 lower to 0.3 higher)
Fat (0-3, final value) Scale from: 0 to 3.	28 (1 study) 48 weeks	⊕⊖⊖⊖ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean fat (0-3, final value) in the control groups was 1.9	The mean fat (0-3, final value) in the intervention groups was 0 higher (0.64 lower to 0.64 higher)
Parenchymal inflammation (0-3, final value) Scale from: 0 to 3.	28 (1 study) 48 weeks	⊕⊕⊖⊖ LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean parenchymal inflammation (0-3, final value) in the control groups was 1.7	The mean parenchymal inflammation (0-3, final value) in the intervention groups was 0.3 lower (0.87 lower to 0.27 higher)
Ballooning injury (0-2, final value) Scale from: 0 to 2.	28 (1 study) 48 weeks	⊕⊖⊖⊖ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean ballooning injury (0-2, final value) in the control groups was 1.3	The mean ballooning injury (0-2, final value) in the intervention groups was 0.1 lower (0.49 lower to 0.29 higher)
Fibrosis (0-4, final value) Scale from: 0 to 4.	28 (1 study) 48 weeks	⊕⊕⊖⊖ LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean fibrosis (0-4, final value) in the control groups was 1.7	The mean fibrosis (0-4, final value) in the intervention groups was 0.3 lower (1.01 lower to 0.41 higher)

(a) Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias.

(b) Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

**Table 60: Clinical evidence profile: lifestyle modification (any diet plus any exercise plus behavioural modification) versus control (RCTs) ≥12 months**

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with lifestyle modification versus control (95% CI)
ALT (U/l) (final value)	154 (1 study)	⊕⊕⊖⊖ LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean ALT (U/l) (final value) in the control groups was 33 U/l	The mean ALT (U/l) (final value) in the intervention groups was 7 lower (11.78 to 2.22 lower)
AST (U/l) (final value)	154 (1 study)	⊕⊕⊕⊖ MODERATE <sup>a</sup> due to risk of bias		The mean AST (U/l) (final value) in the control groups was 33 U/l	The mean AST (U/l) (final value) in the intervention groups was 0 higher (2.53 lower to 2.53 higher)
Intrahepatic triglyceride (%) ( <sup>1</sup> H-MRS, final value)	154 (1 study)	⊕⊕⊖⊖ LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean intrahepatic triglyceride (%) ( <sup>1</sup> H-MRS, final value) in the control groups was 10.1 %	The mean intrahepatic triglyceride (%) ( <sup>1</sup> H-MRS, final value) in the intervention groups was 4.6 lower (6.59 to 2.61 lower)
Liver stiffness (kPa) (FibroScan, final value)	154 (1 study)	⊕⊕⊖⊖ LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean liver stiffness (kpa) (ultrasound, final value) in the control groups was 5.2 kPa	The mean liver stiffness (kpa) (ultrasound, final value) in the intervention groups was 0.6 lower (1.13 to 0.07 lower)
Body weight (kg) (final value)	154 (1 study)	⊕⊕⊖⊖ LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean body weight (kg) (final value) in the control groups was 67.8 kg	The mean body weight (kg) (final value) in the intervention groups was 2.8 lower (6.11 lower to 0.51 higher)

(a) Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias.

(b) Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

**Table 61: Clinical evidence profile: lifestyle modification (any diet plus any exercise plus behavioural modification versus control) (cohort study) ≥12 months**

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with lifestyle modification versus control (95% CI)
ALT (U/l) (final values)	152 (1 study)	⊕⊕⊕⊕ VERY LOW <sup>a</sup> due to risk of bias, imprecision <sup>b</sup>		The mean ALT (U/l) (final values) in the control groups was 45 U/l	The mean ALT (U/l) (final values) in the intervention groups was 7 lower (17.5 lower to 3.5 higher)
AST (U/l) (final values)	152 (1 study)	⊕⊕⊕⊕ VERY LOW <sup>a</sup> due to risk of bias		The mean AST (U/l) (final values) in the control groups was 30 U/l	The mean AST (U/l) (final values) in the intervention groups was 1 lower (3.72 lower to 1.72 higher)
NAFLD prevalence*	152 (1 study)	⊕⊕⊕⊕ VERY LOW <sup>a</sup> due to risk of bias	RR 0.54 (0.44 to 0.66)	930 per 1000	428 fewer per 1000 (from 316 fewer to 521 fewer)

\*This outcome represents the number of people who still had NAFLD after 1 year.

(a) Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias.

(b) Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs

**Table 62: Clinical evidence profile: diet and exercise versus control (RCTs) <12 months**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with Diet and exercise versus control (RCT) (95% CI)
ALT (U/l) (change scores) - Low fat diet and moderate exercise versus control	23 (1 study)	⊕⊕⊕⊕ LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean ALT (U/l) (change scores) - low fat diet and moderate exercise versus control in the control groups was -4.3 U/L	The mean ALT (U/l) (change scores) - low fat diet and moderate exercise versus control in the intervention groups was 23.2 lower (50.99 lower to 4.59 higher)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with Diet and exercise versus control (RCT) (95% CI)
ALT (U/l) (change scores) - Moderate fat diet and moderate exercise versus control	20 (1 study)	⊕⊕⊕⊕ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean ALT (U/l) (change scores) - moderate fat diet and moderate exercise versus control in the control groups was -4.3 U/l	The mean ALT (U/l) (change scores) - moderate fat diet and moderate exercise versus control in the intervention groups was 15.5 lower (58.04 lower to 27.04 higher)
AST (U/l) (change scores) - Low fat diet and moderate exercise	23 (1 study)	⊕⊕⊕⊕ LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean AST (U/l) (change scores) - low fat diet and moderate exercise in the control groups was -2.9 U/l	The mean AST (U/l) (change scores) - low fat diet and moderate exercise in the intervention groups was 13 lower (31.69 lower to 5.69 higher)
AST (U/l) (change scores) - Moderate fat diet and moderate exercise	20 (1 study)	⊕⊕⊕⊕ LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean AST (U/l) (change scores) - moderate fat diet and moderate exercise in the control groups was -2.9 U/l	The mean AST (U/l) (change scores) - moderate fat diet and moderate exercise in the intervention groups was 16.7 lower (51.51 lower to 18.11 higher)
NAS (0-8) (change score) - Low fat diet and moderate exercise Scale from: 0 to 8.	23 (1 study)	⊕⊕⊕⊕ LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean NAS (0-8) (change score) - low fat diet and moderate exercise in the control groups was -0.4	The mean NAS (0-8) (change score) - low fat diet and moderate exercise in the intervention groups was 0.9 lower (2.05 lower to 0.25 higher)
NAS (0-8) (change score) - Moderate fat diet and moderate exercise Scale from: 0 to 8.	20 (1 study)	⊕⊕⊕⊕ LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean NAS (0-8) (change score) - moderate fat diet and moderate exercise in the control groups was -0.4	The mean NAS (0-8) (change score) - moderate fat diet and moderate exercise in the intervention groups was 0.8 lower (1.9 lower to 0.3 higher)
Body weight (kg) - Low fat diet and moderate exercise	23 (1 study)	⊕⊕⊕⊕ LOW <sup>a,b</sup>		The mean body weight (kg) - low fat diet and moderate exercise in the	The mean body weight (kg) - low fat diet and moderate exercise in the intervention

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with Diet and exercise versus control (RCT) (95% CI)
		due to risk of bias, imprecision		control groups was -2.5 kg	groups was 2.3 higher (2.08 lower to 6.68 higher)
Body weight (kg) - Moderate fat diet and moderate exercise	20 (1 study)	⊕⊕⊕⊕ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean body weight (kg) - moderate fat diet and moderate exercise in the control groups was -2.5 kg	The mean body weight (kg) - moderate fat diet and moderate exercise in the intervention groups was 0.5 lower (4.89 lower to 3.89 higher)

(a) Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

(b) Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

**Table 63: Clinical evidence profile: diet and exercise versus control (cohort studies) <12 months**

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with Diet and exercise versus control (95% CI)
ALT (U/l) (final values)	56 (2 studies)	⊕⊕⊕⊕ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean ALT (U/l) (final values) in the control groups was 65.64 U/l	The mean ALT (U/l) (final values) in the intervention groups was 36.69 lower (88.37 lower to 14.98 higher)
AST (U/l) (final values)	51 (2 studies)	⊕⊕⊕⊕ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean AST (U/l) (final values) in the control groups was 56 U/l	The mean AST (U/l) (final values) in the intervention groups was 29.18 lower (68.99 lower to 10.64 higher)
NAFLD progression with FibroScan (0–3)	31	⊕⊕⊕⊕		The mean NAFLD progression with	The mean NAFLD progression with

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with Diet and exercise versus control (95% CI)
severity scale, final values) Scale from: 0 to 3.	(1 study)	VERY LOW <sup>a,b</sup> due to risk of bias, imprecision		FibroScan (0–3 severity scale, final values) in the control groups was 1.53	ultrasound (0–3 severity scale, final values) in the intervention groups was 0.53 lower (0.95 to 0.11 lower)
Body weight (%)	31 (1 study)	⊕⊖⊖⊖ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean body weight (%) in the control groups was 84.08 kg	The mean body weight (%) in the intervention groups was 6.03 lower (15.33 lower to 3.27 higher)

(a) Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

(b) Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs

**Table 64: Clinical evidence profile: diet and exercise versus exercise (RCT) <12 months**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with Diet and exercise versus exercise (RCT) (95% CI)
ALT (U/l) (change scores) - Low fat diet and moderate exercise	21 (1 study)	⊕⊖⊖⊖ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean ALT (U/l) (change scores) - low fat diet and moderate exercise in the control groups was -21.8 U/l	The mean ALT (U/l) (change scores) - low fat diet and moderate exercise in the intervention groups was 5.7 lower (31.17 lower to 19.77 higher)
ALT (U/l) (change scores) - Moderate fat diet and moderate exercise	18 (1 study)	⊕⊖⊖⊖ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean ALT (U/l) (change scores) - moderate fat diet and moderate exercise in the control groups was -21.8 U/l	The mean ALT (U/l) (change scores) - moderate fat diet and moderate exercise in the intervention groups was 2 higher (39.06 lower to 43.06 higher)
AST (U/l) (change scores) -	21	⊕⊖⊖⊖		The mean AST (U/l) (change scores) - low	The mean AST (U/l) (change scores) - low fat

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with Diet and exercise versus exercise (RCT) (95% CI)
Low fat diet and moderate exercise	(1 study)	VERY LOW <sup>a,b</sup> due to risk of bias, imprecision		fat diet and moderate exercise in the control groups was -8.4 U/l	diet and moderate exercise in the intervention groups was 7.5 lower (20.27 lower to 5.27 higher)
AST (U/l) (change scores) - Moderate fat diet and moderate exercise	18 (1 study)	⊕⊕⊕⊕ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean AST (U/l) (change scores) - moderate fat diet and moderate exercise in the control groups was -8.4 U/l	The mean AST (U/l) (change scores) - moderate fat diet and moderate exercise in the intervention groups was 11.2 lower (43.22 lower to 20.82 higher)
NAS (0-8) (change score) - Low fat diet and moderate exercise Scale from: 0 to 8.	21 (1 study)	⊕⊕⊕⊕ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean NAS (0-8) (change score) - low fat diet and moderate exercise in the control groups was -0.8	The mean NAS (0-8) (change score) - low fat diet and moderate exercise in the intervention groups was 0.5 lower (1.67 lower to 0.67 higher)
NAS (0-8) (change score) - Moderate fat diet and moderate exercise Scale from: 0 to 8.	18 (1 study)	⊕⊕⊕⊕ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean NAS (0-8) (change score) - moderate fat diet and moderate exercise in the control groups was -0.8	The mean NAS (0-8) (change score) - moderate fat diet and moderate exercise in the intervention groups was 0.4 lower (1.52 lower to 0.72 higher)
Body weight (kg) (change scores) - Low fat diet and moderate exercise	21 (1 study)	⊕⊕⊕⊕ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean body weight (kg) (change scores) - low fat diet and moderate exercise in the control groups was 0.1 kg	The mean body weight (kg) (change scores) - low fat diet and moderate exercise in the intervention groups was 0.3 lower (4.68 lower to 4.08 higher)
Body weight (kg) (change scores) - Moderate fat diet and moderate exercise	18 (1 study)	⊕⊕⊕⊕ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean body weight (kg) (change scores) - moderate fat diet and moderate exercise in the control groups was 0.1 kg	The mean body weight (kg) (change scores) - moderate fat diet and moderate exercise in the intervention groups was 3.1 lower (7.49 lower to 1.29 higher)



(a) Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias  
 (b) Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs

**Table 65: Clinical evidence profile: diet and exercise versus exercise (cohort study) <12 months**

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with diet and exercise versus Exercise (95% CI)
ALT (U/l) (final value)	39 (1 study)	⊕⊕⊕⊕ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean ALT (U/l) (final value) in the control groups was 44.78 U/l	The mean ALT (U/l) (final value) in the intervention groups was 10.78 lower (24.18 lower to 2.62 higher)
AST (U/l) (final values)	39 (1 study)	⊕⊕⊕⊕ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean AST (U/l) (final values) in the control groups was 30.43 U/l	The mean AST (U/l) (final values) in the intervention groups was 4.87 lower (10.34 lower to 0.6 higher)
Body weight (kg) final values)	39 (1 study)	⊕⊕⊕⊕ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean body weight (kg) final values) in the control groups was 83.9 kg	The mean body weight (kg) final values) in the intervention groups was 5.85 lower (14.11 lower to 2.41 higher)

(a) Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias  
 (b) Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs

**Table 66: Clinical evidence profile: diet and exercise versus diet (RCT) <12 months**

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with diet and exercise versus diet (95% CI)

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with diet and exercise versus diet (95% CI)
ALT (U/l) (final values)	100 (1 study)	⊕⊕⊖⊖ LOW <sup>a</sup> due to risk of bias		The mean ALT (U/l) (final values) in the control groups was 47.91 U/l	The mean ALT (U/l) (final values) in the intervention groups was 14.63 lower (16.92 to 12.34 lower)
AST (U/l) (final values)	100 (1 study)	⊕⊕⊖⊖ LOW <sup>a</sup> due to risk of bias		The mean AST (U/l) (final values) in the control groups was 46.87	The mean AST (U/l) (final values) in the intervention groups was 12.51 lower (14.97 to 10.05 lower)

(a) Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

1

2

3

## 13.4 Economic evidence

### 13.4.1 Published literature

3 No relevant economic evaluations were identified.

4 See also the economic article selection flow chart in Appendix F.

### 13.4.2 Review of economic evidence from NICE public health guidance

6 Relevant economic evidence was identified in recent NICE Public Health guidance that looked at  
7 overweight and obese people (with no reference to whether they also had NAFLD): PH53 (2013)  
8 'Managing overweight and obesity in adults'<sup>123</sup> and PH47 (2014) 'Managing overweight and obesity  
9 among children and young people'.<sup>121</sup> PH53 included a clinical review of behavioural weight  
10 management programme (BWMP) versus control, a clinical review of multicomponent BWMP, and  
11 an original economic evaluation in the form of a decision model. PH47 included a systematic  
12 literature review considering both clinical and economic evidence and an original economic model.

#### 13 PH53:

14 Clinical reviews considered adults ( $\geq 18$  years) classified as overweight or obese, that is, people with a  
15 BMI of  $\geq 25$  kg/m<sup>2</sup> and  $\geq 30$  kg/m<sup>2</sup> respectively, or a BMI of  $\geq 23$  kg/m<sup>2</sup> in Asian populations. Where  
16 overweight or obesity was not an inclusion criterion, they included studies where greater than 80%  
17 of each arm was overweight or obese.

#### 18 PH53 Review 1: Intervention versus control

- 19
- 20 • 30 studies (15 USA, 3 UK, most of the rest European)
  - 21 • Mean BMI 33 (median 33) – 13/30 studies had a maximum BMI as an inclusion criterion; this  
22 ranged from 35 to 50 (average 40). The other 17 had no maximum cut off. [The average BMI from  
the included studies in our clinical review is around 31.5]
  - 23 • At 12 to 18 months there was a statistically significant effect of lifestyle modification programmes  
24 on weight of  $-2.59$  kg (95% CI  $-2.78$  to  $-2.41$ ).
  - 25 • No separate economic search – The 3 clinical studies that included cost-effectiveness analyses  
26 found the modification programmes to be cost-effective. Five of the included studies provided  
27 data on cost per participant; these are listed in Table 67 below.

**Table 67: Costs of interventions**

Study ID	Description of intervention	Cost per participant (or other data if cost per participant not available) <sup>(a)</sup>	
		Intervention	Control
DPP 2002	<ul style="list-style-type: none"> <li>• Lifestyle</li> <li>• Reduction in dietary fat intake to &lt;25% of energy</li> <li>• Minimum 3 physical activity sessions weekly</li> <li>• 16 core sessions lasting 30-60 minutes delivered in 24 weeks</li> <li>• Total of 150 minutes of moderate intensity exercise (for example, brisk walking) per week with target to burn 700kcal/week</li> </ul>	(10 year costs) £2888 £1897 if completed as groups and no individual sessions	(10 year costs) £483
Hersey 2012 (RCT 2)	<ul style="list-style-type: none"> <li>• Dietary advice</li> <li>• Recommendation to increase moderate and vigorous activity</li> <li>• Individual internet intervention</li> <li>• No frequency reported</li> </ul>	RCT 2 (interactive website): £110	£100
Hersey 2012 (RCT 3)	<ul style="list-style-type: none"> <li>• Dietary advice</li> <li>• Recommendation to increase moderate and vigorous activity</li> <li>• Individual intervention delivered by trained health lifestyle coaches</li> <li>• Alternating Telephone and Email support (15-20minutes) every 2 weeks for 18 months (39 sessions)</li> </ul>	RCT 3 (interactive website plus phone/e-mail): £269	£100
Heshka 2003	<ul style="list-style-type: none"> <li>• Weight watchers programme</li> <li>• Energy restricted balanced diet</li> <li>• Minimum physical activity recommendation 30 minutes aerobic activity on 5 or more days a week with 2+ resistance sessions a week.</li> </ul>	Not stated, but authors report that during the study the retail value of 1 voucher (for a Weight Watchers session) was £6. This would result in a maximum of £600 per participant (max session number 104).	Not stated

Study ID	Description of intervention	Cost per participant (or other data if cost per participant not available) <sup>(a)</sup>	
	<ul style="list-style-type: none"> <li>Weekly sessions of 60 minutes for 24 months</li> </ul>		
Jebb 2011	<ul style="list-style-type: none"> <li>Weight watchers programme</li> <li>Energy restricted balanced diet</li> <li>Minimum physical activity recommendation 30 minutes aerobic activity on 5 or more days a week with 2+ resistance sessions a week.</li> <li>Weekly sessions of 60 minutes for 24 months</li> </ul>	Cost per participant not provided. Cost per kilogram of weight loss: UK: £63 Germany: £126 Australia: £85	Cost per participant not provided. Cost per kilogram of weight loss: UK: £105 Germany: £93 Australia: £96
Jolly 2011 (general practice)	<ul style="list-style-type: none"> <li>Delivered by GP</li> <li>Reduced energy low fat diet based on Eatwell plate aiming to lose about 0.5-1kg/week</li> <li>Recommended physical activity</li> <li>Individual in-person</li> <li>GP mainly given by nurses. GPs, nurses and pharmacists all had 2-day training to deliver course</li> <li>12 sessions of approx 20 mins over 12 weeks</li> </ul>	Provider cost: £55 Total cost: £76.87	Not stated
Jolly 2011 (NHS Size Down)	<ul style="list-style-type: none"> <li>Reduced energy low fat diet</li> <li>Recommended physical activity, no specific target</li> <li>Group in-person</li> <li>Lay people taken NVQ Level 3-25 hours of training from dieticians plus assessment to pass</li> <li>8 sessions of 2 hours over 12 weeks</li> </ul>	Provider cost: £70 Total cost: £91.87	Not stated
Jolly 2011 (pharmacy)	<ul style="list-style-type: none"> <li>Delivered by pharmacist</li> <li>Reduced energy low fat diet based on Eatwell plate aiming to lose about 0.5-1kg/week</li> <li>Recommended physical activity</li> <li>Individual in-person</li> <li>GP mainly given by nurses. GPs, nurses and pharmacists all had 2-day training to deliver course</li> </ul>	Provider cost: £90.43 Total cost: £112.30	Not stated

Study ID	Description of intervention	Cost per participant (or other data if cost per participant not available) <sup>(a)</sup>	
	12 sessions of approx 20 mins over 12 weeks		
Jolly 2011 (Rosemary Conley)	<ul style="list-style-type: none"> <li>• Reduced energy low fat diet</li> <li>• Recommended physical activity and a 45-minute dance-based exercise session per week</li> <li>• Group in-person</li> <li>• Delivered by lay person who successfully lost weight with RC and then trained</li> <li>• 12 weekly hour long sessions</li> </ul>	Provider cost: £55 Total cost: £76.87	Not stated
Jolly 2011 (Slimming World)	<ul style="list-style-type: none"> <li>• Low fat low energy density diet</li> <li>• Recommended physical activity, 10x15 minutes of moderate activity or 5x30 minutes weekly</li> <li>• Group in person (delivered by lay person who successfully completed the programme)</li> <li>• 12 weekly hour long sessions</li> </ul>	Provider cost: £49.50 Total cost: £71.37	Not stated
Jolly 2011 (Weight Watchers)	<ul style="list-style-type: none"> <li>• Weight watchers</li> <li>• Low fat diet</li> <li>• Recommended physical activity</li> <li>• Group in person (delivered by lay person who successfully completed the programme)</li> <li>• 12 weekly hour long sessions</li> </ul>	Provider cost: £55 Total cost: £76.87 Using a number of assumptions, authors approximate cost of £77 per life year saved.	Not stated

(a) Converted from US\$ where necessary.

- 1       **PH53 Review 2: Multicomponent intervention comparisons**
- 2       • 43 studies included (26 USA, 3 UK, most of the rest European)
- 3       • Mean BMI 33 (median 33)
- 4       • Direct comparisons found that programmes that involved diet and exercise were more effective
- 5        than those which involved diet only or exercise only.
- 6       • A multivariate model indicated that the presence of set energy prescriptions and contact with a
- 7        dietician were significantly associated with weight loss.
- 8       • Another model looking at behavioural change techniques indicated that a group of techniques
- 9        classed under the 'comparison of behaviour' heading were found to be significantly associated
- 10       with a greater mean difference in weight loss, but this association was no longer significant when
- 11       controlling for presence of set energy prescriptions and involvement of a dietician.

12       **PH53 Economic model:**

13       The model has estimated the potential health and economic consequences of weight management


14       interventions. Five hypothetical interventions were modelled. QALYs gained associated with weight

15       loss were estimated. Base-case intervention cost was £100 based on the clinical review cost data.

16       The model also included future costs averted due to CHD, stroke, hypertension, osteoarthritis,

17       diabetes and cancer

- 18       • Overall, the ICERs were below the NICE threshold (£20,000 per QALY) for most of the
- 19        interventions when costs were set at £100.
- 20       • The parameters which had the most impact on the ICER were BMI, gender, cost of the
- 21        interventions, the number of kilograms lost during the intervention, and BMI regain.
- 22       • For the moderately obese and the morbidly obese groups only very small losses of weight, such as
- 23        0.3 BMI points (or about 1 kg, depending on height) need to be lost for the intervention to be
- 24        estimated to be cost-effective, as long as weight does not return to its pre-intervention trajectory
- 25        for about 5 years.

**Figure 4: PH53: ICER as a function of intervention cost for different BMI reductions****1 PH47**

2 Clinical and economic review:

3 The clinical review considered children and young people aged below 18 who are overweight or  
4 obese and the parents or carers and families of these children and young people.

- 5 • 73 papers, 34 separate programmes, cost-effectiveness data on 11 programmes.  
6 • 14 programmes in the UK, 11 in the USA, 6 in Australia, 3 in Western Europe.  
7 • Pooled (SMD) indicated a small reduction in BMI/zBMI for children in the intervention compared  
8 to those control arm (SMD=-0.17; 95% CI: -0.30 to -0.04, p=0.01).  
9 • In the long term (≥6 months) the pooled SMD indicated a null effect on BMI/zBMI (SMD= -0.07;  
10 95% CI: -0.15 to 0.02, p=0.12).

11 Regarding the intervention components, the clinical review concluded that in order to maximise the  
12 likely effect size and the sustainability of the intervention, the inclusion of the following components  
13 should be considered:

- 14 • Targeting the whole family rather than children only or parents only.  
15 • Providing dietary, physical activity and behavioural advice; particularly emphasising dietary  
16 components and behavioural support for parents.  
17 • Providing a high-intensity rather than low-intensity intervention in terms of contact time and  
18 programme length.

19 Economic evidence is summarised in Table 68 below.



**Table 68: Summary information on studies with health economic data**

Study	Overview	Effectiveness estimate	Cost per child or family	Incremental cost-effectiveness estimate
<b>Lifestyle intervention versus alternate intervention</b>				
Goldfield 2001 Raynor 2002 Quasi-RCT	Obese 8-12s USA 12 month data (7 months post intervention) Cost- effectiveness	BMI z-score change = 19.16% (p<0.001) in both groups (i) individual/ group and (ii) group only interventions	Individual/group : £894 Group only: US\$492 (£316)	Not calculated
Janicke 2009 Project STORY RCT	Overweight 8-14s USA 10 months (6 months) Cost- effectiveness	Family: -0.115 BMI z Parents only: -0.090 BMI z Wait list control: +0.02 BMI z	Family: US\$ 872 (£561) Parents only: US\$ 521 (£335)	Family vs wait list control: £487 Parents only: £372 Per 0.1 decr. in z BMI score (compared to wait list control)
Coppins 2011 Family Project Quasi-RCT	Overweight/ Obese 6-14s UK 24 months (12 months) Costs description	Intervention: -0.41 adj. BMI z (-0.71 to -0.11) Control (cross over at 12 months): +0.16 adj. BMI z (-0.43 to +0.11)	Intervention: £403 Control: £45	Not calculated
Hollingworth 2012 RCTs x10	Ten RCTs of lifestyle interventions vs no/minimal intervention Cost- effectiveness	Median effect = difference in BMI z- score of -0.13 (0.04 to - 0.60) at 12 months	From £108 to £662 per child	Base case: Discounted incremental cost per year of the interventions : £13,589 Ranging from dominant to £66,567 in sensitivity analyses.

Study	Overview	Effectiveness estimate	Cost per child or family	Incremental cost-effectiveness estimate
Hughes 2008 SCOTT RCT	Overweight 5-11s UK 12 months (6 months) Costs description	Median between group difference in change from baseline: -0.04 BMI z (-0.17 to +0.07)	Intervention: £108 Control: £29	Not calculated
<b>Lifestyle intervention versus routine care or control (or before and after data)</b>				
Kalavainen 2009 RCT	Obese 7-9s Finland 12 months (6 months) Cost- effectiveness	Intervention: -0.2 (-0.2 to -0.1) BMI z Control: -0.1 (-0.2 to 0.0)	Intervention: £270 Control: £49 per child	Intervention versus control: £2,210 per unit decrease in BMI z-score at 12 months
Moodie 2008 LEAP 1 RCT	Overweight/ moderately obese 5-9s Australia Lifetime model Cost- effectiveness	Incremental saving of 2,300 BMI units (95% CI -1,100 to 6,000) = 511 DALYs (-90 to 1,156).	Total cost of programme = AUS\$ 6.3m (5.3m to 7.4m)	Discounted incremental cost per DALY saved = AUS\$ 4,670
Robertson 2011/2008 Families for Health UBA	Overweight/ Obese 7-13s UK 24 months (21 months) Cost- effectiveness	Difference in BMI z- score = -0.23 (p=0.027)	Intervention: £517 per family £402 per child	Intervention vs hypothetical group with no change in BMI: £2,543 per unit reduction in BMI z-score at 2 years
Wake 2008 LEAP 1	Overweight/ Obese 5-9s	Adj. difference in BMI z- score = -0.03 (-0.17 to +0.1)	Intervention: £560	Not calculated (cost consequence analysis which reports that the intervention was more expensive and non-significantly more effective)

Study	Overview	Effectiveness estimate	Cost per child or family	Incremental cost-effectiveness estimate
RCT	Australia 15 months (12 months) Cost-consequence		Control: £41	
Wake 2009 LEAP RCT	Overweight/ Obese 5-10s Australia 12 months (9 months) Cost-consequence	Adj. difference in BMI z-score = -0.11 (-0.45 to +0.22)	Intervention: £845 Control: £52	Not calculated (cost consequence analysis which reports that the intervention was more expensive and non-significantly more effective)
YHEC 2010 Tchakehakij 2011 MEND RCT *	Obese 7-13s UK Lifetime model Cost-effectiveness	15.3% children become non-obese after intervention (International not UK def. of obesity)	Intervention: £415.77 per child - direct medical cost savings of £166 per child.	Intervention versus hypothetical group with no change in BMI: discounted incremental cost per QALY £1,671

1 **PH47 Economic model:**

2 The model considered 5 types of interventions: GP referral (£353), parent-only intervention (£389),  
 3 2 types of family interventions (£437, £651), residential intervention (£1980). QALYs gained  
 4 associated with weight loss were estimated. Model also includes future costs averted due to CHD,  
 5 stroke, hypertension, osteoarthritis, diabetes and cancer.


6 Important assumptions:

- 7
- that as cohort members age they stay on the same BMI-percentile relative to their peers
  - interventions which in childhood succeed in lowering a person's BMI-percentile have effects which are maintained throughout life.
- 8
- 9

10 Results:

- 11
- When interventions were analysed according to the percentage BMI reduction that they produced (from 0.5% to 5%), all levels of weight loss proved to be cost-effective up to a cost of about £850 per head in males. Moreover, weight loss of over 3% was cost-effective even up to £2000 per head, provided the weight loss was permanent. In females all levels of weight loss were estimated to be cost-effective for intervention costs up to £600 per head. In addition, weight losses of more than 4% were estimated to be cost-effective at £2000 per head. However, if weight loss was not maintained for a sufficient time then intervention was not cost-effective.
- 12
- 13
- 14
- 15
- 16
- 17

**Figure 5: PH47: ICER as a function of intervention cost for overweight males aged 6–11 for different BMI reductions**



## 13.5 Evidence statements

### 13.5.1 Clinical

#### 3 Lifestyle modification (diet, exercise and behavioural modification) versus control

- 4 • The clinical benefit of lifestyle modification on the progression of NAFLD was observed in a RCT at  
5 less than 12 months (n=154) and another RCT at more than or equal to 12 months (n=28). Clinical  
6 benefits of lifestyle modification at less than 12 months were seen on the improvement of NAFLD  
7 activity score (low quality), parenchymal inflammation (low quality), ballooning injury (very low  
8 quality) and fibrosis (low quality) when compared to education. There was no clinically important  
9 difference seen in the level of liver fat (very low quality) between the lifestyle modification and  
10 education groups. Clinical benefits of lifestyle modification at more than or equal to 12 months  
11 were seen on the percentage of intrahepatic triglycerides (low quality) and liver stiffness (low  
12 quality) when compared to usual care. The clinical benefit of lifestyle modification on the  
13 progression of NAFLD was also seen in a cohort study (n=152) through an increased reduction of  
14 NAFLD prevalence at more than or equal to 12 months when compared to a control group  
15 receiving advice (very low quality).
- 16 • Evidence from a single RCT (n=28) and a cohort study (n=152) demonstrated clinical benefit of  
17 lifestyle modification on ALT levels at more than or equal to 12 months when compared to usual  
18 care (low quality) and advice (very low quality) respectively. However, no clinically important  
19 difference was seen on AST levels from either the RCT (moderate quality) or cohort study (very  
20 low quality).
- 21 • Possible clinical benefit of lifestyle modification was observed at more than or equal to 12 months  
22 from a single RCT (n=28) on body weight (low quality) when compared to usual care.

#### 23 Diet and exercise versus control

- 24 • A single RCT demonstrated clinical benefit of a low fat diet with moderate exercise (n= 23) and a  
25 moderate fat diet with moderate exercise (n=20) on NAFLD progression through the NAFLD  
26 activity score at less than 12 months when compared to standard care (low quality). A cohort  
27 study (n=31) also demonstrated the clinical benefit of diet and exercise on NAFLD progression  
28 measured using transient elastography (FibroScan) at less than 12 months when compared to the  
29 control group (very low quality).
- 30 • RCT evidence demonstrated clinical benefit of the low fat diet with moderate exercise on ALT and  
31 AST levels at less than 12 months when compared to standard care (low quality). However, no  
32 clinically important difference was seen on ALT (very low quality) and AST levels (low quality) for  
33 the moderate fat diet with moderate exercise when compared to standard care. Evidence from 2  
34 cohort studies demonstrated clinical benefit of diet and exercise on ALT (n=56) and AST levels  
35 (n=51) at less than 12 months (very low quality) when compared to control. RCT evidence also  
36 showed clinical benefit of the low fat diet with moderate exercise at less than 12 months on body  
37 weight at when compared to standard care (low quality), with no clinically important difference  
38 seen for the moderate fat diet with moderate exercise when compared to standard care (very low  
39 quality) at less than 12 months. Evidence from a cohort study (n=31) also showed clinical benefit  
40 of diet and exercise on body weight at less than 12 months when compared to control (very low  
41 quality).

#### 42 Diet and exercise versus exercise

- 43 • A single RCT demonstrated no clinically important difference of a low fat diet with moderate  
44 exercise (n=21) or a moderate fat diet with moderate exercise (n=18) on NAFLD progression when  
45 compared to exercise alone at less than 12 months, with the direction of effect favouring diet and  
46 exercise (very low quality).

Lifestyle modification

- 1 • Evidence from the RCT demonstrated no clinically important difference of either the low fat diet  
2 with moderate exercise or moderate fat diet with moderate exercise on ALT or AST levels when  
3 compared to exercise alone at less than 12 months (very low quality), with the direction of effect  
4 for AST levels favouring diet and exercise.
- 5 • The RCT also demonstrated clinically important benefit of the moderate fat diet with moderate  
6 exercise (very low quality) on body weight when compared to exercise alone at less than 12  
7 months, however no clinically important difference of the low fat diet with moderate exercises  
8 and exercise alone was seen (very low quality).
- 9 • Evidence from a cohort study (n=39) demonstrated clinical benefit of diet and exercise on body  
10 weight when compared to exercise alone at less than 12 months (very low quality).

11 **Diet and exercise versus diet**

- 12 • A single RCT (n=39) demonstrated the clinical benefit of diet and exercise on ALT and AST levels  
13 when compared to diet alone at less than 12 months (low quality).

14 **13.5.2 Economic**

- 15 • No relevant economic evaluations were identified.

16 **13.6 Recommendations and link to evidence**

Recommendation	24. Consider the lifestyle interventions in NICE’s <a href="#">obesity</a> guideline for people with NAFLD regardless of their BMI.
Relative values of different outcomes	The GDG agreed that the outcomes that were critical to decision-making were progression of NAFLD, quality of life, and serious adverse events. Progression of NAFLD as measured by liver biopsy was considered of greatest value for decision-making (although only 1 study used change in NAS score on liver biopsy as a primary outcome measure). The GDG agreed that other outcomes described within the identified evidence were also of clinical relevance: specifically, improvements in MRS intrahepatic triglyceride and improvements in transient elastography scores. Reduction in liver enzyme values, loss of weight and non-serious adverse events were all agreed to be appropriate potential surrogate markers for improvement in NAFLD and therefore considered as important outcomes. Absence of steatosis (as shown in 1 study) was also considered to be of clinical relevance.
Trade-off between clinical benefits and harms	The GDG agreed that, in general, the dietary, exercise and behavioural interventions described in the included studies were interventions that were practical to offer to adults, children and young people with NAFLD. Researchers had taken measures to ensure compliance with the interventions being delivered (for example, food diary monitoring of study participants by dietitians).  The GDG noted that 1 study examining changes in liver biopsy scores in people with NAFLD after a lifestyle modification intervention (which used a dietary and exercise intervention) demonstrated no significant change in biopsy scores between participants receiving the lifestyle intervention and those receiving standard care, although there was a trend to improvement with the intervention. In addition, the GDG observed that the included studies consistently demonstrated a pattern of improvement in other relevant outcomes (including MRS intrahepatic triglyceride, transient elastography scores and liver enzymes) to a clinically significant degree. The trend for improvement with lifestyle modification interventions appeared to occur independently of weight loss, and was also seen in children and young people. The greatest reduction in NAFLD prevalence was seen in those who lost the most weight, as shown by absence of steatosis assessed by ultrasound. It was agreed this is consistent with evidence from the review of exercise interventions, and it was noted that weight loss is not the primary factor, as calorie-burning does not directly

	<p>translate into health gain, and the health benefits are independent of weight loss.</p> <p>The GDG noted that the benefits of lifestyle modification in people with NAFLD appeared to be most pronounced in those who were obese. Comparison of the evidence in which participants received very intensive, personalised dietary and exercise interventions with that in which participants received standard dietary and exercise interventions, without behavioural modification, led the GDG to conclude that lifestyle modification interventions with a behavioural component may be more clinically effective than those without. However, the evidence was not strong enough to specify this as a required component of the intervention in the recommendation.</p> <p>The GDG felt that lifestyle modification had some clinical benefit on NAFLD activity score, parenchymal inflammation, ballooning injury, fibrosis and body weight were amongst the clinical outcomes reported.</p> <p>The GDG also felt that lifestyle modification had some clinical benefit on NAFLD prevalence and ALT levels over usual care out of the outcomes reported in this study.</p> <p>Overall, the GDG concluded that the evidence assessed was compelling for demonstrating an improvement in clinically relevant outcomes in adults, children and young people with NAFLD of all BMIs receiving lifestyle modification interventions. Lifestyle modification strategies are already recommended by NICE for people who are obese or overweight as part of public health guidance (see PH53 Recommendation 6 and PH47 Recommendation 8) and the NICE guideline on obesity CG189. The GDG noted that, in addition to the benefits that these interventions provide in terms of weight loss and reduced risk of cardiovascular disease (assessed in the public health guidance), there is also evidence that they provide the additional benefit of reducing the rate of NAFLD progression, and so those recommendations should extend to people with NAFLD. While most interventions are aimed at people with BMI over 25, evidence included in this review suggested that lifestyle modification programmes can be beneficial in populations that include people with NAFLD and a BMI lower than 25. The cost implication of considering lifestyle modification programmes for people with NAFLD regardless of BMI is discussed further below.</p>
Trade-off between net clinical effects and costs	<p>No relevant economic evaluations were identified within the published literature of lifestyle interventions in people with NAFLD.</p> <p>In the absence of such direct evidence, the GDG considered recent NICE public health guidance (PH53<sup>123</sup> and PH47<sup>121</sup>) on similar lifestyle modification interventions for overweight and obese people, whether or not they included people with NAFLD.</p> <p>It was noted that original economic modelling conducted for the purpose of the public health guidance showed the interventions to be cost-effective, assuming that the intervention costs per person would be under £900 for children and £450 for adults, and that a minimum amount of weight loss would be maintained for a sufficient length of time (5 years for adults).</p> <p>The public health guidance concluded that such lifestyle modification interventions are likely to be cost-effective and so recommended them for overweight and obese people. The GDG noted that overweight or obese people who also have NAFLD would receive additional benefits in improvements to their NAFLD at no additional cost, and that these interventions are therefore likely to be even more cost-effective in this group than in people who are overweight but without NAFLD.</p> <p>The GDG noted that currently only short-term lifestyle modifications programmes (up to 12 weeks) funded by the NHS are available in many areas. Though the evidence suggests that people do benefit from even short programmes, longer participation in such programmes may give greater clinical benefit. People who wish to continue in these programmes for longer periods may therefore currently have to pay for additional sessions personally. Long-term participation may therefore depend on ability to pay, as well as on desire to participate which may widen health</p>

	<p>inequalities.</p> <p>The benefits of lifestyle modification programmes for the small minority of people with NAFLD who are not overweight or obese will be smaller, though the costs would be the same. Based on clinical experience the GDG believe that this subset of people with BMI less than 25 represents circa less than 5% of the population with NAFLD. This could still be cost-effective at a threshold of £20,000 per QALY for a relatively low-cost programme if the participant maintains the effects of the programme in the longer term. However, this will be influenced by many factors, including how well suited a programme is for a particular participant and their commitment to the programme. As a result, the GDG was not able to conclude that lifestyle programmes will necessarily be appropriate or cost-effective for all people with NAFLD who are not overweight, but instead recommends that such interventions should be considered by the clinician and the person with NAFLD together on a case-by-case basis.</p>
Quality of evidence	<p>The GDG expressed reservations regarding the quality of some of the evidence, including the heterogeneity of means of diagnosing NAFLD, the small numbers of participants in certain included studies and the short follow-up time in other included studies. Most evidence was ranked as low or very low quality by GRADE criteria due to the high risk of bias found within the studies (detailed below) and the imprecision of the effect estimates. It was agreed that a stronger recommendation could not be made in the absence of larger studies with a longer follow-up time.</p> <p><i>Lifestyle modification (any diet plus any exercise plus behavioural modification)</i></p> <p>The GDG noted that there were only 2 RCTs of 31 and 154 participants, and 1 cohort study of 154 participants looking at the clinical effects of a lifestyle modification intervention on NAFLD. The studies compared the effectiveness of a lifestyle modification intervention against usual care and education. The RCTs reported evidence of moderate to very low quality. This was due to the inadequate blinding in the included studies resulting in a high risk of bias rating as well as the imprecise nature of the results. The quality of evidence reported by the cohort study<sup>157</sup> was very low due to selection bias and the lack of blinding, as well as the imprecision around the results.</p> <p><i>Diet plus exercise</i></p> <p>The GDG expressed concerns regarding the single RCT evidence of small sample size comparing the clinical effects of diet and exercise against usual care. The quality of evidence in the study ranged from low to very low. This was due to the lack of blinding resulting in a high risk of bias rating and the imprecise nature of the results further downgraded the quality of the evidence. The GDG observed that there was evidence of clinical benefit on the NAFLD activity score, ALT and AST levels out of the clinical outcomes reported. There were also 2 cohort studies comparing the clinical effects of diet and exercise with usual care. The GDG were concerned with the small sample size of the studies (of respectively 54 and 24 participants), the short follow-up time, and the very low quality of the evidence. This was due to the lack of blinding and the presence of selection bias, as well as the imprecision around the results. The GDG found diet and exercise had some clinical benefit on NAFLD progression measured using transient elastography, ALT and AST levels over usual care in these studies.</p> <p>The GDG noted the nature of the evidence as very low quality single small studies of short follow-up time, with no clinical benefit observed for diet and exercise. The only benefit of diet and exercise over exercise alone was observed in the cohort study on body weight.</p> <p>The clinical benefit of diet and exercise compared to diet alone was also observed in a single RCT<sup>8</sup> of 100 participants. The clinical evidence was of low quality due to the</p>



## NAFLD

### Lifestyle modification

	<p>lack of blinding, presence of selection bias and incomplete outcome reporting which was due to the high number of drop outs resulting in a very high risk of bias rating. Additionally, the imprecise nature of the results extracted and analysed further downgraded the quality of the evidence. However, the GDG felt there was clinically beneficial effect of diet and exercise on the ALT and AST levels reported in participants with NAFLD, compared to interventions recommending dietary changes alone.</p> <p>The clinical benefit of diet and exercise was compared to exercise alone in an RCT and a cohort study.</p>
Other considerations	<p>The GDG noted that weight loss achieved as part of a lifestyle modification strategy in adults with NAFLD appears to have a longer-term benefit in reducing NAFLD progression, even if the weight loss is maintained for a short time only (for example, 'yo-yo' dieters). As such, weight loss should be recognised as an important desirable outcome for lifestyle modification strategies in adults with NAFLD.</p> <p>The GDG also noted that lifestyle modification strategies offered to children and young people with NAFLD, who have not yet reached their adult height, should ensure that they focus on reducing the rate of weight gain rather than on decreasing weight. This is because weight gain is part of the normal physiological growth and development of children and young people (depending upon their developmental stage).</p>

1

2

# 1 14 Alcohol advice

## 2 14.1 Introduction

3 Through its very definition, people with NAFLD do not consume alcohol in excessive amounts.  
 4 However, given that the definition allows people with fatty liver disease to drink alcohol up to the  
 5 national recommended limits, the regular alcohol consumption of people with NAFLD varies between  
 6 those completely abstinent from alcohol through to those who drink at the national limits. Given that  
 7 there are explanations for why alcohol and obesity related to NAFLD might synergise in their  
 8 deleterious effects on the liver, and also some evidence that alcohol may protect against some of the  
 9 mechanisms responsible for NAFLD, a review of the evidence examining the relationship between  
 10 moderate alcohol consumption and NAFLD is warranted. It is clearly important that if evidence exists  
 11 on which to base firm recommendations to advise people with NAFLD on whether abstinence from  
 12 alcohol is indicated or whether it is safe or even beneficial to drink alcohol within the national limits.

## 13 14.2 Review question: Should people with NAFLD restrict their 14 consumption of alcohol to below national recommended levels?

15 For full details see review protocol in Appendix A.

16 **Table 69: PICO characteristics of review question**

<b>Population</b>	Adults with NAFLD (18 years and over)
<b>Prognostic variable</b>	<ul style="list-style-type: none"> <li>• Alcohol consumption (continuous outcome)</li> </ul> <i>or</i> <ul style="list-style-type: none"> <li>• No alcohol compared with alcohol within national limits/light</li> </ul>
<b>Outcomes</b>	Progression of NAFLD as assessed by: <ul style="list-style-type: none"> <li>• Liver biopsy (for example, NAFLD activity score [NAS] [synonymous with NASH-CRN])</li> <li>• MRI or MRS</li> <li>• Ultrasound (absence of steatosis only)</li> <li>• The Enhanced Liver Fibrosis (ELF) score</li> <li>• Transient elastography</li> <li>• NAFLD fibrosis score</li> </ul>
<b>Key confounding factors</b>	<ul style="list-style-type: none"> <li>• Age</li> <li>• Diabetes</li> <li>• BMI</li> </ul>
<b>Study design</b>	Included: <ul style="list-style-type: none"> <li>• RCTs</li> <li>• Prospective and retrospective longitudinal cohort studies</li> <li>• Systematic reviews</li> </ul> Excluded: <ul style="list-style-type: none"> <li>• Univariate analysis</li> <li>• Conference abstracts</li> <li>• Cross-sectional studies</li> <li>• MVA that control for &lt;3 confounders</li> </ul>

### 14.3 Clinical evidence

Two studies were included in the review,<sup>43,67</sup> these are summarised in Table 70 below. Evidence from these studies is summarised in the GRADE clinical evidence profile below (Table 71). See also the study selection flow chart in Appendix E, study evidence tables in Appendix H, forest plots in Appendix K and excluded studies list in Appendix M.

Both studies were longitudinal in design, with 2 assessments of fatty liver, 1 of which was retrospective,<sup>67</sup> and 1 prospective.<sup>43</sup> One study used histological diagnosis to monitor fibrosis progression,<sup>43</sup> whilst the other study used ultrasound scan to diagnose the presence or absence of fatty liver.<sup>67</sup>

Alcohol intake was monitored in both using questionnaires to calculate the weekly alcohol consumption. In 1 study more information including heavy alcohol episodes and changes in alcohol consumption was also measured.<sup>43</sup>

Similar confounding factors were taken into account in both multivariate analysis including age and BMI.

**Table 70: Summary of studies included in the review**

Study	NAFLD assessment method	Population	Alcohol intake measurement	Comments
Ekstedt 2009 <sup>43</sup>	Histological assessment by a blinded pathologist using Brunt criteria	N= 71 patients diagnosed with NAFLD at baseline who completed a follow-up/ developed cirrhosis. Other aetiologies of fatty liver disease were excluded.  Mean follow-up (SD) = 13.8 (1.2) years	Alcohol intake measured using a modified AUDIT-C questionnaire, self-reported and validated by a physician interview. Patients reported whether current alcohol consumption had changed since first biopsy	Well designed and reported study, with multivariate analysis including diabetes. Not all variables measured in the alcohol assessment were reported in multivariate analysis.
Hashimoto 2015 <sup>67</sup>	Abdominal ultrasound scans. Images were reviewed by a blinded gastroenterologist. Fatty liver diagnosed if there was hepatorenal contrast and liver brightness.	N= 5437 patients who had two health checks, both of which included abdominal ultrasound scans. Included patients who had heavy alcohol intake as well, and therefore likely alcoholic liver disease. Other aetiologies of fatty liver were excluded.  Follow-up time = 10 years	Patients had lifestyle questionnaires administered by clinicians at both baseline and follow-up, detailing weekly alcohol intake. Patients categorised into none to minimal, light, moderate and heavy weekly alcohol intake.	Alcohol limits used were not representative of UK suggested limits. Included patients who had heavy alcohol intake, but these patients were not included in this review. Did not include diabetes in the multivariate analysis.

**Table 71: Clinical evidence profile: Alcohol intake and NAFLD progression/presence**

Quality assessment							Number of patients	Adjusted effects	Quality
No of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations		Pooled effect with 95% CIs [if meta-analysed] or effect and 95% CI in single study	
Heavy episodic drinking ( more than 140g ethanol in 1 drinking episode) for fibrosis progression (>1 stage in Brunt scoring system) <sup>a</sup>									
1	Prospective observational study	no risk of bias	no serious inconsistency	no serious indirectness	no serious imprecision	none	n =71	adjusted OR: 42.148 (5.390, 329.570) p value= <0.0001	HIGH
Light alcohol consumption for men (40-140g/week) for development of fatty liver <sup>b</sup>									
1	Retrospective observational study	serious <sup>c</sup>	no serious inconsistency	serious indirectness <sup>d</sup>	no serious imprecision	none	n = 721	adjusted HR: 0.72 (0.60, 0.86) p value = <0.001	LOW
Light alcohol consumption for women (40-140g/week) for development of fatty liver <sup>b</sup>									
1	Retrospective observational study	serious <sup>c</sup>	no serious inconsistency	serious indirectness <sup>d</sup>	serious imprecision <sup>e</sup>	none	n = 161	adjusted HR: 0.86 (0.52, 1.42) p value =0.56	VERY LOW
Moderate alcohol consumption for men (140-280) for development of fatty liver <sup>b</sup>									
1	Retrospective observational study	serious <sup>c</sup>	no serious inconsistency	serious indirectness <sup>d</sup>	serious imprecision <sup>e</sup>	none	n =611	adjusted HR: 0.80 (0.57, 1.00) p value= <0.001	VERY LOW
Moderate alcohol consumption for men (140-280) for development of fatty liver <sup>b</sup>									
1	Retrospective observational study	serious <sup>c</sup>	no serious inconsistency	serious indirectness <sup>d</sup>	serious imprecision <sup>e</sup>	none	n =47	adjusted HR: 1.23 (0.62, 2.41) p value=0.55	VERY LOW

(a) Multivariate analysis included: age, gender, BMI, diabetes, weight gain, IR HOMA (insulin resistance according to homeostasis model assessment), fibrosis stage at baseline

(b) Multivariate analysis included: age, BMI, smoker status, and regular exercise (defined as >1 episode of any type of sport undertaken per week)

(c) Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias

(d) *Downgraded by 1 increment if the majority of the evidence had serious indirectness, and downgraded by 2 increments if the majority of the evidence was at very serious indirectness*

1. *Imprecision downgraded by 1 as 95% CI crosses the null line.*

## 14.4 Economic evidence

- 2 No relevant economic evaluations were identified.
- 3 See also the economic article selection flow chart in Appendix F.

## 14.5 Evidence statements

### 14.5.1 Clinical

- 6 • One small cohort study (n=71) with a multivariate analysis, reported high quality evidence of an  
7 increased risk of NAFLD progression of fibrosis (OR: 42, 95% CI: 5.390-329.570) for heavy episodic  
8 drinking of alcohol in a population of people with NAFLD in Sweden. Conversely 1 large Japanese  
9 cohort study (n=5437) with a multivariate analysis reported moderate to very low quality  
10 evidence of an increased benefit in male patients who consume light (HR: 0.72, 95% CI: 0.60-0.86)  
11 to moderate (HR: 0.80, 95% CI: 0.57-1.00) alcohol for the regression of NAFLD on  
12 ultrasonography. The same effect was not demonstrated in females in the population studied  
13 (very low quality evidence)

### 14.5.2 Economic

- 15 • No relevant economic evaluations were identified.

## 14.6 Recommendations and link to evidence

<b>Recommendation</b>	<b>25. Explain to people with NAFLD who drink alcohol of the importance of staying within the national recommended limits for alcohol consumption.</b>
<b>Research recommendation</b>	<b>8. Should people with NAFLD restrict their consumption of alcohol to below national limits?</b>
Relative values of different outcomes	The GDG agreed that progression of NAFLD was the only relevant outcome for this review, as assessed by a variety of methods, that it, liver biopsy (including NAS), MRI or MRS, ultrasound (reporting absence of steatosis only), ELF, transient elastography or NAFLD fibrosis score.
Trade-off between clinical benefits and harms	<p>The GDG also discussed the evidence from prospective cohort studies that suggested that the co-existence of obesity and moderate alcohol intake had a super-additive effect on the rates of liver disease incidence, as well as liver-related mortality.</p> <p>The prospective longitudinal study that was included in this review provided evidence that heavy episodic drinking at least once per month ('binge drinking') is a strong risk factor for fibrosis progression in adults with NAFLD. Although the GDG felt that the evidence had limitations (see 'quality of evidence' below), they concluded that light to moderate alcohol intake (up to 280g ethanol per week) was not associated with increased rates of NAFLD.</p> <p>The GDG considered the evidence that appeared to demonstrate a decreased rate of development of NAFLD in men drinking up to 280g of ethanol per week, but no effect of such levels of consumption on NAFLD rates in women. However, based on the identified evidence, the GDG concluded that whilst alcohol consumption within UK recommended levels appears to be safe in people with NAFLD, the limitations of the evidence meant that they were not able to conclude that alcohol intake beyond current UK limits could be deemed safe or recommendable for people with NAFLD. Given the modest amount of evidence that was identified to inform this review</p>

## Alcohol advice

	question and its clear major clinical importance, the GDG concluded that a research recommendation was justified for studies to investigate whether people with NAFLD should restrict their alcohol intake to below national recommended levels.
Trade-off between net clinical effects and costs	<p>No relevant economic evaluations were identified.</p> <p>The cost of alcoholic drinks falls upon people with NAFLD as consumers. The recommendation in this review would either not affect the quantity of alcoholic drinks consumed, or may require advising individuals to reduce their consumption, which would have the additional economic benefit of saving them money.</p>
Quality of evidence	<p>The GDG noted that there was high quality evidence reporting a long follow-up of participants (<math>13.8 \pm 1.2</math> years), and careful evaluation of alcohol intake with multivariate analysis adjusting for key confounders. The GDG noted, however, that in their experience, it is unusual for people to begin heavy episodic drinking after the diagnosis of NAFLD, and it may indicate that the study participants' original level of alcohol consumption may have been self-reported lower than the true values. Whilst the GDG noted the very large number of participants and long length of follow-up within large retrospective cohort study, they expressed several concerns regarding risk of bias due to the study design; for instance, the GDG noted that NAFLD had been diagnosed via ultrasound only, and that people with heavy alcohol intake were included (who may have had alcohol-related liver disease). In light of this concern, data for participants with heavy alcohol intake were not included within this review. The GDG were also concerned about the indirectness of the prognostic factor measured in the study, which used local recommended alcohol limits in analysing the data that were dissimilar to those in the UK. The GDG were also concerned regarding the analysis of the data, and whether it took into account both those who had progressed from baseline and those that had regressed, and noted that this was not clearly reported within the study. The evidence was therefore rated as very low quality due to these risks of bias and indirectness.</p>
Other considerations	<p>The GDG were aware of existing evidence (univariate in design) that has shown a correlation between moderate alcohol intake and fibrosis regression in NAFLD cohorts. In addition, they noted data from the cardiovascular literature consistent with moderate alcohol intake being protective against cardiovascular events, a major cause of morbidity and mortality in people with NAFLD. However, they recognised that this evidence could not be used to formulate recommendations for this review question, as the analysis in these studies does not account for key variables that may also influence changes in fibrosis.</p> <p>The GDG discussed that although no specific recommendation on alcohol intake in teenagers with NAFLD could be made, they agreed that teenagers with NAFLD should be given pragmatic advice about alcohol intake, and advised of the risks of regular excess alcohol consumption and heavy intermittent drinking, both for their NAFLD and for their health more broadly, recognising UK alcohol licensing laws.</p> <p><b>Research recommendation</b></p> <p>The GDG made a high-priority research recommendation to investigate if people with NAFLD should restrict their consumption of alcohol to below national limits. See Appendix P for further details.</p>

1

2

# 1 15 Fructose advice

## 2 15.1 Introduction

3 The sugar fructose, either consumed alone or as part of the sugar molecule sucrose, is an increasingly  
 4 common sugar found in the diet in countries in the western world. It is particularly prevalent in  
 5 sweetened drinks in North America, and increased consumption of fructose has been implicated as 1  
 6 cause of the obesity epidemic in North America and other parts of the world. There are certainly  
 7 plausible bio-mechanisms why carbohydrate consumption of fructose may be more deleterious for  
 8 body weight and, indeed, fatty liver disease than other forms of carbohydrate and sugar. It is  
 9 therefore important to review evidence on whether consuming carbohydrates in the form of fructose  
 10 is indeed deleterious for people at risk of already having NAFLD, so that appropriate dietary advice  
 11 can be given. This chapter considers evidence that is available thus far.

## 12 15.2 Review question: Should people with NAFLD restrict their 13 consumption of fructose or sugar?

14 For full details see review protocol in Appendix A.

15 **Table 72: Characteristics of review question**

<b>Population</b>	<ul style="list-style-type: none"> <li>• Adults with NAFLD (18 years and over)</li> <li>• Young people with NAFLD (11 years or older and younger than 18 years) and children with NAFLD (younger than 11 years)</li> </ul>
<b>Prognostic variable/s under consideration</b>	<ul style="list-style-type: none"> <li>• Fructose intake</li> <li>• Sugar (Sucrose) intake</li> </ul>
<b>Confounding factors</b>	<ul style="list-style-type: none"> <li>• Age</li> <li>• BMI</li> <li>• Diabetes</li> </ul>
<b>Outcomes</b>	<p>Critical outcomes:</p> <ul style="list-style-type: none"> <li>• Progression of NAFLD as assessed by:               <ul style="list-style-type: none"> <li>○ Liver biopsy (for example, NAFLD activity score [NAS] [synonymous with NASH-CRN])</li> <li>○ MRI or MRS</li> <li>○ Ultrasound (absence of steatosis only)</li> <li>○ The Enhanced Liver Fibrosis (ELF) score</li> <li>○ Transient elastography</li> <li>○ NAFLD fibrosis score</li> </ul> </li> </ul> <p>Important outcomes:</p> <ul style="list-style-type: none"> <li>• Liver function tests (for example ALT levels, ALT/AST ratio)</li> <li>• Adverse events</li> </ul>
<b>Study design</b>	<ul style="list-style-type: none"> <li>• Prospective and retrospective cohorts or case-control studies</li> <li>• Randomised trials</li> <li>• Systematic reviews of the above</li> </ul>



### 15.3 Clinical evidence

2 No relevant clinical studies investigating the effects of fructose on NAFLD progression were  
3 identified.

### 15.4 Economic evidence

5 No relevant economic evaluations were identified.

6 See also the economic article selection flow chart in Appendix F.

### 15.5 Evidence statements

#### 15.5.1 Clinical

9 • No relevant clinical evaluations were identified.

#### 15.5.2 Economic

11 • No relevant economic evaluations were identified.

### 15.6 Recommendations and link to evidence

Recommendations	No clinical recommendations.
Relative values of different outcomes	No studies were identified that met the criteria for inclusion. The GDG therefore agreed that no clinical recommendation could be made for this review question.
Trade-off between clinical benefits and harms	In the absence of clinical evidence, no trade-off concerns were identified.
Trade-off between net clinical effects and costs	No relevant economic evaluations were identified. No intervention is being proposed for this review, due to a lack of clinical evidence, and so there are no economic implications.
Quality of evidence	Although there were clinical studies seeking to answer this review question that were identified during the initial database search, these used either a cross-sectional design or univariate analysis only. In addition, the GDG noted that some of the cross-sectional data that was identified was from the USA, where the pattern of fructose consumption is very different from the UK (for example, a greater use of high-fructose corn syrup is used within processed foods in the USA), further limiting the applicability of the findings of these studies to people within the UK. The GDG therefore concluded that such studies were not suitable for further consideration.
Other considerations	The GDG discussed the evidence from pre-clinical studies (for example, intervention studies in rodents) and cross-sectional clinical studies within the obesity and NAFLD literature that has collectively been suggestive of an association between higher levels of fructose consumption and increased rates of NAFLD, along with more rapid progression and increased severity of the condition. However, the GDG recognised that not all of these studies have found the same association, and none of the clinical studies have used multivariate analysis. As such, the GDG considered that there was not enough evidence available at present for them to make a recommendation for this review question.

# 1 16 Caffeine advice

## 2 16.1 Introduction

3 In considering lifestyle advice for people with non-alcoholic fatty liver disease, the issue of  
 4 consumption of caffeine in tea and coffee needs to be considered. Evidence from other liver  
 5 diseases, principally hepatitis C and alcohol-related liver disease, suggests that caffeine consumption  
 6 may be associated with lower risks of fibrosis and cirrhosis. More recently, there have been a  
 7 number of studies examining this issue in people with NAFLD. There are certainly a number of  
 8 plausible mechanistic explanations for why caffeine intake may slow the progression of NAFLD, and  
 9 therefore it is important to review relevant studies in order to advise people with NAFLD either to  
 10 increase or decrease their consumption of caffeine, in light of their diagnosis.

## 11 16.2 Review question: Should people with NAFLD modify their 12 consumption of caffeine from coffee?

13 For full details see review protocol in Appendix A.

14 **Table 73: PICO characteristics of review question**

<b>Population</b>	Adults with NAFLD (18 years and over), young people with NAFLD (11 years or older and younger than 18 years) and children with NAFLD (younger than 11 years)
<b>Prognostic variable</b>	Caffeine from coffee consumption modification
<b>Key confounding factors</b>	None specified
<b>Outcomes</b>	<p><b>Critical outcomes:</b></p> <ul style="list-style-type: none"> <li>• Progression of NAFLD as assessed by:               <ul style="list-style-type: none"> <li>○ Liver biopsy</li> <li>○ MRI/MRS</li> <li>○ Ultrasound (absence of steatosis only)</li> <li>○ The Enhanced Liver Fibrosis (ELF) score</li> <li>○ Transient elastography</li> <li>○ NAFLD fibrosis score</li> </ul> </li> <li>• Serious adverse events</li> <li>• Quality of life</li> </ul> <p><b>Important outcomes:</b></p> <ul style="list-style-type: none"> <li>• Weight</li> <li>• Liver function tests (for example, ALT, AST levels, ALT/AST ratio)</li> </ul>
<b>Study design</b>	RCTs, systematic reviews, cohorts; if none of the previous then case-control studies would be considered.

## 15 16.3 Clinical evidence

16 No studies were identified specifically addressing the effect of caffeine consumption on the  
 17 progression of NAFLD. Two case-control studies were identified looking at the effect caffeine  
 18 consumption on both those with and without NAFLD.<sup>23,55</sup> The diagnostic tests used to identify  
 19 participants with NAFLD differed between the studies (Table 75). Both studies determined coffee

1 intake by self-reported responses to a questionnaire. The validity of the results from the studies  
2 relied on the respondent's ability to provide accurate information. A reliable self-report measure will  
3 produce a consistent result every time it is executed; however, none of the studies evaluated the  
4 consistency of replies (for example by test-retest methods). Furthermore neither of these studies  
5 used validated questionnaires.

6 Further details of the included studies are detailed in Table 75. See also the study selection flow  
7 chart in Appendix E, study evidence tables in Appendix H, forest plots in Appendix K, and excluded  
8 studies list in Appendix M.

9

**Table 74: Summary of studies included in the review**

Study	Type	Population	Quantification of coffee consumption	Follow-up	Outcomes and analysis	Study diagnosis of people with NAFLD
Catalano 2010 <sup>23</sup> Italy	Case-control	n=310 Cases; n=157 NAFLD Controls; n=153  Participants referred by family doctor for evaluation and nutrition counselling at gastroenterology and nutrition unit	<ul style="list-style-type: none"> <li>Coffee drinking habits assessed at gastroenterology and nutrition unit</li> <li>Coffee drinking defined according to the absolute number of cups of coffee (only espresso coffee), and also graded as 1 (0 cups of coffee/day), 2 (1–2 cups of coffee/day) 3 (≥3 cups of coffee/day)</li> </ul>	6 months (no baseline data reported)	<ul style="list-style-type: none"> <li>Coffee consumption (cups/day) <ul style="list-style-type: none"> <li>cases versus controls</li> </ul> </li> <li>Correlation coefficient r for coffee consumption and bright liver score by liver ultrasound</li> <li>Multivariate stepwise linear regression <ul style="list-style-type: none"> <li>β coefficient for bright liver score and coffee consumption</li> </ul> </li> </ul>	Ultrasound (bright liver score ≥1)
Funatsu 2011 <sup>55</sup> Japan	Case-control	n=492 Cases; n=164 NAFLD Controls; n=328  Male office workers between age 25 and 60 years  Matched for age, BMI and exercise level	<ul style="list-style-type: none"> <li>Annual lifestyle questionnaire mailed to participants for self-report prior to annual health check</li> <li>Included questions on all beverage consumption</li> </ul>	5 years	<ul style="list-style-type: none"> <li>Change in coffee consumption (cups/day) over study period for the development of NAFLD (cases versus controls at 5 years)</li> <li>Logistic regression analysis <ul style="list-style-type: none"> <li>Change in coffee consumption over 5 years OR(95%CI) and development of NAFLD using ultrasonographic findings (showing increase in bright liver, increase in liver kidney ratio and/or decrease in liver deep echo)</li> </ul> </li> </ul>	Increase in alanine aminotransferase (ALT) levels for ≥6 months before the study, ultrasonography demonstrating fatty liver

**Table 75: Clinical evidence summary: Coffee consumption as a prognostic factor for NAFLD**

Quality assessment							Adjusted effects		Quality
Number of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Pooled effect with 95% CIs [if meta-analysed] or effect and 95% CI in single study		
<b>NAFLD (presence or absence of fatty liver) (timing of exposure 5 years; assessed with: Ultrasound)</b>									
1	Case-control study	very serious <sup>a</sup>	-	no serious indirectness	no serious imprecision	none	adjusted OR: 0.736 (0.61, 0.89) <sup>b</sup>		LOW

(a) Downgraded by 1 increment if the majority of evidence was at high risk of bias or 2 increments if the majority of evidence was at very high risk of bias.

(b) Adjusted for age, BMI, exercise level, and alcohol intake.

**Table 76: Clinical evidence summary: Coffee consumption in people with NAFLD versus controls**

Quality assessment							Anticipated absolute effects		Quality
No. of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other consideration	Risk with Control	Risk difference with NAFLD (95% CI)	
<b>Coffee consumption (follow-up 3 months - 5 years; measured with: Cups per day; Better indicated by lower values)</b>									
2	Case-control studies	very serious <sup>a</sup>	very serious inconsistency <sup>b</sup>	no serious indirectness	serious imprecision <sup>c</sup>	none	The mean coffee consumption in the control groups was 2.525 cups/day	The mean coffee consumption in the intervention groups was 0.26 cups/day lower (1.14 lower to 0.62 higher)	VERY LOW

(a) Downgraded by 1 increment if the majority of evidence was at high risk of bias or 2 increments if the majority of evidence was at very high risk of bias.

(b) Downgraded by 2 increments because the point estimates vary widely across studies, and the I<sup>2</sup> heterogeneity = 93% (p < 0.0001). With no predefined subgroups to explore heterogeneity the result was analysed using a random effects model. Heterogeneity may be caused by the difference in study follow up times.

(c) Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

**Additional data that could not be meta-analysed or reported in GRADE format**

**Table 77: Direct linear correlations between cups of coffee versus ALT and AST: Catalano 2010<sup>23</sup>**

Characteristic	Cups of coffee/day			
	NAFLD group (n=157)		Control group (n=153)	
	R	p value	R	p value
Cups of coffee/day	1	-	1	-
ALT	-0.091	0.259	0.162	0.046
AST	0.128	0.326	-0.033	0.733

## 16.4 Economic evidence

- 2 No relevant economic evaluations were identified.
- 3 See also the economic article selection flow chart in Appendix F.

## 16.5 Evidence statements

### 16.5.1 Clinical

- 6 • Low quality evidence from 1 case-control study suggested a clinical benefit of drinking coffee for  
7 reduced liver fat content (based on the presence or absence of fatty liver on ultrasound) with an  
8 OR of 0.736 (95% CI 0.61-0.89) when adjusted for age, BMI, exercise level and alcohol intake.  
9 However very low quality evidence from 2 case-control studies suggested no difference in the  
10 amount of coffee consumed between those who have NAFLD and those who do not.

### 16.5.2 Economic

- 12 • No relevant economic evaluations were identified.

## 16.6 Recommendations and link to evidence

Recommendations	No clinical recommendations.
Research recommendation	9. What is the clinical and cost-effectiveness of caffeine from coffee as an anti-fibrotic agent in adults with NAFLD?
Relative values of different outcomes	The GDG agreed that the outcomes that were critical to decision-making were progression of NAFLD, quality of life and occurrence of serious adverse events. Of these, progression of NAFLD as measured by liver biopsy was agreed to be the most important outcome. However, the GDG also agreed that other surrogate markers of NAFLD progression reported within the identified literature (including liver enzyme values) could be considered to be of clinical relevance.
Trade-off between clinical benefits and harms	The GDG agreed that the identified evidence was suggestive of a relationship between increased caffeine intake and slower progression of NAFLD. The GDG also discussed the evidence it was aware of from both pre-clinical settings and from clinical data from other liver diseases that supports the possible role of caffeine as an anti-fibrotic agent. However, as described further below, the GDG had major concerns about the limitations in quality of the available evidence.  The GDG highlighted that no evidence was available about adverse or serious adverse events, and therefore conclusions about potential side effects related to increased caffeine consumption could not be made.
Trade-off between net clinical effects and costs	No economic evidence was identified relating to coffee consumption by people with NAFLD.  In the absence of strong clinical evidence, the GDG is not recommending coffee as an agent for reducing the progression of NAFLD; therefore, there are no economic considerations related to this recommendation.  However, it was noted that if future research provides more solid clinical-effectiveness evidence for the use of coffee by people with NAFLD, backing up positive recommendations, then the costs for its use would mainly fall upon people with NAFLD as consumers.

Quality of evidence	<p>The GDG had significant concerns about the quality of evidence available for this review. In particular, it noted that there were no relevant randomised controlled trials specifically addressing the review question. Those studies that had been identified for inclusion were case control studies involving populations both with and without NAFLD and the evidence from these studies was of low to very low quality by GRADE criteria. The GDG expressed concern that studies tended to measure the caffeine intake of study participants by relying upon self-reporting (using non-validated food questionnaires), where there is a clear risk of recall bias. The GDG also discussed how the size of a standard ‘cup of coffee’ – as well as the amount of caffeine equating to a cup of coffee – was described variably between different studies, as there are no accepted standard definitions for these terms.</p> <p>The GDG reiterated that any evidence for an apparent association between caffeine intake and change in NAFLD status arising from association studies could potentially be explained by confounding factors (for example, an alternative aspect of the metabolic syndrome, or another factor of study participants’ lifestyle or diet not recorded by the researchers). However, the GDG noted that 1 of the studies had included multivariate logistic regression analysis to attempt correction of this aspect.</p>
Other considerations	<p>Whilst this review question sought to identify the relationship between caffeine from coffee and clinical outcomes for people with NAFLD, the GDG also observed that none of the identified studies examined for a relationship between NAFLD progression and the intake of decaffeinated coffee.</p> <p>The overall conclusion from the GDG was that the evidence reviewed was not strong enough to make a clinical recommendation for caffeine as an agent for reducing progression of NAFLD. However, the GDG agreed that since the evidence reviewed was suggestive of a possible therapeutic benefit from caffeine, a research recommendation was justified. Specifically, the GDG noted that a randomised controlled trial to assess the effect of caffeine upon NAFLD progression would be of particular interest.</p> <p><b>Research recommendation</b></p> <p>The GDG made a research recommendation to investigate the clinical and cost-effectiveness of caffeine from coffee as an anti-fibrotic agent to treat adults with NAFLD.</p>



# 17 Pharmacological interventions

## 17.1 Introduction

The application of genetics, molecular biology, mass spectrometry and other basic scientific techniques to analysis of samples from people with NAFLD (as well as murine models of the condition) has helped to better elucidate the mechanisms underpinning the onset and progression of disease in NAFLD. These developments in understanding have resulted in identification of a number of different potential targets for pharmacological intervention, with the aim of preventing, slowing or reversing the hepatic inflammation and fibrosis that may accompany NAFLD. Areas of particular interest to date have included peroxisomal proliferator activated receptor gamma (PPAR  $\gamma$ ) or insulin sensitising drugs such as glitazones, as well as agents with anti-inflammatory/ hepatoprotective properties such as vitamin E.

The recently burgeoning global recognition of the current and potential future burden of NAFLD has emphasised the major, currently unmet, need for efficacious pharmacological interventions for the condition. Over the course of the past decade, research within this area has translated from pre-clinical studies through to randomised clinical trials. Increasing international acceptance of appropriate histological and surrogate end-points within clinical trials of novel therapeutics for NAFLD has helped in improving the quality of trial design within the field.

At the time of writing these guidelines, although no therapeutics are licensed within the UK specifically for the treatment of NAFLD, a number of therapeutics licensed for other indications are recognised to have a potential mechanistic basis and/ or supportive clinical evidence for their role in treating NAFLD, and it was these that this review question sought to evaluate in more detail.

## 17.2 Review question: What is the clinical and cost-effectiveness of pharmacological interventions for adults, young people and children with NAFLD?

For full details see review protocol in Appendix A.

**Table 78: PICO characteristics of review question**

<b>Population</b>	<ul style="list-style-type: none"> <li>• Adults with NAFLD (18 years and over)</li> <li>• Young people with NAFLD (11 years or older and younger than 18 years) and children with NAFLD (younger than 11 years and older than 5 years)</li> </ul>
<b>Interventions</b>	<ul style="list-style-type: none"> <li>• Insulin sensitisers               <ul style="list-style-type: none"> <li>○ Pioglitazone</li> <li>○ Metformin</li> </ul> </li> <li>• Ursodeoxycholic acid</li> <li>• Vitamin E</li> <li>• Pentoxifylline</li> <li>• Statins</li> <li>• Angiotensin-converting-enzyme (ACE) inhibitors</li> <li>• Angiotensin II receptor antagonists, also known as angiotensin receptor blockers (ARBs)</li> <li>• Alpha blockers</li> <li>• Orlistat</li> <li>• GLP-1 (glucagon-like peptide) receptor agonists</li> </ul>

## Pharmacological interventions

	<ul style="list-style-type: none"> <li>• Dipeptidyl peptidase-4 DPP4 enzyme inhibitors</li> </ul>
<b>Comparisons</b>	<ul style="list-style-type: none"> <li>• Placebo</li> <li>• 1 drug versus another drug</li> <li>• 2 drugs versus 1 drug</li> <li>• 2 drugs in combination versus placebo</li> </ul>
<b>Outcomes</b>	<p>Critical outcomes:</p> <ul style="list-style-type: none"> <li>• Progression of NAFLD as assessed by: <ul style="list-style-type: none"> <li>○ Liver biopsy (for example, NAFLD activity score [NAS] [synonymous with NASH-CRN])</li> <li>○ MRI or MRS</li> <li>○ Ultrasound (absence of steatosis only)</li> <li>○ The Enhanced Liver Fibrosis (ELF) score</li> <li>○ Transient elastography</li> <li>○ NAFLD fibrosis score</li> </ul> </li> <li>• Quality of life (for example CLDQ, EQ-5D)</li> <li>• Mortality</li> <li>• Serious adverse events</li> </ul> <p>Important outcomes:</p> <ul style="list-style-type: none"> <li>• Liver function tests (for example ALT levels, ALT/AST ratio)</li> <li>• Adverse events</li> </ul>
<b>Study design</b>	<p>RCTs</p> <p>Systematic reviews of RCTs</p> <p>If no RCTs or SRs identified, cohort studies</p>

### 17.3 Clinical evidence

We searched for randomised trials comparing the effectiveness of a range of pharmacological interventions (alone or in combination) versus placebo or each other for adults, children and young people with NAFLD.

Twenty-seven randomised trials were identified<sup>6,7,16-19,22,40,65,68,93,101,103,104,127,154,156,161,163,164,171,172,175,177,198,207,233,235</sup> these are summarised in Table 79 below.

Evidence from these studies is summarised in the clinical evidence tables below. See also the study selection flow chart in Appendix E, study evidence tables in Appendix H, forest plots in Appendix K, GRADE tables in Appendix J and excluded studies list in Appendix M.

No evidence was identified for ACE inhibitors, ARBs, alpha blockers, GLP-1 receptor agonists or dipeptidyl peptidase-4 DPP4 enzyme inhibitors, despite widening the search to include observational cohort evidence.

**Table 79: Summary of studies included in the review**

Study	Intervention and comparison	Population	Outcomes	Concomitant treatment
<b>Aithal 2008<sup>6</sup></b>	<p>(n=37) Intervention 1: Insulin sensitisers - Pioglitazone. 30 mg/day. Duration 12 months.</p> <p>(n=37) Intervention</p>	(n=74) adults	Progression of NAFLD: decrease/increase in steatosis score, hepatocellular injury, lobular inflammation,	Reduction of calorie intake by 500 kcal/day, modest exercise

## NAFLD

### Pharmacological interventions

Study	Intervention and comparison	Population	Outcomes	Concomitant treatment
	2: Placebo. Not reported. Duration 12 months.		portal inflammation, Mallory-Denk bodies, fibrosis at 12 months  Liver function tests: mean ALT levels at 12 months	
<b>Akcam 2011<sup>7</sup></b>	(n=22) Intervention 1: Insulin sensitisers - Metformin. Oral treatment with 850 mg daily (Glucophage, Bristol-Myers Squibb). Medication taken with meals to minimise gastrointestinal side-effects. Duration 6 months.  (n=23) Intervention 2: Vitamin E. Oral capsules 400 U/daily self-administered. Duration 6 months.	(n=67) young people and children (9-17 years)	Progression of NAFLD: improvements of steatosis detected by ultrasound at 6 months  Adverse events: minor side effects at 6 months  Liver function tests: change in triglycerides at 6 months	Patients in all groups were advised to adopt a diet supplying 30 kcal/kg based on current body weight; 50% of the diets energy was derived from carbohydrates, 30% from lipids, and 20% from proteins. All patients received a list of recommended food portions and possible combinations. All patients were advised to perform at least 30 mins of aerobic physical activity per day. Both groups had diet and exercise advice individually tailored to each patient. Each patient attended individual consultation sessions with a registered paediatric nutritionist, who checked the list of recommended and restricted food and amounts, and compliance with these recommendations.
<b>Belfort 2006<sup>18</sup></b>	(n=26) Intervention 1: Insulin sensitisers - Pioglitazone. 30 mg/day (increased to 45 mg/day after 2 months), Actos. Duration 6 months.  (n=21) Intervention 2: Placebo. Placebo. Duration 6 months.	(n=55; no information given on number randomised to each group) adults	Progression of NAFLD: number of patients with improvement in steatosis, ballooning necrosis, lobular inflammation and fibrosis at 6 months; number of patients with a	Patients were asked to reduce their caloric intake by 500 kcal/day prior to randomisation.

NAFLD

Pharmacological interventions

Study	Intervention and comparison	Population	Outcomes	Concomitant treatment
			reduction in steatosis score and fibrosis score of $\geq 2$ at 6 months  Liver function tests: mean ALT levels at 6 months, mean AST levels at 6 months	
<b>Bugianesi 2005<sup>22</sup></b>	(n=28) Intervention 1: Vitamin E. 400 IU twice per day (daily dose of 800 IU). Duration 12 months.  (n=29) Intervention 2: Insulin sensitisers - Metformin. 2000 mg/d, dosage was progressively increased from 250 mg/d twice to reduce gastrointestinal side effects. Duration 12 months.  Comments: Accounts for the Bologna arm (n=29) only	(n=110) adults	Liver function tests: number of patients with normalised ALT levels at 12 months	Patients were advised to walk or jog at least 30 mins per day
<b>Dufour 2006<sup>40</sup> (Balmer 2009<sup>17</sup>)</b>	(n=14) Intervention 1: Combination of 2 pharmacological interventions. Ursodeoxycholic acid (UDSA) (250 mg) and vitamin E (400 IU), UDSA 12-15 mg/kg/day and 400 IU vitamin twice a day. Duration 2 years.  (n=14) Intervention 2: Ursodeoxycholic acid. UDCA 250 mg 12-15 mg/kg/day. Duration 2 years.  (n=13) Intervention 3: Placebo. Placebo tablets. Duration 2 years.	(n=41) adults	2 pharmacological interventions versus UDCA: Progression of NAFLD: steatosis at 2 years  2 pharmacological interventions versus placebo: Progression of NAFLD: steatosis at 2 years  UDCA versus placebo: Progression of NAFLD: steatosis at 2 years	Patients informed of the benefits of regularly exercising and if overweight, of weight loss.
<b>Harrison</b>	(n=25) Intervention	(n=50) adults	Liver function tests:	a single multivitamin

## Pharmacological interventions

Study	Intervention and comparison	Population	Outcomes	Concomitant treatment
2009 <sup>65</sup>	<p>1: Vitamin E. 800 IU vitamin E per day. Duration 36 weeks.</p> <p>(n=25) Intervention 2: Combination of 2 pharmacological interventions. 120 mg orlistat orally 3 times a day with meals + 800 IU vitamin E per day. Duration 36 weeks.</p>		<p>mean ALT levels at 36 weeks; mean AST levels at 36 weeks</p>	<p>tablet at bedtime, 1400-calorie/day diet</p>
Haukeland 2009 <sup>68</sup>	<p>(n=24) Intervention 1: Insulin sensitisers - Metformin. Treatment started with one tablet a day (500 mg) and study medication increased every week until a maximal daily dose of 2500 mg or 3000 mg (if bodyweight &gt;90 kg) was reached after 4 or 5 weeks. If side-effects occurred the dose was reduced temporarily or permanently to a level that was tolerated by the person.. Duration 6 months.</p> <p>(n=24) Intervention 2: Placebo. Treatment started with one tablet a day (placebo) and study medication increased every week until a maximal daily dose of 2500 mg or 3000 mg (if bodyweight &gt;90 kg) was reached after 4 or 5 weeks. If side-effects occurred the dose was reduced temporarily or permanently to a level that was tolerated by the person. Unclear what placebo tablet</p>	(n=48) adults	<p>Progression of NAFLD: proportion with improvement in steatosis, ballooning necrosis score, lobular inflammation score and fibrosis score at 6 months; proportion with improvement in NAS at 6 months</p> <p>Liver function tests: median reduction of serum ALT at 6 months; median reduction of serum AST at 6 months</p>	<p>At enrolment all participants received general advice about healthy lifestyle, that is, physical activity at least 30 mins daily and a diet low in fat, particularly saturated fat, and refined carbohydrates.</p>

## NAFLD

### Pharmacological interventions

Study	Intervention and comparison	Population	Outcomes	Concomitant treatment
	contained.. Duration 6 months.			
<b>Lee 2008</b> <sup>102</sup>	(n=11) Intervention 1: Pentoxifylline. 400 mg 3 times a day. Duration 12 weeks.  (n=9) Intervention 2: Placebo. Three times a day. Duration 12 weeks.	(n=20) adults	Liver function tests: mean ALT levels at 12 weeks; mean AST levels at 12 weeks	low-calorie diet (1500 kcal/day for men, 1200 kcal/day for women), daily exercise
<b>Leuschner 2010</b> <sup>103</sup>	(n=95) Intervention 1: Ursodeoxycholic acid. 23-28 mg/kg of body weight/day; administered in 3 divided doses daily. Duration 18 months.  (n=91) Intervention 2: Placebo. Administered in 3 divided doses daily. Duration 18 months.	(n=186) adults	Progression of NAFLD: change in NAS, steatosis, ballooning, lobular inflammation and fibrosis at 18 months  Liver function tests: change in mean ALT levels at 18 months, change in mean AST levels at 18 months	Not reported
<b>Lindor 2004</b> <sup>104</sup>	(n=80) Intervention 1: Ursodeoxycholic acid. 13-15 mg/kg body weight/day; administered orally in 4 divided doses. Duration 24 months.  (n=86) Intervention 2: Placebo. Administered orally in 4 divided doses per day. Duration 24 months.	(n=174) adults	Progression of NAFLD: mean overall steatosis difference at 24 months; mean overall fibrosis difference at 24 months  Liver function tests: mean ALT difference at 24 months; mean AST difference at 24 months	Not reported
<b>Nelson 2009</b> <sup>127</sup>	(n=10) Intervention 1: Statins. 40 mg simvastatin once per day. Duration 12 months.  (n=6) Intervention 2: Placebo. Once per day. Duration 12 months.	(n=16) adults	Progression of NAFLD: mean fibrosis stage at 12 months; percentage of steatosis at 12 months, necroinflammatory activity at 12 months  Liver function tests: mean ALT levels at	Not reported

NAFLD

Pharmacological interventions

Study	Intervention and comparison	Population	Outcomes	Concomitant treatment
			12 months; mean AST levels at 12 months	
<p><b>PIVENS trial: Sanyal 2010<sup>163</sup> (Bell 2012<sup>19</sup>)</b></p>	<p>(n=80) Intervention 1: Insulin sensitisers - Pioglitazone. Pioglitazone at 30 mg once per day, with a vitamin E like placebo. Duration 96 weeks.</p> <p>(n=84) Intervention 2: Vitamin E. Vitamin E at 800 IU a day with pioglitazone like placebo. Duration 96 weeks.</p> <p>(n=83) Intervention 3: Placebo. Pioglitazone like placebo and vitamin E like placebo once a day. Duration 96 weeks.</p>	(n=247) adults	<p>Pioglitazone versus vitamin E:</p> <p>Mortality: mortality at 96 weeks</p> <p>Progression of NAFLD: total NAS at 96 weeks; improvement in steatosis at 96 weeks; improvement fibrosis at 96 weeks, improvement in histological features of the liver at 96 weeks, improvement in lobular inflammation at 96 weeks, improvement in hepatocellular ballooning at 96 weeks, resolution of definite NASH at 96 weeks</p> <p>Serious adverse events: severe adverse events at 96 weeks</p> <p>Adverse events: cardiovascular adverse events at 96 weeks</p> <p>Liver function tests: ALT levels at 96 weeks; AST levels at 96 weeks</p> <p>Pioglitazone versus placebo:</p> <p>Progression of NAFLD: total NAS at 96 weeks; improvement in steatosis at 96 weeks; improvement fibrosis at 96 weeks,</p>	Not reported

NAFLD

Pharmacological interventions

Study	Intervention and comparison	Population	Outcomes	Concomitant treatment
			<p>improvement in histological features of the liver at 96 weeks, improvement in lobular inflammation at 96 weeks, improvement in hepatocellular ballooning at 96 weeks, resolution of definite NASH at 96 weeks</p> <p>Serious adverse events: severe adverse events at 96 weeks</p> <p>Adverse events: cardiovascular adverse events at 96 weeks</p> <p>Liver function tests: ALT levels at 96 weeks; AST levels at 96 weeks</p> <p>Vitamin E versus placebo:</p> <p>Mortality: mortality at 96 weeks</p> <p>Progression of NAFLD: total NAS at 96 weeks; improvement in steatosis at 96 weeks; improvement fibrosis at 96 weeks, improvement in histological features of the liver at 96 weeks, improvement in lobular inflammation at 96 weeks, improvement in hepatocellular ballooning at 96 weeks, resolution of definite NASH at 96 weeks</p>	



NAFLD

Pharmacological interventions

Study	Intervention and comparison	Population	Outcomes	Concomitant treatment
			Serious adverse events: severe adverse events at 96 weeks Adverse events: cardiovascular adverse events at 96 weeks Liver function tests: ALT levels at 96 weeks; AST levels at 96 weeks	
<b>Ratziu 2011</b> <sup>154</sup>	(n=62) Intervention 1: Ursodeoxycholic acid. 28-35 mg/kg body weight/day (500-mg film-coated Urso-DS tablets, Axcan Pharma). Duration 12 months.  (n=64) Intervention 2: Placebo. No specific information given. Duration 12 months.	(n=192) adults	Liver function tests: percentage of patients with normalised ALT levels at 6 months; mean change of ALT levels at 12 months; percentage of patients with normalised ALT levels at 12 months	Patients were encouraged to follow a health a diet and exercise. No specific dietary instructions were given.
<b>Razavizade 2013</b> <sup>156</sup>	(n=40) Intervention 1: Insulin sensitisers - Pioglitazone. 30 mg/day. Duration 4 months.  (n=40) Intervention 2: Insulin sensitisers - Metformin. 1 g/day (to reduce side effects patients received 500 mg/day at first, dose was increased to 1 g/day if tolerated well). Duration 4 months.	(n=80) adults	Liver function tests: mean change in ALT levels at 4 months; mean change in AST levels at 4 months	Lifestyle modification, calorie intake controlled by dietician
<b>Santos 2003</b> <sup>161</sup>	(n=15) Intervention 1: Ursodeoxycholic acid. 10 mg/kg body weight/day (divided into two daily doses). Duration 3 months.  (n=15) Intervention 2: Placebo. Not reported. Duration 3 months.	(n=30) adults	Progression of NAFLD: hepatic density at 3 months  Liver function tests: mean ALT levels at 3 months	Not reported

## Pharmacological interventions

Study	Intervention and comparison	Population	Outcomes	Concomitant treatment
<b>Sanyal 2004</b> <sup>164</sup>	<p>(n=10) Intervention 1: Combination of 2 pharmacological interventions. Combination of vitamin E (400 IU daily) and pioglitazone (30 mg daily). The vitamin E was given in its natural form. Doses were selected based on the available literature. Higher doses of vitamin E were not used for fear of augmenting the risk for hepatotoxicity with pioglitazone.. Duration 6 months.</p> <p>(n=10) Intervention 2: Vitamin E. 400 IU orally every day. Vitamin E was given in its natural form. Doses were selected based on the available literature. Higher doses of vitamin E were not used for fear of augmenting the risk for hepatotoxicity with pioglitazone.. Duration 6 months.</p>	(n=20) adults	<p>Progression of NAFLD: percentage change from baseline for histological outcomes at 6 months</p> <p>Liver function tests: normalisation of ALT levels at 6 months</p>	All patients were given standardised recommendations about diet and exercise in accordance with the National Heart Lung and Blood Institute guidelines.
<b>Shargorodsky 2012</b> <sup>171</sup>	<p>(n=32) Intervention 1: Insulin sensitisers - Metformin. 850-1700 mg/day, orally. Duration 12 months.</p> <p>(n=31) Intervention 2: Placebo. Matching the metformin treatment plan. Duration 12 months.</p>	(n=63) adults	Liver function tests: mean ALT levels at 4 months; mean AST levels at 4 months; mean ALT levels at 12 months; mean AST levels at 12 months	Not reported
<b>Sharma 2012</b> <sup>172</sup>	(n=30) Intervention 1: Pentoxifylline. 1200 mg/day in 3 divided doses, orally. Duration 6 months.	(n=60) adults	Progression of NAFLD: mean fibrosis stage, steatosis stage, ballooning and lobular	Reduction of calorie intake by 500 kcal/day, modest exercise regularly at least 5 days per week

## NAFLD

### Pharmacological interventions

Study	Intervention and comparison	Population	Outcomes	Concomitant treatment
	(n=30) Intervention 2: Insulin sensitisers - Pioglitazone. 30 mg/day. Duration 6 months.		inflammation at 6 months  Liver function tests: mean ALT levels at 6 months; mean AST levels at 6 months	
<b>Shiasi Arani 2014</b> <sup>175</sup>	(n=36) Intervention 1: Metformin 1g/day (n=28) Intervention 2: Metformin 1.5g/day (n=28) Intervention 3: Vitamin E 400U/day (n=27) Intervention 4: Vitamin E 800U	(n=128) young people and children	Remission of NAFLD (ultrasound)	Advise on diet, exercise and weight loss program.
<b>Shields 2009</b> <sup>177</sup>	(n=9) Intervention 1: Insulin sensitisers - Metformin. 500 mg/day, dose increased to 1000 mg/d if serum aminotransferases did not show improvement at 3-month follow-up. Duration 12 months.  (n=10) Intervention 2: Placebo. following metformin treatment plan, dose increased following the same treatment plan as metformin if serum aminotransferases did not show improvement at 3-month follow-up. Duration 12 months.	(n=19) adults	Progression of NAFLD: mean NAS at 12 months; mean steatosis score, ballooning, intra-acinar inflammation and fibrosis at 12 months  Liver function tests: mean change in ALT levels at 12 months; mean change in AST levels at 12 months	DASH (Dietary Approaches to Stop Hypertension) diet emphasizing fruit, vegetables and lowering saturated fat and cholesterol; advised to complete 30 mins of aerobic exercise 4x/week
<b>Tock 2010</b> <sup>198</sup>	(n=21) Intervention 1: Insulin sensitisers - Metformin. 500 mg twice per day. Duration 12 months.  (n=14) Intervention 2: Placebo. Following the metformin treatment plan. Duration 12 months.	(n=35) young people and children	Liver function tests: mean ALT levels at 6 months; mean AST levels at 6 months; mean ALT levels at 12 months; mean AST levels at 12 months	Nutritional therapy (weekly dietetics lessons, reduction of food intake to calorie levels recommended by the dietary reference intake for patients with low levels of physical activity of the same age and gender),

NAFLD

Pharmacological interventions

Study	Intervention and comparison	Population	Outcomes	Concomitant treatment
				exercise therapy (60-minute aerobic sessions 3 times a week), psychological therapy (weekly psychological orientation group sessions)
<b>TONIC trial: Lavine 2011<sup>94</sup></b>	<p>(n=57) Intervention 1: Insulin sensitisers - Metformin. 500 mg twice daily, oral. Duration 96 weeks.</p> <p>(n=58) Intervention 2: Vitamin E. 400 IU twice daily. Duration 96 weeks.</p> <p>(n=58) Intervention 3: Placebo. Vitamin E placebo twice daily, metformin placebo twice daily. Duration 96 weeks.</p>	<p>(n=173) young people and children</p>	<p>Metformin versus placebo:</p> <p>QOL: mean change in self-reported QOL (Pediatric Quality of Life Inventory: physical and psychosocial) at 96 weeks; mean change in parent-guardian-reported QOL (Pediatric Quality of Life Inventory: physical and psychosocial) at 96 weeks</p> <p>Progression of NAFLD: mean change in NAS at 96 weeks; change in fibrosis score, steatosis score, lobular inflammation score ballooning, degeneration score and resolution of NASH at 96 weeks</p> <p>Liver function tests: mean change in ALT levels from baseline at 24 weeks; mean change in ALT levels from baseline at 96 weeks; mean change in AST levels from baseline at 96 weeks</p> <p>Vitamin E versus placebo:</p> <p>QOL: mean change in self-reported QOL (Pediatric</p>	<p>Intervention 1: vitamin E placebo twice daily</p> <p>Intervention 2: metformin placebo twice daily</p> <p>Intervention 3: none</p>

NAFLD

Pharmacological interventions

Study	Intervention and comparison	Population	Outcomes	Concomitant treatment
			<p>Quality of Life Inventory: physical and psychosocial) at 96 weeks; mean change in parent-guardian-reported QOL (Pediatric Quality of Life Inventory: physical and psychosocial) at 96 weeks</p> <p>Progression of NAFLD: mean change in NAS at 96 weeks; change in fibrosis score, steatosis score, lobular inflammation score, ballooning degeneration score and resolution of NASH at 96 weeks</p> <p>Liver function tests: mean change in ALT levels from baseline at 24 weeks; mean change in ALT levels from baseline at 96 weeks; mean change in AST levels from baseline at 96 weeks</p> <p>Metformin versus placebo:                      QOL: mean change in self-reported QOL (Pediatric Quality of Life Inventory: physical and psychosocial) at 96 weeks; mean change in parent-guardian-reported QOL (Pediatric Quality of Life Inventory: physical and psychosocial) at 96 weeks</p> <p>Progression of NAFLD: mean change in NAS at 96</p>	

NAFLD

Pharmacological interventions

Study	Intervention and comparison	Population	Outcomes	Concomitant treatment
			weeks; change in fibrosis score, steatosis score, lobular inflammation score, ballooning degeneration score and resolution of NASH at 96 weeks Liver function tests: mean change in ALT levels from baseline at 24 weeks; mean change in ALT levels from baseline at 96 weeks; mean change in AST levels from baseline at 96 weeks	
<b>Wagner 2011</b> <sup>207</sup>	(n=21) Intervention 1: Pentoxifylline. 400 mg 3 times per day. Duration 12 months.  (n=9) Intervention 2: Placebo. Three times per day. Duration 12 months.	(n=30) adults	Progression of NAFLD: mean change in NAS at 12 months; mean change in fibrosis score, steatosis grade, lobular inflammation and hepatocyte ballooning at 12 months  Liver function tests: mean change in ALT levels at 12 months; mean change in AST levels at 12 months; normalisation of ALT levels at 12 months; normalisation of AST levels at 12 months	Not reported
<b>Zein 2011</b> <sup>233</sup>	(n=26) Intervention 1: Pentoxifylline. 400 mg orally 3 times per day. Duration 12 months.  (n=29) Intervention 2: Placebo. Orally 3	(n=55) adults	Progression of NAFLD: mean change of NAS at 12 months; NAS decreased by $\geq 2$ points at 12 months; mean change in steatosis,	Not reported

## Pharmacological interventions

Study	Intervention and comparison	Population	Outcomes	Concomitant treatment
	times per day. Duration 12 months.		lobular inflammation, ballooning and fibrosis from baseline at 12 months  Adverse events: any side effects at 12 months  Liver function tests: normalisation or improvement of $\geq 30\%$ in ALT levels from baseline at 12 months; normalisation or improvement of $\geq 30\%$ in AST levels from baseline at 12 months	
<b>Zelber-sagi 2006</b> <sup>237</sup>	(n=26) Intervention 1: Orlistat. 120 mg 3 times a day. Duration 6 months.  (n=26) Intervention 2: Placebo. Placebo tablets supplied by Roche were indistinguishable from the orlistat tablets. Duration 6 months.	(n=52) adults (not specified as adults but age range of 18-75 years suggests that it is)	Progression of NAFLD: ultrasound assessed reversal of fatty liver (percentage of group with normal echogenicity) at 6 months; histopathologically assessed decrease in steatosis (number of patients with improved grading) at 6 months; histopathologically assessed at least one degree of improvement of fibrosis at 6 months  Liver function tests: decrease in ALT levels from baseline at 6 months; decrease in AST levels from baseline at 6 months	Nutritional therapy based on a balanced low-energy diet prescribed by a nutritionist. Diet included 104.5 kJ/day for ideal body weight, with an emphasis on reduced intake of both fat ( $\leq 30\%$ of daily calories) and simple carbohydrates. Patients were encouraged to perform physical activity 2-4 times a week (40mins of walking at 5-6 km/h)

**Table 80: Clinical evidence summary: pioglitazone versus placebo for adults with NAFLD**

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with pioglitazone versus placebo (95% CI)
<b>Critical progression of NAFLD outcomes</b>					
Decrease in fibrosis >12 months Histology (Brunt)	61 (1 study) 12 months	⊕⊕⊖⊖ LOW <sup>b</sup> due to imprecision	RR 1.45 (0.59 to 3.58)	Moderate	
				200 per 1000	90 more per 1000 (from 82 fewer to 516 more)
Increase in fibrosis >12 months Histology (Brunt)	61 (1 study) 12 months	⊕⊕⊕⊕ HIGH	OR 0.11 (0.02 to 0.58)	Moderate	
				200 per 1000	200 fewer per 1000 (from 350 fewer to 50 fewer) <sup>c</sup>
Improvement in fibrosis >12 months	142 (1 study)	⊕⊕⊖⊖ LOW <sup>a,b</sup> due to risk of bias, imprecision	RR 1.74 (1.03 to 2.93)	Moderate	
				193 per 1000	143 more per 1000 (from 6 more to 372 more)
Reduction in fibrosis score of ≥2, ≥3 to <12 months Histology (Kleiner)	18 (1 study) 6 months	⊕⊖⊖⊖ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision	RR 2.5 (0.37 to 16.89)	Moderate	
				167 per 1000	251 more per 1000 (from 105 fewer to 1000 more)
Improvement in fibrosis ≥3 to <12 months Histology (Kleiner)	47 (1 study) 6 months	⊕⊖⊖⊖ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision	RR 1.38 (0.66 to 2.88)	Moderate	
				333 per 1000	127 more per 1000 (from 113 fewer to 626 more)
Decrease in steatosis score >12 months Histology (Brunt)	61 (1 study) 12 months	⊕⊕⊖⊖ LOW <sup>b</sup> due to imprecision	RR 1.32 (0.73 to 2.39)	Moderate	
				367 per 1000	117 more per 1000 (from 99 fewer to 510 more)
Increase in steatosis score >12 months Histology (Brunt)	61 (1 study) 12 months	⊕⊕⊖⊖ LOW <sup>b</sup> due to imprecision	RR 0.32 (0.04 to 2.93)	Moderate	
				100 per 1000	68 fewer per 1000 (from 96 fewer to 193 more)



Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with pioglitazone versus placebo (95% CI)
Improvement in steatosis >12 months	142 (1 study)	⊕⊕⊕⊖ MODERATE <sup>a</sup> due to risk of bias	RR 2.18 (1.56 to 3.03)	Moderate	
				313 per 1000	369 more per 1000 (from 175 more to 635 more)
Reduction in steatosis score of ≥2, ≥3 to <12 months Histology (Kleiner)	35 (1 study) 6 months	⊕⊕⊖⊖ LOW <sup>a</sup> due to risk of bias	OR 8.84 (1.92 to 40.63)	Moderate	
				0 per 1000	429 more per 1000 (from 202.5 more to 654.6 more) <sup>c</sup>
Decrease in hepatocellular injury >12 months Histology (Brunt)	61 (1 study) 12 months	⊕⊕⊕⊖ MODERATE <sup>b</sup> due to imprecision	RR 3.23 (0.98 to 10.59)	Moderate	
				100 per 1000	223 more per 1000 (from 2 fewer to 959 more)
Increase in hepatocellular injury >12 months Histology (Brunt)	61 (1 study) 12 months	⊕⊕⊕⊖ MODERATE <sup>b</sup> due to imprecision	RR 0.32 (0.12 to 0.89)	Moderate	
				400 per 1000	272 fewer per 1000 (from 44 fewer to 352 fewer)
Improvement in hepatocellular ballooning >12 months	142 (1 study)	⊕⊕⊖⊖ LOW <sup>a,b</sup> due to risk of bias, imprecision	RR 1.5 (1 to 2.24)	Moderate	
				289 per 1000	145 more per 1000 (from 0 more to 358 more)
Improvement in ballooning necrosis ≥3 to <12 months Histology (Kleiner)	47 (1 study) 6 months	⊕⊖⊖⊖ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision	RR 2.26 (0.97 to 5.26)	Moderate	
				238 per 1000	300 more per 1000 (from 7 fewer to 1000 more)
Decrease in lobular inflammation >12 months Histology (Brunt)	61 (1 study) 12 months	⊕⊕⊕⊖ MODERATE <sup>b</sup> due to imprecision	RR 1.69 (0.83 to 3.44)	Moderate	
				267 per 1000	184 more per 1000 (from 45 fewer to 651 more)
Increase in lobular inflammation >12 months Histology (Brunt)	61 (1 study) 12 months	⊕⊕⊖⊖ LOW <sup>b</sup> due to imprecision	RR 1.29 (0.31 to 5.29)	Moderate	
				100 per 1000	29 more per 1000 (from 69 fewer to 429 more)

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with pioglitazone versus placebo (95% CI)
Improvement in lobular inflammation >12 months	142 (1 study)	⊕⊕⊕⊖ LOW <sup>a,b</sup> due to risk of bias, imprecision	RR 1.7 (1.23 to 2.35)	Moderate	
				349 per 1000	244 more per 1000 (from 80 more to 471 more)
Improvement in lobular inflammation ≥3 to <12 months Histology (Kleiner)	47 (1 study) 6 months	⊕⊖⊖⊖ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision	RR 2.29 (1.1 to 4.76)	Moderate	
				286 per 1000	369 more per 1000 (from 29 more to 1000 more)
Decrease in portal inflammation >12 months Histology (Brunt)	61 (1 study) 12 months	⊕⊕⊖⊖ LOW <sup>b</sup> due to imprecision	RR 1.11 (0.46 to 2.67)	Moderate	
				233 per 1000	26 more per 1000 (from 126 fewer to 389 more)
Increase in portal inflammation >12 months Histology (Brunt)	61 (1 study) 12 months	⊕⊕⊖⊖ LOW <sup>b</sup> due to imprecision	RR 0.7 (0.33 to 1.5)	Moderate	
				367 per 1000	110 fewer per 1000 (from 246 fewer to 184 more)
Decrease in Mallory-Denk bodies >12 months Histology (Brunt)	61 (1 study) 12 months	⊕⊕⊕⊖ MODERATE <sup>b</sup> due to imprecision	RR 7.74 (1.03 to 58.21)	Moderate	
				33 per 1000	222 more per 1000 (from 1 more to 1000 more)
Increase in Mallory-Denk bodies >12 months Histology (Brunt)	61 (1 study) 12 months	⊕⊕⊕⊖ MODERATE <sup>b</sup> due to imprecision	OR 0.12 (0.01 to 1.22)	Moderate	
				100 per 1000	100 fewer per 1000 (from 219 fewer to 19 more) <sup>c</sup>
Improvement in histologic features of the liver >12 months	142 (1 study)	⊕⊕⊖⊖ LOW <sup>a,b</sup> due to risk of bias, imprecision	RR 1.74 (1.03 to 2.93)	Moderate	
				193 per 1000	143 more per 1000 (from 6 more to 372 more)
Resolution of definite NASH >12 months	142 (1 study)	⊕⊕⊕⊖ MODERATE <sup>a</sup> due to risk of bias	RR 2.3 (1.44 to 3.76)	Moderate	
				205 per 1000	266 more per 1000 (from 90 more to 566 more)

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with pioglitazone versus placebo (95% CI)
Please see for additional data that could not be meta-analysed or graded.					
<b>Critical serious adverse event outcomes</b>					
Severe adverse events >12 months	163 (1 study) 96 weeks	⊕⊕⊖⊖ LOW <sup>a,b</sup> due to risk of bias, imprecision	RR 0.21 (0.05 to 0.92)	Moderate 121 per 1000	96 fewer per 1000 (from 10 fewer to 115 fewer)
<b>Critical mortality outcomes</b>					
No evidence identified					
<b>Critical quality of life outcomes</b>					
Please see Table 98 for additional data that could not be meta-analysed or graded.					
<b>Important liver function test outcomes</b>					
ALT levels >12 months (final values)	74 (1 study) 12 months	⊕⊕⊖⊖ LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean ALT levels >12 months (final values) in the control groups was 77.2 u/L	The mean ALT levels >12 months (final values) in the intervention groups was 21.3 lower (37.44 to 5.16 lower)
ALT levels ≥3 to <12 months (final values)	47 (1 study) 6 months	⊕⊖⊖⊖ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean ALT levels ≥3 to <12 months (final values) in the control groups was 40 U/litre	The mean ALT levels ≥3 to <12 months (final values) in the intervention groups was 12 lower (20.61 to 3.39 lower)
AST levels ≥3 to <12 months (final values)	47 (1 study) 6 months	⊕⊖⊖⊖ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean AST levels ≥3 to <12 months (final values) in the control groups was 33 U/litre	The mean AST levels ≥3 to <12 months (final values) in the intervention groups was 5 lower (10.05 lower to 0.05 higher)
Please see Table 98 for additional data that could not be meta-analysed or graded.					
<b>Important adverse event outcomes</b>					

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with pioglitazone versus placebo (95% CI)
Adverse events (cardiovascular) >12 months	163 (1 study) 96 weeks	⊕⊖⊖⊖ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision	RR 0.86 (0.4 to 1.89)	Moderate 145 per 1000	20 fewer per 1000 (from 87 fewer to 129 more)
<p>a Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p> <p>b Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs</p> <p>c ARD calculated manually due to single study with zero events in one arm.</p>					

(a) Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias.

(b) Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

(c) ARD calculated manually due to single study with zero events in 1 arm.

**Table 81: Clinical evidence summary: metformin versus placebo for adults with NAFLD**

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with metformin versus placebo (95% CI)
<b>Critical progression of NAFLD outcomes</b>					
Proportion with Improvement in NAFLD activity score $\geq 3$ to <12 months Histology (NAS)	44 (1 study) 12-31 months	⊕⊕⊖⊖ LOW <sup>a,b</sup> due to risk of bias, imprecision	RR 0.4 (0.15 to 1.05)	Moderate 500 per 1000	300 fewer per 1000 (from 425 fewer to 25 more)
Proportion with Improvement in fibrosis score $\geq 3$ to <12 months Histology (NAS)	44 (1 study) 12-31 months	⊕⊖⊖⊖ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision	RR 0.3 (0.04 to 2.47)	Moderate 167 per 1000	117 fewer per 1000 (from 160 fewer to 245 more)

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with metformin versus placebo (95% CI)
Proportion with Improvement in steatosis $\geq 3$ to <12 months Histology (NAS)	44 (1 study) 12-31 months	⊕⊕⊕⊕ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision	RR 0.67 (0.27 to 1.67)	Moderate 375 per 1000	124 fewer per 1000 (from 274 fewer to 251 more)
Proportion with Improvement in lobular inflammation score $\geq 3$ to <12 months Histology (NAS)	44 (1 study) 12-31 months	⊕⊕⊕⊕ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision	RR 0.45 (0.14 to 1.47)	Moderate 333 per 1000	183 fewer per 1000 (from 286 fewer to 157 more)
Proportion with Improvement in ballooning necrosis score $\geq 3$ to <12 months Histology (NAS)	44 (1 study) 12-31 months	⊕⊕⊕⊕ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision	RR 0.4 (0.05 to 3.55)	Moderate 125 per 1000	75 fewer per 1000 (from 119 fewer to 319 more)
Please see Table 100 for additional data that could not be meta-analysed or graded.					
<b>Critical mortality outcomes</b>					
No evidence identified					
<b>Critical serious adverse event outcomes</b>					
No evidence identified					
<b>Critical quality of life outcomes</b>					
No evidence identified					
<b>Important liver function test outcomes</b>					
Final ALT levels >12 months	41 (1 study) 12 months	⊕⊕⊕⊕ VERY LOW <sup>a,b</sup> due to risk of bias,		The mean final ALT levels >12 months in the control groups was	The mean final ALT levels >12 months in the intervention groups was 7.1 higher

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with metformin versus placebo (95% CI)
		imprecision		32.1 U/l	(5.95 lower to 20.15 higher)
Final ALT levels $\geq 3$ to <12 months	52 (1 study) 4 months	⊕⊕⊕⊕ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean final ALT levels $\geq 3$ to <12 months in the control groups was 29.7 U/l	The mean final ALT levels $\geq 3$ to <12 months in the intervention groups was 0.4 lower (9.24 lower to 8.44 higher)
Final AST levels >12 months	41 (1 study) 12 months	⊕⊕⊕⊕ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean final AST levels >12 months in the control groups was 29.3 U/l	The mean final AST levels >12 months in the intervention groups was 1.3 higher (6.2 lower to 8.8 higher)
Final AST levels $\geq 3$ to <12 months	52 (1 study) 4 months	⊕⊕⊕⊕ LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean final AST levels $\geq 3$ to <12 months in the control groups was 27.4 U/l	The mean final AST levels $\geq 3$ to <12 months in the intervention groups was 2 lower (6.9 lower to 2.9 higher)

Please see Table 100 for additional data that could not be meta-analysed or graded.

- 1 (a) Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias.
- 2 (b) Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

### 3 Table 82: Clinical evidence summary: metformin versus placebo for children and young people with NAFLD

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with metformin versus placebo (95% CI)
<b>Critical progression of NAFLD outcomes</b>					
NAFLD activity score >12	97	⊕⊕⊕⊕		The mean NAFLD activity score >12 months	The mean NAFLD activity score >12 months

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with metformin versus placebo (95% CI)
months (change score) composite score	(1 study) 96 weeks	MODERATE <sup>b</sup> due to imprecision		(change score) in the control groups was -0.7	(change score) in the intervention groups was 0.4 lower (1.22 lower to 0.42 higher)
Fibrosis score >12 months (change scores) Histology	97 (1 study) 96 weeks	⊕⊕⊕⊖ MODERATE <sup>b</sup> due to imprecision		The mean fibrosis score >12 weeks (change scores) in the control groups was -0.2	The mean fibrosis score >12 weeks (change scores) in the intervention groups was 0.2 lower (0.69 lower to 0.29 higher)
Steatosis score >12 months (change score) Histology	97 (1 study) 96 weeks	⊕⊕⊕⊖ MODERATE <sup>b</sup> due to imprecision		The mean steatosis score >12 months (change score) in the control groups was -0.4	The mean steatosis score >12 months (change score) in the intervention groups was 0.2 lower (0.69 lower to 0.29 higher)
Ballooning degeneration score >12 months (change score) Histological scoring system	97 (1 study) 96 weeks	⊕⊕⊖⊖ LOW <sup>b</sup> due to imprecision		The mean ballooning degeneration score >12 months (change score) in the control groups was 0.1	The mean ballooning degeneration score >12 months (change score) in the intervention groups was 0.4 lower (0.71 to 0.09 lower)
Lobular inflammation score >12 months (change score) Histology	97 (1 study) 96 weeks	⊕⊕⊕⊖ MODERATE <sup>b</sup> due to imprecision		The mean lobular inflammation score >12 months (change score) in the control groups was -0.3	The mean lobular inflammation score >12 months (change score) in the intervention groups was 0.1 lower (0.45 lower to 0.25 higher)
Resolution of NASH >12 months	97 (1 study)	⊕⊕⊖⊖ LOW <sup>b</sup> due to imprecision	RR 1.37 (0.71 to 2.64)	Moderate 234 per 1000	87 more per 1000 (from 68 fewer to 384 more)
<b>Critical quality of life outcomes</b>					

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with metformin versus placebo (95% CI)
Parent reported paediatric QOL Inventory (physical, 0-100) >12 months (change score) paediatric QOL Inventory	100 (1 study) 96 weeks	⊕⊕⊕⊕ HIGH		The mean parent reported paediatric QOL inventory (physical, 0-100) >12 months (change score) in the control groups was 4.8	The mean parent reported paediatric QOL inventory (physical, 0-100) >12 months (change score) in the intervention groups was 0.7 lower (10.55 lower to 9.15 higher)
Self-reported paediatric QOL Inventory (physical, 0-100) >12 months (change score) paediatric QOL Inventory	100 (1 study) 96 weeks	⊕⊕⊕⊕ HIGH		The mean self-reported paediatric QOL inventory (physical, 0-100) >12 months (change score) in the control groups was 5.4	The mean self-reported paediatric QOL inventory (physical, 0-100) >12 months (change score) in the intervention groups was 0 higher (7.45 lower to 7.45 higher)
Parent reported paediatric QOL Inventory (psychosocial, 0-100) >12 months (change score) paediatric QOL Inventory	100 (1 study) 96 weeks	⊕⊕⊕⊖ MODERATE <sup>b</sup> due to imprecision		The mean parent reported paediatric QOL inventory (psychosocial, 0-100) >12 months (change score) in the control groups was 6.1	The mean parent reported paediatric QOL inventory (psychosocial, 0-100) >12 months (change score) in the intervention groups was 4.2 lower (14.3 lower to 5.9 higher)
Self-reported paediatric QOL Inventory (psychosocial, 0-100) >12 months (change score) paediatric QOL Inventory	100 (1 study) 96 weeks	⊕⊕⊕⊕ HIGH		The mean self-reported paediatric QOL inventory (psychosocial, 0-100) >12 months (change score) in the control groups was 5.6	The mean self-reported paediatric QOL inventory (psychosocial, 0-100) >12 months (change score) in the intervention groups was 1.6 lower (8.54 lower to 5.34 higher)
<b>Critical serious adverse event outcomes</b>					
No evidence identified.					
<b>Critical mortality outcomes</b>					
No evidence identified.					
<b>Important liver function test outcomes</b>					
ALT levels >12 months - Change score	115 (1 study)	⊕⊕⊕⊕ HIGH		The mean ALT levels >12 months - change score in the control groups was	The mean ALT levels >12 months - change score in the intervention groups was



Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with metformin versus placebo (95% CI)
Serology	96 weeks			-35.2 IU/L	6.5 lower (36.18 lower to 23.18 higher)
ALT levels >12 months - Final values Serology	29 (1 study) 12 months	⊕⊕⊕⊕ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean ALT levels >12 months - final values in the control groups was 57.25 IU/L	The mean ALT levels >12 months - final values in the intervention groups was 16.14 lower (38.45 lower to 6.17 higher)
ALT levels ≥3 to <12 months - Change score Serology	115 (1 study) 96 weeks	⊕⊕⊕⊕ HIGH		The mean ALT levels ≥3 to <12 months - change score in the control groups was -24.5 IU/L	The mean ALT levels ≥3 to <12 months - change score in the intervention groups was 21.5 higher (3.83 lower to 46.83 higher)
ALT levels ≥3 to <12 months - Final value Serology	29 (1 study) 12 months	⊕⊕⊕⊕ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean ALT levels ≥3 to <12 months - final value in the control groups was 48.25 IU/L	The mean ALT levels ≥3 to <12 months - final value in the intervention groups was 8.61 lower (21.14 lower to 3.92 higher)
AST levels >12 months - Change scores Serology	100 (1 study) 96 weeks	⊕⊕⊕⊕ HIGH		The mean AST levels >12 months - change scores in the control groups was -20.4 IU/L	The mean AST levels >12 months - change scores in the intervention groups was 1.1 lower (18.63 lower to 16.43 higher)
AST levels >12 months - Final value serology	29 (1 study) 12 months	⊕⊕⊕⊕ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean AST levels >12 months - final value in the control groups was 33 IU/L	The mean AST levels >12 months - final value in the intervention groups was 4.23 lower (15.27 lower to 6.81 higher)
AST levels ≥3 to <12 months Final value Serology	29 (1 study) 12 months	⊕⊕⊕⊕ VERY LOW <sup>a,b</sup> due to risk of		The mean AST levels ≥3 to <12 months (final value) in the control groups was 26.75 IU/L	The mean AST levels ≥3 to <12 months (final value) in the intervention groups was 0.03 higher

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with metformin versus placebo (95% CI)
		bias, imprecision			(6.19 lower to 6.25 higher)
<b>Important adverse event outcomes</b>					
No evidence identified.					

(a) Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias.

(b) Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

**Table 83: Clinical evidence summary: vitamin E versus placebo for adults with NAFLD**

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with vitamin E versus placebo (95% CI)
<b>Critical progression of NAFLD outcomes</b>					
Improvement in histologic features of the liver >12 months	152 (1 study)	⊕⊕⊕⊖ MODERATE <sup>a</sup> due to risk of bias	RR 2.02 (1.23 to 3.32)	Moderate	
				193 per 1000	197 more per 1000 (from 44 more to 448 more)
Improvement in steatosis >12 months	152 (1 study)	⊕⊕⊖⊖ LOW <sup>a,b</sup> due to risk of bias, imprecision	RR 1.56 (1.08 to 2.24)	Moderate	
				313 per 1000	175 more per 1000 (from 25 more to 388 more)
Improvement in lobular inflammation >12 months	152 (1 study)	⊕⊕⊖⊖ LOW <sup>a,b</sup> due to risk of bias, imprecision	RR 1.56 (1.08 to 2.24)	Moderate	
				349 per 1000	195 more per 1000 (from 28 more to 433 more)
Improvement in hepatocellular ballooning >12 months	152 (1 study)	⊕⊕⊖⊖ LOW <sup>a</sup>	RR 1.3 (0.92 to 1.81)	Moderate	
				349 per 1000	105 more per 1000

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with vitamin E versus placebo (95% CI)
		due to risk of bias, imprecision	1.85)	1000	(from 28 fewer to 297 more)
Improvement in fibrosis >12 months	152 (1 study)	⊕⊕⊕⊖ LOW <sup>a,b</sup> due to risk of bias, imprecision	RR 1.18 (0.79 to 1.75)	Moderate 313 per 1000	56 more per 1000 (from 66 fewer to 235 more)
Resolution of definite NASH >12 months	152 (1 study)	⊕⊕⊕⊖ LOW <sup>a,b</sup> due to risk of bias, imprecision	RR 1.56 (0.96 to 2.63)	236 per 1000	132 more per 1000 (from 9 fewer to 385 more)
Please see Table 101 for additional data that could not be meta-analysed or graded.					
<b>Critical serious adverse event outcomes</b>					
Serious adverse events >12 months	167 (1 study) 96 weeks	⊕⊖⊖⊖ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision	RR 0.6 (0.28 to 1.73)	Moderate 121 per 1000	48 fewer per 1000 (from 87 fewer to 88 more)
<b>Critical mortality outcomes</b>					
Mortality >12 months	167 (1 study) 96 weeks	⊕⊖⊖⊖ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision	OR 7.3 (0.14 to 368)	Moderate 0 per 1000	12 more per 1000 (from 21 fewer to 44 more) <sup>c</sup>
<b>Critical quality of life outcomes</b>					
Please see Table 101 for additional data that could not be meta-analysed or graded.					
<b>Important adverse event outcomes</b>					
Adverse events (cardiovascular) >12 months	167 (1 study) 96 weeks	⊕⊖⊖⊖ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision	RR 0.99 (0.47 to 2.07)	Moderate 145 per 1000	1 fewer per 1000 (from 77 fewer to 155 more)

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with vitamin E versus placebo (95% CI)
Important liver function test outcomes					
Please see Table 101 for additional data that could not be meta-analysed or graded.					

(a) Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias.

(b) Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

(c) ARD calculated manually due to single study with zero events in 1 arm.

**Table 84: Clinical evidence summary: vitamin E versus placebo for children and young people with NAFLD**

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with vitamin E versus placebo (95% CI)
<b>Critical progression of NAFLD outcomes</b>					
NAFLD activity score (0-8, change score) >12 months composite score	97 (1 study) 96 weeks	⊕⊕⊕⊖ MODERATE <sup>a</sup> due to imprecision		The mean NAFLD activity score (0-8, change score) >12 months in the control groups was -0.7	The mean NAFLD activity score (0-8, change score) >12 months in the intervention groups was 1.1 lower (1.92 to 0.28 lower)
Fibrosis score (0-4, change score) >12 months Histology	97 (1 study) 96 weeks	⊕⊕⊕⊕ HIGH		The mean fibrosis score (0-4, change score) >12 months in the control groups was -0.2	The mean fibrosis score (0-4, change score) >12 months in the intervention groups was 0.1 lower (0.59 lower to 0.39 higher)
Steatosis score (0-4, change score) >12 months Histology	97 (1 study) 96 weeks	⊕⊕⊕⊖ MODERATE <sup>a</sup> due to imprecision		The mean steatosis score (0-4, change score) >12 months in the control groups was -0.4	The mean steatosis score (0-4, change score) >12 months in the intervention groups was 0.4 lower (0.89 lower to 0.09 higher)
Ballooning degeneration score >12 months	97 (1 study)	⊕⊕⊕⊖ MODERATE <sup>a</sup> due to		The mean ballooning degeneration score >12 months in the control groups was	The mean ballooning degeneration score >12 months in the intervention groups was 0.61 lower

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with vitamin E versus placebo (95% CI)
Histology	96 weeks	imprecision		0.1	(0.92 to 0.3 lower)
Lobular inflammation score (0-2, change score) >12 months Histology	97 (1 study) 96 weeks	⊕⊕⊕⊕ HIGH		The mean lobular inflammation score (0-2, change score) >12 months in the control groups was -0.3	The mean lobular inflammation score (0-2, change score) >12 months in the intervention groups was 0 higher (0.35 lower to 0.35 higher)
Resolution of NASH >12 months	97 (1 study) 96 weeks	⊕⊕⊕⊖ MODERATE <sup>a</sup> due to imprecision	RR 2.14 (1.19 to 3.84)	Moderate 234 per 1000	267 per 1000 (from 44 more to 665 more)
<b>Critical quality of life outcomes</b>					
Parent-reported QoL (physical, 0-100, change score) >12 months QoL scale	99 (1 study) 96 weeks	⊕⊕⊕⊖ MODERATE <sup>a</sup> due to imprecision		The mean parent-reported QoL (physical, 0-100, change score) >12 months in the control groups was 4.8	The mean parent-reported QoL (physical, 0-100, change score) >12 months in the intervention groups was 3.3 lower (14.34 lower to 7.74 higher)
Self-reported QoL (physical, 0-100, change score) >12 months QoL scale	99 (1 study) 96 weeks	⊕⊕⊕⊖ MODERATE <sup>a</sup> due to imprecision		The mean self-reported QoL (physical, 0-100, change score) >12 months in the control groups was 5.4	The mean self-reported QoL (physical, 0-100, change score) >12 months in the intervention groups was 2.2 higher (5.41 lower to 9.81 higher)
Parent-reported QoL (psychosocial, 0-100, change score) >12 months QoL scale	99 (1 study) 96 weeks	⊕⊕⊕⊕ HIGH		The mean parent-reported QoL (psychosocial, 0-100, change score) >12 months in the control groups was 5.6	The mean parent-reported QoL (psychosocial, 0-100, change score) >12 months in the intervention groups was 0.4 higher (7.81 lower to 8.61 higher)
Self-reported QoL (psychosocial, 0-100, change score) >12 months	99 (1 study)	⊕⊕⊕⊕ HIGH		The mean self-reported QoL (psychosocial, 0-100, change score) >12	The mean self-reported QoL (psychosocial, 0-100, change score) >12 months in the

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with vitamin E versus placebo (95% CI)
score) >12 months QoL scale	96 weeks			months in the control groups was 5.6	intervention groups was 0.4 higher (6.67 lower to 7.47 higher)
<b>Critical serious adverse event outcomes</b>					
No evidence identified.					
<b>Critical mortality outcomes</b>					
No evidence identified.					
<b>Important liver function test outcomes</b>					
ALT levels (change score) >12 months Serology	116 (1 study) 96 weeks	⊕⊕⊕⊖ MODERATE <sup>a</sup> due to imprecision		The mean ALT levels (change score) >12 months in the control groups was -35.2 IU/L	The mean ALT levels (change score) >12 months in the intervention groups was 13.1 lower (41.01 lower to 14.81 higher)
ALT levels (change score) >12 months serology	116 (1 study) 96 weeks	⊕⊕⊕⊖ MODERATE <sup>a</sup> due to imprecision		The mean ALT levels (change score) ≥3 to <12 months in the control groups was -24.5 IU/L	The mean ALT levels (change score) ≥3 to <12 months in the intervention groups was 24.7 lower (48.14 to 1.26 lower)
AST levels (change score) >12 months Serology	99 (1 study) 96 weeks	⊕⊕⊕⊕ HIGH		The mean AST levels (change score) >12 months in the control groups was -20.4 IU/L	The mean AST levels (change score) >12 months in the intervention groups was 2.4 lower (18.16 lower to 13.36 higher)
<b>Important adverse event outcomes</b>					
No evidence identified.					

(a) Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

**Table 85: Clinical evidence summary: ursodeoxycholic acid (UDCA) versus placebo for adults with NAFLD**

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with UDCA versus placebo (95% CI)
<b>Critical progression of NAFLD outcomes</b>					
NAFLD activity score (0-8) >12 months (change score) Histology (NAS). Scale from: 0 to 8.	137 (1 study) 18 months	⊕⊕⊕⊖ MODERATE <sup>a</sup> due to risk of bias		The mean NAFLD activity score (0-8) >12 months (change score) in the control groups was -1.03	The mean NAFLD activity score (0-8) >12 months (change score) in the intervention groups was 0.19 lower (0.62 lower to 0.24 higher)
Fibrosis (0-3) >12 months (change score) Histology (NAS/Brunt). Scale from: 0 to 3.	242 (2 studies) 18-24 months	⊕⊕⊕⊖ MODERATE <sup>a</sup> due to risk of bias		The mean fibrosis (0-3) >12 months (change score) in the control groups was 0.04	The mean fibrosis (0-3) >12 months (change score) in the intervention groups was 0.05 lower (0.18 lower to 0.08 higher)
Change in steatosis >12 months (change score) Histology (NAS/Brunt)	244 (2 studies) 18-24 months	⊕⊕⊕⊖ MODERATE <sup>a</sup> due to risk of bias		The mean change in steatosis >12 months (change score) in the control groups was -0.39	The mean change in steatosis >12 months (change score) in the intervention groups was 0.07 lower (0.23 lower to 0.1 higher)
Steatosis (0-4) >12 months (final value) Histology (NAS). Scale from: 0 to 4.	27 (1 study) 2 years	⊕⊕⊖⊖ LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean steatosis (0-4) >12 months (final value) in the control groups was 2.5	The mean steatosis (0-4) >12 months (final value) in the intervention groups was 0.1 higher (0.81 lower to 1.01 higher)
Change in ballooning >12 months (change score) Histology (NAS)	137 (1 study) 18 months	⊕⊕⊕⊖ MODERATE <sup>a</sup> due to risk of bias		The mean change in ballooning >12 months (change score) in the control groups was -0.21	The mean change in ballooning >12 months (change score) in the intervention groups was 0.09 higher (0.09 lower to 0.27 higher)
Change in lobular inflammation >12	137	⊕⊕⊖⊖		The mean change in lobular	The mean change in lobular inflammation

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with UDCA versus placebo (95% CI)
months (change score) Histology (NAS)	(1 study)	LOW <sup>a,b</sup> due to risk of bias, imprecision		inflammation >12 months (change score) in the control groups was -0.15	>12 months (change score) in the intervention groups was 0.23 lower (0.43 to 0.03 lower)
Hepatic density ≥3 to <12 months (change score) CT	30 (1 study) 3 months	⊕⊖⊖⊖ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean hepatic density ≥3 to <12 months (change score) in the control groups was 48.1	The mean hepatic density ≥3 to <12 months (change score) in the intervention groups was 3 higher (9.85 lower to 15.85 higher)
<b>Critical mortality outcomes</b>					
No evidence identified					
<b>Critical serious adverse event outcomes</b>					
No evidence identified					
<b>Critical quality of life outcomes</b>					
No evidence identified					
<b>Important liver function test outcomes</b>					
Normalised ALT levels >12 months	115 (1 study) 12 months	⊕⊕⊕⊖ MODERATE <sup>a</sup> due to risk of bias	RR 5.07 (1.53 to 16.84)	Moderate 48 per 1000	195 more per 1000 (from 25 more to 760 more)
ALT levels >12 months (change score)	417 (3 studies) 12-24 months	⊕⊕⊖⊖ LOW <sup>a,c</sup> due to risk of bias, inconsistency		The mean ALT levels >12 months (change score) in the control groups was 31.6 IU/L	The mean ALT levels >12 months (change score) in the intervention groups was 11.07 lower (28.32 to 6.17 more)
Normalised ALT levels ≥3 to <12	118	⊕⊕⊖⊖	RR 2.14	Moderate	



Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with UDCA versus placebo (95% CI)
months	(1 study) 6 months	LOW <sup>b</sup> due to imprecision	(0.68 to 6.72)	66 per 1000	75 more per 1000 (from 21 fewer to 378 more)
ALT levels ≥3 to <12 months (final value)	30 (1 study) 3 months	⊕⊖⊖⊖ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean ALT levels ≥3 to <12 months (final value) in the control groups was 43.7 IU/l	The mean ALT levels ≥3 to <12 months (final value) in the intervention groups was 8.5 higher (7.28 lower to 24.28 higher)
AST levels >12 months (change score)	304 (2 studies) 18-24 months	⊕⊕⊖⊖ LOW <sup>a</sup> due to risk of bias		The mean AST levels >12 months (change score) in the control groups was 17.5 IU/L	The mean AST levels >12 months (change score) in the intervention groups was 1.74 lower (12.33 lower to 8.84 higher)
<b>Important adverse event outcomes</b>					
No evidence identified					

- 1 (a) Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias.
- 2 (b) Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.
- 3 (c) Downgraded by 1 or 2 increments because heterogeneity,  $I^2=57%$ ,  $p=0.10$ . Sub-grouping by extra hepatic conditions not possible due to insufficient data reported by included papers.

4 **Table 86: Clinical evidence summary: pentoxifylline versus placebo for adults with NAFLD**

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with pentoxifylline versus placebo (95% CI)
<b>Critical progression of NAFLD outcomes</b>					
NAFLD activity score decreased by ≥2 points >12 months Histology (NAS)	46 (1 study) 12 months	⊕⊕⊖⊖ LOW <sup>a,b</sup> due to risk of	RR 3.25 (1.19 to	Moderate 154 per 1000	347 more per 1000

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with pentoxifylline versus placebo (95% CI)
		bias, imprecision	8.86)		(from 29 more to 1000 more)
NAFLD activity score (0-8, change score) >12 months Histology (NAS)	72 (2 studies) 12 months	⊕⊕⊕⊖ MODERATE <sup>b</sup> due to risk of bias		The mean NAFLD activity score (0-8, change score) >12 months in the control groups was -0.2	The mean NAFLD activity score (0-8, change score) >12 months in the intervention groups was 1.38 lower (1.99 to 0.78 lower)
Change in fibrosis (change score) >12 months Histology (NAS)	72 (2 studies) 12 months	⊕⊕⊕⊖ MODERATE <sup>b</sup> due to risk of bias		The mean change in fibrosis (change score) >12 months in the control groups was 0.4	The mean change in fibrosis (change score) >12 months in the intervention groups was 0.6 lower (0.78 to 0.42 lower)
Change in steatosis (change score) >12 months Histology (NAS)	72 (2 studies) 12 months	⊕⊕⊕⊕ HIGH		The mean change in steatosis (change score) >12 months in the control groups was -0.5	The mean change in steatosis (change score) >12 months in the intervention groups was 0.27 lower (0.47 to 0.07 lower)
Hepatocyte ballooning (change score) >12 months Histology (NAS)	72 (2 studies) 12 months	⊕⊕⊖⊖ LOW <sup>b,d</sup> due to imprecision, inconsistency		The mean hepatocyte ballooning (change score) >12 months in the control groups was -0.07	The mean hepatocyte ballooning (change score) >12 months in the intervention groups was 0.33 lower (0.72 to 0.05 higher)
Lobular inflammation (change score) >12 months Histology (NAS)	72 (2 studies) 12 months	⊕⊕⊕⊖ MODERATE <sup>a</sup> due to imprecision		The mean lobular inflammation (change score) >12 months in the control groups was 0.19	The mean lobular inflammation (change score) >12 months in the intervention groups was 0.43 lower (0.64 to 0.22 lower)
<b>Critical mortality outcomes</b>					

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with pentoxifylline versus placebo (95% CI)
No evidence identified					
<b>Critical severe adverse event outcomes</b>					
No evidence identified					
<b>Critical quality of life outcomes</b>					
No evidence identified					
<b>Important liver function test outcomes</b>					
Normalisation in ALT levels >12 months	26 (2 studies) 12 months	⊕⊕⊖⊖ LOW <sup>a,b</sup> due to risk of bias, imprecision	RR 2.24 (1.15 to 5.02)	Moderate 187 per 1000	262 more per 1000 (from 28 more to 752 more)
ALT levels (change score) >12 months	26 (1 study) 12 months	⊕⊕⊖⊖ LOW <sup>a</sup> due to imprecision		The mean ALT levels (change score) >12 months in the control groups was -12 IU/L	The mean ALT levels (change score) >12 months in the intervention groups was 13.1 lower (35.9 lower to 9.7 higher)
ALT levels (final value) ≥3 to <12 months	20 (1 study) 3 months	⊕⊕⊕⊖ MODERATE <sup>a</sup> due to imprecision		The mean ALT levels (final value) ≥3 to <12 months in the control groups was 75.44 IU/l	The mean ALT levels (final value) ≥3 to <12 months in the intervention groups was 24.71 lower (49.21 to 0.21 lower)
Normalisation of AST levels >12 months	75 (1 study) 12 months	⊕⊖⊖⊖ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision	OR 9.65 (1.23 to 75.43)	Moderate 187 per 1000	500 more per 1000 (from 160 more to 840 more) <sup>c</sup>
AST levels (change score) >12 months	26	⊕⊕⊖⊖		The mean AST levels (change score)	The mean AST levels (change score) >12

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with pentoxifylline versus placebo (95% CI)
	(1 study) 12 months	LOW <sup>a</sup> due to imprecision		>12 months in the control groups was -10.1 l/L	months in the intervention groups was 10.6 lower (31.02 lower to 9.82 higher)
AST levels (final values) ≥3 to <12 months	20 (1 study) 3 months	⊕⊕⊕⊖ MODERATE <sup>a</sup> due to imprecision		The mean AST levels (final values) ≥3 to <12 months in the control groups was 49.33 IU/l	The mean AST levels (final values) ≥3 to <12 months in the intervention groups was 16.15 lower (29.33 to 2.97 lower)
Please see Table 102 for additional data that could not be meta-analysed or graded.					
<b>Important adverse event outcomes</b>					
Adverse events >12 months	53 (1 study) 12 months	⊕⊕⊖⊖ LOW <sup>a</sup> due to imprecision	RR 0.88 (0.49 to 1.57)	Moderate 500 per 1000	60 fewer per 1000 (from 255 fewer to 285 more)

- 1 (a) Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.
- 2 (b) Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias.
- 3 (c) ARD calculated manually due to single study with zero events in 1 arm.
- 4 (d) Downgraded by 1 or 2 increments because heterogeneity,  $I^2=74%$ ,  $p=0.045$ . Sub-group analysis not possible due to insufficient information reported in included papers.

5 **Table 87: Clinical evidence summary: statins versus placebo for adults with NAFLD**

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with statins versus placebo (95% CI)
<b>Critical progression of NAFLD outcomes</b>					
Fibrosis stage (final score) >12 months	16 (1 study)	⊕⊖⊖⊖ VERY LOW <sup>a,b</sup>		The mean fibrosis stage (final score) >12 months in the control groups was	The mean fibrosis stage (final score) >12 months in the intervention groups was

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with statins versus placebo (95% CI)
Histology	12 months	due to risk of bias, imprecision		1	0.5 higher (0.75 lower to 1.75 higher)
Percentage Steatosis (final value) >12 months Histology	16 (1 study) 12 months	⊕⊖⊖⊖ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean percentage steatosis (final value) >12 months in the control groups was 20 %	The mean percentage steatosis (final value) >12 months in the intervention groups was 3.8 higher (17.66 lower to 25.26 higher)
Necroinflammatory activity (final score) >12 months	16 (1 study)	⊕⊖⊖⊖ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean necroinflammatory activity (final score) >12 months in the control groups was 1	The mean necroinflammatory activity >12 months in the intervention groups was 0.4 higher (0.76 lower to 1.56 higher)
<b>Critical mortality outcomes</b>					
No evidence identified					
<b>Critical severe adverse event outcomes</b>					
No evidence identified					
<b>Critical quality of life outcomes</b>					
No evidence identified					
<b>Important liver function test outcomes</b>					
ALT levels (final values) >12 months	16 (1 study) 12 months	⊕⊖⊖⊖ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean ALT levels (final values) >12 months in the control groups was 75.3 U/L	The mean ALT levels (final values) >12 months in the intervention groups was 25.8 lower (48.67 to 2.93 lower)
AST levels (final value) >12	16	⊕⊖⊖⊖		The mean AST levels (final value) >12	The mean AST levels (final value) >12

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with statins versus placebo (95% CI)
months	(1 study) 12 months	VERY LOW <sup>a,b</sup> due to risk of bias, imprecision		months in the control groups was 49.3 U/L	months in the intervention groups was 12.8 lower (23.22 to 2.38 lower)
<b>Important adverse event outcomes</b>					
No evidence identified					

(a) Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias.

(b) Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

**Table 88: Clinical evidence summary: orlistat versus placebo for adults with NAFLD**

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with orlistat versus placebo (95% CI)
<b>Critical progression of NAFLD outcomes</b>					
≥1 degree improvement in fibrosis ≥3 to <12 months Histopathology (Brunt)	22 (1 study) 6 months	⊕⊕⊕⊕ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision	RR 1.67 (0.52 to 5.33)	Moderate	
				273 per 1000	183 more per 1000 (from 131 fewer to 1000 more)
Improved steatosis ≥3 to <12 months Histopathology (Brunt)	22 (1 study) 6 months	⊕⊕⊕⊕ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision	RR 0.5 (0.11 to 2.19)	Moderate	
				364 per 1000	182 fewer per 1000 (from 324 fewer to 433 more)
Reversal of fatty liver ≥3 to <12 months ultrasound (% with normal echogenicity)	44 (1 study) 6 months	⊕⊕⊕⊕ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision	RR 1.37 (0.42 to 4.43)	Moderate	
				174 per 1000	64 more per 1000 (from 101 fewer to 597 more)

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with orlistat versus placebo (95% CI)
<b>Critical mortality outcomes</b>					
No evidence identified					
<b>Critical severe adverse event outcomes</b>					
No evidence identified					
<b>Critical quality of life outcomes</b>					
No evidence identified					
<b>Important liver function test outcomes</b>					
ALT levels (change score) >12 months	44 (1 study) 6 months	⊕⊕⊕⊖ MODERATE <sup>b</sup> due to imprecision		The mean ALT levels (change score) >12 months in the control groups was -12.7 U/L	The mean ALT levels (change score) >12 months in the intervention groups was 17.9 lower (45.38 lower to 9.58 higher)
AST levels (change score) >12 months	44 (1 study) 6 months	⊕⊕⊕⊖ MODERATE <sup>b</sup> due to imprecision		The mean AST levels (change score) >12 months in the control groups was -8.8 U/L	The mean AST levels (change score) >12 months in the intervention groups was 10.1 lower (25.87 lower to 5.67 higher)
<b>Important adverse event outcomes</b>					
No evidence identified					

- 1 (a) Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias.
- 2 (b) Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

3 **Table 89: Clinical evidence summary: pioglitazone versus metformin for adults with NAFLD**

Outcomes	No of	Quality of the	Relative	Anticipated absolute effects
----------	-------	----------------	----------	------------------------------

	participants (studies) Follow up	evidence (GRADE)	effect (95% CI)	Risk with control	Risk difference with pioglitazone versus metformin (95% CI)
<b>Critical progression of NAFLD outcomes</b>					
No evidence identified					
<b>Critical mortality outcomes</b>					
No evidence identified					
<b>Critical severe adverse event outcomes</b>					
No evidence identified					
<b>Critical quality of life outcomes</b>					
No evidence identified					
<b>Important liver function test outcomes</b>					
ALT levels >12 months (change score)	80 (1 study) 4 months	⊕⊕⊕⊖ MODERATE <sup>a</sup> due to imprecision		The mean ALT levels >12 months (change score) in the control groups was -21.75 U/L	The mean ALT levels >12 months (change score) in the intervention groups was 15.77 lower (33.09 lower to 1.55 higher)
AST levels >12 months (change score)	80 (1 study) 4 months	⊕⊕⊕⊖ MODERATE <sup>a</sup> due to imprecision		The mean AST levels >12 months (change score) in the control groups was -10.82 U/L	The mean AST levels >12 months (change score) in the intervention groups was 2.92 lower (12.84 lower to 7 higher)
<b>Important adverse event outcomes</b>					
No evidence identified					

(a) Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

**Table 90: Clinical evidence summary: pioglitazone versus vitamin E for adults with NAFLD**

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with pioglitazone versus vitamin E (95% CI)
<b>Critical progression of NAFLD outcomes</b>					



Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with pioglitazone versus vitamin E (95% CI)
Improvement in histologic features of the liver >12 months	150 (1 study)	⊕⊕⊖⊖ LOW <sup>a,b</sup> due to risk of bias, imprecision	RR 0.86 (0.58 to 1.26)	Moderate 429 per 1000	60 fewer per 1000 (from 180 fewer to 112 more)
Improvement in steatosis	142 (1 study)	⊕⊕⊖⊖ LOW <sup>a,b</sup> due to risk of bias, imprecision	RR 1.4 (1.11 to 1.76)	Moderate 536 per 1000	214 more per 1000 (from 59 more to 407 more)
Improvement in lobular inflammation >12 months	142 (1 study)	⊕⊕⊖⊖ LOW <sup>a,b</sup> due to risk of bias, imprecision	RR 1.22 (0.95 to 1.57)	Moderate 536 per 1000	118 more per 1000 (from 27 fewer to 306 more)
Improvement in hepatocellular ballooning >12 months	142 (1 study)	⊕⊕⊖⊖ LOW <sup>a,b</sup> due to risk of bias, imprecision	RR 0.95 (0.7 to 1.3)	Moderate 500 per 1000	25 fewer per 1000 (from 150 fewer to 150 more)
Improvement in fibrosis >12 months	150 (1 study)	⊕⊕⊖⊖ LOW <sup>a,b</sup> due to risk of bias, imprecision	RR 1.18 (0.83 to 1.66)	Moderate 405 per 1000	73 more per 1000 (from 69 fewer to 267 more)
Resolution of definite NASH >12 months	150 (1 study)	⊕⊕⊖⊖ LOW <sup>a,b</sup> due to risk of bias, imprecision	RR 1.45 (1.01 to 2.07)	Moderate 357 per 1000	161 more per 1000 (from 4 more to 382 more)
Please see Table 99 for additional data that could not be meta-analysed or graded.					
<b>Critical mortality outcomes</b>					
Mortality >12 months	164 (1 study)	⊕⊖⊖⊖ VERY LOW <sup>a,b</sup> due to risk of bias,	OR 0.14 (0 to 7.16)	Moderate 12 per	12 fewer per 1000

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with pioglitazone versus vitamin E (95% CI)
	6 months	imprecision		1000	(from 45 fewer to 21 more) <sup>c</sup>
<b>Critical severe adverse event outcomes</b>					
Severe adverse events >12 months	164 (1 study) 6 months	⊕⊖⊖⊖ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision	RR 0.3 (0.06 to 1.4)	Moderate 83 per 1000	58 fewer per 1000 (from 78 fewer to 33 more)
<b>Critical quality of life outcomes</b>					
Please see Table 99 for additional data that could not be meta-analysed or graded.					
<b>Important liver function test outcomes</b>					
Please see Table 99 for additional data that could not be meta-analysed or graded.					
<b>Important adverse event outcomes</b>					
Adverse events (cardiovascular) >12 months	164 (1 study) 6 months	⊕⊖⊖⊖ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision	RR 0.88 (0.4 to 1.91)	Moderate 143 per 1000	17 fewer per 1000 (from 86 fewer to 130 more)

(a) Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias.

(b) Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

(c) ARD calculated manually due to single study with zero events in 1 arm.

**Table 91: Clinical evidence summary: metformin versus vitamin E for adults with NAFLD**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with metformin versus vitamin E (95% CI)
<b>Critical progression of NAFLD outcomes</b>					
No evidence identified					

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with metformin versus vitamin E (95% CI)
<b>Critical mortality outcomes</b>					
No evidence identified					
<b>Critical severe adverse event outcomes</b>					
No evidence identified					
<b>Critical quality of life outcomes</b>					
No evidence identified					
<b>Important liver function test outcomes</b>					
Normalised ALT levels >12 months	57 (1 study) 12 months	⊕⊕⊕⊖ MODERATE <sup>a</sup> due to imprecision	RR 3.14 (1.16 to 8.47)	Moderate 143 per 1000	306 more per 1000 (from 23 more to 1000 more)
<b>Important adverse event outcomes</b>					
No evidence identified					

(a) Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

**Table 92: Clinical evidence summary: metformin versus vitamin E for children and young people with NAFLD**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with metformin versus vitamin E (95% CI)
<b>Critical quality of life outcomes</b>					
Self-reported paediatric QoL Inventory (physical, 0-100) >12 months (change score) Scale from: 0 to 100.	101 (1 study)	⊕⊕⊕⊖ MODERATE <sup>a</sup> due to imprecision		The mean self-reported paediatric qol inventory (physical, 0-100) >12 months (change score) in the control groups was	The mean self-reported paediatric qol inventory (physical, 0-100) >12 months (change score) in the intervention groups was

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with metformin versus vitamin E (95% CI)
				7.6	2.2 lower (8.76 lower to 4.36 higher)
Self-reported paediatric QoL Inventory (psychosocial, 0-100) >12 months (change score) Scale from: 0 to 100.	101 (1 study)	⊕⊕⊕⊕ HIGH		The mean self-reported paediatric qol inventory (psychosocial, 0-100) >12 months (change score) in the control groups was 6	The mean self-reported paediatric qol inventory (psychosocial, 0-100) >12 months (change score) in the intervention groups was 2 lower (10.57 lower to 6.57 higher)
Parent-reported paediatric QoL Inventory (physical, 0-100) >12 months (change score) Scale from: 0 to 100.	101 (1 study)	⊕⊕⊕⊕ HIGH		The mean parent-reported paediatric qol inventory (physical, 0-100) >12 months (change score) in the control groups was 1.5	The mean parent-reported paediatric qol inventory (physical, 0-100) >12 months (change score) in the intervention groups was 2.6 higher (9.38 lower to 14.58 higher)
Parent-reported paediatric QoL Inventory (psychosocial, 0-100) >12 months (change score) Scale from: 0 to 100.	101 (1 study)	⊕⊕⊕⊖ MODERATE <sup>a</sup> due to imprecision		The mean parent-reported paediatric qol inventory (psychosocial, 0-100) >12 months (change score) in the control groups was 4.3	The mean parent-reported paediatric qol inventory (psychosocial, 0-100) >12 months (change score) in the intervention groups was 2.4 lower (10.54 lower to 5.74 higher)
<b>Critical progression of NAFLD outcomes</b>					
Fibrosis score (change score) >12 months	100 (1 study)	⊕⊕⊕⊕ HIGH		The mean fibrosis score (change score) >12 months in the control groups was -0.3	The mean fibrosis score (change score) >12 months in the intervention groups was 0.1 lower (0.51 lower to 0.31 higher)
Steatosis score (change score) >12 months	100 (1 study)	⊕⊕⊕⊖ MODERATE <sup>a</sup>		The mean steatosis score (change score) >12 months in the control groups	The mean steatosis score (change score) >12 months in the intervention groups

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with metformin versus vitamin E (95% CI)
		due to imprecision		was -0.8	was 0.2 higher (0.21 lower to 0.61 higher)
Lobular inflammation score (change score) >12 months	100 (1 study)	⊕⊕⊕⊖ MODERATE <sup>a</sup> due to imprecision		The mean lobular inflammation score (change score) >12 months in the control groups was -0.4	The mean lobular inflammation score (change score) >12 months in the intervention groups was 0.1 higher (0.18 lower to 0.38 higher)
Ballooning degeneration score (change score) >12 months	100 (1 study)	⊕⊕⊕⊖ MODERATE <sup>a</sup> due to imprecision		The mean ballooning degeneration score (change score) >12 months in the control groups was -0.5	The mean ballooning degeneration score (change score) >12 months in the intervention groups was 0.2 higher (0.21 lower to 0.61 higher)
NAFLD activity score (change score) >12 months	100 (1 study)	⊕⊕⊕⊖ MODERATE <sup>a</sup> due to imprecision		The mean NAFLD activity score (change score) >12 months in the control groups was -1.8	The mean NAFLD activity score (change score) >12 months in the intervention groups was 0.7 higher (0.13 lower to 1.53 higher)
Resolution of NASH >12 months	100 (1 study)	⊕⊕⊕⊖ MODERATE <sup>a</sup> due to imprecision	RR 0.64 (0.39 to 1.04)	Moderate 500 per 1000	180 fewer per 1000 (from 305 fewer to 20 more)
Remission of NAFLD* (Ultrasound)	127 (1 study) 4 months	⊕⊖⊖⊖⊖ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision	RR 0.41 (0.19 to 0.9)	Moderate 273 per 1000	161 fewer per 1000 (from 27 fewer to 221 fewer)

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with metformin versus vitamin E (95% CI)
Remission of NAFLD <sup>≠</sup> (ultrasound)	127 (1 study) 4 months	⊕⊕⊕⊕ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision	RR 0.51 (0.25 to 1.05)	Moderate 273 per 1000	134 fewer per 1000 (from 205 fewer to 14 more)
<b>Critical mortality outcomes</b>					
No evidence identified					
<b>Critical severe adverse event outcomes</b>					
No evidence identified					
<b>Important liver function test outcomes</b>					
Change in triglycerides ≥3 to <12 months (change score) serology	45 (1 study) 6 months	⊕⊕⊕⊕ LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean change in triglycerides ≥3 to <12 months (change score) in the control groups was 14.5 mg/dl	The mean change in triglycerides ≥3 to <12 months (change score) in the intervention groups was 11 higher (16.68 lower to 38.68 higher)
ALT levels (change score) >12 months	101 (1 study)	⊕⊕⊕⊕ HIGH		The mean ALT levels (change score) >12 months in the control groups was -48.3	The mean ALT levels (change score) >12 months in the intervention groups was 6.6 higher (20.85 lower to 34.05 higher)
AST levels (change score) >12 months	101 (1 study)	⊕⊕⊕⊕ HIGH		The mean AST levels (change score) >12 months in the control groups was -32.8	The mean AST levels (change score) >12 months in the intervention groups was 1.3 higher (15.08 lower to 17.68 higher)
<b>Important adverse event outcomes</b>					

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with metformin versus vitamin E (95% CI)
Adverse events ≥3 to <12 months adverse events	45 (1 study)	⊕⊕⊖⊖ LOW <sup>a,b</sup> due to risk of bias, imprecision	Peto odds ratio 8.11 (0.49 to 133.96)	Moderate 0 per 1000	91 more per 1000 (from 49 fewer to 204 more)
*Metformin 1 g versus vitamin E (400 and 800U) ≠ Metformin 1.5 g versus vitamin E (400 and 800U)					

(a) Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias.

(b) Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

**Table 93: Clinical evidence summary: pentoxifylline versus pioglitazone for adults with NAFLD**

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with pentoxifylline versus pioglitazone (95% CI)
<b>Critical progression of NAFLD outcomes</b>					
Fibrosis stage (final value) ≥3 to <12 months Histology (Brunt)	46 (1 study) 6 months	⊕⊖⊖⊖ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean fibrosis stage (final value) ≥3 to <12 months in the control groups was 0.9	The mean fibrosis stage (final value) ≥3 to <12 months in the intervention groups was 0.01 higher (0.46 lower to 0.48 higher)
Steatosis stage (final value)	46 (1 study) 6 months	⊕⊕⊖⊖ LOW <sup>a,b</sup> due to risk of		The mean steatosis stage (final value) in the control groups was 1	The mean steatosis stage (final value) in the intervention groups was 0.25 higher

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with pentoxifylline versus pioglitazone (95% CI)
		bias, imprecision			(0.18 lower to 0.68 higher)
Hepatocellular ballooning (final value) $\geq 3$ to <12 months Histology (Brunt)	46 (1 study) 6 months	$\oplus\oplus\ominus\ominus$ LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean hepatocellular ballooning (final value) $\geq 3$ to <12 months in the control groups was 1.09	The mean hepatocellular ballooning (final value) $\geq 3$ to <12 months in the intervention groups was 0.07 higher (0.34 lower to 0.48 higher)
Lobular inflammation (final value) $\geq 3$ to <12 months Histology (Brunt)	46 (1 study) 6 months	$\oplus\oplus\ominus\ominus$ LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean lobullular inflammation (final value) $\geq 3$ to <12 months in the control groups was 0.45	The mean lobullular inflammation (final value) $\geq 3$ to <12 months in the intervention groups was 0.3 higher (0.01 to 0.59 higher)
<b>Critical mortality outcomes</b>					
No evidence identified					
<b>Critical severe adverse event outcomes</b>					
No evidence identified					
<b>Critical quality of life outcomes</b>					
No evidence identified					
<b>Important liver function test outcomes</b>					
ALT levels (final value) $\geq 3$ to <12 months	59 (1 study) 6 months	$\oplus\oplus\ominus\ominus$ LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean ALT levels (final value) $\geq 3$ to <12 months in the control groups was 34 IU/L	The mean ALT levels (final value) $\geq 3$ to <12 months in the intervention groups was 2.9 higher (6.24 lower to 12.04 higher)
AST levels (final value) $\geq 3$ to <12 months	59 (1 study)	$\oplus\oplus\ominus\ominus$ LOW <sup>a,b</sup> due to risk of		The mean AST levels (final value) $\geq 3$ to <12 months in the control groups was	The mean AST levels (final value) $\geq 3$ to <12 months in the intervention groups was



Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with pentoxifylline versus pioglitazone (95% CI)
	6 months	bias, imprecision		27.7 IU/L	0.2 lower (5 lower to 4.6 higher)
<b>Important adverse event outcomes</b>					
No evidence identified					

(a) Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias.

(b) Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

**Table 94: Clinical evidence summary: UDCA plus vitamin E versus UDCA for adults with NAFLD**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with UDCA plus vitamin E versus UDCA (95% CI)
<b>Critical progression of NAFLD outcomes</b>					
Steatosis (0-4, final value) >12 months Scale from: 0 to 4.	28 (1 study) 2 years	⊕⊕⊖⊖ LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean steatosis (0-4, final value) >12 months in the control groups was 2.6	The mean steatosis (0-4, final value) >12 months in the intervention groups was 1.2 lower (2.17 lower to 0.23 lower)
Please see Table 99 for additional data that could not be meta-analysed or graded.					
<b>Critical mortality outcomes</b>					
No evidence identified					
<b>Critical severe adverse event outcomes</b>					
No evidence identified					
<b>Critical quality of life outcomes</b>					
No evidence identified					
<b>Important liver function test outcomes</b>					

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with UDCA plus vitamin E versus UDCA (95% CI)
No evidence identified					
<b>Important adverse event outcomes</b>					
No evidence identified					

(a) Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias.

(b) Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

**Table 95: Clinical evidence summary: UDCA plus vitamin E versus placebo for adults with NAFLD**

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with UDCA plus vitamin E versus placebo (95% CI)
<b>Critical progression of NAFLD outcomes</b>					
Steatosis (0-4, final value) >12 months Scale from: 0 to 4.	27 (1 study) 2 years	⊕⊕⊖⊖ LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean steatosis (0-4, final value) >12 months in the control groups was 2.5	The mean steatosis (0-4, final value) >12 months in the intervention groups was 1.1 lower (2.16 lower to 0.04 lower)
Please see Table 27 for additional data that could not be meta-analysed or graded.					
<b>Critical mortality outcomes</b>					
No evidence identified					
<b>Critical severe adverse event outcomes</b>					
No evidence identified					
<b>Critical quality of life outcomes</b>					
No evidence identified					
<b>Important liver function test outcomes</b>					
No evidence identified					
<b>Important adverse event outcomes</b>					

Outcomes	No of Participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with Control	Risk difference with UDCA plus vitamin E versus placebo (95% CI)
No evidence identified					

(a) Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias.

(b) Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

**Table 96: Clinical evidence summary: Orlistat plus vitamin E versus vitamin E for adults with NAFLD**

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with orlistat plus vitamin E versus vitamin E (95% CI)
<b>Critical progression of NAFLD outcomes</b>					
Please see Table 28 for additional data that could not be meta-analysed or graded.					
<b>Critical mortality outcomes</b>					
No evidence identified					
<b>Critical severe adverse event outcomes</b>					
No evidence identified					
<b>Critical quality of life outcomes</b>					
No evidence identified					
<b>Important liver function test outcomes</b>					
ALT levels (final values) $\geq 3$ to <12 months	41 (1 study) 36 weeks	⊕⊖⊖⊖ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean ALT levels (final values) $\geq 3$ to <12 months in the control groups was 38 U/L	The mean ALT levels (final values) $\geq 3$ to <12 months in the intervention groups was 15 higher (5.62 lower to 35.62 higher)
AST levels (final values) $\geq 3$ to <12 months	41 (1 study) 36 weeks	⊕⊖⊖⊖ VERY LOW <sup>a,b</sup> due to risk of bias, imprecision		The mean AST levels (final values) $\geq 3$ to <12 months in the control groups was 32 U/L	The mean AST levels (final values) $\geq 3$ to <12 months in the intervention groups was 4 higher (7.93 lower to 15.93 higher)
<b>Important adverse event outcomes</b>					

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with orlistat plus vitamin E versus vitamin E (95% CI)
No evidence identified					

(a) Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias.

(b) Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

**Table 97: Clinical evidence summary: pioglitazone plus vitamin E versus vitamin E for adults with NAFLD**

Outcomes	No of participants (studies) Follow up	Quality of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects	
				Risk with control	Risk difference with pioglitazone plus vitamin E versus vitamin E (95% CI)
<b>Critical progression of NAFLD outcomes</b>					
Please see Table 103 for additional data that could not be meta-analysed or graded.					
<b>Critical mortality outcomes</b>					
No evidence identified					
<b>Critical severe adverse event outcomes</b>					
No evidence identified					
<b>Critical quality of life outcomes</b>					
No evidence identified					
<b>Important liver function test outcomes</b>					
Normalisation of ALT levels $\geq 3$ to $< 12$ months	20 (1 study) 6 months	⊕⊕⊖⊖ LOW <sup>a,b</sup> due to risk of bias, imprecision	RR 0.9 (0.69 to 1.18)	Moderate	
				1000 per 1000	100 fewer per 1000 (from 310 fewer to 180 more)
<b>Important adverse event outcomes</b>					
No evidence identified					

(a) Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias.

(b) Downgraded by 1 increment if the confidence interval crossed 1 MID or by 2 increments if the confidence interval crossed both MIDs.

**Table 98: Additional data that could not be meta-analysed: pioglitazone versus placebo for adults with NAFLD**

Study	Outcome	Pioglitazone		Placebo		Risk of bias
		Results	No. analysed	Results	No. analysed	
PIVENS trial: Sanyal 2010 <sup>163</sup>	<b>Progression of NAFLD @ ≥12 months (CRITICAL)</b>					
	Total NAS @ 96 weeks	-1.9	70	-0.5	72	High
	<b>Quality of Life @ ≥12 months (CRITICAL)</b>					
	SF-36 (physical component) @ 96 weeks	-0.9	70	-0.3	74	High
	SF-36 (mental component) @ 96 weeks	-1.9	70	0.4	74	High
	<b>Liver function tests @ ≥12 months (IMPORTANT)</b>					
	ALT levels @ 96 weeks	-40.8 U/L	70	-20.1 U/L	74	High
	AST levels @ 96 weeks	-20.4 U/L	70	-3.8 U/L	74	High

**Table 99: Additional data that could not be meta-analysed: pioglitazone versus vitamin E for adults with NAFLD**

Study	Outcome	Pioglitazone		Vitamin E		Risk of bias
		Results	No. analysed	Results	No. analysed	
PIVENS trial: Sanyal 2010 <sup>163</sup>	<b>Progression of NAFLD @ ≥12 months (CRITICAL)</b>					
	Total NAS @ 96 weeks	-1.9	70	-1.9	80	Very high
	<b>Quality of Life @ ≥12 months (CRITICAL)</b>					
	SF-36 (physical component) @ 96 weeks	-0.9	70	0.4	78	High
	SF-36 (mental component) @ 96 weeks	-1.9	70	-0.5	78	High
	<b>Liver function tests @ ≥12 months (IMPORTANT)</b>					
	ALT levels @ 96 weeks	-40.8 U/L	70	-37.0 U/L	78	High
	AST levels @ 96 weeks	-20.4 U/L	70	-21.3 U/L	78	High

**Table 100: Additional data that could not be meta-analysed: metformin versus placebo for adults with NAFLD**

Study	Outcome	Metformin		Placebo		Risk of bias
		Results	No. analysed	Results	No. analysed	
Shields 2009 <sup>177</sup>	<b>Progression of NAFLD @ ≥12 months (CRITICAL)</b>					
	Mean NAFLD activity score @ 12 months	3.8	9	3.4	7	Very high
	Mean fibrosis (final value) @ 12 months	1.56	9	1.9	7	Very high
	Mean steatosis (final value) @ 12 months	1.91	9	1.58	7	Very high
	Mean ballooning (final value) @ 12 months	1.74	9	1.5	7	Very high
	Mean intra-acinar (lobular) inflammation (final value) @ 12 months	1.36	9	1.28	7	Very high
Shields 2009 <sup>177</sup>	<b>Liver function tests @ ≥12 months (CRITICAL)</b>					
	Mean change in ALT levels @ 12 months	-21.5 U/L	9	-40.7 U/L	7	Very high
	Mean change in AST levels @ 12 months	-5.7 U/L	9	-20.1 U/L	7	Very high
Haukeland 2009 <sup>68</sup>	<b>Liver function tests @ ≥3 to &lt;12 months (IMPORTANT)</b>					
	Median reduction of serum ALT @ 6 months	22 U/L	16	15 U/L	24	Very high
	Median reduction of serum AST @ 6 months	8 U/L	16	No median reduction	24	Very high

2

**Table 101: Additional data that could not be meta-analysed: vitamin E versus placebo for adults with NAFLD**

Study	Outcome	Vitamin E		Placebo		Risk of bias
		Results	No. analysed	Results	No. analysed	
PIVENS trial: Sanyal 2010 <sup>163</sup>	<b>Progression of NAFLD @ ≥12 months (CRITICAL)</b>					

Study	Outcome	Vitamin E		Placebo		Risk of bias
		Results	No. analysed	Results	No. analysed	
	Total NAFLD activity score @ 96 weeks	-1.9	80	-0.5	72	Very high
	<b>Quality of life @ ≥12 months (CRITICAL)</b>					
	SF-36 score (physical component) @ 96 weeks	0.4	78	0.3	74	High
	SF-36 score (mental component) @ 96 weeks	-0.5	78	0.4	74	High
	<b>Liver function tests @ ≥12 months (IMPORTANT)</b>					
	ALT levels @ 96 weeks	-37 U/L	78	-20.1 U/L	74	High
	AST levels @ 96 weeks	-21.7 U/L	78	-3.8 U/L	74	High

1

**Table 102: Additional data that could not be meta-analysed: pentoxifylline versus placebo for adults with NAFLD**

Study	Outcome	Pentoxifylline		Placebo		Risk of bias
		Results	No. analysed	Results	No. analysed	
Zein 2011 <sup>233</sup>	<b>Liver function tests @ ≥12 months (IMPORTANT)</b>					
	Normalisation or improvement of ≥30% in AST levels from baseline @ 12 months	The difference between treatment groups regarding normalisation or improvement of 30% or more from baseline did not reach statistical significance.				High

2

**Table 103: Additional data that could not be meta-analysed: pioglitazone plus vitamin E versus vitamin E for adults with NAFLD**

Study	Outcome	Vitamin E + pioglitazone		Vitamin E		Risk of bias
		Results	No. analysed	Results	No. analysed	
Sanyal 2004 <sup>164</sup>	<b>Progression of NAFLD @ ≥3 to &lt;12 months (CRITICAL)</b>					
	Percent change from baseline for histological outcomes @ 6 months	Combination therapy was superior to vitamin E alone in terms of change in degree of steatosis. There was no significant difference in the two arms when comparing cytologic ballooning, Mallory's hyaline, pericellular fibrosis, or portal fibrosis.				Very high

**Table 104: Additional data that could not be meta-analysed: UDCA plus vitamin E for adults with NAFLD**

Study	Comparators	Outcome	UDCA + vitamin E		Comparator		Risk of bias
			Results	No. analysed	Results	No. analysed	
Dufour 2006 <sup>40</sup>	UDCA, placebo	<b>Progression of NAFLD @ &gt;12 months (CRITICAL)</b>					
		Change in activity index (steatosis, hepatocellular injury and parenchymal inflammation) @ 2 years	There was a significant decrease in the activity index (steatosis, hepatocellular injury and parenchymal inflammation) after 2 years in the group receiving a combination of UDCA and vitamin E from the baseline value, however there was no significant change in either the UDCA or placebo group.				High

**Table 105: Additional data that could not be meta-analysed: Orlistat plus vitamin E versus vitamin E for adults with NAFLD**

Study	Outcome	Orlistat + vitamin E		Vitamin E		Risk of bias
		Results	No. analysed	Results	No. analysed	
Harrison 2009 <sup>65</sup>	<b>Progression of NAFLD @ &gt;12 months (CRITICAL)</b>					
	Change in hepatic steatosis, ballooning, inflammation, NAS and fibrosis assessed by liver biopsy @ 36 weeks	There were no significant differences between the two groups in biopsy findings for hepatic steatosis, ballooning, inflammation, NAS, or fibrosis at the end of therapy.				Very high



## 17.4 Economic evidence

### 17.4.1 Published literature

3 One economic evaluation was identified that compared lifestyle modification, vitamin E and  
4 pioglitazone in a cohort of people with NASH.<sup>109</sup> This is summarised in the economic evidence profile  
5 below (Table 106) and the economic evidence table in Appendix I.

6 No relevant economic evaluations were identified for any of the other pharmacological interventions  
7 considered in this chapter.

8 See also the economic article selection flow chart in Appendix F.

9

**Table 106: Economic evidence profile: lifestyle modification versus vitamin E and versus pioglitazone**

Study	Applicability	Limitations	Other comments	Incremental cost	Incremental effects	Cost-effectiveness	Uncertainty
Mahady 2012 <sup>109</sup> (Australia)	Partially applicable <sup>(a)</sup>	Potentially serious limitations <sup>(b)</sup>	<ul style="list-style-type: none"> <li>• Cost-utility analysis</li> <li>• Markov decision model, annual cycle length</li> <li>• Comparing lifestyle modification, vitamin E, and pioglitazone in people with NASH and stage F3–F4 fibrosis</li> <li>• Health states: NASH, compensated cirrhosis, decompensated cirrhosis, HCC, liver transplantation</li> </ul>	<p><u>Vitamin E versus lifestyle modification:</u> £2,295 (lifestyle modification cheaper)</p> <p><u>Pioglitazone versus lifestyle modification:</u> £5,966 (lifestyle modification cheaper)</p> <p><u>Pioglitazone versus vitamin E:</u> £3,671 (vitamin E cheaper)</p>	<p><u>Vitamin E versus lifestyle modification:</u> 0.59 QALYs (favouring vitamin E)</p> <p><u>Pioglitazone versus lifestyle modification:</u> 4.73 QALYs (favouring pioglitazone)</p> <p><u>Pioglitazone versus vitamin E:</u> 4.14 QALYs (favouring pioglitazone)</p>	<p>Vitamin E is extendedly dominated (that is, a combination of the other 2 Interventions is both cheaper and more effective)</p> <p><u>Pioglitazone versus lifestyle modification:</u> £1261.31 per QALY gained (95% CI: NR; p=NR)</p>	<p>In the 2-way sensitivity analysis and across a range of probabilities of 2–6% per year for the development of cirrhosis, pioglitazone remained cost-effective compared with lifestyle modification until its annual cost was greater than £7,342 (base case £778).</p> <p>Vitamin E remained cost-effective compared with lifestyle modification irrespective of cohort starting age and until extreme cost limits.</p> <p>When the likelihood for people with advanced fibrosis to develop cirrhosis was decreased to below 2% per year, then neither vitamin E nor pioglitazone were cost-effective compared to lifestyle modification.</p>

Note: Abbreviations: HCC: hepatocellular carcinoma

(a) Differences in healthcare system may make results less applicable to UK; some utility values based on authors' assumptions; utility values were obtained from other causes of chronic liver disease.

(b) Resource use based on authors' assumptions, no probabilistic analysis conducted.

## 117.4.2 Unit costs

2 See Table 91 in Appendix O.

## 317.5 Evidence statements

### 417.5.1 Clinical

#### 17.5.1.1 Pioglitazone versus placebo for NAFLD

##### 6 Adult population

- 7 • Clinical benefit of pioglitazone on the progression of NAFLD when compared to placebo was  
8 observed in 3 RCTs, with sample sizes ranging from 47 to 142. Benefit was seen on the  
9 improvement of fibrosis at greater than 12 months (high quality), improvement in steatosis at  
10 greater than or equal to 3 to less than 12 months (very low quality) and greater than 12 months  
11 (low quality), decrease in hepatocellular injury at greater than 12 months (moderate quality),  
12 improvement of hepatic ballooning at greater than 12 months (low quality), improvement of  
13 lobular inflammation at equal to or greater than 3 to less than 12 months (very low quality) and  
14 greater than 12 months (low quality), decrease in Mallory-Denk bodies at greater than 12 months  
15 (moderate quality) improvement of histologic features of the liver at greater than 12 months (low  
16 quality) and the resolution of NASH at greater than 12 months (moderate quality). Outcomes  
17 reporting no clinically important benefit were also observed (very low to high quality), although  
18 the direction of effect favoured pioglitazone for all the outcomes, with the exception of increase  
19 in lobular inflammation which favoured placebo (moderate quality).
- 20 • Evidence from a single RCT (n=163) demonstrated clinical benefit of pioglitazone when compared  
21 to placebo for severe adverse events at greater than 12 months (low quality), but no clinically  
22 important benefit on adverse cardiovascular events at greater than 12 months (very low quality),  
23 although the direction of effect favoured pioglitazone
- 24 • Evidence from 2 RCTS demonstrated clinical benefit of pioglitazone on ALT levels at equal to or  
25 greater than 3 to less than 12 months (n=74, very low quality) and greater than 12 months (n=47,  
26 low quality) when compared to placebo. A reduction in the levels of AST was also observed from a  
27 single RCT (n=74, very low quality) at greater than 12 months.

##### 28 Children and young people

- 29 • No clinical evidence

#### 317.5.1.2 Metformin versus placebo for NAFLD

##### 31 Adults population

- 32 • A single RCT (n=44) demonstrated clinical harm of metformin when compared to placebo for the  
33 progression of NAFLD at greater than 12 months (very low to low quality), with the direction of  
34 effect favouring placebo.
- 35 • Evidence from a single RCT showed metformin to have no clinically important benefit on liver  
36 enzymes ALT and AST when compared to placebo at equal to or greater than 3 to less than 12  
37 months (n=52) and greater than 12 months (n=41), very low to low quality).

**1 Children and young people**

- 2 • Evidence from a single RCT (n=97) demonstrated no clinically important benefit of metformin on  
3 the progression of NAFLD when compared to placebo at greater than 12 months (low to  
4 moderate quality), although the direction of effect favoured metformin.
- 5 • Evidence from a single RCT (n=100) demonstrated no clinically important benefit of metformin on  
6 quality of life when compared to placebo at greater than 12 months (moderate to high quality),  
7 with the direction of effect favouring placebo.
- 8 • Evidence from 2 RCTs, with sample sizes of 29 and 115) demonstrated no clinically important  
9 benefit of metformin on the reduction liver enzymes ALT and AST when compared to placebo at  
10 equal to or greater than 3 to less than 12 months and greater than 12 months (low to moderate  
11 quality), although the direction of effect for most the outcomes favoured metformin.

**117.5.1.3 Vitamin E versus placebo for NAFLD****13 Adults population**

- 14 • Clinical benefit of vitamin E on the progression of NAFLD when compared to placebo was  
15 observed in a single RCT (n=152). Benefit was seen on the improvement of histologic features of  
16 liver disease at greater than 12 months (moderate quality) and improvement in steatosis at  
17 greater than 12 months (low quality). Outcomes demonstrating no clinically important benefit  
18 were also reported (low quality), although the direction of effect favoured vitamin E for all the  
19 outcomes.
- 20 • Evidence from the RCT demonstrated no clinically important benefit of vitamin E on the  
21 occurrence of serious adverse events, adverse events or mortality when compared to placebo at  
22 greater than 12 months (very low quality).

**23 Children and young people**

- 24 • A single RCT (n=97) demonstrated clinical benefit of vitamin E on the progression of NAFLD when  
25 compared to placebo from the resolution of NASH at greater than 12 months (moderate quality).  
26 Outcomes demonstrating no clinically important benefit were also reported (low quality),  
27 although the direction of effect favoured vitamin E.
- 28 • There was no clinically important benefit of vitamin E when compared to placebo on quality of life  
29 outcomes from a single study (n=99) at greater than 12 months (moderate to high quality).
- 30 • Evidence from a single RCT demonstrated no clinically important benefit of vitamin E on the  
31 reduction of liver enzymes ALT (n=116) and AST (n=96) when compared to placebo at equal to or  
32 greater than 3 to less than 12 months and greater than 12 months (moderate to high quality),  
33 although the direction of effect favoured vitamin E.

**317.5.1.4 Ursodeoxycholic acid versus placebo for NAFLD****35 Adults population**

- 36 • Evidence from 3 RCTs (n=27, 137 and 242) showed no clinical benefit of UDCA on the progression  
37 of NAFLD when compared to placebo at greater than 12 months (very low to moderate quality).
- 38 • A single RCT demonstrated clinical benefit of UDCA on normalised ALT levels when compared to  
39 placebo from at greater than 12 months (moderate quality). However outcomes from 3 RCTs  
40 (n=30, 115 and 118) demonstrated no clinically important benefit on either ALT levels or AST  
41 levels at equal to or greater than 3 to less than 12 months and greater than 12 months (very low  
42 to low quality) although the direction of effect favoured UDCA.

**1 Children and young people**

- 2 • No clinical evidence

**17.5.1.5 Pentoxifylline versus placebo for NAFLD****4 Adults population**

- 5 • Evidence from a single RCT (n=46) demonstrated clinical benefit of pentoxifylline on the  
6 progression of NAFLD through a decrease in NAFLD activity score by greater than or equal to 2  
7 points when compared to placebo at greater than 12 months (low quality). However outcomes  
8 reported from 2 RCTs (n=72) demonstrated no clinically important benefit at greater than 12  
9 months (low to high quality).
- 10 • Clinical benefit of pentoxifylline on the ALT and AST levels was demonstrated by 2 RCTs (sample  
11 size for outcomes ranging from 20 to 75 people) when compared to placebo at equal to or greater  
12 than 3 to less than 12 months and greater than 12 months (very low to moderate quality).  
13 Outcomes reporting no clinically important benefit were also observed (low quality), although the  
14 direction of effect favoured pentoxifylline for all the outcomes.
- 15 • A single RCT (53) demonstrated no clinically important benefit of pentoxifylline on adverse events  
16 when compared to placebo at greater than 12 months (low quality), although the direction of  
17 effect favoured pentoxifylline.

**18 Children and young people**

- 19 • No clinical evidence

**20.5.1.6 Statins versus placebo for NAFLD****21 Adults population**

- 22 • A single RCT (n=16) demonstrated no clinically important benefit of statins on the progression of  
23 NAFLD when compared to placebo at greater than 12 months (very low quality), with the  
24 direction of effect favouring placebo. However, clinical benefit of statins on ALT and AST levels  
25 when compared to placebo at greater than 12 months (very low quality) was seen.

**26 Children and young people**

- 27 • No clinical evidence

**28.5.1.7 Orlistat versus placebo for NAFLD****29 Adults population**

- 30 • Clinical evidence from a single RCT demonstrated no clinically important benefit of orlistat on the  
31 progression of NAFLD when compared to placebo at equal to or greater than 3 to less than 12  
32 months (very low quality), with the direction of effect favouring orlistat for the improvement of  
33 fibrosis (n=22) and reversal of fatty liver (44), however favouring placebo for improvement of  
34 steatosis (n=22).
- 35 • The RCT also demonstrated no clinically important benefit of orlistat on ALT or AST levels when  
36 compared to placebo at greater than 12 months (moderate quality), although the direction of  
37 effect favoured orlistat (n=44).

**38 Children and young people**

- 39 • No clinical evidence

**17.5.1.8 Pioglitazone versus metformin for NAFLD****2 Adults population**

- 3 • A single RCT (n=80) demonstrated no clinically important benefit of pioglitazone when compared  
4 to metformin on ALT and AST levels at greater than 12 months (moderate quality), with the  
5 direction of effect favouring pioglitazone.

**6 Children and young people**

- 7 • No clinical evidence

**17.5.1.9 Pioglitazone versus vitamin E for NAFLD****9 Adults population**

- 10 • A single study (sample sizes for outcomes varying from 142 to 150 people) demonstrated clinical  
11 benefit of pioglitazone on the progression of NAFLD when compared to vitamin E at greater than  
12 12 months (low quality). Outcomes reporting no clinically important benefit were also observed at  
13 greater than 12 months (low quality).
- 14 • A single RCT (n=64) demonstrated no clinically important benefit of pioglitazone on mortality  
15 when compared to vitamin E at greater than 12 months (very low quality), although the direction  
16 of effect favoured pioglitazone. This study also showed no clinically important benefit of  
17 pioglitazone on severe adverse events or adverse events when compared to vitamin E at greater  
18 than 12 months (very low quality), although the direction of effect favoured pioglitazone.

**19 Children and young people**

- 20 • No clinical evidence

**17.5.1.10 Metformin versus vitamin E for NAFLD****22 Adults population**

- 23 • A single RCT (n=57) demonstrated clinical benefit of metformin on normalised ALT levels when  
24 compared to vitamin E at greater than 12 months (moderate quality).

**25 Children and young people**

- 26 • A single RCT (sample size for outcomes varying from 100 to 101) demonstrated no clinically  
27 important benefit of metformin on quality of life when compared to vitamin E at greater than 12  
28 months (moderate), although the direction of effect favoured vitamin E for the majority of  
29 outcomes.
- 30 • One RCTs demonstrated clinical benefit of vitamin E on the progression of NAFLD when compared  
31 to metformin from the remission of NAFLD at <12 months (n=127, very low quality). Outcomes  
32 demonstrating no clinically important benefit were also reported (moderate quality) at greater  
33 than 12 months.
- 34 • A single RCT demonstrated no clinically important benefit of metformin on liver function tests  
35 when compared to vitamin E at equal to or greater than 3 to less than 12 months (n=45 and  
36 greater than 12 months (n=101, low to high quality), although the direction of effect favoured  
37 vitamin E.
- 38 • A single RCT demonstrated no clinically important benefit of metformin on adverse events when  
39 compared to vitamin E at equal to or greater than 3 to less than 12 months (n=101, moderate),  
40 although the direction of effect favoured vitamin E.

**17.5.1.11 Pentoxifylline versus pioglitazone for NAFLD****2 Adult population**

- 3 • Clinical evidence from a single RCT (n=46) demonstrated no clinically important benefit of  
4 pentoxifylline compared to pioglitazone on the progression of NAFLD at equal to or greater than 3  
5 to less than 12 months (very low to low quality).
- 6 • Clinical evidence from a single RCT (n=59) demonstrated no clinically important benefit of  
7 pentoxifylline compared to pioglitazone on ALT or AST levels at equal to or greater than 3 to less  
8 than 12 months (low quality).

**9 Children and young people**

- 10 • No clinical evidence

**17.5.1.12 Ursodeoxycholic acid plus vitamin E versus ursodeoxycholic acid for NAFLD****12 Adult population**

- 13 • Clinical evidence from a single RCT (n=28) demonstrated no clinically important benefit of UDCA  
14 plus vitamin E compared to UDCA alone on the progression of NAFLD at greater than 12 months  
15 (low quality).

**16 Children and young people**

- 17 • No clinical evidence

**17.5.1.13 Ursodeoxycholic acid plus vitamin E versus placebo for NAFLD****19 Adult population**

- 20 • Clinical evidence from a single RCT (n=27) demonstrated no clinically important benefit of UDCA  
21 plus vitamin E compared to UDCA alone on the progression of NAFLD at greater than 12 months  
22 (low quality).

**23 Children and young people**

- 24 • No clinical evidence

**17.5.1.14 Orlistat plus vitamin E versus vitamin E for NAFLD****26 Adult population**

- 27 • A single RCT (n=41) demonstrated no clinically important benefit of orlistat plus vitamin E on ALT  
28 and AST levels when compared to vitamin E alone at equal to or greater than 3 to less than 12  
29 months and greater than 12 months (very low quality), although the direction of effect favoured  
30 vitamin E.

**31 Children and young people**

- 32 • No clinical evidence

**17.5.1.15 Pioglitazone plus vitamin E versus vitamin E for NAFLD****2 Adult population**

- 3 • A single RCT (n=41) demonstrated no clinically important benefit of pioglitazone plus vitamin E on
- 4 normalised ALT levels when compared to vitamin E alone at equal to or greater than 3 to less than
- 5 12 months and greater than 12 months (very low quality), although the direction of effect
- 6 favoured vitamin E.

**7 Children and young people**

- 8 • No clinical evidence

**17.5.2 Economic**

- 10 • One cost-utility analysis that compared lifestyle modification, vitamin E and pioglitazone in adults
- 11 with NASH and advanced fibrosis found that:
  - 12 o pioglitazone was cost-effective compared to lifestyle modification (ICER: £1,261 per QALY
  - 13 gained)
  - 14 o vitamin E was extendedly dominated (that is, a combination of the other 2 interventions was
  - 15 less costly and more effective).
  - 16 This analysis was assessed as partially applicable with potentially serious limitations.

**17.6 Recommendations and link to evidence**

<b>Recommendations</b>	<p><b>26. In secondary care settings only, consider pioglitazone<sup>c</sup> or vitamin E<sup>d</sup> for adults with advanced liver fibrosis, whether they have diabetes or not.</b></p> <p><b>27. Before prescribing pioglitazone<sup>c</sup> or vitamin E<sup>d</sup>, take into account any comorbidities that the person has and the risk of adverse events associated with these conditions.</b></p> <p><b>28. In secondary or tertiary care settings only, consider vitamin E<sup>d</sup> for children and young people with advanced liver fibrosis, whether they have diabetes or not.</b></p> <p><b>29. Offer the ELF test to people with advanced liver fibrosis 2 years after they start new pharmacological therapy to assess if treatment is effective.</b></p>
------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

<sup>c</sup> When prescribing pioglitazone, exercise particular caution if the person is at high risk of the adverse effects of the drug. Pioglitazone is contraindicated in people with a history of heart failure, previous or active bladder cancer and uninvestigated macroscopic haematuria (visible red blood cells in urine). Known risk factors for these conditions, including increased age, should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details.

<sup>d</sup> At the time of consultation (December 2015), neither pioglitazone nor vitamin E had UK marketing authorisation for this indication. The healthcare professional should follow relevant professional guidance, taking full responsibility for the decision to use this test. Informed consent should be obtained and documented. See the General Medical Council's prescribing guidance: prescribing unlicensed medicines for further information.



	<p><b>30.If an adult’s ELF test score has risen, stop either vitamin E or pioglitazone and consider switching to the other pharmacological therapy.</b></p> <p><b>31.If a child or young person’s ELF test score has risen, stop vitamin E.</b></p> <p><b>32.Be aware that people with NAFLD who are taking statins should keep taking statins.</b></p> <p><b>33.Only consider stopping statins if liver blood tests double within 3 months of starting statins, including in people with abnormal baseline liver blood tests.</b></p>
<p><b>Research recommendations</b></p>	<p><b>10.What is the clinical and cost-effectiveness of pentoxifylline in the management of people with NAFLD?</b></p> <p><b>11.What is the clinical and cost-effectiveness of pharmacological therapy in children and young people with advanced liver fibrosis?</b></p>
<p>Relative values of different outcomes</p>	<p>The GDG agreed that the outcomes that were critical to decision-making were progression of NAFLD, quality of life, mortality and serious adverse events. Progression of NAFLD as measured by liver biopsy was considered to be of greatest value for decision-making. The GDG noted that reduction in NASH activity score (NAS) by at least 2 points and no worsening of fibrosis was now widely accepted as the major successful end point in trials of pharmacological agents in people with NAFLD, but that other histological end points (for example, disappearance of NASH) were also reported and were clinically relevant, and merited inclusion. The GDG also agreed that pharmacological studies using other proxy measures to assess progression of NAFLD (that is, MRI, MRS or transient elastography) should also be included. Improvement in liver enzymes and adverse events were agreed by the GDG to be important (but not critical) outcomes.</p>
<p>Trade-off between clinical benefits and harms</p>	<p><b>Pioglitazone:</b></p> <p>All of the identified evidence was from adults with NAFLD. The GDG noted that in the largest double-blind RCT identified (comparing pioglitazone (30 mg/day) to placebo as treatment to slow the histological progression of NASH in adults when used over 96 weeks), participants randomised to taking pioglitazone achieved greater reduction in hepatocellular ballooning, steatosis, lobular inflammation, and total NAS score (as well as significantly higher rates of resolution of NASH) compared to participants taking placebo. All of which the GDG considered to be of relevant clinical benefit. The GDG also noted that no participants within this study had diabetes, but felt that there was no strong reason for suspecting that these results should be any different for adults with NASH and diabetes.</p> <p>The other evidence for pioglitazone in adults with NASH that were considered by the GDG also demonstrated histological improvement in many clinically relevant domains; however, the evidence was more consistent for pioglitazone causing a reduction in steatosis and inflammation, and stabilisation of fibrosis rather than any definite improvement in fibrosis. There was also evidence of an improvement in liver enzymes related to the use of pioglitazone. The GDG noted that participants in 1 study all had impaired glucose tolerance or type 2 diabetes mellitus.</p> <p>Collectively, the GDG felt that there was sufficient evidence to conclude that pioglitazone does have evidence for clinical effectiveness in slowing or reversing progression in adults with NASH, regardless of whether they are diabetic or not. However, the GDG also noted the recent concerns that had arisen about the safety</p>

of pioglitazone, along with other members of the glitazone family. It noted that rosiglitazone had its UK license revoked in 2010 because of evidence suggesting an increased number of myocardial ischaemic events in association with its use. Rosiglitazone has also been associated with weight gain that is not always fully reversible upon stopping the medication; this could potentially worsen other metabolic parameters in people with NAFLD. The GDG also discussed the evidence for glitazones causing fluid retention and therefore potentially precipitating cardiac failure; this is clearly particularly a limitation for a condition such as NAFLD, where cardiovascular events are the major cause of morbidity and mortality. Concerns have also been raised about an elevated fracture risk in women and a possible increased rate of bladder cancer in relation to the use of the medication.

The GDG concluded that there is a potential role for pioglitazone in treating adults with NASH, but that it should only be prescribed by an expert within secondary care, and only after a balanced evaluation of potential risks and benefits of its use by the prescribing clinician and careful counselling of the recipient of potential side effects.

As there was no evidence for the use of pioglitazone in children, and pioglitazone did not have a UK marketing authorisation for use in children at the time of writing, as well as the glitazone safety concerns discussed earlier, the GDG felt they could not extrapolate from the adult evidence to inform a recommendation for children.

#### **Metformin:**

Evidence was identified that included children, young people and adults with NAFLD. The GDG noted that no evidence of improvement in any histological domain was found with the use of metformin compared to placebo in adults with NASH. In fact, the GDG noted that participants within the treatment arm tended to have more marked histological progression of NASH than those in the placebo arm. Further data reviewed by the GDG demonstrated that adults with NAFLD treated with metformin had no better liver enzyme values than those treated with placebo.

Evidence for metformin in children and young people with NAFLD was agreed as showing no consistent, clinically significant improvement in histological parameters, liver enzymes or quality of life in those treated with metformin compared to placebo.

The GDG concluded that metformin is not an effective treatment for NAFLD in children, young people or adults, and should not be recommended for this indication.

#### **Vitamin E:**

Evidence was identified that included children, young people and adults with NAFLD. The GDG noted that evidence comparing the use of vitamin E to placebo as treatment to slow the histological progression of NASH in adults over 96 weeks, demonstrated clinical benefit of vitamin E on the improvement of hepatocellular ballooning, fibrosis score, and NAS score. No increase in serious adverse events or adverse events was found in the group using vitamin E compared to those treated with placebo. The GDG also noted that all participants within this study were non-diabetic, but felt that there was no strong reason for suspecting that these results should be any different for adults with NASH and diabetes.

The GDG also discussed evidence for progression of NAFLD over 96 weeks in children being treated with either placebo or vitamin E (at 800 IU per day).<sup>94</sup> Approximately 40% of the participants in each arm of the study had NASH on initial liver biopsy. Evidence indicated a reduction in NAS score and ballooning in those treated with vitamin E, as well as a trend towards a reduction in fibrosis, steatosis and lobular inflammation. A trend towards improvement in liver enzymes was also noted, although no change in quality of life measures was observed.

As such, the GDG concluded that the evidence demonstrated that vitamin E does

have clinical effectiveness at slowing or reversing progression in adults, children or young people with NASH, regardless of whether they are diabetic or not.

Furthermore, the GDG noted that recommending vitamin E for adults with NASH would provide an alternative treatment option to pioglitazone for those people with cardiovascular complications.

However, the GDG also discussed significant concerns that have been raised amongst clinicians regarding the safety of long-term use of vitamin E; specifically, vitamin E use may be associated with an increased risk of haemorrhagic stroke, and elevated rates of prostate cancer in men older than 50 years. The increased rates of prostate cancer appear to become significant when vitamin E is administered for more than 3 years. The GDG also discussed data suggesting that long-term vitamin E supplementation is associated with an increase in overall mortality.

The GDG concluded that there is a potential role for vitamin E in treating children, young people and adults with NASH, but that it should only be prescribed by an expert within secondary or tertiary care, and only after a balanced evaluation of potential risks and benefits of its use by the prescribing clinician, and careful counselling of the recipient and their parents or carers of the potential side effects. A decision to prescribe vitamin E should also only be made after taking into account economic considerations of pharmacological management of NAFLD (see below).

#### **Ursodeoxycholic acid (UDCA):**

All of the identified evidence was from studies involving adults only. The GDG agreed that overall, the identified evidence demonstrated treatment with UDCA resulted in no improvements in liver histology and liver enzymes better than placebo. As such, the GDG agreed that UDCA should not be recommended as a treatment for NAFLD.

#### **Pentoxifylline:**

The GDG reviewed the evidence for pentoxifylline compared to placebo as treatments to slow or reverse progression of NASH in adults; no evidence involving children or young people was identified. Evidence was from 2 RCTs of relatively small populations (55 and 30 participants). The GDG noted that people given 12 months of pentoxifylline had a higher rate of improvement in NAS score (of at least 2 points) compared to those given placebo; however, there was no evidence of a clinically relevant improvement in any other histological parameter that is, fibrosis, stasis, ballooning or lobular inflammation. Histological changes were similar in adults with NASH treated with pentoxifylline compared to those treated with pioglitazone<sup>172</sup>. Identified studies demonstrated a pattern towards a greater improvement in liver enzymes in those treated with pentoxifylline compared to participants receiving placebo.

The GDG concluded that, although the reviewed data were suggestive of a possible clinical benefit in adults with NAFLD, the small size of the studies and modest evidence supporting improvements in critical outcomes meant that the GDG could not currently recommend pentoxifylline as a treatment for adults with NAFLD. However, the GDG felt that the data reviewed were compelling enough to make a research recommendation for further studies to be undertaken to assess the clinical and cost-effectiveness of pentoxifylline as a treatment for NAFLD.

#### **Statins:**

The GDG reviewed evidence from 1 RCT demonstrating an improvement in liver enzymes in those treated with statins, but no improvement of steatosis or fibrosis. The GDG concluded that statins should not be recommended as a treatment for NAFLD.

## Pharmacological interventions

	<p><b>Orlistat:</b></p> <p>All evidence for orlistat was from a single small RCT of adults with NAFLD. The GDG noted that any improvements in liver histology that could be attributable to orlistat were, at most, small. Orlistat in combination with vitamin E did not result in any greater improvement in liver enzymes than treatment with vitamin E alone in adults with NAFLD. The GDG concluded that there was not enough evidence to recommend orlistat as treatment for adults with NAFLD.</p>
Trade-off between net clinical effects and costs	<p>One economic evaluation was identified, comparing lifestyle interventions, pioglitazone and vitamin E in adults with NASH and F3–F4 fibrosis (Mahady 2012). This evaluation used data from the same studies assessing clinical effectiveness of pioglitazone and vitamin E as those reviewed by the GDG. Analysis within this study identified pioglitazone in combination with lifestyle intervention to be cost-effective compared to lifestyle intervention alone (ICER: £1,261.31 per QALY gained), while vitamin E with lifestyle intervention was not cost-effective compared to the other 2 interventions. The GDG noted that the cost of pioglitazone quoted within this evaluation was greater than that currently paid by the NHS, suggesting that this study may in fact underestimate the current cost-effectiveness of pioglitazone with lifestyle intervention.</p> <p>In light of this economic evaluation, the GDG agreed that where clinicians felt that either pioglitazone or vitamin E were equally as appropriate treatment options for an adult with NASH on grounds of clinical effectiveness, then pioglitazone should be chosen because of its better cost-effectiveness.</p>
Quality of evidence	<p>For the majority of evidence in this review, the quality ranged from a GRADE rating of moderate to very low. This was due to the lack of blinding, presence of selection bias and incomplete outcome reporting due to the high number of drop outs in some of the included studies resulting in a high or very high risk of bias rating. Additionally, the imprecise nature of the results extracted and analysed in this review further downgraded the quality of the evidence. High quality GRADE ratings were seen for the critical outcome progression of NAFLD in adult studies when comparing pioglitazone to placebo and pentoxifylline to placebo. High quality GRADE rating was also seen in evidence for children and young people when comparing metformin to placebo for the outcomes quality of life and ALT and AST levels, vitamin E to placebo for the outcomes progression of NAFLD, quality of life and AST levels, and metformin to vitamin E for the outcomes progression of NAFLD, quality of life and ALT and AST levels.</p> <p>The impression of the GDG was that the randomised studies included tended to be well-designed, with many using strict criteria to diagnose NAFLD and appropriate histological re-evaluation after a reasonable duration of pharmacological treatment as the primary outcome. As already described, the GDG noted that the single largest RCT that had been included had excluded participants with confirmed diabetes mellitus. The GDG discussed that, although many people with NASH also have diabetes, the advantage of this study design was that it removed diabetes (and the pharmacological treatment of it) as a possible confounding factor.</p> <p>The economic study included in this review was assessed as partially applicable with potentially serious limitations.</p>
Other considerations	<p>The GDG discussed that although the ‘Severity’ review within this guideline had made a recommendation regarding a clinically and cost-effective non-invasive means of identifying advanced fibrosis (F3 and F4) (ELF score <math>\geq 10.51</math>), no comparable recommendation could be made for the non-invasive identification of NASH. The GDG discussed the implications of this regarding the interpretation of evidence within this review, since histologically confirmed NASH was a component of the entry criterion for many of the RCTs that had been included. The GDG then further discussed that natural history studies of NAFLD had consistently demonstrated that the vast majority of people with NAFLD who have histologically confirmed F3 or F4</p>

fibrosis also have NASH on biopsy (>90%) (although many people with NASH on biopsy do not also have advanced fibrosis). As such, the GDG concluded that, within the framework of these guidelines, the non-invasive identification of advanced fibrosis in people with NAFLD should be taken as a means of assuming that the person also has NASH.

The GDG recognised that this approach meant that the majority of people with NASH and advanced hepatic fibrosis would be identified by application of these guidelines, but that people with NASH and no or early fibrosis (F1 or F2) were likely to be missed. However, the GDG discussed further that since severe hepatic fibrosis (but not NASH) has consistently been shown to be of prognostic value in people with NAFLD – and therefore people with advanced fibrosis are the cohort requiring closest monitoring and who have the most to gain from pharmacotherapy to slow/reverse the condition – that the cohort of people with NASH and severe fibrosis were the most important to identify. The GDG concluded that it would be an acknowledged compromise within these guidelines that the majority of people with NASH and advanced fibrosis would be identified at the expense of missing some people with NASH and early fibrosis.

Given the potential side effect profile of pioglitazone and vitamin E – as well as the observation by the GDG from the reviewed evidence that not all adults with NASH gained clinical benefit from its use - the GDG concluded that assessment of treatment response was merited at some point after starting the medication, to allow re-evaluation about whether the benefits of continuing therapy still outweighed the potential risks. Since the largest RCT examining the role of pioglitazone or vitamin E in treating NASH had reported their histological endpoints after 96 weeks of treatment, the GDG agreed that the repeat ELF should be performed after people had been taking pioglitazone for 2 years. The GDG discussed that people failing to meet this end point of treatment response should either stop pharmacological treatment altogether, or be treated with an alternative pharmacological agent if appropriate.

The GDG discussed that although metformin and statins were not to be recommended as pharmacological treatments for NAFLD itself, the strong association between NAFLD and the metabolic syndrome means that many adults with NAFLD have clear indications for their use (that is, type 2 diabetes mellitus or dyslipidaemia). In this review, subgroup analysis was conducted if data were available for treatment effects with people with NAFLD and specific extra-hepatic conditions. The GDG emphasised that there was no suggestion from the reviewed evidence that people with NAFLD already taking these medications should stop them at all. The GDG particularly stressed that statin-related drug-induced liver injury is a much rarer condition than is believed by many clinicians, and that otherwise-unexplained minor abnormalities in liver enzymes in those taking statins were by no means a contraindication to continuing their use. Therefore based on their clinical experience, the GDG suggested doubling in liver blood test values within three months (a broadly accepted definition of drug-induced liver injury) as a threshold for considering when to consider stopping statins.

The GDG also discussed the recently published phase 2 multi-centre double-blind placebo-controlled trial of the use of obeticholic acid as treatment of non-cirrhotic adults with NASH.<sup>128</sup> A reduction in NAS by at least 2 points and no worsening of fibrosis was the primary outcome. The trial was stopped prematurely at a planned interim analysis because of significantly more participants reaching the primary outcome in the treatment arm compared to the placebo arm. However, given that obeticholic acid is not currently licensed for prescription within the UK, no evidence related to its use could be formally considered by the GDG. The GDG was also aware of significant ongoing research in the pharmaceutical industry regarding the role of novel therapeutic agents in treating NAFLD (including clinical trials underway at the time of writing these guidelines). The GDG agreed that if these trials reported promising results, an update of this guideline may be warranted.

**Research recommendations**

The GDG made a research recommendation to investigate the clinical and cost-effectiveness of pentoxifylline to treat NAFLD.

The GDG also made a high-priority research recommendation to investigate the clinical and cost-effectiveness of pharmacological therapy to treat advanced fibrosis in children and young people. See Appendix P for further details.

## 1 18 Acronyms and abbreviations

Acronym or abbreviation	Description
APRI	AST-to-platelet ratio index
ARFI	Acoustic radiation force impulse
ALT	Alanine transaminase
AST	Aspartate aminotransferase
BMI	Body mass index
CAP	Controlled attenuation parameter
CHD	Coronary heart disease
CK18	Plasma cytokeratin 18
CKD	Chronic kidney disease
CVD	Cardiovascular disease
DHA	Docosahexaenoic acid
DM	Diabetes mellitus
ELF	Enhanced liver fibrosis
EPA	Eicosapentaenoic acid
FIB4	Fibrosis 4 (diagnostic test)
FLI	Fatty liver index
GGT	Gamma-glutamyl-transferase
HbA1c	Glycated haemoglobin
HBVsAg	Hepatitis B surface antigen
HBV	Hepatitis B virus
HCV	Hepatitis C virus
HDL	High-density lipoprotein
HOMA-IR	Homeostatic model assessment (HOMA) used to quantify insulin resistance (IR) and beta-cell function.
LDL	Low-density lipoprotein
MI	Myocardial infarction
MRE	Magnetic resonance elastography
MRI	Magnetic resonance imaging
MRI (RSID)	MRI relative signal intensity decrease
MRI (PDFF)	MRI proton density fat fraction
MRS	Magnetic resonance spectroscopy
MS	Metabolic syndrome
NAFLD	Non-alcoholic fatty liver disease
NAS	NAFLD activity score
NASH	Non-alcoholic steatohepatitis
NASH-CRN	NASH Clinical Research Network
PAD	Peripheral artery disease
PCOS	Polycystic ovarian syndrome
PUFA	Polyunsaturated fatty acid
QUICKI	Quantitative insulin sensitivity check index
TE	Transient elastography

NAFLD

Acronyms and abbreviations

<b>Acronym or abbreviation</b>	<b>Description</b>
T2D	Type 2 diabetes
TIA	Transient ischaemic attack (mini stroke)
VLCD	Very low calorie diet
95%CI	95% confidence interval



# 19 Glossary

2 The NICE Glossary can be found at [www.nice.org.uk/glossary](http://www.nice.org.uk/glossary).

## 319.1 Guideline-specific terms

Term	Definition
Acoustic radiation force impulse imaging	An ultrasound-based elastography method enabling quantitative measurement of tissue stiffness.
Advanced liver fibrosis	A grade of F3 or above using the Kleiner (NASH-CRN) or the SAF score. This is referred to as bridging fibrosis (the presence of fibrosis that reaches from one portal area to another). Also see: Fibrosis
Alanine transaminase (ALT)	An enzyme found mainly inside liver cells.
Aspartate aminotransferase (AST)	An enzyme found mainly inside red blood cells, liver, heart, muscle tissue, pancreas, and kidneys.
AST-to-platelet ratio index (APRI)	A minimally invasive diagnostic test calculated by an algorithm using AST and platelet count.
BARD	A minimally invasive diagnostic test calculated by an algorithm using AST/ALT ratio, BMI and the presence of diabetes.
Cirrhosis	A chronic disease of the liver marked by degeneration of cells, inflammation, and fibrous thickening of tissue.
Controlled attenuation parameter (CAP)	A non-invasive method for the detection of hepatic steatosis based on transient elastography.
Cytokeratin 18	A protein found inside cells.
Ferritin	A protein found inside cells that stores iron.
Fib4	A minimally invasive diagnostic test calculated by an algorithm using age, ALT, AST and platelet count.
FibroScan	See 'transient elastography'.
Fibrosis	Where scar tissue is formed in an inflamed liver. Fibrosis can take a variable time to develop and, even with scar tissue present, the liver keeps on functioning quite well. However, continued build-up of scar tissue may lead to cirrhosis.
Fibrotest	A minimally invasive diagnostic test calculated with a formula including age, gender, bilirubin, GGT, apolipoprotein A1, haptoglobin, and $\alpha$ -2 macroglobulin.
Hepatic steatosis	Accumulation of fat on the liver.
High-density lipoprotein	One of the 5 major groups of lipoproteins. Lipoprotein molecules enable to transportation of lipids (fat molecules). High-density lipoprotein particles transfer fats away from cells, artery walls and tissues and back to low-density lipoprotein particles and to the liver for other disposition.
Liver biopsy	A diagnostic test in which a small sample of tissue is removed from the liver using a needle.
Liver blood tests	Blood tests for 2 main liver enzymes: aspartate aminotransferase and alanine aminotransferase.
Low-density lipoprotein	One of the 5 major groups of lipoproteins. Lipoprotein molecules enable to transportation of lipids (fat molecules). Low-density lipoprotein particles transport cholesterol from the liver to the tissues of the body.
Magnetic resonance	A non-invasive MRI based technique that generates quantitative maps of

## NAFLD

### Glossary

Term	Definition
elastography (MRE)	tissue stiffness.
Magnetic resonance imaging (MRI)	A type of scan that uses strong magnetic fields and radio waves to produce detailed images of the inside of the body.
Magnetic resonance spectroscopy (MRS)	A non-invasive MRI based technique for the characterization of tissue used to study metabolic changes.
Non-alcoholic steatohepatitis	A state in which fatty accumulation in the liver (steatosis) is combined with inflammation and the thickening and scarring of connective tissue (fibrosis).
NAFLD activity score (NAS)	A score of how likely someone is to have non-alcoholic steatohepatitis (NASH) – and how severe if so – based on liver biopsy. A score of 2 or less is steatosis alone, 3-4 conventionally seen as borderline NASH, at least 5 seen as definite NASH. This was first proposed by the NASH Clinical Research Network (CRN), and has been adopted in many academic studies and increasingly by clinical histopathology labs.
NAFLD fibrosis score	A minimally invasive diagnostic test calculated by an algorithm using age, BMI, presence of impaired fasting glucose or diabetes, AST/ALT ratio, platelet count and albumin.
NAFLD liver fat score	A minimally invasive diagnostic test calculated by an algorithm using presence of metabolic syndrome or diabetes, insulin, AST and AST/ALT ratio.
Negative likelihood ratio	The probability of an individual with the condition having a negative test or the probability of an individual without the condition having a negative test. Indicates how much to increase the probability of disease.
Omega-3 fatty acid	An unsaturated fatty acid of a kind occurring chiefly in fish oils. Important for metabolism.
Percutaneous liver biopsy	See 'liver biopsy'
Positive likelihood ratio	The probability of an individual with a condition having a positive test or the probability of an individual without a condition having a positive test. Indicates how much to increase the probability of disease.
Probiotics	Live bacteria and yeasts naturally found in your body that help your digestive system. Probiotics can also be found in some foods (for example, yoghurts) and supplements.
Serum biomarker	A characteristic within blood that can be objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to therapeutic intervention.
Serum triglycerides	See 'triglycerides'.
Statins	A group of medicines that help lower the level of low-density lipoprotein cholesterol in the blood by reducing the production of it inside the liver (see 'low-density lipoprotein').
Steatosis	See 'hepatic steatosis'
Steatotest	A minimally invasive diagnostic test calculated with a formula including alpha2-macroglobin, apolipoprotein A1, haptoglobin, total bilirubin, AST, ALT, GGT, fasting glucose, total cholesterol, tryglicerides, weight and height, adjusted for age and gender.
Transient elastography	A non-invasive test for the assessment of liver fibrosis through measuring stiffness of the liver.
Triglycerides	The main form of natural fats and oils in the body. Formed from glycerol and 3 fatty acid groups.
Ultrasound	A device that uses high frequency sound waves to create an image of parts of the inside of the body (for example, the liver).

## 19.2 General terms

Term	Definition
Abstract	Summary of a study, which may be published alone or as an introduction to a full scientific paper.
Algorithm (in guidelines)	A flow chart of the clinical decision pathway described in the guideline, where decision points are represented with boxes, linked with arrows.
Allocation concealment	The process used to prevent advance knowledge of group assignment in an RCT. The allocation process should be impervious to any influence by the individual making the allocation, by being administered by someone who is not responsible for recruiting participants.
Applicability	How well the results of a study or NICE evidence review can answer a clinical question or be applied to the population being considered.
Arm (of a clinical study)	Subsection of individuals within a study who receive 1 particular intervention, for example placebo arm.
Association	Statistical relationship between 2 or more events, characteristics or other variables. The relationship may or may not be causal.
Base case analysis	In an economic evaluation, this is the main analysis based on the most plausible estimate of each input. In contrast, see Sensitivity analysis.
Baseline	The initial set of measurements at the beginning of a study (after run-in period where applicable), with which subsequent results are compared.
Bias	Influences on a study that can make the results look better or worse than they really are. (Bias can even make it look as if a treatment works when it does not.) Bias can occur by chance, deliberately or as a result of systematic errors in the design and execution of a study. It can also occur at different stages in the research process, for example, during the collection, analysis, interpretation, publication or review of research data. For examples see selection bias, performance bias, information bias, confounding factor, and publication bias.
Blinding	A way to prevent researchers, doctors and patients in a clinical trial from knowing which study group each patient is in so they cannot influence the results. The best way to do this is by sorting patients into study groups randomly. The purpose of 'blinding' or 'masking' is to protect against bias. A single-blinded study is 1 in which patients do not know which study group they are in (for example whether they are taking the experimental drug or a placebo). A double-blinded study is 1 in which neither patients nor the researchers and doctors know which study group the patients are in. A triple blind study is 1 in which neither the patients, clinicians or the people carrying out the statistical analysis know which treatment patients received.
Carer (caregiver)	Someone who looks after family, partners or friends in need of help because they are ill, frail or have a disability.
Case-control study	A study to find out the cause(s) of a disease or condition. This is done by comparing a group of patients who have the disease or condition (cases) with a group of people who do not have it (controls) but who are otherwise as similar as possible (in characteristics thought to be unrelated to the causes of the disease or condition). This means the researcher can look for aspects of their lives that differ to see if they may cause the condition. For example, a group of people with lung cancer might be compared with a group of people the same age that do not have lung cancer. The researcher could compare how long both groups had been exposed to tobacco smoke.

Term	Definition
	Such studies are retrospective because they look back in time from the outcome to the possible causes of a disease or condition.
Case series	Report of a number of cases of a given disease, usually covering the course of the disease and the response to treatment. There is no comparison (control) group of patients.
Clinical efficacy	The extent to which an intervention is active when studied under controlled research conditions.
Clinical effectiveness	How well a specific test or treatment works when used in the 'real world' (for example, when used by a doctor with a patient at home), rather than in a carefully controlled clinical trial. Trials that assess clinical effectiveness are sometimes called management trials. Clinical effectiveness is not the same as efficacy.
Clinician	A healthcare professional who provides patient care. For example, a doctor, nurse or physiotherapist.
Cochrane Review	The Cochrane Library consists of a regularly updated collection of evidence-based medicine databases including the Cochrane Database of Systematic Reviews (reviews of randomised controlled trials prepared by the Cochrane Collaboration).
Cohort study	A study with 2 or more groups of people – cohorts – with similar characteristics. One group receives a treatment, is exposed to a risk factor or has a particular symptom and the other group does not. The study follows their progress over time and records what happens. See also observational study.
Comorbidity	A disease or condition that someone has in addition to the health problem being studied or treated.
Confidence interval (CI)	There is always some uncertainty in research. This is because a small group of patients is studied to predict the effects of a treatment on the wider population. The confidence interval is a way of expressing how certain we are about the findings from a study, using statistics. It gives a range of results that is likely to include the 'true' value for the population. The CI is usually stated as '95% CI', which means that the range of values has a 95 in a 100 chance of including the 'true' value. For example, a study may state that "based on our sample findings, we are 95% certain that the 'true' population blood pressure is not higher than 150 and not lower than 110". In such a case the 95% CI would be 110 to 150. A wide confidence interval indicates a lack of certainty about the true effect of the test or treatment – often because a small group of patients has been studied. A narrow confidence interval indicates a more precise estimate (for example, if a large number of patients have been studied).
Confounding factor	Something that influences a study and can result in misleading findings if it is not understood or appropriately dealt with. For example, a study of heart disease may look at a group of people that exercises regularly and a group that does not exercise. If the ages of the people in the 2 groups are different, then any difference in heart disease rates between the 2 groups could be because of age rather than exercise. Therefore age is a confounding factor.
Consensus methods	Techniques used to reach agreement on a particular issue. Consensus methods may be used to develop NICE guidance if there is not enough good quality research evidence to give a clear answer to a question. Formal consensus methods include Delphi and nominal group techniques.
Control group	A group of people in a study who do not receive the treatment or test being studied. Instead, they may receive the standard treatment

Term	Definition
	(sometimes called 'usual care') or a dummy treatment (placebo). The results for the control group are compared with those for a group receiving the treatment being tested. The aim is to check for any differences. Ideally, the people in the control group should be as similar as possible to those in the treatment group, to make it as easy as possible to detect any effects due to the treatment.
Cost-benefit analysis (CBA)	Cost-benefit analysis is 1 of the tools used to carry out an economic evaluation. The costs and benefits are measured using the same monetary units (for example, pounds sterling) to see whether the benefits exceed the costs.
Cost-consequences analysis (CCA)	Cost-consequences analysis is 1 of the tools used to carry out an economic evaluation. This compares the costs (such as treatment and hospital care) and the consequences (such as health outcomes) of a test or treatment with a suitable alternative. Unlike cost-benefit analysis or cost-effectiveness analysis, it does not attempt to summarise outcomes in a single measure (like the quality-adjusted life year) or in financial terms. Instead, outcomes are shown in their natural units (some of which may be monetary) and it is left to decision-makers to determine whether, overall, the treatment is worth carrying out.
Cost-effectiveness analysis (CEA)	Cost-effectiveness analysis is 1 of the tools used to carry out an economic evaluation. The benefits are expressed in non-monetary terms related to health, such as symptom-free days, heart attacks avoided, deaths avoided or life years gained (that is, the number of years by which life is extended as a result of the intervention).
Cost-effectiveness model	An explicit mathematical framework, which is used to represent clinical decision problems and incorporate evidence from a variety of sources in order to estimate the costs and health outcomes.
Cost-utility analysis (CUA)	Cost-utility analysis is 1 of the tools used to carry out an economic evaluation. The benefits are assessed in terms of both quality and duration of life, and expressed as quality-adjusted life years (QALYs). See also utility.
Deterministic analysis	In economic evaluation, this is an analysis that uses a point estimate for each input. In contrast, see Probabilistic analysis
Discounting	Costs and perhaps benefits incurred today have a higher value than costs and benefits occurring in the future. Discounting health benefits reflects individual preference for benefits to be experienced in the present rather than the future. Discounting costs reflects individual preference for costs to be experienced in the future rather than the present.
Disutility	The loss of quality of life associated with having a disease or condition. See Utility
Dominance	A health economics term. When comparing tests or treatments, an option that is both less effective and costs more is said to be 'dominated' by the alternative.
Drop-out	A participant who withdraws from a trial before the end.
Economic evaluation	An economic evaluation is used to assess the cost-effectiveness of healthcare interventions (that is, to compare the costs and benefits of a healthcare intervention to assess whether it is worth doing). The aim of an economic evaluation is to maximise the level of benefits – health effects – relative to the resources available. It should be used to inform and support the decision-making process; it is not supposed to replace the judgement of healthcare professionals.  There are several types of economic evaluation: cost-benefit analysis, cost-consequences analysis, cost-effectiveness analysis, cost-minimisation analysis and cost-utility analysis. They use similar methods to define and

Term	Definition
	evaluate costs, but differ in the way they estimate the benefits of a particular drug, programme or intervention.
Effect (as in effect measure, treatment effect, estimate of effect, effect size)	A measure that shows the magnitude of the outcome in 1 group compared with that in a control group. For example, if the absolute risk reduction is shown to be 5% and it is the outcome of interest, the effect size is 5%. The effect size is usually tested, using statistics, to find out how likely it is that the effect is a result of the treatment and has not just happened by chance (that is, to see if it is statistically significant).
Effectiveness	How beneficial a test or treatment is under usual or everyday conditions, compared with doing nothing or opting for another type of care.
Efficacy	How beneficial a test, treatment or public health intervention is under ideal conditions (for example, in a laboratory), compared with doing nothing or opting for another type of care.
EQ-5D (EuroQol 5 dimensions)	A standardised instrument used to measure health-related quality of life. It provides a single index value for health status.
Evidence	Information on which a decision or guidance is based. Evidence is obtained from a range of sources including randomised controlled trials, observational studies, expert opinion (of clinical professionals or patients).
Exclusion criteria (literature review)	Explicit standards used to decide which studies should be excluded from consideration as potential sources of evidence.
Exclusion criteria (clinical study)	Criteria that define who is not eligible to participate in a clinical study.
Extended dominance	If Option A is both more clinically effective than Option B and has a lower cost per unit of effect, when both are compared with a do-nothing alternative then Option A is said to have extended dominance over Option B. Option A is therefore cost-effective and should be preferred, other things remaining equal.
Extrapolation	An assumption that the results of studies of a specific population will also hold true for another population with similar characteristics.
Follow-up	Observation over a period of time of an individual, group or initially defined population whose appropriate characteristics have been assessed in order to observe changes in health status or health-related variables.
Generalisability	The extent to which the results of a study hold true for groups that did not participate in the research. See also external validity.
Gold standard	A method, procedure or measurement that is widely accepted as being the best available to test for or treat a disease.
GRADE, GRADE profile	A system developed by the GRADE Working Group to address the shortcomings of present grading systems in healthcare. The GRADE system uses a common, sensible and transparent approach to grading the quality of evidence. The results of applying the GRADE system to clinical trial data are displayed in a table known as a GRADE profile.
Harms	Adverse effects of an intervention.
Hazard ratio (HR)	Hazard is similar in notion to risk, but is subtly different in that it measures instantaneous risk and may change continuously. A hazard ratio is interpreted in a similar way to a risk ratio, because it describes how many times more (or less) likely a participant is to suffer the event at a particular point in time if they receive the experimental rather than the control intervention.
Health economics	Study or analysis of the cost of using and distributing healthcare resources.
Health-related quality of life	A measure of the effects of an illness to see how it affects someone's day-

Term	Definition
(HRQoL)	to-day life.
Heterogeneity or Lack of homogeneity	The term is used in meta-analyses and systematic reviews to describe when the results of a test or treatment (or estimates of its effect) differ significantly in different studies. Such differences may occur as a result of differences in the populations studied, the outcome measures used or because of different definitions of the variables involved. It is the opposite of homogeneity.
Imprecision	Results are imprecise when studies include relatively few patients and few events and thus have wide confidence intervals around the estimate of effect.
Inclusion criteria (literature review)	Explicit criteria used to decide which studies should be considered as potential sources of evidence.
Incremental analysis	The analysis of additional costs and additional clinical outcomes with different interventions.
Incremental cost	The extra cost linked to using 1 test or treatment rather than another. Or the additional cost of doing a test or providing a treatment more frequently.
Incremental cost-effectiveness ratio (ICER)	The difference in the mean costs in the population of interest divided by the differences in the mean outcomes in the population of interest for 1 treatment compared with another.
Incremental net benefit (INB)	The value (usually in monetary terms) of an intervention net of its cost compared with a comparator intervention. The INB can be calculated for a given cost-effectiveness (willingness to pay) threshold. If the threshold is £20,000 per QALY gained then the INB is calculated as: (£20,000 × QALYs gained) – Incremental cost.
Indirectness	The available evidence is different to the review question being addressed, in terms of PICO (population, intervention, comparison and outcome).
Intention-to-treat analysis (ITT)	An assessment of the people taking part in a clinical trial, based on the group they were initially (and randomly) allocated to. This is regardless of whether or not they dropped out, fully complied with the treatment or switched to an alternative treatment. Intention-to-treat analyses are often used to assess clinical effectiveness because they mirror actual practice: that is, not everyone complies with treatment and the treatment people receive may be changed according to how they respond to it.
Intervention	In medical terms this could be a drug treatment, surgical procedure, diagnostic or psychological therapy. Examples of public health interventions could include action to help someone to be physically active or to eat a more healthy diet.
Intraoperative	The period of time during a surgical procedure.
Length of stay	The total number of days a participant stays in hospital.
Licence	See 'Product licence'.
Life years gained	Mean average years of life gained per person as a result of the intervention compared with an alternative intervention.
Likelihood ratio	The likelihood ratio combines information about the sensitivity and specificity. It tells you how much a positive or negative result changes the likelihood that a patient would have the disease. The likelihood ratio of a positive test result (LR+) is sensitivity divided by (1 minus specificity).
Logistic regression or Logit model	In statistics, logistic regression is a type of analysis used for predicting the outcome of a binary dependent variable based on 1 or more predictor variables. It can be used to estimate the log of the odds (known as the 'logit').

Term	Definition
Markov model	A method for estimating long-term costs and effects for recurrent or chronic conditions, based on health states and the probability of transition between them within a given time period (cycle).
Meta-analysis	A method often used in systematic reviews. Results from several studies of the same test or treatment are combined to estimate the overall effect of the treatment.
Multivariate model	A statistical model for analysis of the relationship between 2 or more predictor (independent) variables and the outcome (dependent) variable.
Negative predictive value (NPV)	In screening or diagnostic tests: A measure of the usefulness of a screening or diagnostic test. It is the proportion of those with a negative test result who do not have the disease, and can be interpreted as the probability that a negative test result is correct. It is calculated as follows: $NPV = TN/(TN+FN)$
Net monetary benefit (NMB)	The value in monetary terms of an intervention net of its cost. The NMB can be calculated for a given cost-effectiveness threshold. If the threshold is £20,000 per QALY gained then the NMB for an intervention is calculated as: $(£20,000 \times \text{mean QALYs}) - \text{mean cost}$ . The most preferable option (that is, the most clinically effective option to have an ICER below the threshold selected) will be the treatment with the highest NMB.
Observational study	Individuals or groups are observed or certain factors are measured. No attempt is made to affect the outcome. For example, an observational study of a disease or treatment would allow 'nature' or usual medical care to take its course. Changes or differences in 1 characteristic (for example, whether or not people received a specific treatment or intervention) are studied without intervening. There is a greater risk of selection bias than in experimental studies.
Odds ratio (OR)	Odds are a way to represent how likely it is that something will happen (the probability). An odds ratio compares the probability of something in 1 group with the probability of the same thing in another. An odds ratio of 1 between 2 groups would show that the probability of the event (for example a person developing a disease, or a treatment working) is the same for both. An odds ratio greater than 1 means the event is more likely in the first group. An odds ratio less than 1 means that the event is less likely in the first group. Sometimes probability can be compared across more than 2 groups – in this case, 1 of the groups is chosen as the 'reference category', and the odds ratio is calculated for each group compared with the reference category. For example, to compare the risk of dying from lung cancer for non-smokers, occasional smokers and regular smokers, non-smokers could be used as the reference category. Odds ratios would be worked out for occasional smokers compared with non-smokers and for regular smokers compared with non-smokers. See also confidence interval, relative risk, risk ratio.
Opportunity cost	The loss of other healthcare programmes displaced by investment in or introduction of another intervention. This may be best measured by the health benefits that could have been achieved had the money been spent on the next best alternative healthcare intervention.
Outcome	The impact that a test, treatment, policy, programme or other intervention has on a person, group or population. Outcomes from interventions to improve the public's health could include changes in knowledge and behaviour related to health, societal changes (for example, a reduction in crime rates) and a change in people's health and wellbeing or health status.



Term	Definition
	In clinical terms, outcomes could include the number of patients who fully recover from an illness or the number of hospital admissions, and an improvement or deterioration in someone's health, functional ability, symptoms or situation. Researchers should decide what outcomes to measure before a study begins.
P value	<p>The p value is a statistical measure that indicates whether or not an effect is statistically significant.</p> <p>For example, if a study comparing 2 treatments found that 1 seems more effective than the other, the p value is the probability of obtaining these results by chance. By convention, if the p value is below 0.05 (that is, there is less than a 5% probability that the results occurred by chance) it is considered that there probably is a real difference between treatments. If the p value is 0.001 or less (less than a 1% probability that the results occurred by chance), the result is seen as highly significant.</p> <p>If the p value shows that there is likely to be a difference between treatments, the confidence interval describes how big the difference in effect might be.</p>
Placebo	A fake (or dummy) treatment given to participants in the control group of a clinical trial. It is indistinguishable from the actual treatment (which is given to participants in the experimental group). The aim is to determine what effect the experimental treatment has had – over and above any placebo effect caused because someone has received (or thinks they have received) care or attention.
Positive predictive value (PPV)	In screening or diagnostic tests: A measure of the usefulness of a screening or diagnostic test. It is the proportion of those with a positive test result who have the disease, and can be interpreted as the probability that a positive test result is correct. It is calculated as follows: $PPV = TP / (TP + FP)$
Power (statistical)	The ability to demonstrate an association when 1 exists. Power is related to sample size; the larger the sample size, the greater the power and the lower the risk that a possible association could be missed.
Prevalence	See Pre-test probability.
Primary care	Healthcare delivered outside hospitals. It includes a range of services provided by GPs, nurses, health visitors, midwives and other healthcare professionals and allied health professionals such as dentists, pharmacists and opticians.
Primary outcome	The outcome of greatest importance, usually the 1 in a study that the power calculation is based on.
Probabilistic analysis	In economic evaluation, this is an analysis that uses a probability distribution for each input. In contrast, see Deterministic analysis.
Product licence	An authorisation from the MHRA to market a medicinal product.
Prognosis	A probable course or outcome of a disease. Prognostic factors are patient or disease characteristics that influence the course. Good prognosis is associated with low rate of undesirable outcomes; poor prognosis is associated with a high rate of undesirable outcomes.
Prospective study	A research study in which the health or other characteristic of participants is monitored (or 'followed up') for a period of time, with events recorded as they happen. This contrasts with retrospective studies.
Publication bias	Publication bias occurs when researchers publish the results of studies showing that a treatment works well and do not publish those showing it did not have any effect. If this happens, analysis of the published results will not give an accurate idea of how well the treatment works. This type of bias can be assessed by a funnel plot.

Term	Definition
Quality of life	See 'Health-related quality of life'.
Quality-adjusted life year (QALY)	<p>A measure of the state of health of a person or group in which the benefits, in terms of length of life, are adjusted to reflect the quality of life. One QALY is equal to 1 year of life in perfect health.</p> <p>QALYS are calculated by estimating the years of life remaining for a patient following a particular treatment or intervention and weighting each year with a quality of life score (on a scale of 0 to 1). It is often measured in terms of the person's ability to perform the activities of daily life, freedom from pain and mental disturbance.</p>
Randomisation	Assigning participants in a research study to different groups without taking any similarities or differences between them into account. For example, it could involve using a random numbers table or a computer-generated random sequence. It means that each individual (or each group in the case of cluster randomisation) has the same chance of receiving each intervention.
Randomised controlled trial (RCT)	A study in which a number of similar people are randomly assigned to 2 (or more) groups to test a specific drug or treatment. One group (the experimental group) receives the treatment being tested, the other (the comparison or control group) receives an alternative treatment, a dummy treatment (placebo) or no treatment at all. The groups are followed up to see how effective the experimental treatment was. Outcomes are measured at specific times and any difference in response between the groups is assessed statistically. This method is also used to reduce bias.
RCT	See 'Randomised controlled trial'.
Receiver operated characteristic (ROC) curve	A graphical method of assessing the accuracy of a diagnostic test. Sensitivity is plotted against 1 minus specificity. A perfect test will have a positive, vertical linear slope starting at the origin. A good test will be somewhere close to this ideal.
Reference standard	The test that is considered to be the best available method to establish the presence or absence of the outcome – this may not be the 1 that is routinely used in practice.
Relative risk (RR)	<p>The ratio of the risk of disease or death among those exposed to certain conditions compared with the risk for those who are not exposed to the same conditions (for example, the risk of people who smoke getting lung cancer compared with the risk for people who do not smoke).</p> <p>If both groups face the same level of risk, the relative risk is 1. If the first group had a relative risk of 2, subjects in that group would be twice as likely to have the event happen. A relative risk of less than 1 means the outcome is less likely in the first group. Relative risk is sometimes referred to as risk ratio.</p>
Resource implication	The likely impact in terms of finance, workforce or other NHS resources.
Retrospective study	A research study that focuses on the past and present. The study examines past exposure to suspected risk factors for the disease or condition. Unlike prospective studies, it does not cover events that occur after the study group is selected.
Review question	In guideline development, this term refers to the questions about treatment and care that are formulated to guide the development of evidence-based recommendations.
Selection bias	<p>Selection bias occurs if:</p> <ol style="list-style-type: none"> <li>The characteristics of the people selected for a study differ from the wider population from which they have been drawn, or</li> <li>There are differences between groups of participants in a study in terms</li> </ol>

Term	Definition
	of how likely they are to get better.
Sensitivity	<p>How well a test detects the thing it is testing for.</p> <p>If a diagnostic test for a disease has high sensitivity, it is likely to pick up all cases of the disease in people who have it (that is, give a 'true positive' result). But if a test is too sensitive it will sometimes also give a positive result in people who do not have the disease (that is, give a 'false positive').</p> <p>For example, if a test were developed to detect if a woman is 6 months pregnant, a very sensitive test would detect everyone who was 6 months pregnant, but would probably also include those who are 5 and 7 months pregnant.</p> <p>If the same test were more specific (sometimes referred to as having higher specificity), it would detect only those who are 6 months pregnant, and someone who was 5 months pregnant would get a negative result (a 'true negative'). But it would probably also miss some people who were 6 months pregnant (that is, give a 'false negative').</p> <p>Breast screening is a 'real-life' example. The number of women who are recalled for a second breast screening test is relatively high because the test is very sensitive. If it were made more specific, people who do not have the disease would be less likely to be called back for a second test but more women who have the disease would be missed.</p>
Sensitivity analysis	<p>A means of representing uncertainty in the results of economic evaluations. Uncertainty may arise from missing data, imprecise estimates or methodological controversy. Sensitivity analysis also allows for exploring the generalisability of results to other settings. The analysis is repeated using different assumptions to examine the effect on the results.</p> <p>One-way simple sensitivity analysis (univariate analysis): each parameter is varied individually in order to isolate the consequences of each parameter on the results of the study.</p> <p>Multi-way simple sensitivity analysis (scenario analysis): 2 or more parameters are varied at the same time and the overall effect on the results is evaluated.</p> <p>Threshold sensitivity analysis: the critical value of parameters above or below which the conclusions of the study will change are identified.</p> <p>Probabilistic sensitivity analysis: probability distributions are assigned to the uncertain parameters and are incorporated into evaluation models based on decision analytical techniques (for example, Monte Carlo simulation).</p>
Significance (statistical)	A result is deemed statistically significant if the probability of the result occurring by chance is less than 1 in 20 ( $p < 0.05$ ).
Specificity	<p>The proportion of true negatives that are correctly identified as such. For example in diagnostic testing the specificity is the proportion of non-cases correctly diagnosed as non-cases.</p> <p>See related term 'Sensitivity'.</p> <p>In terms of literature searching a highly specific search is generally narrow and aimed at picking up the key papers in a field and avoiding a wide range of papers.</p>
Stakeholder	<p>An organisation with an interest in a topic that NICE is developing a clinical guideline or piece of public health guidance on. Organisations that register as stakeholders can comment on the draft scope and the draft guidance. Stakeholders may be:</p> <ul style="list-style-type: none"> <li>• manufacturers of drugs or equipment</li> <li>• national patient and carer organisations</li> </ul>

## Glossary

Term	Definition
	<ul style="list-style-type: none"> <li>• NHS organisations</li> <li>• organisations representing healthcare professionals.</li> </ul>
State transition model	See Markov model
Systematic review	A review in which evidence from scientific studies has been identified, appraised and synthesised in a methodical way according to predetermined criteria. It may include a meta-analysis.
Time horizon	The time span over which costs and health outcomes are considered in a decision analysis or economic evaluation.
Transition probability	In a state transition model (Markov model), this is the probability of moving from 1 health state to another over a specific period of time.
Treatment allocation	Assigning a participant to a particular arm of a trial.
Univariate	Analysis which separately explores each variable in a data set.
Utility	In health economics, a 'utility' is the measure of the preference or value that an individual or society places upon a particular health state. It is generally a number between 0 (representing death) and 1 (perfect health). The most widely used measure of benefit in cost-utility analysis is the quality-adjusted life year, but other measures include disability-adjusted life years (DALYs) and healthy year equivalents (HYEs).
Youden's Index	A way of summarising the performance of a diagnostic test (sensitivity + specificity – 1). Values range from 0 to 1. A zero value means the diagnostic test gives the same proportion of positive results for groups with and without the disease, that is, the test is not informative. A value of 1 indicates that there are no false positives or false negatives, i.e. the test is perfect.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12

## 1 20 Reference list

- 2
- 3 1 Review Manager (RevMan) [Computer program]. Version 5. Copenhagen. The Nordic Cochrane  
4 Centre, The Cochrane Collaboration, 2015. Available from: <http://tech.cochrane.org/Revman>
- 5 2 WinBUGS [Computer programme] version 1.4. Cambridge. MRC Biostatistics Unit, University of  
6 Cambridge, 2015. Available from: [http://www.mrc-bsu.cam.ac.uk/software/bugs/the-bugs-](http://www.mrc-bsu.cam.ac.uk/software/bugs/the-bugs-project-winbugs/)  
7 [project-winbugs/](http://www.mrc-bsu.cam.ac.uk/software/bugs/the-bugs-project-winbugs/)
- 8 3 Adams LA, George J, Bugianesi E, Rossi E, De Boer WB, van der Poorten D et al. Complex non-  
9 invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver  
10 disease. *Journal of Gastroenterology and Hepatology*. 2011; 26(10):1536-1543
- 11 4 Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver  
12 disease: a longitudinal study of 103 patients with sequential liver biopsies. *Journal of Hepatology*.  
13 2005; 42:132-138
- 14 5 Aida Y, Abe H, Tomita Y, Nagano T, Seki N, Sugita T et al. Serum cytokeratin 18 fragment level as a  
15 noninvasive biomarker for non-alcoholic fatty liver disease. *International Journal of Clinical and*  
16 *Experimental Medicine*. 2014; 7(11):4191-4198
- 17 6 Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I et al. Randomized, placebo-  
18 controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis.  
19 *Gastroenterology*. 2008; 135(4):1176-1184
- 20 7 Akcam M, Boyaci A, Pirgon O, Kaya S, Uysal S, Dundar BN. Therapeutic effect of metformin and  
21 vitamin E versus prescriptive diet in obese adolescents with fatty liver. *International Journal for*  
22 *Vitamin and Nutrition Research*. 2011; 81(6):398-406
- 23 8 Al-Jiffri O, Al-Sharif FM, Abd El-Kader SM, Ashmawy EM. Weight reduction improves markers of  
24 hepatic function and insulin resistance in type-2 diabetic patients with non-alcoholic fatty liver.  
25 *African Health Sciences*. 2013; 13(3):667-672
- 26 9 Alisi A, Bedogni G, Baviera G, Giorgio V, Porro E, Paris C et al. Randomised clinical trial: The  
27 beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. *Alimentary*  
28 *Pharmacology and Therapeutics*. 2014; 39(11):1276-1285
- 29 10 Aller R, de Luis DA, Izaola O, Conde R, Gonzalez Sagrado M, Primo D et al. Effect of a probiotic on  
30 liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized  
31 clinical trial. *European Review for Medical and Pharmacological Sciences*. 2011; 15(9):1090-1095
- 32 11 Angulo P, George J, Day CP, Vanni E, Russell L, De la Cruz AC et al. Serum ferritin levels lack  
33 diagnostic accuracy for liver fibrosis in patients with nonalcoholic fatty liver disease. *Clinical*  
34 *Gastroenterology and Hepatology*. 2014; 12(7):1163
- 35 12 Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC et al. The NAFLD fibrosis score:  
36 A noninvasive system that identifies liver fibrosis in patients with NAFLD. *Hepatology*. 2007;  
37 45(4):846-854

## Reference list

- 
- 1 13 Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P et al.  
2 Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients  
3 with nonalcoholic fatty liver disease. *Gastroenterology*. 2015; 149(2):389-397
- 4 14 Argo CK, Patrie JT, Lackner C, Henry TD, De Lange EE, Weltman AL et al. Effects of n-3 fish oil on  
5 metabolic and histological parameters in NASH: A double-blind, randomized, placebo-controlled  
6 trial. *Journal of Hepatology*. 2015; 62(1):190-197
- 7 15 Bae JC, Rhee EJ, Lee WY, Park SE, Park CY, Oh KW et al. Combined effect of nonalcoholic fatty  
8 liver disease and impaired fasting glucose on the development of type 2 diabetes: A 4-year  
9 retrospective longitudinal study. *Diabetes Care*. 2011; 34(3):727-729
- 10 16 Balmer ML, Schmitter K, Dufour J-F. The effect of ursodeoxycholic acid (UCDA) in combination  
11 with vitamin E on adipokines in patients with NASH. *Journal of Hepatology*. 2008; 48(Suppl  
12 2):S337
- 13 17 Balmer ML, Siegrist K, Zimmermann A, Dufour JF. Effects of ursodeoxycholic acid in combination  
14 with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis. *Liver  
15 International*. 2009; 29(8):1184-1188
- 16 18 Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J et al. A placebo-controlled trial of  
17 pioglitazone in subjects with nonalcoholic steatohepatitis. *New England Journal of Medicine*.  
18 2006; 355(22):2297-2307
- 19 19 Bell LN, Wang J, Muralidharan S, Chalasani S, Fullenkamp AM, Wilson LA et al. Relationship  
20 between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a  
21 pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with  
22 nonalcoholic steatohepatitis trial follow-up study. *Hepatology*. 2012; 56(4):1311-1318
- 23 20 Borman MA, Ladak F, Crotty P, Pollett A, Kirsch R, Pomier-Layrargues G et al. The Fatty Liver  
24 Index has limited utility for the detection and quantification of hepatic steatosis in obese  
25 patients. *Hepatology International*. 2013; 7(2):592-599
- 26 21 Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC et al. Prevalence of  
27 hepatic steatosis in an urban population in the United States: impact of ethnicity. *Hepatology  
28 (Baltimore, Md )*. 2004; 40(6):1387-1395
- 29 22 Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N et al. A randomized controlled  
30 trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.  
31 *American Journal of Gastroenterology*. 2005; 100(5):1082-1090
- 32 23 Catalano D, Martines GF, Tonzuso A, Pirri C, Trovato FM, Trovato GM. Protective role of coffee in  
33 non-alcoholic fatty liver disease (NAFLD). *Digestive Diseases and Sciences*. 2010; 55(11):3200-  
34 3206
- 35 24 Chan WK, Ida NH, Cheah PL, Goh KL. Progression of liver disease in non-alcoholic fatty liver  
36 disease: a prospective clinicopathological follow-up study. *Journal of Digestive Diseases*. 2014;  
37 15:545-552
- 38 25 Chan W-K, Sthaneshwar P, Mustapha NRN, Mahadeva S. Limited utility of plasma M30 in  
39 discriminating non-alcoholic steatohepatitis from steatosis - A comparison with routine  
40 biochemical markers. *PLoS One*. 2014; 9(9)

## Reference list

- 1 26 Chang Y, Jung H-S, Yun KE, Cho J, Cho YK, Ryu S. Cohort study of non-alcoholic fatty liver disease,  
2 nafld fibrosis score, and the risk of incident diabetes in a korean population. *American Journal of*  
3 *Gastroenterology*. 2013; 108(12):1861-1868
- 4 27 Chang Y, Ryu S, Sung E, Woo H-Y, Oh E, Cha K et al. Nonalcoholic fatty liver disease predicts  
5 chronic kidney disease in nonhypertensive and nondiabetic Korean men. *Metabolism: Clinical*  
6 *and Experimental*. 2008; 57(4):569-576
- 7 28 Chen SM, Liu CY, Li SR, Huang HT, Tsai CY, Jou HJ. Effects of therapeutic lifestyle program on  
8 ultrasound-diagnosed nonalcoholic fatty liver disease. *Journal of the Chinese Medical*  
9 *Association*. 2008; 71(11):551-558
- 10 29 Chiang HJ, Lin LH, Li CW, Lin CC, Chiang HW, Huang TL et al. Magnetic resonance fat  
11 quantification in living donor liver transplantation. *Transplantation Proceedings*. 2014; 46(3):666-  
12 668
- 13 30 Chon YE, Jung KS, Kim SU, Park JY, Park YN, Kim DY et al. Controlled attenuation parameter (CAP)  
14 for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a  
15 native Korean population. *Liver International*. 2014; 34(1):102-109
- 16 31 Cichoz-Lach H, Celinski K, Prozorow-Krol B, Swatek J, Slomka M, Lach T. The BARD score and the  
17 NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver  
18 disease. *Medical Science Monitor*. 2012; 18(12):CR735-CR740
- 19 32 Crossan C, Tsochatzis EA, Longworth L, Gurusamy K, Davidson B, Rodriguez-Peralvarez M et al.  
20 Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and  
21 cirrhosis in patients with chronic liver disease: systematic review and economic evaluation.  
22 *Health Technology Assessment (Winchester, England)*. 2015; 19(9):1-410
- 23 33 Cui J, Ang B, Haufe W, Hernandez C, Verna EC, Sirlin CB et al. Comparative diagnostic accuracy of  
24 magnetic resonance elastography vs. eight clinical prediction rules for non-invasive diagnosis of  
25 advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease: a prospective study.  
26 *Alimentary Pharmacology and Therapeutics*. 2015; 41(12):1271-1280
- 27 34 Cusi K, Chang Z, Harrison S, Lomonaco R, Bril F, Orsak B et al. Limited value of plasma cytokeratin-  
28 18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. *Journal*  
29 *of Hepatology*. 2014; 60(1):167-174
- 30 35 Dasarathy S, Dasarathy J, Khiyami A, Joseph R, Lopez R, McCullough AJ. Validity of real time  
31 ultrasound in the diagnosis of hepatic steatosis: a prospective study. *Journal of Hepatology*.  
32 2009; 51(6):1061-1067
- 33 36 de Ledinghen V, Vergniol J, Foucher J, Merrouche W, Le Bail B. Non-invasive diagnosis of liver  
34 steatosis using controlled attenuation parameter (CAP) and transient elastography. *Liver*  
35 *International*. 2012; 32(6):911-918
- 36 37 de Marco R, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M. Cause-specific mortality in  
37 type 2 diabetes. The Verona Diabetes Study. *Diabetes Care*. 1999; 22(5):756-761
- 38 38 de Moura Almeida A, Cotrim HP, Barbosa DBV, de Athayde LGM, Santos AS, Bitencourt AGV et al.  
39 Fatty liver disease in severe obese patients: diagnostic value of abdominal ultrasound. *World*  
40 *Journal of Gastroenterology*. 2008; 14(9):1415-1418

## Reference list

- 1 39 Demir M, Lang S, Schlattjan M, Drebber U, Wedemeyer I, Nierhoff D et al. NIKEL: A New  
2 Inexpensive and Non-Invasive Scoring System to Exclude Advanced Fibrosis in Patients with  
3 NAFLD. *PLoS One*. 2013; 8(3)
- 4 40 Dufour JF, Oneta CM, Gonvers JJ, Bihl F, Cerny A, Cereda JM et al. Randomized placebo-  
5 controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. *Clinical*  
6 *Gastroenterology and Hepatology*. 2006; 4(12):1537-1543
- 7 41 Dvorak K, Stritesky J, Petrtyl J, Vitek L, Sroubkova R, Lenicek M et al. Use of non-invasive  
8 parameters of non-alcoholic steatohepatitis and liver fibrosis in daily practice - An exploratory  
9 case-control study. *PLoS One*. 2014; 9(10)
- 10 42 Eckard C, Cole R, Lockwood J, Torres DM, Williams CD, Shaw JC et al. Prospective histopathologic  
11 evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial.  
12 *Therapeutic Advances in Gastroenterology*. 2013; 6(4):249-259
- 13 43 Ekstedt M, Franzen LE, Holmqvist M, Bendtsen P, Mathiesen UL, Bodemar G et al. Alcohol  
14 consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease.  
15 *Scandinavian Journal of Gastroenterology*. 2009; 44(3):366-374
- 16 44 Ekstedt M, Franzen LE, Mathiesen UL, Kechagias S. Low clinical relevance of the nonalcoholic  
17 fatty liver disease activity score (NAS) in predicting fibrosis progression. *Scandinavian Journal of*  
18 *Gastroenterology*. 2012; 47:108-115
- 19 45 Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S et al. Fibrosis stage is the  
20 strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.  
21 *Hepatology (Baltimore, Md )*. 2014;
- 22 46 El Azeem HA, Khalek ESA, El-Akabawy H, Naeim H, Khalik HA, Alfifi AA. Association between  
23 nonalcoholic fatty liver disease and the incidence of cardiovascular and renal events. *Journal of*  
24 *the Saudi Heart Association*. 2013; 25(4):239-246
- 25 47 Eslamparast T, Poustchi H, Zamani F, Sharafkhan M, Malekzadeh R, Hekmatdoost A. Synbiotic  
26 supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-  
27 controlled pilot study. *American Journal of Clinical Nutrition*. 2014; 99(3):535-542
- 28 48 Evans CD, Oien KA, MacSween RN, Mills PR. Non-alcoholic steatohepatitis: a common cause of  
29 progressive chronic liver injury? *Journal of Clinical Pathology*. 2002; 55:689-692
- 30 49 Fassio E, Alvarez E, Dominguez N, Landeira G, Longo C. Natural history of nonalcoholic  
31 steatohepatitis: a longitudinal study of repeat liver biopsies. *Hepatology*. 2004; 40(4):820-826
- 32 50 Fedchuk L, Nascimbeni F, Pais R, Charlotte F, Housset C, Ratzu V et al. Performance and  
33 limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. *Alimentary*  
34 *Pharmacology and Therapeutics*. 2014; 40(10):1209-1222
- 35 51 Feldstein AE, Alkhouri N, De VR, Alisi A, Lopez R, Nobili V. Serum cytokeratin-18 fragment levels  
36 are useful biomarkers for nonalcoholic steatohepatitis in children. *American Journal of*  
37 *Gastroenterology*. 2013; 108(9):1526-1531
- 38 52 Feldstein AE, Papouchado BG, Angulo P, Sanderson S, Adams L, Gores GJ. Hepatic stellate cells  
39 and fibrosis progression in patients with nonalcoholic fatty liver disease. *Clinical*  
40 *Gastroenterology and Hepatology*. 2005; 3:384-389



## Reference list

- 1 53 Feldstein AE, Wieckowska A, Lopez AR, Liu Y-C, Zein NN, McCullough AJ. Cytokeratin-18 fragment  
2 levels as noninvasive biomarkers for nonalcoholic steatohepatitis: A multicenter validation study.  
3 *Hepatology*. 2009; 50(4):1072-1078
- 4 54 Ferraioli G, Tinelli C, Lissandrin R, Zicchetti M, Dal Bello B, Filice G et al. Controlled attenuation  
5 parameter for evaluating liver steatosis in chronic viral hepatitis. *World Journal of*  
6 *Gastroenterology*. 2014; 20(21):6626-6631
- 7 55 Funatsu K, Yamashita T, Nakamura H. Coffee consumption is associated with a lower incidence of  
8 fatty liver in middle-aged men. *Journal of Health Science*. 2011; 57(5):406-413
- 9 56 Goh GBB, Pagadala MR, Dasarathy J, Unalp-Arida A, Sargent R, Hawkins C et al. Clinical spectrum  
10 of non-alcoholic fatty liver disease in diabetic and non-diabetic patients. *BBA Clinical*. 2015;  
11 3:141-145
- 12 57 GRADE Working Group. The Grading of Recommendations Assessment, Development and  
13 Evaluation (GRADE) Working Group website. 2011. Available from:  
14 <http://www.gradeworkinggroup.org/> [Last accessed: 1 October 2011]
- 15 58 Grigorescu M, Crisan D, Radu C, Grigorescu MD, Sparchez Z, Serban A. A novel  
16 pathophysiological-based panel of biomarkers for the diagnosis of nonalcoholic steatohepatitis.  
17 *Journal of Physiology and Pharmacology*. 2012; 63(4):347-353
- 18 59 Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S et al. Noninvasive markers of  
19 fibrosis in nonalcoholic fatty liver disease: Validating the European liver fibrosis panel and  
20 exploring simple markers. *Hepatology*. 2008; 47(2):455-460
- 21 60 Hallsworth K, Fattakhova G, Hollingsworth K, Thoma C, Moore S, Taylor R et al. Resistance  
22 exercise improves liver lipid, fat oxidation and glucose control in adults with non-alcoholic fatty  
23 liver disease independent of weight loss. *Journal of Hepatology*. 2011; 54:S337
- 24 61 Hallsworth K, Fattakhova G, Hollingsworth KG, Thoma C, Moore S, Day CP et al. Resistance  
25 exercise improves liver fat and glucose control in people with non-alcoholic fatty liver disease.  
26 *Diabetologia*. 2011; 54:S246-S247
- 27 62 Hallsworth K, Fattakhova G, Hollingsworth KG, Thoma C, Moore S, Taylor R et al. Resistance  
28 exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of  
29 weight loss. *Gut*. 2011; 60(9):1278-1283
- 30 63 Hamabe A, Uto H, Imamura Y, Kusano K, Mawatari S, Kumagai K et al. Impact of cigarette  
31 smoking on onset of nonalcoholic fatty liver disease over a 10-year period. *Journal of*  
32 *Gastroenterology*. 2011; 46(6):769-778
- 33 64 Hamaguchi E, Takamura T, Sakurai M, Mizukoshi E, Zen Y, Takeshita Y et al. Histological course of  
34 nonalcoholic fatty liver disease in Japanese patients: tight glycemic control, rather than weight  
35 reduction, ameliorates liver fibrosis. *Diabetes Care*. 2010; 33:284-286
- 36 65 Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with  
37 nonalcoholic steatohepatitis: A randomized, prospective trial. *Hepatology*. 2009; 49(1):80-86
- 38 66 Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease: a  
39 clinical histopathological study. *American Journal of Gastroenterology*. 2003; 98:2042-2047

## Reference list

- 1 67 Hashimoto Y, Hamaguchi M, Kojima T, Ohshima Y, Ohbora A, Kato T et al. The modest alcohol  
2 consumption reduces the incidence of fatty liver in men: A population-based large-scale cohort  
3 study. *Journal of Gastroenterology and Hepatology*. 2015; 30(3):546-552
- 4 68 Haukeland JW, Konopski Z, Eggesbø HB, Volkmann HL, Raschpichler G, Bjørø K et al. Metformin in  
5 patients with non-alcoholic fatty liver disease: a randomized, controlled trial. *Scandinavian  
6 Journal of Gastroenterology*. 2009; 44(7):853-860
- 7 69 Health and Safety Legislation. The Ionising Radiation (Medical Exposure) Regulations 2000  
8 (Statutory Instrument 2000 No. 1059). 2000. Available from:  
9 <http://www.legislation.hmso.gov.uk/si/si2000/20001059.htm> [Last accessed: 19 November  
10 2015]
- 11 70 Hepburn MJ, Vos JA, Fillman EP, Lawitz EJ. The accuracy of the report of hepatic steatosis on  
12 ultrasonography in patients infected with hepatitis C in a clinical setting: a retrospective  
13 observational study. *BMC Gastroenterology*. 2005; 5:14
- 14 71 HH AK, Henderson J, Vanhoesen K, Ghishan F, Bhattacharyya A. Nonalcoholic fatty liver disease in  
15 children: a single center experience. *Clinical Gastroenterology and Hepatology*. 2008; 6:799-802
- 16 72 Huang K-W, Leu H-B, Wang Y-J, Luo J-C, Lin H-C, Lee F-Y et al. Patients with nonalcoholic fatty  
17 liver disease have higher risk of colorectal adenoma after negative baseline colonoscopy.  
18 *Colorectal Disease*. 2013; 15(7):830-835
- 19 73 Hui AY, Wong VW, Chan HL, Liew CT, Chan JL, Chan FK et al. Histological progression of non-  
20 alcoholic fatty liver disease in Chinese patients. *Alimentary Pharmacology and Therapeutics*.  
21 2005; 21:407-413
- 22 74 Imamura Y, Uto H, Hiramane Y, Hosoyamada K, Ijuin S, Yoshifuku S et al. Increasing prevalence of  
23 diabetes mellitus in association with fatty liver in a Japanese population. *Journal of  
24 Gastroenterology*. 2014; 49(10):1406-1413
- 25 75 Janczyk W, Lebensztejn D, Wierzbicka-Rucinska A, Mazur A, Neuhoff-Murawska J, Matusik P et al.  
26 Omega-3 Fatty acids therapy in children with nonalcoholic Fatty liver disease: a randomized  
27 controlled trial. *Journal of Pediatrics*. 2015; 166(6):1358-1363
- 28 76 Jenks SJ, Conway BR, Hor TJ, Williamson RM, Mclachlan S, Robertson C et al. Hepatic steatosis  
29 and non-alcoholic fatty liver disease are not associated with decline in renal function in people  
30 with Type 2 diabetes. *Diabetic Medicine*. 2014; 31(9):1039-1046
- 31 77 Joka D, Wahl K, Moeller S, Schlue J, Vaske B, Bahr MJ et al. Prospective biopsy-controlled  
32 evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic  
33 steatohepatitis. *Hepatology*. 2012; 55(2):455-464
- 34 78 Jun MJ, Shim JH, Kim SY, Seo N, Kim KM, Lim YS et al. Clinical implications of preoperative and  
35 intraoperative liver biopsies for evaluating donor steatosis in living related liver transplantation.  
36 *Liver Transplantation*. 2014; 20(4):437-445
- 37 79 Junior WS, Nonino-Borges CB. Clinical predictors of different grades of nonalcoholic fatty liver  
38 disease. *Obesity Surgery*. 2012; 22(2):248-252
- 39 80 Kasturiratne A, Weerasinghe S, Dassanayake AS, Rajindrajith S, de Silva AP, Kato N et al. Influence  
40 of non-alcoholic fatty liver disease on the development of diabetes mellitus. *Journal of  
41 Gastroenterology and Hepatology*. 2013; 28(1):142-147

## Reference list

- 1 81 Kawamura Y, Saitoh S, Arase Y, Ikeda K, Fukushima T, Hara T et al. Three-dimensional magnetic  
2 resonance imaging for stringent diagnosis of advanced fibrosis associated with nonalcoholic  
3 steatohepatitis. *Hepatology International*. 2013; 7(3):850-858
- 4 82 Khosravi S, Alavian SM, Zare A, Fereshtehnejad S-M, Daryani NE, Keramati MR et al. Non-  
5 alcoholic fatty liver disease and correlation of serum alanin aminotransferase level with  
6 histopathologic findings. *Hepatitis Monthly*. 2011; 11(6):452-458
- 7 83 Kim CH, Park JY, Lee KU, Kim JH, Kim HK. Fatty liver is an independent risk factor for the  
8 development of Type 2 diabetes in Korean adults. *Diabetic Medicine*. 2008; 25(4):476-481
- 9 84 Kim D, Kim WR, Talwalkar JA, Kim HJ, Ehman RL. Advanced fibrosis in nonalcoholic fatty liver  
10 disease : Noninvasive assessment with MR elastography. *Radiology*. 2013; 268(2):411-419
- 11 85 Kim NH, Kim JH, Kim YJ, Yoo HJ, Kim HY, Seo JA et al. Clinical and metabolic factors associated  
12 with development and regression of nonalcoholic fatty liver disease in nonobese subjects. *Liver  
13 International*. 2014; 34(4):604-611
- 14 86 Kim YS, Jung ES, Hur W, Bae SH, Choi JY, Song MJ et al. Noninvasive predictors of nonalcoholic  
15 steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease.  
16 *Clinical and Molecular Hepatology*. 2013; 19(2):120-130
- 17 87 Kleiner DE, Brunt EM, Van NM, Behling C, Contos MJ, Cummings OW et al. Design and validation  
18 of a histological scoring system for nonalcoholic fatty liver disease. *Hepatology*. 2005;  
19 41(6):1313-1321
- 20 88 Koelblinger C, Krssak M, Maresch J, Wrba F, Kaczirek K, Gruenberger T et al. Hepatic steatosis  
21 assessment with 1H-spectroscopy and chemical shift imaging at 3.0 T before hepatic surgery:  
22 reliable enough for making clinical decisions? *European Journal of Radiology*. 2012; 81(11):2990-  
23 2995
- 24 89 Kruger FC, Daniels CR, Kidd M, Swart G, Brundyn K, van RC et al. APRI: A simple bedside marker  
25 for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH. *South African  
26 Medical Journal*. 2011; 101(7):477-480
- 27 90 Kumar R, Rastogi A, Sharma MK, Bhatia V, Tyagi P, Sharma P et al. Liver stiffness measurements  
28 in patients with different stages of nonalcoholic fatty liver disease: Diagnostic performance and  
29 clinicopathological correlation. *Digestive Diseases and Sciences*. 2013; 58(1):265-274
- 30 91 Lassailly G, Caiazzo R, Hollebecque A, Buob D, Leteurtre E, Arnalsteen L et al. Validation of  
31 noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in  
32 patients with morbid obesity. *European Journal of Gastroenterology and Hepatology*. 2011;  
33 23(6):499-506
- 34 92 Lau K, Lorbeer R, Haring R, Schmidt CO, Wallaschofski H, Nauck M et al. The association between  
35 fatty liver disease and blood pressure in a population-based prospective longitudinal study.  
36 *Journal of Hypertension*. 2010; 28(9):1829-1835
- 37 93 Lavine JE, Schwimmer JB, Molleston JP, Chalasani NP, Rosenthal P, Murray KF et al. Vitamin E,  
38 metformin or placebo for treatment of nonalcoholic fatty liver disease in children. *Hepatology*.  
39 2010; 52(Suppl S1):374A

## Reference list

- 1 94 Lavine JE, Schwimmer JB, Natta ML, Molleston JP, Murray KF, Rosenthal P et al. Effect of vitamin  
2 E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the  
3 TONIC randomized controlled trial. *JAMA*. 2011; 305(16):1659-1668
- 4 95 Lazo M, Hernaez R, Bonekamp S, Kamel IR, Brancati FL, Guallar E et al. Non-alcoholic fatty liver  
5 disease and mortality among US adults: Prospective cohort study. *BMJ*. 2011; 343(7836):1245
- 6 96 Lee JY, Kim KM, Lee SG, Yu E, Lim YS, Lee HC et al. Prevalence and risk factors of non-alcoholic  
7 fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver  
8 biopsies in a single center. *Journal of Hepatology*. 2007; 47(2):239-244
- 9 97 Lee K. Metabolic syndrome predicts the incidence of hepatic steatosis in Koreans. *Obesity  
10 Research and Clinical Practice*. 2010; 4(3):e217-e224
- 11 98 Lee SS, Park SH, Kim HJ, Kim SY, Kim MY, Kim DY et al. Non-invasive assessment of hepatic  
12 steatosis: prospective comparison of the accuracy of imaging examinations. *Journal of  
13 Hepatology*. 2010; 52(4):579-585
- 14 99 Lee TH, Han SH, Yang JD, Kim D, Ahmed M. Prediction of advanced fibrosis in nonalcoholic fatty  
15 liver disease: An enhanced model of BARD score. *Gut and Liver*. 2013; 7(3):323-328
- 16 100 Lee YI, Lim Y-S, Park HS. Colorectal neoplasms in relation to non-alcoholic fatty liver disease in  
17 Korean women: A retrospective cohort study. *Journal of Gastroenterology and Hepatology*. 2012;  
18 27(1):91-95
- 19 101 Lee Y-M, Sutedja DS, Wai C-T, Dan Y-Y, Aung M-O, Zhou L et al. A randomized controlled pilot  
20 study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH). *Hepatology  
21 International*. 2008; 2(2):196-201
- 22 102 Lee YS, Kek BLK, Poh LKS, Saw SM, Loke KY. Association of raised liver transaminases with  
23 physical inactivity, increased waist-hip ratio, and other metabolic morbidities in severely obese  
24 children. *Journal of Pediatric Gastroenterology and Nutrition*. 2008; 47(2):172-178
- 25 103 Leuschner UF, Lindenthal B, Herrmann G, Arnold JC, Rössle M, Cordes HJ et al. High-dose  
26 ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized,  
27 placebo-controlled trial. *Hepatology*. 2010; 52(2):472-479
- 28 104 Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P et al. Ursodeoxycholic  
29 acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. *Hepatology*.  
30 2004; 39(3):770-778
- 31 105 Loomba R, Wolfson T, Ang B, Hooker J, Behling C, Peterson M et al. Magnetic resonance  
32 elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a  
33 prospective study. *Hepatology*. 2014; 60(6):1920-1928
- 34 106 Lupsor M, Badea R, Stefanescu H, Grigorescu M, Serban A, Radu C et al. Performance of  
35 unidimensional transient elastography in staging non-alcoholic steatohepatitis. *Journal of  
36 Gastrointestinal and Liver Diseases*. 2010; 19(1):53-60
- 37 107 Lupsor-Platon M, Feier D, Stefanescu H, Tamas A, Botan E, Sparchez Z et al. Diagnostic accuracy  
38 of controlled attenuation parameter measured by transient elastography for the non-invasive  
39 assessment of liver steatosis: a prospective study. *Journal of Gastrointestinal and Liver Diseases*.  
40 2015; 24(1):35-42

## Reference list

- 1 108 Mahadeva S, Mahfudz AS, Vijayanathan A, Goh K-L, Kulenthiran A, Cheah P-L. Performance of  
2 transient elastography (TE) and factors associated with discordance in non-alcoholic fatty liver  
3 disease. *Journal of Digestive Diseases*. 2013; 14(11):604-610
- 4 109 Mahady SE, Wong G, Craig JC, George J. Pioglitazone and vitamin E for nonalcoholic  
5 steatohepatitis: a cost utility analysis. *Hepatology*. 2012; 56(6):2172-2179
- 6 110 Malik R, Chang M, Bhaskar K, Nasser I, Curry M, Schuppan D et al. The clinical utility of  
7 biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with  
8 nonalcoholic fatty liver disease. *Journal of Gastroenterology and Hepatology*. 2009; 24(4):564-  
9 568
- 10 111 Manousou P, Kalambokis G, Grillo F, Watkins J, Xirouchakis E, Pleguezuelo M et al. Serum ferritin  
11 is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic  
12 fatty liver disease patients. *Liver International : Official Journal of the International Association  
13 for the Study of the Liver*. 2011; 31(5):730-739
- 14 112 Marsman HA, van der Pool AE, Verheij J, Padmos J, Ten Kate FJW, Dwarkasing RS et al. Hepatic  
15 steatosis assessment with CT or MRI in patients with colorectal liver metastases after  
16 neoadjuvant chemotherapy. *Journal of Surgical Oncology*. 2011; 104(1):10-16
- 17 113 Masaki K, Takaki S, Hyogo H, Kobayashi T, Fukuhara T, Naeshiro N et al. Utility of controlled  
18 attenuation parameter measurement for assessing liver steatosis in Japanese patients with  
19 chronic liver diseases. *Hepatology Research*. 2013; 43(11):1182-1189
- 20 114 Mathiesen UL, Franzen LE, Aselius H, Resjo M, Jacobsson L, Foberg U et al. Increased liver  
21 echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in  
22 asymptomatic patients with mild/moderate abnormalities of liver transaminases. *Digestive and  
23 Liver Disease*. 2002; 34(7):516-522
- 24 115 McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring  
25 systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.  
26 *Gut*. 2010; 59(9):1265-1269
- 27 116 McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD  
28 progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for  
29 prognosis and clinical management. *Journal of Hepatology*. 2014;(0)
- 30 117 Mennesson N, Dumortier J, Hervieu V, Milot L, Guillaud O, Scoazec JY et al. Liver steatosis  
31 quantification using magnetic resonance imaging: a prospective comparative study with liver  
32 biopsy. *Journal of Computer Assisted Tomography*. 2009; 33(5):672-677
- 33 118 Morling JR, Fallowfield JA, Williamson RM, Robertson CM, Glancy S, Guha IN et al. gamma-  
34 Glutamyltransferase, but not markers of hepatic fibrosis, is associated with cardiovascular  
35 disease in older people with type 2 diabetes mellitus: the Edinburgh Type 2 Diabetes Study.  
36 *Diabetologia*. 2015; 58(7):1484-1493
- 37 119 Myers RP, Pollett A, Kirsch R, Pomier-Layrargues G, Beaton M, Levstik M et al. Controlled  
38 Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based  
39 on transient elastography. *Liver International*. 2012; 32(6):902-910
- 40 120 National Clinical Guideline Centre. Cirrhosis: assessment and management of cirrhosis. NICE  
41 clinical guideline. {In development, NG number unknown, due to publish June 2016}. London.  
42 National Clinical Guideline Centre, 2016. Available from:

## Reference list

- 1 <https://www.nice.org.uk/guidance/indevelopment/gid-cgwave0683>; {update webpage when  
2 published}
- 3 121 National Institute for Health and Care Excellence. Managing overweight and obesity among  
4 children and young people: lifestyle weight management services. NICE public health guidance 47.  
5 London. National Institute for Health and Care Excellence, 2013. Available from:  
6 <http://guidance.nice.org.uk/PH47>
- 7 122 National Institute for Health and Care Excellence. Developing NICE guidelines: the manual.  
8 London. National Institute for Health and Care Excellence, 2014. Available from:  
9 <http://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20overview>
- 10 123 National Institute for Health and Care Excellence. Managing overweight and obesity in adults -  
11 lifestyle weight management services. NICE public health guidance 53. London. National Institute  
12 for Health and Care Excellence, 2014. Available from: <http://guidance.nice.org.uk/PH53>
- 13 124 National Institute for Health and Clinical Excellence. Social value judgements: principles for the  
14 development of NICE guidance. 2nd edition. London: National Institute for Health and Clinical  
15 Excellence; 2008. Available from:  
16 <http://www.nice.org.uk/media/C18/30/SVJ2PUBLICATION2008.pdf>
- 17 125 National Institute for Health and Clinical Excellence. The guidelines manual. London: National  
18 Institute for Health and Clinical Excellence; 2012. Available from:  
19 <http://publications.nice.org.uk/the-guidelines-manual-pmg6/>
- 20 126 National Institute for Health and Clinical Excellence. Guide to the methods of technology  
21 appraisal 2013. 2nd edition. London: National Institute for Health and Clinical Excellence; 2013.  
22 Available from: <http://publications.nice.org.uk/pmg9>
- 23 127 Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA. A pilot study using simvastatin in the  
24 treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial. *Journal of*  
25 *Clinical Gastroenterology*. 2009; 43(10):990-994
- 26 128 Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF et al.  
27 Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic  
28 steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. *The Lancet*. 2015;  
29 385(9972):956-965
- 30 129 Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A, Tonascia J et al.  
31 Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease.  
32 *Hepatology*. 2010; 52(3):913-924
- 33 130 Nobili V, Alisi A, Della CC, Rise P, Galli C, Agostoni C et al. Docosahexaenoic acid for the treatment  
34 of fatty liver: randomised controlled trial in children. *Nutrition, Metabolism, and Cardiovascular*  
35 *Diseases : NMCD*. 2013; 23(11):1066-1070
- 36 131 Nobili V, Parkes J, Bottazzo G, Marcellini M, Cross R, Newman D et al. Performance of ELF Serum  
37 Markers in Predicting Fibrosis Stage in Pediatric Non-Alcoholic Fatty Liver Disease.  
38 *Gastroenterology*. 2009; 136(1):160-167
- 39 132 Nobili V, Vizzutti F, Arena U, Abraldes JG, Marra F, Pietrobattista A et al. Accuracy and  
40 reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic  
41 steatohepatitis. *Hepatology*. 2008; 48(2):442-448

## Reference list

- 1 133 Novielli N, Cooper NJ, Abrams KR, Sutton AJ. How is evidence on test performance synthesized  
2 for economic decision models of diagnostic tests? A systematic appraisal of Health Technology  
3 Assessments in the UK since 1997. *Value in Health*. 2010; 13(8):952-957
- 4 134 Organisation for Economic Co-operation and Development (OECD). Purchasing power parities  
5 (PPP). 2014. Available from: <http://www.oecd.org/std/ppp> [Last accessed: 15 January 2014]
- 6 135 Pacifico L, Bonci E, Di MM, Versacci P, Andreoli G, Silvestri LM et al. A double-blind, placebo-  
7 controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on  
8 hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic  
9 fatty liver disease. *Nutrition, Metabolism, and Cardiovascular Diseases : NMCD*. 2015; 25(8):734-  
10 741
- 11 136 Pacifico L, Di MM, Panebianco V, Martino F, Bezzi M, Catalano C et al. Prospective evaluation of  
12 the accuracy of magnetic resonance for fat quantification in pediatric nonalcoholic fatty liver  
13 disease. *Journal of Pediatric Gastroenterology and Nutrition*. 2010; 50:E15-E16
- 14 137 Pais R, Charlotte F, Fedchuk L, Bedossa P, Lebray P, Poynard T et al. A systematic review of  
15 follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. *Journal*  
16 *of Hepatology*. 2013; 59:550-556
- 17 138 Palmentieri B, de Sio I, La Mura V, Masarone M, Vecchione R, Bruno S et al. The role of bright  
18 liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. *Digestive*  
19 *and Liver Disease*. 2006; 38(7):485-489
- 20 139 Palmeri ML, Wang MH, Rouze NC, Abdelmalek MF, Guy CD, Moser B et al. Noninvasive  
21 evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with  
22 nonalcoholic fatty liver disease. *Journal of Hepatology*. 2011; 55(3):666-672
- 23 140 Paparo F, Cenderello G, Revelli M, Bacigalupo L, Rutigliani M, Zefiro D et al. Diagnostic value of  
24 MRI proton density fat fraction for assessing liver steatosis in chronic viral C hepatitis. *BioMed*  
25 *Research International*. 2015; 2015:758164
- 26 141 Papatheodoridis GV, Hadziyannis E, Tsochatzis E, Georgiou A, Kafiri G, Tiniakos DG et al. Serum  
27 apoptotic caspase activity in chronic hepatitis C and nonalcoholic fatty liver disease. *Journal of*  
28 *Clinical Gastroenterology*. 2010; 44(4):e87-e95
- 29 142 Park SK, Seo MH, Shin HC, Ryou J-H. Clinical availability of non-alcoholic fatty liver disease as an  
30 early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study.  
31 *Hepatology*. 2013; 57(4):1378-1383
- 32 143 Pathik P, Ravindra S, Ajay C, Prasad B, Jatin P, Prabha S. Fibroscan versus simple noninvasive  
33 screening tools in predicting fibrosis in high-risk nonalcoholic fatty liver disease patients from  
34 western India. *Annals of Gastroenterology*. 2015; 28(2):281-286
- 35 144 Perazzo H, Ngo Y, Lebray P, Seurat N, Rutka F, Couteau M et al. Prognostic value of liver fibrosis  
36 and steatosis biomarkers in type-2 diabetes and dyslipidaemia. *Alimentary Pharmacology and*  
37 *Therapeutics*. 2014; 40(9):1081-1093
- 38 145 Perez NE, Siddiqui FA, Mutchnick MG, Dhar R, Tobi M, Ullah N et al. Ultrasound diagnosis of fatty  
39 liver in patients with chronic liver disease: a retrospective observational study. *Journal of Clinical*  
40 *Gastroenterology*. 2007; 41(6):624-629

## Reference list

- 1 146 Perez-Gutierrez OZ, Hernandez-Rocha C, Candia-Balboa RA, Arrese MA, Benitez C, Brizuela-  
2 Alcantara DC et al. Validation study of systems for noninvasive diagnosis of fibrosis in  
3 nonalcoholic fatty liver disease in Latin population. *Annals of Hepatology*. 2013; 12(3):416-424
- 4 147 Petta S, Di M, V, Camma C, Butera G, Cabibi D, Craxi A. Reliability of liver stiffness measurement  
5 in non-alcoholic fatty liver disease: The effects of body mass index. *Alimentary Pharmacology and  
6 Therapeutics*. 2011; 33(12):1350-1360
- 7 148 Pickhardt PJ, Hahn L, Munoz del Rio A, Park SH, Reeder SB, Said A. Natural history of hepatic  
8 steatosis: observed outcomes for subsequent liver and cardiovascular complications. *AJR  
9 American Journal of Roentgenology*. 2014; 202(4):752-758
- 10 149 Pisto P, Santaniemi M, Bloigu R, Ukkola O, Kesaniemi YA. Fatty liver predicts the risk for  
11 cardiovascular events in middle-aged population: A population-based cohort study. *BMJ Open*.  
12 2014; 4(3)
- 13 150 Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR et al. Randomized  
14 controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. *Hepatology*.  
15 2010; 51(1):121-129
- 16 151 Pugh CJA, Cuthbertson DJ, Sprung VS, Kemp GJ, Richardson P, Umpleby AM et al. Exercise  
17 training improves cutaneous microvascular function in nonalcoholic fatty liver disease. *American  
18 Journal of Physiology Endocrinology and Metabolism*. 2013; 305(1):E50-E58
- 19 152 Qureshi K, Clements RH, Abrams GA. The utility of the "NAFLD fibrosis score" in morbidly obese  
20 subjects with NAFLD. *Obesity Surgery*. 2008; 18(3):264-270
- 21 153 Raszeja-Wyszomirska J, Szymanik B, Lawniczak M, Kajor M, Chwist A, Milkiewicz P et al.  
22 Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease  
23 (NAFLD). *BMC Gastroenterology*. 2010; 10:67
- 24 154 Ratziu V, Ledinghen V, Oberti F, Mathurin P, Wartelle-Bladou C, Renou C et al. A randomized  
25 controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. *Journal of  
26 Hepatology*. 2011; 54(5):1011-1019
- 27 155 Ratziu V, Massard J, Charlotte F, Messous D, Imbert-Bismut F, Bonyhay L et al. Diagnostic value of  
28 biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with  
29 non-alcoholic fatty liver disease. *BMC Gastroenterology*. 2006; 6:6
- 30 156 Razavizade M, Jamali R, Arj A, Matini SM, Moraveji A, Taherkhani E. The effect of pioglitazone  
31 and metformin on liver function tests, insulin resistance, and liver fat content in nonalcoholic  
32 fatty liver disease: A randomized double blinded clinical trial. *Hepatitis Monthly*. 2013; 13(5)
- 33 157 Reinehr T, Schmidt C, Toschke AM, Andler W. Lifestyle intervention in obese children with non-  
34 alcoholic fatty liver disease: 2-year follow-up study. *Archives of Disease in Childhood*. 2009;  
35 94(6):437-442
- 36 158 Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of  
37 sensitivity and specificity produces informative summary measures in diagnostic reviews. *J Clin  
38 Epidemiol*. 2005; 58(10):982-990
- 39 159 Ruffillo G, Fassio E, Alvarez E, Landeira G, Longo C, Dominguez N et al. Comparison of NAFLD  
40 fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease. *Journal of  
41 Hepatology*. 2011; 54(1):160-163



## Reference list

- 1 160 Ryou JH, Suh YJ, Shin HC, Cho YK, Choi JM, Park SK. Clinical association between non-alcoholic  
2 fatty liver disease and the development of hypertension. *Journal of Gastroenterology and*  
3 *Hepatology*. 2014; 29(11):1926-1931
- 4 161 Santos VN, Lanzoni VP, Szejnfeld J, Shigueoka D, Parise ER. A randomized double-blind study of  
5 the short-time treatment of obese patients with nonalcoholic fatty liver disease with  
6 ursodeoxycholic acid. *Brazilian Journal of Medical and Biological Research = Revista Brasileira De*  
7 *Pesquisas Médicas e Biológicas / Sociedade Brasileira De Biofísica [Et Al ]*. 2003; 36(6):723-729
- 8 162 Sanyal AJ, Abdelmalek MF, Suzuki A, Cummings OW, Chojkier M. No significant effects of ethyl-  
9 eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial.  
10 *Gastroenterology*. 2014; 147(2):377-384
- 11 163 Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM et al. Pioglitazone, vitamin  
12 E, or placebo for nonalcoholic steatohepatitis. *New England Journal of Medicine*. 2010;  
13 362(18):1675-1685
- 14 164 Sanyal AJ, Mofrad PS, Contos MJ, Sargeant C, Luketic VA, Sterling RK et al. A pilot study of vitamin  
15 E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. *Clinical*  
16 *Gastroenterology and Hepatology*. 2004; 2(12):1107-1115
- 17 165 Sasso M, Tengher-Barna I, Zioli M, Miette V, Fournier C, Sandrin L et al. Novel controlled  
18 attenuation parameter for noninvasive assessment of steatosis using Fibroscan(): validation in  
19 chronic hepatitis C. *Journal of Viral Hepatitis*. 2012; 19(4):244-253
- 20 166 Sasso M, Beaugrand M, de Ledinghen V, Douvin C, Marcellin P, Poupon R et al. Controlled  
21 attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the  
22 evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with  
23 chronic liver disease from various causes. *Ultrasound in Medicine and Biology*. 2010;  
24 36(11):1825-1835
- 25 167 Schwimmer JB, Middleton MS, Behling C, Newton KP, Awai HI, Paiz MN et al. Magnetic resonance  
26 imaging and liver histology as biomarkers of hepatic steatosis in children with nonalcoholic fatty  
27 liver disease. *Hepatology (Baltimore, Md )*. 2015; 61(6):1887-1895
- 28 168 Scorletti E, Bhatia L, McCormick KG, Clough GF, Nash K, Calder PC et al. Design and rationale of  
29 the WELCOME trial: a randomised, placebo controlled study to test the efficacy of purified long  
30 chain omega-3 fatty treatment in non-alcoholic fatty liver disease. *Contemporary Clinical Trials*.  
31 2014; 37(2):301-311
- 32 169 Scorletti E, Bhatia L, McCormick KG, Clough GF, Nash K, Hodson L et al. Effects of purified  
33 eicosapentaenoic and docosahexaenoic acids in non-alcoholic fatty liver disease: Results from  
34 the \*WELCOME study. *Hepatology*. 2014;
- 35 170 Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Comparison of Noninvasive  
36 Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. *Clinical Gastroenterology*  
37 *and Hepatology*. 2009; 7(10):1104-1112
- 38 171 Shargorodsky M, Omelchenko E, Matas Z, Boaz M, Gavish D. Relation between augmentation  
39 index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatitis:  
40 effects beyond glucose lowering? *Cardiovascular Diabetology*. 2012; 11:61
- 41 172 Sharma BC, Kumar A, Garg V, Reddy RS, Sakhuja P, Sarin SK. A Randomized Controlled Trial  
42 Comparing Efficacy of Pentoxifylline and Pioglitazone on Metabolic Factors and Liver Histology in

## Reference list

- 
- 1 Patients with Non-alcoholic Steatohepatitis. *Journal of Clinical and Experimental Hepatology*.  
2 2012; 2(4):333-337
- 3 173 Shen F, Zheng RD, Mi YQ, Wang XY, Pan Q, Chen GY et al. Controlled attenuation parameter for  
4 non-invasive assessment of hepatic steatosis in Chinese patients. *World Journal of*  
5 *Gastroenterology*. 2014; 20(16):4702-4711
- 6 174 Shen J, Chan HL, Wong GL, Chan AW, Choi PC, Chan HY et al. Assessment of non-alcoholic fatty  
7 liver disease using serum total cell death and apoptosis markers. *Alimentary Pharmacology and*  
8 *Therapeutics*. 2012; 36(11-12):1057-1066
- 9 175 Shiasi Arani K, Taghavi Ardakani A, Moazami Goudarzi R, Talari HR, Hami K, Akbari H et al. Effect  
10 of vitamin E and metformin on fatty liver disease in obese children- randomized clinical trial.  
11 *Iranian Journal of Public Health*. 2014; 43(10):1417-1423
- 12 176 Shibata M, Kihara Y, Taguchi M, Tashiro M, Otsuki M. Nonalcoholic fatty liver disease is a risk  
13 factor for type 2 diabetes in middle-aged Japanese men. *Diabetes Care*. 2007; 30(11):2940-2944
- 14 177 Shields WW, Thompson KE, Grice GA, Harrison SA, Coyle WJ. The effect of metformin and  
15 standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance  
16 and nonalcoholic steatohepatitis (NASH): A pilot trial. *Therapeutic Advances in Gastroenterology*.  
17 2009; 2(3):157-163
- 18 178 Singh DK, Sakhuja P, Malhotra V, Gondal R, Sarin SK. Independent predictors of steatohepatitis  
19 and fibrosis in Asian Indian patients with non-alcoholic steatohepatitis. *Digestive Diseases and*  
20 *Sciences*. 2008; 53(7):1967-1976
- 21 179 Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis Progression in Nonalcoholic  
22 Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-  
23 Biopsy Studies. *Clinical Gastroenterology and Hepatology*. 2014; epublication
- 24 180 Sookoian S, Castano G, Burgueno AL, Gianotti TF, Rosselli MS, Pirola CJ. A diagnostic model to  
25 differentiate simple steatosis from nonalcoholic steatohepatitis based on the likelihood ratio  
26 form of Bayes theorem. *Clinical Biochemistry*. 2009; 42(7-8):624-629
- 27 181 Sorrentino P, Terracciano L, D'Angelo S, Ferbo U, Bracigliano A, Vecchione R. Predicting fibrosis  
28 worsening in obese patients with NASH through parenchymal fibronectin, HOMA-IR, and  
29 hypertension. *American Journal of Gastroenterology*. 2010; 105(2):336-344
- 30 182 Spadaro L, Magliocco O, Spampinato D, Piro S, Oliveri C, Alagona C et al. Effects of n-3  
31 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. *Digestive and Liver*  
32 *Disease*. 2008; 40(3):194-199
- 33 183 Speliotes EK, Massaro JM, Hoffmann U, Vasan RS, Meigs JB, Sahani DV et al. Fatty liver is  
34 associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart  
35 Study. *Hepatology*. 2010; 51(6):1979-1987
- 36 184 Steadman R, Myers RP, Leggett L, Lorenzetti D, Noseworthy T, Rose S et al. A health technology  
37 assessment of transient elastography in adult liver disease. *Canadian Journal of*  
38 *Gastroenterology*. 2013; 27(3):149-158
- 39 185 Sullivan S, Kirk EP, Patterson B, Klein S. Effect of endurance exercise on non-alcoholic fatty liver  
40 disease. *Gastroenterology*. 2011; 140(5 SUPPL. 1):S700

## Reference list

- 1 186 Sullivan S, Kirk EP, Mittendorfer B, Patterson BW, Klein S. Randomized trial of exercise effect on  
2 intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease. *Hepatology*.  
3 2012; 55(6):1738-1745
- 4 187 Sumida Y, Yoneda M, Hyogo H, Itoh Y, Ono M, Fujii H et al. Validation of the FIB4 index in a  
5 Japanese nonalcoholic fatty liver disease population. *BMC Gastroenterology*. 2012; 12
- 6 188 Sung KC, Kim BS, Cho YK, Park DI, Woo S, Kim S et al. Predicting incident fatty liver using simple  
7 cardio-metabolic risk factors at baseline. *BMC Gastroenterology*. 2012; 12:84
- 8 189 Sung KC, Wild SH, Byrne CD. Development of new fatty liver, or resolution of existing fatty liver,  
9 over five years of follow-up, and risk of incident hypertension. *Journal of Hepatology*. 2014;  
10 60(5):1040-1045
- 11 190 Tang A, Desai A, Hamilton G, Wolfson T, Gamst A, Lam J et al. Accuracy of MR imaging-estimated  
12 proton density fat fraction for classification of dichotomized histologic steatosis grades in  
13 nonalcoholic fatty liver disease. *Radiology*. 2015; 274(2):416-425
- 14 191 Targher G, Bertolini LF, Rodella S FAU - Tessari R, Tessari RF, Zenari LF, Lippi GF et al.  
15 Nonalcoholic fatty liver disease is independently associated with an increased incidence of  
16 cardiovascular events in type 2 diabetic patients. *Cardiovascular and Metabolic Risk*. 2005;(1935-  
17 5548 (Electronic))
- 18 192 Targher G, Mantovani A, Pichiri I, Mingolla L, Cavalieri V, Mantovani W et al. Nonalcoholic fatty  
19 liver disease is independently associated with an increased incidence of chronic kidney disease in  
20 patients with type 1 diabetes. *Diabetes Care*. 2014; 37(6):1729-1736
- 21 193 Targher G, Valbusa F, Bonapace S, Bertolini L, Zenari L, Rodella S et al. Non-Alcoholic Fatty Liver  
22 Disease Is Associated with an Increased Incidence of Atrial Fibrillation in Patients with Type 2  
23 Diabetes. *PLoS One*. 2013; 8(2)
- 24 194 Targher G, Chonchol M, Bertolini L, Rodella S, Zenari L, Lippi G et al. Increased risk of CKD among  
25 type 2 diabetics with nonalcoholic fatty liver disease. *Journal of the American Society of  
26 Nephrology*. 2008; 19(8):1564-1570
- 27 195 Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a  
28 follow-up study. *Hepatology*. 1995; 22:1714-1719
- 29 196 Thoma C, Hallsworth K, Hollingsworth K, Anstee Q, Taylor R, Day C et al. High-intensity  
30 intermittent exercise therapy reduces liver fat and improves body composition in adults with  
31 non-alcoholic fatty liver disease. *Journal of Hepatology*. 2013; 58:S550-S551
- 32 197 Thoma C, Hallsworth K, Hollingsworth K, Taylor R, Day CP, Trenell M. Unsupervised high-intensity  
33 intermittent training reduces liver fat and improves body composition in adults with non-  
34 alcoholic fatty liver disease (NAFLD). *Diabetic Medicine*. 2013; 30:60
- 35 198 Tock L, Damaso AR, de Piano A, Carnier J, Sanches PL, Lederman HM et al. Long-term effects of  
36 metformin and lifestyle modification on nonalcoholic Fatty liver disease obese adolescents.  
37 *Journal of Obesity*. 2010; 2010
- 38 199 Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S et al. Therapeutic effects of  
39 restricted diet and exercise in obese patients with fatty liver. *Journal of Hepatology*. 1997;  
40 27(1):103-107

## Reference list

- 1 200 Urdzik J, Bjerner T, Wanders A, Weis J, Duraj F, Haglund U et al. The value of pre-operative  
2 magnetic resonance spectroscopy in the assessment of steatohepatitis in patients with colorectal  
3 liver metastasis. *Journal of Hepatology*. 2012; 56(3):640-646
- 4 201 Vajro P, Mandato C, Licenziati MR, Franzese A, Vitale DF, Lenta S et al. Effects of *Lactobacillus*  
5 *rhamnosus* strain GG in pediatric obesity-related liver disease. *Journal of Pediatric*  
6 *Gastroenterology and Nutrition*. 2011; 52(6):740-743
- 7 202 Van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate  
8 approach and meta-regression. *Statistics in Medicine*. 2002; 21(4):589-624
- 9 203 Van Houwelingen HC, Zwinderman KH, Stijnen T. A bivariate approach to meta-analysis. *Statistics*  
10 *in Medicine*. 1993; 12(24):2273-2284
- 11 204 van Werven JR, Marsman HA, Nederveen AJ, Smits NJ, ten Kate FJ, van Gulik TM et al.  
12 Assessment of hepatic steatosis in patients undergoing liver resection: comparison of US, CT, T1-  
13 weighted dual-echo MR imaging, and point-resolved 1H MR spectroscopy. *Radiology*. 2010;  
14 256(1):159-168
- 15 205 van Werven JR, Schreuder TCMA, Aarts EO, Nederveen AJ, Meijer JWR, Berends FJ et al. Hepatic  
16 steatosis in morbidly obese patients undergoing gastric bypass surgery: assessment with open-  
17 system 1H-MR spectroscopy. *AJR American Journal of Roentgenology*. 2011; 196(6):W736-W742
- 18 206 Verma S, Jensen D, Hart J, Mohanty SR. Predictive value of ALT levels for non-alcoholic  
19 steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). *Liver*  
20 *International*. 2013; 33(9):1398-1405
- 21 207 Wagner LB, Koppe SW, Brunt EM, Gottstein J, Gardikiotes K, Green RM et al. Pentoxifylline for  
22 the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. *Annals of*  
23 *Hepatology*. 2011; 10(3):277-286
- 24 208 Wang CC, Hsieh TC, Tseng TC, Wang PC, Hsu CS, Lin HH et al. Factors affecting the diagnostic  
25 accuracy of ultrasonography in assessing the severity of hepatic steatosis. *Journal of the*  
26 *Formosan Medical Association*. 2014; 113(4):249-254
- 27 209 Wang CY, Lu W, Hu DS, Wang GD, Cheng XJ. Diagnostic value of controlled attenuation  
28 parameter for liver steatosis in patients with chronic hepatitis B. *World Journal of*  
29 *Gastroenterology*. 2014; 20(30):10585-10590
- 30 210 Wang JH, Hung CH, Kuo FY, Eng HL, Chen CH, Lee CM et al. Ultrasonographic quantification of  
31 hepatic-renal echogenicity difference in hepatic steatosis diagnosis. *Digestive Diseases and*  
32 *Sciences*. 2013; 58(10):2993-3000
- 33 211 Webb M, Yeshua H, Zelber-Sagi S, Santo E, Brazowski E, Halpern Z et al. Diagnostic value of a  
34 computerized hepatorenal index for sonographic quantification of liver steatosis. *AJR American*  
35 *Journal of Roentgenology*. 2009; 192(4):909-914
- 36 212 Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY et al. Disease progression of non-  
37 alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. *Gut*. 2010;  
38 59:969-974
- 39 213 Wong VWS, Vergniol J, Wong GLH, Foucher J, Chan AWH, Chermak F et al. Liver stiffness  
40 measurement using XL probe in patients with nonalcoholic fatty liver disease. *American Journal*  
41 *of Gastroenterology*. 2012; 107(12):1862-1871

## Reference list

- 1 214 Wong VWS, Vergniol J, Wong GLH, Foucher J, Chan HLY, Le BB et al. Diagnosis of fibrosis and  
2 cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. *Hepatology*. 2010;  
3 51(2):454-462
- 4 215 Wong VWS, Wong GLH, Chim AML, Tse AML, Tsang SWC, Hui AY et al. Validation of the NAFLD  
5 fibrosis score in a Chinese population with low prevalence of advanced fibrosis. *American Journal*  
6 *of Gastroenterology*. 2008; 103(7):1682-1688
- 7 216 Wong VWS, Wong GLH, Yip GWK, Lo AOS, Limquiaco J, Chu WCW et al. Coronary artery disease  
8 and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. *Gut*. 2011;  
9 60(12):1721-1727
- 10 217 Wong VW-S, Chan RS-M, Wong GL-H, Cheung BH-K, Chu WC-W, Yeung DK-W et al. Community-  
11 based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized  
12 controlled trial. *Journal of Hepatology*. 2013; 59(3):536-542
- 13 218 Wong VW-S, Won GL-H, Chim AM-L, Chu WC-W, Yeung DK-W, Li KC-T et al. Treatment of  
14 nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. *Annals of Hepatology*.  
15 2013; 12(2):256-262
- 16 219 Wu CH, Ho MC, Jeng YM, Hsu CY, Liang PC, Hu RH et al. Quantification of hepatic steatosis: a  
17 comparison of the accuracy among multiple magnetic resonance techniques. *Journal of*  
18 *Gastroenterology and Hepatology*. 2014; 29(4):807-813
- 19 220 Xu C, Yu C, Ma H, Xu L, Miao M, Li Y. Prevalence and risk factors for the development of  
20 nonalcoholic fatty liver disease in a nonobese Chinese population: the Zhejiang Zhenhai Study.  
21 *American Journal of Gastroenterology*. 2013; 108(8):1299-1304
- 22 221 Xun YH, Fan JG, Zang GQ, Liu H, Jiang YM, Xiang J et al. Suboptimal performance of simple  
23 noninvasive tests for advanced fibrosis in Chinese patients with nonalcoholic fatty liver disease.  
24 *Journal of Digestive Diseases*. 2012; 13(11):588-595
- 25 222 Yajima Y, Ohta K, Narui T, Abe R, Suzuki H, Ohtsuki M. Ultrasonographical diagnosis of fatty liver:  
26 significance of the liver-kidney contrast. *Tohoku Journal of Experimental Medicine*. 1983;  
27 139(1):43-50
- 28 223 Yamada T, Fukatsu M, Suzuki S, Wada T, Yoshida T, Joh T. Fatty liver predicts impaired fasting  
29 glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup. *Journal of*  
30 *Gastroenterology and Hepatology*. 2010; 25(2):352-356
- 31 224 Yamazaki H, Tsuboya T, Tsuji K, Dohke M, Maguchi H. Independent association between  
32 improvement of nonalcoholic fatty liver disease and reduced incidence of type 2 diabetes.  
33 *Diabetes Care*. 2015; 38(9):1673-1679
- 34 225 Yilmaz Y, Dolar E, Ulukaya E, Akgoz S, Keskin M, Kiyici M et al. Soluble forms of extracellular  
35 cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. *World*  
36 *Journal of Gastroenterology*. 2007; 13(6):837-844
- 37 226 Yoneda M, Imajo K, Eguchi Y, Fujii H, Sumida Y, Hyogo H et al. Noninvasive scoring systems in  
38 patients with nonalcoholic fatty liver disease with normal alanine aminotransferase levels.  
39 *Journal of Gastroenterology*. 2013; 48(9):1051-1060

## Reference list

- 1 227 Yoneda M, Mawatari H, Fujita K, Endo H, Iida H, Nozaki Y et al. Noninvasive assessment of liver  
2 fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD).  
3 Digestive and Liver Disease. 2008; 40(5):371-378
- 4 228 Yoneda M, Suzuki K, Kato S, Fujita K, Nozaki Y, Hosono K et al. Nonalcoholic fatty liver disease:  
5 US-based acoustic radiation force impulse elastography. Radiology. 2010; 256(2):640-647
- 6 229 Yoneda M, Thomas E, Sumida Y, Imajo K, Eguchi Y, Hyogo H et al. Clinical usage of serum ferritin  
7 to assess liver fibrosis in patients with non-alcoholic fatty liver disease: Proceed with caution.  
8 Hepatology Research. 2015; 44(14):E499-E502
- 9 230 Younossi ZM, Otgonsuren M, Henry L, Venkatesan C, Mishra A, Erario M et al. Association of Non-  
10 alcoholic Fatty Liver Disease (NAFLD) with Hepatocellular Carcinoma (HCC) in the United States  
11 from 2004-2009. Hepatology (Baltimore, Md ). 2015;
- 12 231 Younossi ZM, Page S, Rafiq N, Birerdinc A, Stepanova M, Hossain N et al. A biomarker panel for  
13 non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis. Obesity Surgery. 2011;  
14 21(4):431-439
- 15 232 Younossi ZM, Stepanova M, Rafiq N, Makhlof H, Younoszai Z, Agrawal R et al. Pathologic criteria  
16 for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related  
17 mortality. Hepatology. 2011; 53(6):1874-1882
- 18 233 Zein CO, Yerian LM, Gogate P, Lopez R, Kirwan JP, Feldstein AE et al. Pentoxifylline improves  
19 nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology. 2011;  
20 54(5):1610-1619
- 21 234 Zelber-Sagi S, Buch A, Webb M, Yeshua H, Kiss O, Fliss N et al. The effect of resistance training on  
22 non-alcoholic fatty liver disease (NAFLD) a randomized clinical trial. Journal of Hepatology. 2012;  
23 56:S526-S527
- 24 235 Zelber-Sagi S, Kessler A, Brazowsky E, Webb M, Lurie Y, Santo M et al. A double-blind randomized  
25 placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clinical  
26 Gastroenterology and Hepatology. 2006; 4(5):639-644
- 27 236 Zelber-Sagi S, Buch A, Yeshua H, Vaisman N, Webb M, Harari G et al. Effect of resistance training  
28 on non-alcoholic fatty-liver disease a randomized-clinical trial. World Journal of  
29 Gastroenterology. 2014; 20(15):4382-4392
- 30 237 Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, Oren R. Prevalence of primary non-alcoholic fatty liver  
31 disease in a population-based study and its association with biochemical and anthropometric  
32 measures. Liver International. 2006; 26(7):856-863

33

34